KR101141951B1 - 흑색종용 다중-항원 벡터 - Google Patents
흑색종용 다중-항원 벡터 Download PDFInfo
- Publication number
- KR101141951B1 KR101141951B1 KR1020067004548A KR20067004548A KR101141951B1 KR 101141951 B1 KR101141951 B1 KR 101141951B1 KR 1020067004548 A KR1020067004548 A KR 1020067004548A KR 20067004548 A KR20067004548 A KR 20067004548A KR 101141951 B1 KR101141951 B1 KR 101141951B1
- Authority
- KR
- South Korea
- Prior art keywords
- leu
- ser
- gly
- pro
- val
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title claims abstract description 55
- 201000001441 melanoma Diseases 0.000 title claims abstract description 24
- 239000013598 vector Substances 0.000 title abstract description 31
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 49
- 239000013604 expression vector Substances 0.000 claims abstract description 17
- 108091007433 antigens Proteins 0.000 claims description 38
- 102000036639 antigens Human genes 0.000 claims description 38
- 229940023860 canarypox virus HIV vaccine Drugs 0.000 claims description 38
- 239000000203 mixture Substances 0.000 claims description 33
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 18
- 230000028993 immune response Effects 0.000 claims description 18
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 17
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims description 16
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims description 16
- 108010084313 CD58 Antigens Proteins 0.000 claims description 15
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims description 15
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- -1 gp100M Proteins 0.000 claims description 14
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 claims description 11
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 claims description 10
- 102100031413 L-dopachrome tautomerase Human genes 0.000 claims description 10
- 101710093778 L-dopachrome tautomerase Proteins 0.000 claims description 10
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 claims description 10
- 101710173694 Short transient receptor potential channel 2 Proteins 0.000 claims description 10
- 238000009472 formulation Methods 0.000 claims description 7
- 241000124008 Mammalia Species 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 2
- 101001005728 Homo sapiens Melanoma-associated antigen 1 Proteins 0.000 claims 3
- 101001057131 Homo sapiens Melanoma-associated antigen D4 Proteins 0.000 claims 3
- 102100025050 Melanoma-associated antigen 1 Human genes 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 79
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 67
- 229920001184 polypeptide Polymers 0.000 abstract description 53
- 150000007523 nucleic acids Chemical class 0.000 abstract description 51
- 108020004707 nucleic acids Proteins 0.000 abstract description 39
- 102000039446 nucleic acids Human genes 0.000 abstract description 39
- 201000011510 cancer Diseases 0.000 abstract description 32
- 239000013603 viral vector Substances 0.000 abstract description 6
- 210000004027 cell Anatomy 0.000 description 66
- 238000000034 method Methods 0.000 description 36
- 108090000623 proteins and genes Proteins 0.000 description 34
- 230000002163 immunogen Effects 0.000 description 26
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 21
- 108091028043 Nucleic acid sequence Proteins 0.000 description 20
- 239000013612 plasmid Substances 0.000 description 19
- 108020004414 DNA Proteins 0.000 description 15
- 241000282414 Homo sapiens Species 0.000 description 15
- 230000014509 gene expression Effects 0.000 description 15
- 235000001014 amino acid Nutrition 0.000 description 14
- 230000004044 response Effects 0.000 description 14
- 238000006467 substitution reaction Methods 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- 239000002671 adjuvant Substances 0.000 description 13
- 239000012634 fragment Substances 0.000 description 13
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 12
- 239000002246 antineoplastic agent Substances 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 12
- 239000003623 enhancer Substances 0.000 description 12
- 108010050848 glycylleucine Proteins 0.000 description 12
- 238000009396 hybridization Methods 0.000 description 12
- 150000001413 amino acids Chemical class 0.000 description 11
- 108010057821 leucylproline Proteins 0.000 description 11
- 229940024606 amino acid Drugs 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108091026890 Coding region Proteins 0.000 description 9
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 9
- 206010070834 Sensitisation Diseases 0.000 description 9
- 125000003275 alpha amino acid group Chemical group 0.000 description 9
- 108010047857 aspartylglycine Proteins 0.000 description 9
- 230000001105 regulatory effect Effects 0.000 description 9
- 229960005486 vaccine Drugs 0.000 description 9
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 8
- 241000700605 Viruses Species 0.000 description 8
- 108010005233 alanylglutamic acid Proteins 0.000 description 8
- 125000000539 amino acid group Chemical group 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 230000004927 fusion Effects 0.000 description 8
- 108010053725 prolylvaline Proteins 0.000 description 8
- 230000008313 sensitization Effects 0.000 description 8
- 241000894007 species Species 0.000 description 8
- 102000004127 Cytokines Human genes 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 7
- 241000880493 Leptailurus serval Species 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 108010079364 N-glycylalanine Proteins 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 108010054813 diprotin B Proteins 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 238000013518 transcription Methods 0.000 description 7
- 230000035897 transcription Effects 0.000 description 7
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 6
- 238000012217 deletion Methods 0.000 description 6
- 230000037430 deletion Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 6
- 108010089804 glycyl-threonine Proteins 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 239000002502 liposome Substances 0.000 description 6
- 108010029020 prolylglycine Proteins 0.000 description 6
- 108010090894 prolylleucine Proteins 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 230000002103 transcriptional effect Effects 0.000 description 6
- PKVWNYGXMNWJSI-CIUDSAMLSA-N Gln-Gln-Gln Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O PKVWNYGXMNWJSI-CIUDSAMLSA-N 0.000 description 5
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 5
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 5
- 108010065805 Interleukin-12 Proteins 0.000 description 5
- PMGDADKJMCOXHX-UHFFFAOYSA-N L-Arginyl-L-glutamin-acetat Natural products NC(=N)NCCCC(N)C(=O)NC(CCC(N)=O)C(O)=O PMGDADKJMCOXHX-UHFFFAOYSA-N 0.000 description 5
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 5
- 235000018417 cysteine Nutrition 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 108010017391 lysylvaline Proteins 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 108091033319 polynucleotide Proteins 0.000 description 5
- 102000040430 polynucleotide Human genes 0.000 description 5
- 239000002157 polynucleotide Substances 0.000 description 5
- 238000010561 standard procedure Methods 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 4
- 102100032366 C-C motif chemokine 7 Human genes 0.000 description 4
- 101100505161 Caenorhabditis elegans mel-32 gene Proteins 0.000 description 4
- 102000019034 Chemokines Human genes 0.000 description 4
- 108010012236 Chemokines Proteins 0.000 description 4
- 102000001301 EGF receptor Human genes 0.000 description 4
- 108060006698 EGF receptor Proteins 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- BUEFQXUHTUZXHR-LURJTMIESA-N Gly-Gly-Pro zwitterion Chemical compound NCC(=O)NCC(=O)N1CCC[C@H]1C(O)=O BUEFQXUHTUZXHR-LURJTMIESA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 4
- ULXYQAJWJGLCNR-YUMQZZPRSA-N Leu-Asp-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O ULXYQAJWJGLCNR-YUMQZZPRSA-N 0.000 description 4
- CHJKEDSZNSONPS-DCAQKATOSA-N Leu-Pro-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O CHJKEDSZNSONPS-DCAQKATOSA-N 0.000 description 4
- 108050008953 Melanoma-associated antigen Proteins 0.000 description 4
- 108010002311 N-glycylglutamic acid Proteins 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- MVIJMIZJPHQGEN-IHRRRGAJSA-N Phe-Ser-Val Chemical compound CC(C)[C@@H](C([O-])=O)NC(=O)[C@H](CO)NC(=O)[C@@H]([NH3+])CC1=CC=CC=C1 MVIJMIZJPHQGEN-IHRRRGAJSA-N 0.000 description 4
- BGWKULMLUIUPKY-BQBZGAKWSA-N Pro-Ser-Gly Chemical compound OC(=O)CNC(=O)[C@H](CO)NC(=O)[C@@H]1CCCN1 BGWKULMLUIUPKY-BQBZGAKWSA-N 0.000 description 4
- SFTZWNJFZYOLBD-ZDLURKLDSA-N Ser-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CO SFTZWNJFZYOLBD-ZDLURKLDSA-N 0.000 description 4
- BNGDYRRHRGOPHX-IFFSRLJSSA-N Thr-Glu-Val Chemical compound CC(C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)[C@@H](C)O)C(O)=O BNGDYRRHRGOPHX-IFFSRLJSSA-N 0.000 description 4
- XKWABWFMQXMUMT-HJGDQZAQSA-N Thr-Pro-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O XKWABWFMQXMUMT-HJGDQZAQSA-N 0.000 description 4
- NDZYTIMDOZMECO-SHGPDSBTSA-N Thr-Thr-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O NDZYTIMDOZMECO-SHGPDSBTSA-N 0.000 description 4
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 4
- 206010046865 Vaccinia virus infection Diseases 0.000 description 4
- MIKHIIQMRFYVOR-RCWTZXSCSA-N Val-Pro-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C(C)C)N)O MIKHIIQMRFYVOR-RCWTZXSCSA-N 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 108010050025 alpha-glutamyltryptophan Proteins 0.000 description 4
- 230000000118 anti-neoplastic effect Effects 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 108010008355 arginyl-glutamine Proteins 0.000 description 4
- 108010093581 aspartyl-proline Proteins 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 108010049041 glutamylalanine Proteins 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 150000003904 phospholipids Chemical class 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 108010031719 prolyl-serine Proteins 0.000 description 4
- 230000001177 retroviral effect Effects 0.000 description 4
- 239000001509 sodium citrate Substances 0.000 description 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 108010061238 threonyl-glycine Proteins 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 241001430294 unidentified retrovirus Species 0.000 description 4
- 208000007089 vaccinia Diseases 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 108010082808 4-1BB Ligand Proteins 0.000 description 3
- WMYJZJRILUVVRG-WDSKDSINSA-N Ala-Gly-Gln Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCC(N)=O WMYJZJRILUVVRG-WDSKDSINSA-N 0.000 description 3
- NCQMBSJGJMYKCK-ZLUOBGJFSA-N Ala-Ser-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O NCQMBSJGJMYKCK-ZLUOBGJFSA-N 0.000 description 3
- WNHNMKOFKCHKKD-BFHQHQDPSA-N Ala-Thr-Gly Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O WNHNMKOFKCHKKD-BFHQHQDPSA-N 0.000 description 3
- QOIGKCBMXUCDQU-KDXUFGMBSA-N Ala-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](C)N)O QOIGKCBMXUCDQU-KDXUFGMBSA-N 0.000 description 3
- NKBQZKVMKJJDLX-SRVKXCTJSA-N Arg-Glu-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O NKBQZKVMKJJDLX-SRVKXCTJSA-N 0.000 description 3
- UXHYOWXTJLBEPG-GSSVUCPTSA-N Asn-Thr-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O UXHYOWXTJLBEPG-GSSVUCPTSA-N 0.000 description 3
- FRSGNOZCTWDVFZ-ACZMJKKPSA-N Asp-Asp-Gln Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O FRSGNOZCTWDVFZ-ACZMJKKPSA-N 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- XTHUKRLJRUVVBF-WHFBIAKZSA-N Cys-Gly-Ser Chemical compound SC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O XTHUKRLJRUVVBF-WHFBIAKZSA-N 0.000 description 3
- 108091029865 Exogenous DNA Proteins 0.000 description 3
- PRBLYKYHAJEABA-SRVKXCTJSA-N Gln-Arg-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O PRBLYKYHAJEABA-SRVKXCTJSA-N 0.000 description 3
- YPFFHGRJCUBXPX-NHCYSSNCSA-N Gln-Pro-Val Chemical compound CC(C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCC(N)=O)C(O)=O YPFFHGRJCUBXPX-NHCYSSNCSA-N 0.000 description 3
- VYOILACOFPPNQH-UMNHJUIQSA-N Gln-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)N)N VYOILACOFPPNQH-UMNHJUIQSA-N 0.000 description 3
- QXUPRMQJDWJDFR-NRPADANISA-N Glu-Val-Ser Chemical compound CC(C)[C@H](NC(=O)[C@@H](N)CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O QXUPRMQJDWJDFR-NRPADANISA-N 0.000 description 3
- SOEGEPHNZOISMT-BYPYZUCNSA-N Gly-Ser-Gly Chemical compound NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O SOEGEPHNZOISMT-BYPYZUCNSA-N 0.000 description 3
- JQFILXICXLDTRR-FBCQKBJTSA-N Gly-Thr-Gly Chemical compound NCC(=O)N[C@@H]([C@H](O)C)C(=O)NCC(O)=O JQFILXICXLDTRR-FBCQKBJTSA-N 0.000 description 3
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 3
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 3
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 3
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 3
- TVYWVSJGSHQWMT-AJNGGQMLSA-N Ile-Leu-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)O)N TVYWVSJGSHQWMT-AJNGGQMLSA-N 0.000 description 3
- 102100037850 Interferon gamma Human genes 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- SITWEMZOJNKJCH-UHFFFAOYSA-N L-alanine-L-arginine Natural products CC(N)C(=O)NC(C(O)=O)CCCNC(N)=N SITWEMZOJNKJCH-UHFFFAOYSA-N 0.000 description 3
- QJXHMYMRGDOHRU-NHCYSSNCSA-N Leu-Ile-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(O)=O QJXHMYMRGDOHRU-NHCYSSNCSA-N 0.000 description 3
- SXWQMBGNFXAGAT-FJXKBIBVSA-N Met-Gly-Thr Chemical compound CSCC[C@H](N)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O SXWQMBGNFXAGAT-FJXKBIBVSA-N 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- XMBSYZWANAQXEV-UHFFFAOYSA-N N-alpha-L-glutamyl-L-phenylalanine Natural products OC(=O)CCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XMBSYZWANAQXEV-UHFFFAOYSA-N 0.000 description 3
- 230000004988 N-glycosylation Effects 0.000 description 3
- 102000004473 OX40 Ligand Human genes 0.000 description 3
- 108010042215 OX40 Ligand Proteins 0.000 description 3
- ALJGSKMBIUEJOB-FXQIFTODSA-N Pro-Ala-Cys Chemical compound C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@@H]1CCCN1 ALJGSKMBIUEJOB-FXQIFTODSA-N 0.000 description 3
- KDBHVPXBQADZKY-GUBZILKMSA-N Pro-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 KDBHVPXBQADZKY-GUBZILKMSA-N 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 3
- 241000714474 Rous sarcoma virus Species 0.000 description 3
- 241000607142 Salmonella Species 0.000 description 3
- GJFYFGOEWLDQGW-GUBZILKMSA-N Ser-Leu-Gln Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CO)N GJFYFGOEWLDQGW-GUBZILKMSA-N 0.000 description 3
- JCLAFVNDBJMLBC-JBDRJPRFSA-N Ser-Ser-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JCLAFVNDBJMLBC-JBDRJPRFSA-N 0.000 description 3
- CUXJENOFJXOSOZ-BIIVOSGPSA-N Ser-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CO)N)C(=O)O CUXJENOFJXOSOZ-BIIVOSGPSA-N 0.000 description 3
- OQSQCUWQOIHECT-YJRXYDGGSA-N Ser-Tyr-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OQSQCUWQOIHECT-YJRXYDGGSA-N 0.000 description 3
- 108010074687 Signaling Lymphocytic Activation Molecule Family Member 1 Proteins 0.000 description 3
- 102100029215 Signaling lymphocytic activation molecule Human genes 0.000 description 3
- 230000024932 T cell mediated immunity Effects 0.000 description 3
- 230000005867 T cell response Effects 0.000 description 3
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 239000004098 Tetracycline Substances 0.000 description 3
- IEZVHOULSUULHD-XGEHTFHBSA-N Thr-Ser-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O IEZVHOULSUULHD-XGEHTFHBSA-N 0.000 description 3
- 108020004440 Thymidine kinase Proteins 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 description 3
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 3
- NHXZRXLFOBFMDM-AVGNSLFASA-N Val-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)C(C)C NHXZRXLFOBFMDM-AVGNSLFASA-N 0.000 description 3
- HTONZBWRYUKUKC-RCWTZXSCSA-N Val-Thr-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O HTONZBWRYUKUKC-RCWTZXSCSA-N 0.000 description 3
- JVGDAEKKZKKZFO-RCWTZXSCSA-N Val-Val-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)N)O JVGDAEKKZKKZFO-RCWTZXSCSA-N 0.000 description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 108010047495 alanylglycine Proteins 0.000 description 3
- 108010087924 alanylproline Proteins 0.000 description 3
- 230000005975 antitumor immune response Effects 0.000 description 3
- 108010013835 arginine glutamate Proteins 0.000 description 3
- 108010068380 arginylarginine Proteins 0.000 description 3
- 108010062796 arginyllysine Proteins 0.000 description 3
- 108010040443 aspartyl-aspartic acid Proteins 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 108010078144 glutaminyl-glycine Proteins 0.000 description 3
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 3
- JYPCXBJRLBHWME-UHFFFAOYSA-N glycyl-L-prolyl-L-arginine Natural products NCC(=O)N1CCCC1C(=O)NC(CCCN=C(N)N)C(O)=O JYPCXBJRLBHWME-UHFFFAOYSA-N 0.000 description 3
- 108010028295 histidylhistidine Proteins 0.000 description 3
- 108010025306 histidylleucine Proteins 0.000 description 3
- 108010018006 histidylserine Proteins 0.000 description 3
- 150000002430 hydrocarbons Chemical group 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000003701 inert diluent Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 108010044374 isoleucyl-tyrosine Proteins 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 108010054155 lysyllysine Proteins 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 229960002180 tetracycline Drugs 0.000 description 3
- 229930101283 tetracycline Natural products 0.000 description 3
- 235000019364 tetracycline Nutrition 0.000 description 3
- 150000003522 tetracyclines Chemical class 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000011830 transgenic mouse model Methods 0.000 description 3
- 108010084932 tryptophyl-proline Proteins 0.000 description 3
- 108010038745 tryptophylglycine Proteins 0.000 description 3
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 210000002845 virion Anatomy 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- AXFMEGAFCUULFV-BLFANLJRSA-N (2s)-2-[[(2s)-1-[(2s,3r)-2-amino-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]pentanedioic acid Chemical compound CC[C@@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O AXFMEGAFCUULFV-BLFANLJRSA-N 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- HPZMWTNATZPBIH-UHFFFAOYSA-N 1-methyladenine Chemical compound CN1C=NC2=NC=NC2=C1N HPZMWTNATZPBIH-UHFFFAOYSA-N 0.000 description 2
- RFLVMTUMFYRZCB-UHFFFAOYSA-N 1-methylguanine Chemical compound O=C1N(C)C(N)=NC2=C1N=CN2 RFLVMTUMFYRZCB-UHFFFAOYSA-N 0.000 description 2
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 2
- PEZMQPADLFXCJJ-ZETCQYMHSA-N 2-[[2-[[(2s)-1-(2-aminoacetyl)pyrrolidine-2-carbonyl]amino]acetyl]amino]acetic acid Chemical compound NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)NCC(O)=O PEZMQPADLFXCJJ-ZETCQYMHSA-N 0.000 description 2
- FZWGECJQACGGTI-UHFFFAOYSA-N 2-amino-7-methyl-1,7-dihydro-6H-purin-6-one Chemical compound NC1=NC(O)=C2N(C)C=NC2=N1 FZWGECJQACGGTI-UHFFFAOYSA-N 0.000 description 2
- OVONXEQGWXGFJD-UHFFFAOYSA-N 4-sulfanylidene-1h-pyrimidin-2-one Chemical compound SC=1C=CNC(=O)N=1 OVONXEQGWXGFJD-UHFFFAOYSA-N 0.000 description 2
- OIVLITBTBDPEFK-UHFFFAOYSA-N 5,6-dihydrouracil Chemical compound O=C1CCNC(=O)N1 OIVLITBTBDPEFK-UHFFFAOYSA-N 0.000 description 2
- DCPSTSVLRXOYGS-UHFFFAOYSA-N 6-amino-1h-pyrimidine-2-thione Chemical compound NC1=CC=NC(S)=N1 DCPSTSVLRXOYGS-UHFFFAOYSA-N 0.000 description 2
- YBPLKDWJFYCZSV-ZLUOBGJFSA-N Ala-Asn-Cys Chemical compound C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CS)C(=O)O)N YBPLKDWJFYCZSV-ZLUOBGJFSA-N 0.000 description 2
- NJIFPLAJSVUQOZ-JBDRJPRFSA-N Ala-Cys-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](C)N NJIFPLAJSVUQOZ-JBDRJPRFSA-N 0.000 description 2
- CXQODNIBUNQWAS-CIUDSAMLSA-N Ala-Gln-Arg Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N CXQODNIBUNQWAS-CIUDSAMLSA-N 0.000 description 2
- RXTBLQVXNIECFP-FXQIFTODSA-N Ala-Gln-Gln Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O RXTBLQVXNIECFP-FXQIFTODSA-N 0.000 description 2
- FUSPCLTUKXQREV-ACZMJKKPSA-N Ala-Glu-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O FUSPCLTUKXQREV-ACZMJKKPSA-N 0.000 description 2
- VBRDBGCROKWTPV-XHNCKOQMSA-N Ala-Glu-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N1CCC[C@@H]1C(=O)O)N VBRDBGCROKWTPV-XHNCKOQMSA-N 0.000 description 2
- PUBLUECXJRHTBK-ACZMJKKPSA-N Ala-Glu-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O PUBLUECXJRHTBK-ACZMJKKPSA-N 0.000 description 2
- OMMDTNGURYRDAC-NRPADANISA-N Ala-Glu-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O OMMDTNGURYRDAC-NRPADANISA-N 0.000 description 2
- OKIKVSXTXVVFDV-MMWGEVLESA-N Ala-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](C)N OKIKVSXTXVVFDV-MMWGEVLESA-N 0.000 description 2
- HHRAXZAYZFFRAM-CIUDSAMLSA-N Ala-Leu-Asn Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O HHRAXZAYZFFRAM-CIUDSAMLSA-N 0.000 description 2
- SUMYEVXWCAYLLJ-GUBZILKMSA-N Ala-Leu-Gln Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O SUMYEVXWCAYLLJ-GUBZILKMSA-N 0.000 description 2
- MNZHHDPWDWQJCQ-YUMQZZPRSA-N Ala-Leu-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O MNZHHDPWDWQJCQ-YUMQZZPRSA-N 0.000 description 2
- OYJCVIGKMXUVKB-GARJFASQSA-N Ala-Leu-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N OYJCVIGKMXUVKB-GARJFASQSA-N 0.000 description 2
- XSTZMVAYYCJTNR-DCAQKATOSA-N Ala-Met-Leu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(O)=O XSTZMVAYYCJTNR-DCAQKATOSA-N 0.000 description 2
- CNQAFFMNJIQYGX-DRZSPHRISA-N Ala-Phe-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CC=CC=C1 CNQAFFMNJIQYGX-DRZSPHRISA-N 0.000 description 2
- OLVCTPPSXNRGKV-GUBZILKMSA-N Ala-Pro-Pro Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 OLVCTPPSXNRGKV-GUBZILKMSA-N 0.000 description 2
- FFZJHQODAYHGPO-KZVJFYERSA-N Ala-Pro-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)N FFZJHQODAYHGPO-KZVJFYERSA-N 0.000 description 2
- YHBDGLZYNIARKJ-GUBZILKMSA-N Ala-Pro-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)N YHBDGLZYNIARKJ-GUBZILKMSA-N 0.000 description 2
- SAHQGRZIQVEJPF-JXUBOQSCSA-N Ala-Thr-Lys Chemical compound C[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(O)=O)CCCCN SAHQGRZIQVEJPF-JXUBOQSCSA-N 0.000 description 2
- VHAQSYHSDKERBS-XPUUQOCRSA-N Ala-Val-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O VHAQSYHSDKERBS-XPUUQOCRSA-N 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- XKJMBINCVNINCA-UHFFFAOYSA-N Alfalone Chemical compound CON(C)C(=O)NC1=CC=C(Cl)C(Cl)=C1 XKJMBINCVNINCA-UHFFFAOYSA-N 0.000 description 2
- SGYSTDWPNPKJPP-GUBZILKMSA-N Arg-Ala-Arg Chemical compound NC(=N)NCCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SGYSTDWPNPKJPP-GUBZILKMSA-N 0.000 description 2
- CPSHGRGUPZBMOK-CIUDSAMLSA-N Arg-Asn-Gln Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O CPSHGRGUPZBMOK-CIUDSAMLSA-N 0.000 description 2
- IGULQRCJLQQPSM-DCAQKATOSA-N Arg-Cys-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(O)=O IGULQRCJLQQPSM-DCAQKATOSA-N 0.000 description 2
- LMPKCSXZJSXBBL-NHCYSSNCSA-N Arg-Gln-Val Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O LMPKCSXZJSXBBL-NHCYSSNCSA-N 0.000 description 2
- ZATRYQNPUHGXCU-DTWKUNHWSA-N Arg-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CCCN=C(N)N)N)C(=O)O ZATRYQNPUHGXCU-DTWKUNHWSA-N 0.000 description 2
- LVMUGODRNHFGRA-AVGNSLFASA-N Arg-Leu-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O LVMUGODRNHFGRA-AVGNSLFASA-N 0.000 description 2
- AWMAZIIEFPFHCP-RCWTZXSCSA-N Arg-Pro-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O AWMAZIIEFPFHCP-RCWTZXSCSA-N 0.000 description 2
- XWGJDUSDTRPQRK-ZLUOBGJFSA-N Asn-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O XWGJDUSDTRPQRK-ZLUOBGJFSA-N 0.000 description 2
- CIBWFJFMOBIFTE-CIUDSAMLSA-N Asn-Arg-Gln Chemical compound C(C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N)CN=C(N)N CIBWFJFMOBIFTE-CIUDSAMLSA-N 0.000 description 2
- VKCOHFFSTKCXEQ-OLHMAJIHSA-N Asn-Asn-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O VKCOHFFSTKCXEQ-OLHMAJIHSA-N 0.000 description 2
- HJRBIWRXULGMOA-ACZMJKKPSA-N Asn-Gln-Asp Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O HJRBIWRXULGMOA-ACZMJKKPSA-N 0.000 description 2
- ZSVJVIOVABDTTL-YUMQZZPRSA-N Asp-Gly-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)O)N ZSVJVIOVABDTTL-YUMQZZPRSA-N 0.000 description 2
- MVRGBQGZSDJBSM-GMOBBJLQSA-N Asp-Pro-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC(=O)O)N MVRGBQGZSDJBSM-GMOBBJLQSA-N 0.000 description 2
- ZVGRHIRJLWBWGJ-ACZMJKKPSA-N Asp-Ser-Gln Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(O)=O ZVGRHIRJLWBWGJ-ACZMJKKPSA-N 0.000 description 2
- UTLCRGFJFSZWAW-OLHMAJIHSA-N Asp-Thr-Asn Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)O)N)O UTLCRGFJFSZWAW-OLHMAJIHSA-N 0.000 description 2
- 101150039990 B13R gene Proteins 0.000 description 2
- 108010006654 Bleomycin Proteins 0.000 description 2
- 101710155834 C-C motif chemokine 7 Proteins 0.000 description 2
- 108700012434 CCL3 Proteins 0.000 description 2
- 108010029697 CD40 Ligand Proteins 0.000 description 2
- 102100032937 CD40 ligand Human genes 0.000 description 2
- 102100025221 CD70 antigen Human genes 0.000 description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 102000000013 Chemokine CCL3 Human genes 0.000 description 2
- 108010055166 Chemokine CCL5 Proteins 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 2
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 description 2
- KEBJBKIASQVRJS-WDSKDSINSA-N Cys-Gln-Gly Chemical compound C(CC(=O)N)[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CS)N KEBJBKIASQVRJS-WDSKDSINSA-N 0.000 description 2
- PORWNQWEEIOIRH-XHNCKOQMSA-N Cys-Gln-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CS)N)C(=O)O PORWNQWEEIOIRH-XHNCKOQMSA-N 0.000 description 2
- POSRGGKLRWCUBE-CIUDSAMLSA-N Cys-Met-Glu Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CS)N POSRGGKLRWCUBE-CIUDSAMLSA-N 0.000 description 2
- XCDDSPYIMNXECQ-NAKRPEOUSA-N Cys-Pro-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CS XCDDSPYIMNXECQ-NAKRPEOUSA-N 0.000 description 2
- SWJYSDXMTPMBHO-FXQIFTODSA-N Cys-Pro-Ser Chemical compound [H]N[C@@H](CS)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O SWJYSDXMTPMBHO-FXQIFTODSA-N 0.000 description 2
- KZZYVYWSXMFYEC-DCAQKATOSA-N Cys-Val-Leu Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O KZZYVYWSXMFYEC-DCAQKATOSA-N 0.000 description 2
- 108010090461 DFG peptide Proteins 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- 102000050554 Eph Family Receptors Human genes 0.000 description 2
- 108091008815 Eph receptors Proteins 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 208000000666 Fowlpox Diseases 0.000 description 2
- JSYULGSPLTZDHM-NRPADANISA-N Gln-Ala-Val Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O JSYULGSPLTZDHM-NRPADANISA-N 0.000 description 2
- JXFLPKSDLDEOQK-JHEQGTHGSA-N Gln-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCC(N)=O JXFLPKSDLDEOQK-JHEQGTHGSA-N 0.000 description 2
- HWEINOMSWQSJDC-SRVKXCTJSA-N Gln-Leu-Arg Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O HWEINOMSWQSJDC-SRVKXCTJSA-N 0.000 description 2
- IOFDDSNZJDIGPB-GVXVVHGQSA-N Gln-Leu-Val Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O IOFDDSNZJDIGPB-GVXVVHGQSA-N 0.000 description 2
- GURIQZQSTBBHRV-SRVKXCTJSA-N Gln-Lys-Arg Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O GURIQZQSTBBHRV-SRVKXCTJSA-N 0.000 description 2
- BJPPYOMRAVLXBY-YUMQZZPRSA-N Gln-Met-Gly Chemical compound CSCC[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CCC(=O)N)N BJPPYOMRAVLXBY-YUMQZZPRSA-N 0.000 description 2
- LVRKAFPPFJRIOF-GARJFASQSA-N Gln-Met-Pro Chemical compound CSCC[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)N)N LVRKAFPPFJRIOF-GARJFASQSA-N 0.000 description 2
- FITIQFSXXBKFFM-NRPADANISA-N Gln-Val-Ser Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O FITIQFSXXBKFFM-NRPADANISA-N 0.000 description 2
- HNAUFGBKJLTWQE-IFFSRLJSSA-N Gln-Val-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)N)N)O HNAUFGBKJLTWQE-IFFSRLJSSA-N 0.000 description 2
- SOEXCCGNHQBFPV-DLOVCJGASA-N Gln-Val-Val Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(O)=O SOEXCCGNHQBFPV-DLOVCJGASA-N 0.000 description 2
- WZZSKAJIHTUUSG-ACZMJKKPSA-N Glu-Ala-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(O)=O WZZSKAJIHTUUSG-ACZMJKKPSA-N 0.000 description 2
- MTAOBYXRYJZRGQ-WDSKDSINSA-N Glu-Gly-Asp Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O MTAOBYXRYJZRGQ-WDSKDSINSA-N 0.000 description 2
- HPJLZFTUUJKWAJ-JHEQGTHGSA-N Glu-Gly-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O HPJLZFTUUJKWAJ-JHEQGTHGSA-N 0.000 description 2
- QXDXIXFSFHUYAX-MNXVOIDGSA-N Glu-Ile-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCC(O)=O QXDXIXFSFHUYAX-MNXVOIDGSA-N 0.000 description 2
- HVYWQYLBVXMXSV-GUBZILKMSA-N Glu-Leu-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O HVYWQYLBVXMXSV-GUBZILKMSA-N 0.000 description 2
- HQOGXFLBAKJUMH-CIUDSAMLSA-N Glu-Met-Ser Chemical compound CSCC[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCC(=O)O)N HQOGXFLBAKJUMH-CIUDSAMLSA-N 0.000 description 2
- BDISFWMLMNBTGP-NUMRIWBASA-N Glu-Thr-Asp Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O BDISFWMLMNBTGP-NUMRIWBASA-N 0.000 description 2
- WGYHAAXZWPEBDQ-IFFSRLJSSA-N Glu-Val-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O WGYHAAXZWPEBDQ-IFFSRLJSSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 2
- PYTZFYUXZZHOAD-WHFBIAKZSA-N Gly-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)CN PYTZFYUXZZHOAD-WHFBIAKZSA-N 0.000 description 2
- UGVQELHRNUDMAA-BYPYZUCNSA-N Gly-Ala-Gly Chemical compound [NH3+]CC(=O)N[C@@H](C)C(=O)NCC([O-])=O UGVQELHRNUDMAA-BYPYZUCNSA-N 0.000 description 2
- OCDLPQDYTJPWNG-YUMQZZPRSA-N Gly-Asn-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)CN OCDLPQDYTJPWNG-YUMQZZPRSA-N 0.000 description 2
- LCNXZQROPKFGQK-WHFBIAKZSA-N Gly-Asp-Ser Chemical compound NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O LCNXZQROPKFGQK-WHFBIAKZSA-N 0.000 description 2
- MQVNVZUEPUIAFA-WDSKDSINSA-N Gly-Cys-Gln Chemical compound C(CC(=O)N)[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)CN MQVNVZUEPUIAFA-WDSKDSINSA-N 0.000 description 2
- KTSZUNRRYXPZTK-BQBZGAKWSA-N Gly-Gln-Glu Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O KTSZUNRRYXPZTK-BQBZGAKWSA-N 0.000 description 2
- JLJLBWDKDRYOPA-RYUDHWBXSA-N Gly-Gln-Tyr Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 JLJLBWDKDRYOPA-RYUDHWBXSA-N 0.000 description 2
- QPDUVFSVVAOUHE-XVKPBYJWSA-N Gly-Gln-Val Chemical compound CC(C)[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)CN)C(O)=O QPDUVFSVVAOUHE-XVKPBYJWSA-N 0.000 description 2
- HDNXXTBKOJKWNN-WDSKDSINSA-N Gly-Glu-Asn Chemical compound NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O HDNXXTBKOJKWNN-WDSKDSINSA-N 0.000 description 2
- FSPVILZGHUJOHS-QWRGUYRKSA-N Gly-His-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CNC=N1 FSPVILZGHUJOHS-QWRGUYRKSA-N 0.000 description 2
- UUYBFNKHOCJCHT-VHSXEESVSA-N Gly-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)CN UUYBFNKHOCJCHT-VHSXEESVSA-N 0.000 description 2
- NNCSJUBVFBDDLC-YUMQZZPRSA-N Gly-Leu-Ser Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O NNCSJUBVFBDDLC-YUMQZZPRSA-N 0.000 description 2
- NSVOVKWEKGEOQB-LURJTMIESA-N Gly-Pro-Gly Chemical compound NCC(=O)N1CCC[C@H]1C(=O)NCC(O)=O NSVOVKWEKGEOQB-LURJTMIESA-N 0.000 description 2
- HFPVRZWORNJRRC-UWVGGRQHSA-N Gly-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)CN HFPVRZWORNJRRC-UWVGGRQHSA-N 0.000 description 2
- YOBGUCWZPXJHTN-BQBZGAKWSA-N Gly-Ser-Arg Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCN=C(N)N YOBGUCWZPXJHTN-BQBZGAKWSA-N 0.000 description 2
- OHUKZZYSJBKFRR-WHFBIAKZSA-N Gly-Ser-Asp Chemical compound [H]NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O OHUKZZYSJBKFRR-WHFBIAKZSA-N 0.000 description 2
- WNGHUXFWEWTKAO-YUMQZZPRSA-N Gly-Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CN WNGHUXFWEWTKAO-YUMQZZPRSA-N 0.000 description 2
- JSLVAHYTAJJEQH-QWRGUYRKSA-N Gly-Ser-Phe Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 JSLVAHYTAJJEQH-QWRGUYRKSA-N 0.000 description 2
- IMRNSEPSPFQNHF-STQMWFEESA-N Gly-Ser-Trp Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)O IMRNSEPSPFQNHF-STQMWFEESA-N 0.000 description 2
- RHRLHXQWHCNJKR-PMVVWTBXSA-N Gly-Thr-His Chemical compound NCC(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 RHRLHXQWHCNJKR-PMVVWTBXSA-N 0.000 description 2
- TVTZEOHWHUVYCG-KYNKHSRBSA-N Gly-Thr-Thr Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O TVTZEOHWHUVYCG-KYNKHSRBSA-N 0.000 description 2
- 108010022901 Heparin Lyase Proteins 0.000 description 2
- SVVULKPWDBIPCO-BZSNNMDCSA-N His-Phe-Leu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O SVVULKPWDBIPCO-BZSNNMDCSA-N 0.000 description 2
- VIJMRAIWYWRXSR-CIUDSAMLSA-N His-Ser-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CN=CN1 VIJMRAIWYWRXSR-CIUDSAMLSA-N 0.000 description 2
- DEMIXZCKUXVEBO-BWAGICSOSA-N His-Thr-Tyr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)NC(=O)[C@H](CC2=CN=CN2)N)O DEMIXZCKUXVEBO-BWAGICSOSA-N 0.000 description 2
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 description 2
- 101000797758 Homo sapiens C-C motif chemokine 7 Proteins 0.000 description 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 2
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 2
- SPQWWEZBHXHUJN-KBIXCLLPSA-N Ile-Glu-Ser Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O SPQWWEZBHXHUJN-KBIXCLLPSA-N 0.000 description 2
- SVBAHOMTJRFSIC-SXTJYALSSA-N Ile-Ile-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(=O)N)C(=O)O)N SVBAHOMTJRFSIC-SXTJYALSSA-N 0.000 description 2
- FTUZWJVSNZMLPI-RVMXOQNASA-N Ile-Met-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)N1CCC[C@@H]1C(=O)O)N FTUZWJVSNZMLPI-RVMXOQNASA-N 0.000 description 2
- RQJUKVXWAKJDBW-SVSWQMSJSA-N Ile-Ser-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N RQJUKVXWAKJDBW-SVSWQMSJSA-N 0.000 description 2
- MGUTVMBNOMJLKC-VKOGCVSHSA-N Ile-Trp-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](C(C)C)C(=O)O)N MGUTVMBNOMJLKC-VKOGCVSHSA-N 0.000 description 2
- KXUKTDGKLAOCQK-LSJOCFKGSA-N Ile-Val-Gly Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O KXUKTDGKLAOCQK-LSJOCFKGSA-N 0.000 description 2
- YHFPHRUWZMEOIX-CYDGBPFRSA-N Ile-Val-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)O)N YHFPHRUWZMEOIX-CYDGBPFRSA-N 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102100025390 Integrin beta-2 Human genes 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- RCFDOSNHHZGBOY-UHFFFAOYSA-N L-isoleucyl-L-alanine Natural products CCC(C)C(N)C(=O)NC(C)C(O)=O RCFDOSNHHZGBOY-UHFFFAOYSA-N 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- LZDNBBYBDGBADK-UHFFFAOYSA-N L-valyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)C(C)C)C(O)=O)=CNC2=C1 LZDNBBYBDGBADK-UHFFFAOYSA-N 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- BQSLGJHIAGOZCD-CIUDSAMLSA-N Leu-Ala-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O BQSLGJHIAGOZCD-CIUDSAMLSA-N 0.000 description 2
- STAVRDQLZOTNKJ-RHYQMDGZSA-N Leu-Arg-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O STAVRDQLZOTNKJ-RHYQMDGZSA-N 0.000 description 2
- TWQIYNGNYNJUFM-NHCYSSNCSA-N Leu-Asn-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O TWQIYNGNYNJUFM-NHCYSSNCSA-N 0.000 description 2
- FGNQZXKVAZIMCI-CIUDSAMLSA-N Leu-Asp-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CS)C(=O)O)N FGNQZXKVAZIMCI-CIUDSAMLSA-N 0.000 description 2
- KTFHTMHHKXUYPW-ZPFDUUQYSA-N Leu-Asp-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O KTFHTMHHKXUYPW-ZPFDUUQYSA-N 0.000 description 2
- VQPPIMUZCZCOIL-GUBZILKMSA-N Leu-Gln-Ala Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(O)=O VQPPIMUZCZCOIL-GUBZILKMSA-N 0.000 description 2
- KAFOIVJDVSZUMD-UHFFFAOYSA-N Leu-Gln-Gln Natural products CC(C)CC(N)C(=O)NC(CCC(N)=O)C(=O)NC(CCC(N)=O)C(O)=O KAFOIVJDVSZUMD-UHFFFAOYSA-N 0.000 description 2
- HVJVUYQWFYMGJS-GVXVVHGQSA-N Leu-Glu-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O HVJVUYQWFYMGJS-GVXVVHGQSA-N 0.000 description 2
- FIYMBBHGYNQFOP-IUCAKERBSA-N Leu-Gly-Gln Chemical compound CC(C)C[C@@H](C(=O)NCC(=O)N[C@@H](CCC(=O)N)C(=O)O)N FIYMBBHGYNQFOP-IUCAKERBSA-N 0.000 description 2
- HYIFFZAQXPUEAU-QWRGUYRKSA-N Leu-Gly-Leu Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC(C)C HYIFFZAQXPUEAU-QWRGUYRKSA-N 0.000 description 2
- POZULHZYLPGXMR-ONGXEEELSA-N Leu-Gly-Val Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O POZULHZYLPGXMR-ONGXEEELSA-N 0.000 description 2
- YWYQSLOTVIRCFE-SRVKXCTJSA-N Leu-His-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(O)=O)C(O)=O YWYQSLOTVIRCFE-SRVKXCTJSA-N 0.000 description 2
- BKTXKJMNTSMJDQ-AVGNSLFASA-N Leu-His-Gln Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N BKTXKJMNTSMJDQ-AVGNSLFASA-N 0.000 description 2
- CSFVADKICPDRRF-KKUMJFAQSA-N Leu-His-Leu Chemical compound CC(C)C[C@H]([NH3+])C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C([O-])=O)CC1=CN=CN1 CSFVADKICPDRRF-KKUMJFAQSA-N 0.000 description 2
- SGIIOQQGLUUMDQ-IHRRRGAJSA-N Leu-His-Val Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](C(C)C)C(=O)O)N SGIIOQQGLUUMDQ-IHRRRGAJSA-N 0.000 description 2
- HRTRLSRYZZKPCO-BJDJZHNGSA-N Leu-Ile-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O HRTRLSRYZZKPCO-BJDJZHNGSA-N 0.000 description 2
- NRFGTHFONZYFNY-MGHWNKPDSA-N Leu-Ile-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 NRFGTHFONZYFNY-MGHWNKPDSA-N 0.000 description 2
- YOKVEHGYYQEQOP-QWRGUYRKSA-N Leu-Leu-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O YOKVEHGYYQEQOP-QWRGUYRKSA-N 0.000 description 2
- XVZCXCTYGHPNEM-UHFFFAOYSA-N Leu-Leu-Pro Natural products CC(C)CC(N)C(=O)NC(CC(C)C)C(=O)N1CCCC1C(O)=O XVZCXCTYGHPNEM-UHFFFAOYSA-N 0.000 description 2
- ONPJGOIVICHWBW-BZSNNMDCSA-N Leu-Lys-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 ONPJGOIVICHWBW-BZSNNMDCSA-N 0.000 description 2
- LZHJZLHSRGWBBE-IHRRRGAJSA-N Leu-Lys-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O LZHJZLHSRGWBBE-IHRRRGAJSA-N 0.000 description 2
- BMVFXOQHDQZAQU-DCAQKATOSA-N Leu-Pro-Asp Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(=O)O)C(=O)O)N BMVFXOQHDQZAQU-DCAQKATOSA-N 0.000 description 2
- JDBQSGMJBMPNFT-AVGNSLFASA-N Leu-Pro-Val Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(O)=O JDBQSGMJBMPNFT-AVGNSLFASA-N 0.000 description 2
- KZZCOWMDDXDKSS-CIUDSAMLSA-N Leu-Ser-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O KZZCOWMDDXDKSS-CIUDSAMLSA-N 0.000 description 2
- RGUXWMDNCPMQFB-YUMQZZPRSA-N Leu-Ser-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O RGUXWMDNCPMQFB-YUMQZZPRSA-N 0.000 description 2
- MVHXGBZUJLWZOH-BJDJZHNGSA-N Leu-Ser-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O MVHXGBZUJLWZOH-BJDJZHNGSA-N 0.000 description 2
- SBANPBVRHYIMRR-UHFFFAOYSA-N Leu-Ser-Pro Natural products CC(C)CC(N)C(=O)NC(CO)C(=O)N1CCCC1C(O)=O SBANPBVRHYIMRR-UHFFFAOYSA-N 0.000 description 2
- ILDSIMPXNFWKLH-KATARQTJSA-N Leu-Thr-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O ILDSIMPXNFWKLH-KATARQTJSA-N 0.000 description 2
- AIMGJYMCTAABEN-GVXVVHGQSA-N Leu-Val-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O AIMGJYMCTAABEN-GVXVVHGQSA-N 0.000 description 2
- YQFZRHYZLARWDY-IHRRRGAJSA-N Leu-Val-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCCN YQFZRHYZLARWDY-IHRRRGAJSA-N 0.000 description 2
- VKVDRTGWLVZJOM-DCAQKATOSA-N Leu-Val-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O VKVDRTGWLVZJOM-DCAQKATOSA-N 0.000 description 2
- QESXLSQLQHHTIX-RHYQMDGZSA-N Leu-Val-Thr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O QESXLSQLQHHTIX-RHYQMDGZSA-N 0.000 description 2
- YRWCPXOFBKTCFY-NUTKFTJISA-N Lys-Ala-Trp Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CCCCN)N YRWCPXOFBKTCFY-NUTKFTJISA-N 0.000 description 2
- GJJQCBVRWDGLMQ-GUBZILKMSA-N Lys-Glu-Ala Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O GJJQCBVRWDGLMQ-GUBZILKMSA-N 0.000 description 2
- IMAKMJCBYCSMHM-AVGNSLFASA-N Lys-Glu-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN IMAKMJCBYCSMHM-AVGNSLFASA-N 0.000 description 2
- SEZADXQOJJTXPG-VFAJRCTISA-N Lys-Thr-Trp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CCCCN)N)O SEZADXQOJJTXPG-VFAJRCTISA-N 0.000 description 2
- OZVXDDFYCQOPFD-XQQFMLRXSA-N Lys-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCCN)N OZVXDDFYCQOPFD-XQQFMLRXSA-N 0.000 description 2
- 102000000440 Melanoma-associated antigen Human genes 0.000 description 2
- OSOLWRWQADPDIQ-DCAQKATOSA-N Met-Asp-Leu Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O OSOLWRWQADPDIQ-DCAQKATOSA-N 0.000 description 2
- MSSJHBAKDDIRMJ-SRVKXCTJSA-N Met-Lys-Gln Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(O)=O MSSJHBAKDDIRMJ-SRVKXCTJSA-N 0.000 description 2
- DBMLDOWSVHMQQN-XGEHTFHBSA-N Met-Ser-Thr Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O DBMLDOWSVHMQQN-XGEHTFHBSA-N 0.000 description 2
- XZFYRXDAULDNFX-UHFFFAOYSA-N N-L-cysteinyl-L-phenylalanine Natural products SCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XZFYRXDAULDNFX-UHFFFAOYSA-N 0.000 description 2
- 108010066427 N-valyltryptophan Proteins 0.000 description 2
- 108700019961 Neoplasm Genes Proteins 0.000 description 2
- 102000048850 Neoplasm Genes Human genes 0.000 description 2
- 101100342977 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) leu-1 gene Proteins 0.000 description 2
- 102100034640 PWWP domain-containing DNA repair factor 3A Human genes 0.000 description 2
- 108050007154 PWWP domain-containing DNA repair factor 3A Proteins 0.000 description 2
- 108010067372 Pancreatic elastase Proteins 0.000 description 2
- WFDAEEUZPZSMOG-SRVKXCTJSA-N Phe-Cys-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(O)=O WFDAEEUZPZSMOG-SRVKXCTJSA-N 0.000 description 2
- TXJJXEXCZBHDNA-ACRUOGEOSA-N Phe-Phe-His Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC3=CN=CN3)C(=O)O)N TXJJXEXCZBHDNA-ACRUOGEOSA-N 0.000 description 2
- AAERWTUHZKLDLC-IHRRRGAJSA-N Phe-Pro-Asp Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(O)=O AAERWTUHZKLDLC-IHRRRGAJSA-N 0.000 description 2
- MMJJFXWMCMJMQA-STQMWFEESA-N Phe-Pro-Gly Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)C1=CC=CC=C1 MMJJFXWMCMJMQA-STQMWFEESA-N 0.000 description 2
- JXQVYPWVGUOIDV-MXAVVETBSA-N Phe-Ser-Ile Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JXQVYPWVGUOIDV-MXAVVETBSA-N 0.000 description 2
- MCIXMYKSPQUMJG-SRVKXCTJSA-N Phe-Ser-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O MCIXMYKSPQUMJG-SRVKXCTJSA-N 0.000 description 2
- 102000004211 Platelet factor 4 Human genes 0.000 description 2
- 108090000778 Platelet factor 4 Proteins 0.000 description 2
- BNBBNGZZKQUWCD-IUCAKERBSA-N Pro-Arg-Gly Chemical compound NC(N)=NCCC[C@@H](C(=O)NCC(O)=O)NC(=O)[C@@H]1CCCN1 BNBBNGZZKQUWCD-IUCAKERBSA-N 0.000 description 2
- GRIRJQGZZJVANI-CYDGBPFRSA-N Pro-Arg-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H]1CCCN1 GRIRJQGZZJVANI-CYDGBPFRSA-N 0.000 description 2
- VCYJKOLZYPYGJV-AVGNSLFASA-N Pro-Arg-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O VCYJKOLZYPYGJV-AVGNSLFASA-N 0.000 description 2
- UTAUEDINXUMHLG-FXQIFTODSA-N Pro-Asp-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H]1CCCN1 UTAUEDINXUMHLG-FXQIFTODSA-N 0.000 description 2
- SGCZFWSQERRKBD-BQBZGAKWSA-N Pro-Asp-Gly Chemical compound OC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]1CCCN1 SGCZFWSQERRKBD-BQBZGAKWSA-N 0.000 description 2
- HJSCRFZVGXAGNG-SRVKXCTJSA-N Pro-Gln-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1 HJSCRFZVGXAGNG-SRVKXCTJSA-N 0.000 description 2
- NMELOOXSGDRBRU-YUMQZZPRSA-N Pro-Glu-Gly Chemical compound OC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H]1CCCN1 NMELOOXSGDRBRU-YUMQZZPRSA-N 0.000 description 2
- JMVQDLDPDBXAAX-YUMQZZPRSA-N Pro-Gly-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H]1CCCN1 JMVQDLDPDBXAAX-YUMQZZPRSA-N 0.000 description 2
- AQSMZTIEJMZQEC-DCAQKATOSA-N Pro-His-Ser Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CO)C(=O)O AQSMZTIEJMZQEC-DCAQKATOSA-N 0.000 description 2
- FMLRRBDLBJLJIK-DCAQKATOSA-N Pro-Leu-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1 FMLRRBDLBJLJIK-DCAQKATOSA-N 0.000 description 2
- CLJLVCYFABNTHP-DCAQKATOSA-N Pro-Leu-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O CLJLVCYFABNTHP-DCAQKATOSA-N 0.000 description 2
- VTFXTWDFPTWNJY-RHYQMDGZSA-N Pro-Leu-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O VTFXTWDFPTWNJY-RHYQMDGZSA-N 0.000 description 2
- DWGFLKQSGRUQTI-IHRRRGAJSA-N Pro-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1 DWGFLKQSGRUQTI-IHRRRGAJSA-N 0.000 description 2
- FRVUYKWGPCQRBL-GUBZILKMSA-N Pro-Met-Cys Chemical compound CSCC[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@@H]1CCCN1 FRVUYKWGPCQRBL-GUBZILKMSA-N 0.000 description 2
- FYKUEXMZYFIZKA-DCAQKATOSA-N Pro-Pro-Gln Chemical compound [H]N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(O)=O FYKUEXMZYFIZKA-DCAQKATOSA-N 0.000 description 2
- ZMLRZBWCXPQADC-TUAOUCFPSA-N Pro-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@@H]2CCCN2 ZMLRZBWCXPQADC-TUAOUCFPSA-N 0.000 description 2
- FIODMZKLZFLYQP-GUBZILKMSA-N Pro-Val-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O FIODMZKLZFLYQP-GUBZILKMSA-N 0.000 description 2
- YDTUEBLEAVANFH-RCWTZXSCSA-N Pro-Val-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]1CCCN1 YDTUEBLEAVANFH-RCWTZXSCSA-N 0.000 description 2
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 2
- 102100038358 Prostate-specific antigen Human genes 0.000 description 2
- 101150071286 SPI-2 gene Proteins 0.000 description 2
- IDQFQFVEWMWRQQ-DLOVCJGASA-N Ser-Ala-Phe Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O IDQFQFVEWMWRQQ-DLOVCJGASA-N 0.000 description 2
- QWZIOCFPXMAXET-CIUDSAMLSA-N Ser-Arg-Gln Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(O)=O QWZIOCFPXMAXET-CIUDSAMLSA-N 0.000 description 2
- VQBLHWSPVYYZTB-DCAQKATOSA-N Ser-Arg-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CO)N VQBLHWSPVYYZTB-DCAQKATOSA-N 0.000 description 2
- UBRXAVQWXOWRSJ-ZLUOBGJFSA-N Ser-Asn-Asp Chemical compound C([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CO)N)C(=O)N UBRXAVQWXOWRSJ-ZLUOBGJFSA-N 0.000 description 2
- VMVNCJDKFOQOHM-GUBZILKMSA-N Ser-Gln-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)N VMVNCJDKFOQOHM-GUBZILKMSA-N 0.000 description 2
- HVKMTOIAYDOJPL-NRPADANISA-N Ser-Gln-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O HVKMTOIAYDOJPL-NRPADANISA-N 0.000 description 2
- SNVIOQXAHVORQM-WDSKDSINSA-N Ser-Gly-Gln Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O SNVIOQXAHVORQM-WDSKDSINSA-N 0.000 description 2
- ZOPISOXXPQNOCO-SVSWQMSJSA-N Ser-Ile-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](CO)N ZOPISOXXPQNOCO-SVSWQMSJSA-N 0.000 description 2
- FUMGHWDRRFCKEP-CIUDSAMLSA-N Ser-Leu-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O FUMGHWDRRFCKEP-CIUDSAMLSA-N 0.000 description 2
- QMCDMHWAKMUGJE-IHRRRGAJSA-N Ser-Phe-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(O)=O QMCDMHWAKMUGJE-IHRRRGAJSA-N 0.000 description 2
- FKYWFUYPVKLJLP-DCAQKATOSA-N Ser-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CO FKYWFUYPVKLJLP-DCAQKATOSA-N 0.000 description 2
- NVNPWELENFJOHH-CIUDSAMLSA-N Ser-Ser-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)N NVNPWELENFJOHH-CIUDSAMLSA-N 0.000 description 2
- SNXUIBACCONSOH-BWBBJGPYSA-N Ser-Thr-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CO)C(O)=O SNXUIBACCONSOH-BWBBJGPYSA-N 0.000 description 2
- HAYADTTXNZFUDM-IHRRRGAJSA-N Ser-Tyr-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(O)=O HAYADTTXNZFUDM-IHRRRGAJSA-N 0.000 description 2
- JGUWRQWULDWNCM-FXQIFTODSA-N Ser-Val-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O JGUWRQWULDWNCM-FXQIFTODSA-N 0.000 description 2
- SIEBDTCABMZCLF-XGEHTFHBSA-N Ser-Val-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SIEBDTCABMZCLF-XGEHTFHBSA-N 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 241000607768 Shigella Species 0.000 description 2
- FQPQPTHMHZKGFM-XQXXSGGOSA-N Thr-Ala-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O FQPQPTHMHZKGFM-XQXXSGGOSA-N 0.000 description 2
- CAJFZCICSVBOJK-SHGPDSBTSA-N Thr-Ala-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O CAJFZCICSVBOJK-SHGPDSBTSA-N 0.000 description 2
- XYEXCEPTALHNEV-RCWTZXSCSA-N Thr-Arg-Arg Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O XYEXCEPTALHNEV-RCWTZXSCSA-N 0.000 description 2
- RKDFEMGVMMYYNG-WDCWCFNPSA-N Thr-Gln-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O RKDFEMGVMMYYNG-WDCWCFNPSA-N 0.000 description 2
- UBDDORVPVLEECX-FJXKBIBVSA-N Thr-Gly-Met Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(O)=O UBDDORVPVLEECX-FJXKBIBVSA-N 0.000 description 2
- BVOVIGCHYNFJBZ-JXUBOQSCSA-N Thr-Leu-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O BVOVIGCHYNFJBZ-JXUBOQSCSA-N 0.000 description 2
- FLPZMPOZGYPBEN-PPCPHDFISA-N Thr-Leu-Ile Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O FLPZMPOZGYPBEN-PPCPHDFISA-N 0.000 description 2
- SCSVNSNWUTYSFO-WDCWCFNPSA-N Thr-Lys-Glu Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O SCSVNSNWUTYSFO-WDCWCFNPSA-N 0.000 description 2
- MCDVZTRGHNXTGK-HJGDQZAQSA-N Thr-Met-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(O)=O MCDVZTRGHNXTGK-HJGDQZAQSA-N 0.000 description 2
- JMBRNXUOLJFURW-BEAPCOKYSA-N Thr-Phe-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N2CCC[C@@H]2C(=O)O)N)O JMBRNXUOLJFURW-BEAPCOKYSA-N 0.000 description 2
- WTMPKZWHRCMMMT-KZVJFYERSA-N Thr-Pro-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O WTMPKZWHRCMMMT-KZVJFYERSA-N 0.000 description 2
- AAZOYLQUEQRUMZ-GSSVUCPTSA-N Thr-Thr-Asn Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC(N)=O AAZOYLQUEQRUMZ-GSSVUCPTSA-N 0.000 description 2
- VBMOVTMNHWPZJR-SUSMZKCASA-N Thr-Thr-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O VBMOVTMNHWPZJR-SUSMZKCASA-N 0.000 description 2
- OMRWDMWXRWTQIU-YJRXYDGGSA-N Thr-Tyr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CS)C(=O)O)N)O OMRWDMWXRWTQIU-YJRXYDGGSA-N 0.000 description 2
- MNYNCKZAEIAONY-XGEHTFHBSA-N Thr-Val-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O MNYNCKZAEIAONY-XGEHTFHBSA-N 0.000 description 2
- 102100031372 Thymidine phosphorylase Human genes 0.000 description 2
- 108700023160 Thymidine phosphorylases Proteins 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- SCQBNMKLZVCXNX-ZFWWWQNUSA-N Trp-Arg-Gly Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)O)N SCQBNMKLZVCXNX-ZFWWWQNUSA-N 0.000 description 2
- ZCPCXVJOMUPIDD-IHPCNDPISA-N Trp-Asp-Phe Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)N)C(O)=O)C1=CC=CC=C1 ZCPCXVJOMUPIDD-IHPCNDPISA-N 0.000 description 2
- JVTHMUDOKPQBOT-NSHDSACASA-N Trp-Gly-Gly Chemical compound C1=CC=C2C(C[C@H]([NH3+])C(=O)NCC(=O)NCC([O-])=O)=CNC2=C1 JVTHMUDOKPQBOT-NSHDSACASA-N 0.000 description 2
- AIISTODACBDQLW-WDSOQIARSA-N Trp-Leu-Arg Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)=CNC2=C1 AIISTODACBDQLW-WDSOQIARSA-N 0.000 description 2
- DTPWXZXGFAHEKL-NWLDYVSISA-N Trp-Thr-Glu Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O DTPWXZXGFAHEKL-NWLDYVSISA-N 0.000 description 2
- LNGFWVPNKLWATF-ZVZYQTTQSA-N Trp-Val-Glu Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O LNGFWVPNKLWATF-ZVZYQTTQSA-N 0.000 description 2
- DYEGCOJHFNJBKB-UFYCRDLUSA-N Tyr-Arg-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 DYEGCOJHFNJBKB-UFYCRDLUSA-N 0.000 description 2
- ADECJAKCRKPSOR-ULQDDVLXSA-N Tyr-His-Arg Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N)O ADECJAKCRKPSOR-ULQDDVLXSA-N 0.000 description 2
- GULIUBBXCYPDJU-CQDKDKBSSA-N Tyr-Leu-Ala Chemical compound [O-]C(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]([NH3+])CC1=CC=C(O)C=C1 GULIUBBXCYPDJU-CQDKDKBSSA-N 0.000 description 2
- ARMNWLJYHCOSHE-KKUMJFAQSA-N Tyr-Pro-Gln Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(O)=O ARMNWLJYHCOSHE-KKUMJFAQSA-N 0.000 description 2
- QKXAEWMHAAVVGS-KKUMJFAQSA-N Tyr-Pro-Glu Chemical compound N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O QKXAEWMHAAVVGS-KKUMJFAQSA-N 0.000 description 2
- CCEVJBJLPRNAFH-BVSLBCMMSA-N Tyr-Val-Trp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC3=CC=C(C=C3)O)N CCEVJBJLPRNAFH-BVSLBCMMSA-N 0.000 description 2
- XEYUMGGWQCIWAR-XVKPBYJWSA-N Val-Gln-Gly Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)NCC(=O)O)N XEYUMGGWQCIWAR-XVKPBYJWSA-N 0.000 description 2
- KZKMBGXCNLPYKD-YEPSODPASA-N Val-Gly-Thr Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O KZKMBGXCNLPYKD-YEPSODPASA-N 0.000 description 2
- UKEVLVBHRKWECS-LSJOCFKGSA-N Val-Ile-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](C(C)C)N UKEVLVBHRKWECS-LSJOCFKGSA-N 0.000 description 2
- FTKXYXACXYOHND-XUXIUFHCSA-N Val-Ile-Leu Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O FTKXYXACXYOHND-XUXIUFHCSA-N 0.000 description 2
- APQIVBCUIUDSMB-OSUNSFLBSA-N Val-Ile-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](C(C)C)N APQIVBCUIUDSMB-OSUNSFLBSA-N 0.000 description 2
- AEMPCGRFEZTWIF-IHRRRGAJSA-N Val-Leu-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O AEMPCGRFEZTWIF-IHRRRGAJSA-N 0.000 description 2
- BZOSBRIDWSSTFN-AVGNSLFASA-N Val-Leu-Met Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H](C(C)C)N BZOSBRIDWSSTFN-AVGNSLFASA-N 0.000 description 2
- BTWMICVCQLKKNR-DCAQKATOSA-N Val-Leu-Ser Chemical compound CC(C)[C@H]([NH3+])C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C([O-])=O BTWMICVCQLKKNR-DCAQKATOSA-N 0.000 description 2
- YTNGABPUXFEOGU-SRVKXCTJSA-N Val-Pro-Arg Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O YTNGABPUXFEOGU-SRVKXCTJSA-N 0.000 description 2
- VIKZGAUAKQZDOF-NRPADANISA-N Val-Ser-Glu Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O VIKZGAUAKQZDOF-NRPADANISA-N 0.000 description 2
- UGFMVXRXULGLNO-XPUUQOCRSA-N Val-Ser-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O UGFMVXRXULGLNO-XPUUQOCRSA-N 0.000 description 2
- LLJLBRRXKZTTRD-GUBZILKMSA-N Val-Val-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(=O)O)N LLJLBRRXKZTTRD-GUBZILKMSA-N 0.000 description 2
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 2
- 241000607626 Vibrio cholerae Species 0.000 description 2
- 102100026497 Zinc finger protein 654 Human genes 0.000 description 2
- 108010081404 acein-2 Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 238000001261 affinity purification Methods 0.000 description 2
- 108010086434 alanyl-seryl-glycine Proteins 0.000 description 2
- 108010044940 alanylglutamine Proteins 0.000 description 2
- 108010070944 alanylhistidine Proteins 0.000 description 2
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 2
- 230000001772 anti-angiogenic effect Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 229940034982 antineoplastic agent Drugs 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 108010091092 arginyl-glycyl-proline Proteins 0.000 description 2
- 108010077245 asparaginyl-proline Proteins 0.000 description 2
- 108010038633 aspartylglutamate Proteins 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 229960001561 bleomycin Drugs 0.000 description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000009566 cancer vaccine Methods 0.000 description 2
- 229940022399 cancer vaccine Drugs 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000001246 colloidal dispersion Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 108010069495 cysteinyltyrosine Proteins 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- XBGGUPMXALFZOT-UHFFFAOYSA-N glycyl-L-tyrosine hemihydrate Natural products NCC(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 XBGGUPMXALFZOT-UHFFFAOYSA-N 0.000 description 2
- 108010066198 glycyl-leucyl-phenylalanine Proteins 0.000 description 2
- 108010074027 glycyl-seryl-phenylalanine Proteins 0.000 description 2
- 108010010147 glycylglutamine Proteins 0.000 description 2
- 108010077515 glycylproline Proteins 0.000 description 2
- 108010087823 glycyltyrosine Proteins 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 108010092114 histidylphenylalanine Proteins 0.000 description 2
- 108010085325 histidylproline Proteins 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 210000003000 inclusion body Anatomy 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 108010044311 leucyl-glycyl-glycine Proteins 0.000 description 2
- 108010047926 leucyl-lysyl-tyrosine Proteins 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 108010009298 lysylglutamic acid Proteins 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 210000002752 melanocyte Anatomy 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 238000002493 microarray Methods 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 2
- UPBAOYRENQEPJO-UHFFFAOYSA-N n-[5-[[5-[(3-amino-3-iminopropyl)carbamoyl]-1-methylpyrrol-3-yl]carbamoyl]-1-methylpyrrol-3-yl]-4-formamido-1-methylpyrrole-2-carboxamide Chemical compound CN1C=C(NC=O)C=C1C(=O)NC1=CN(C)C(C(=O)NC2=CN(C)C(C(=O)NCCC(N)=N)=C2)=C1 UPBAOYRENQEPJO-UHFFFAOYSA-N 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 108010073025 phenylalanylphenylalanine Proteins 0.000 description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 229950003608 prinomastat Drugs 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 108010014614 prolyl-glycyl-proline Proteins 0.000 description 2
- 108010077112 prolyl-proline Proteins 0.000 description 2
- 108010093296 prolyl-prolyl-alanine Proteins 0.000 description 2
- 108010070643 prolylglutamic acid Proteins 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 108010026333 seryl-proline Proteins 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 108010031491 threonyl-lysyl-glutamic acid Proteins 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 102000027257 transmembrane receptors Human genes 0.000 description 2
- 108091008578 transmembrane receptors Proteins 0.000 description 2
- 108010080629 tryptophan-leucine Proteins 0.000 description 2
- 108010009962 valyltyrosine Proteins 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- 229960004528 vincristine Drugs 0.000 description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- GJLXVWOMRRWCIB-MERZOTPQSA-N (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanamide Chemical compound C([C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=C(O)C=C1 GJLXVWOMRRWCIB-MERZOTPQSA-N 0.000 description 1
- JSPNNZKWADNWHI-PNANGNLXSA-N (2r)-2-hydroxy-n-[(2s,3r,4e,8e)-3-hydroxy-9-methyl-1-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadeca-4,8-dien-2-yl]heptadecanamide Chemical compound CCCCCCCCCCCCCCC[C@@H](O)C(=O)N[C@H]([C@H](O)\C=C\CC\C=C(/C)CCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JSPNNZKWADNWHI-PNANGNLXSA-N 0.000 description 1
- PKOHVHWNGUHYRE-ZFWWWQNUSA-N (2s)-1-[2-[[(2s)-2-amino-3-(1h-indol-3-yl)propanoyl]amino]acetyl]pyrrolidine-2-carboxylic acid Chemical compound O=C([C@H](CC=1C2=CC=CC=C2NC=1)N)NCC(=O)N1CCC[C@H]1C(O)=O PKOHVHWNGUHYRE-ZFWWWQNUSA-N 0.000 description 1
- BVRKOQJETMBIDK-VIFPVBQESA-N (2s)-2-amino-n-methyl-3-phenylpropanamide Chemical compound CNC(=O)[C@@H](N)CC1=CC=CC=C1 BVRKOQJETMBIDK-VIFPVBQESA-N 0.000 description 1
- GTXSRFUZSLTDFX-HRCADAONSA-N (2s)-n-[(2s)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-4-methyl-2-[[(2s)-2-sulfanyl-4-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)butanoyl]amino]pentanamide Chemical compound CNC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](S)CCN1C(=O)N(C)C(C)(C)C1=O GTXSRFUZSLTDFX-HRCADAONSA-N 0.000 description 1
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 1
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 1
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- SATCOUWSAZBIJO-UHFFFAOYSA-N 1-methyladenine Natural products N=C1N(C)C=NC2=C1NC=N2 SATCOUWSAZBIJO-UHFFFAOYSA-N 0.000 description 1
- WJNGQIYEQLPJMN-IOSLPCCCSA-N 1-methylinosine Chemical compound C1=NC=2C(=O)N(C)C=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O WJNGQIYEQLPJMN-IOSLPCCCSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- HLYBTPMYFWWNJN-UHFFFAOYSA-N 2-(2,4-dioxo-1h-pyrimidin-5-yl)-2-hydroxyacetic acid Chemical compound OC(=O)C(O)C1=CNC(=O)NC1=O HLYBTPMYFWWNJN-UHFFFAOYSA-N 0.000 description 1
- TZZNWMJZDWYJAZ-UHFFFAOYSA-N 2-(4-oxo-2-phenylchromen-8-yl)acetic acid Chemical compound OC(=O)CC1=CC=CC(C(C=2)=O)=C1OC=2C1=CC=CC=C1 TZZNWMJZDWYJAZ-UHFFFAOYSA-N 0.000 description 1
- YSAJFXWTVFGPAX-UHFFFAOYSA-N 2-[(2,4-dioxo-1h-pyrimidin-5-yl)oxy]acetic acid Chemical compound OC(=O)COC1=CNC(=O)NC1=O YSAJFXWTVFGPAX-UHFFFAOYSA-N 0.000 description 1
- SVBOROZXXYRWJL-UHFFFAOYSA-N 2-[(4-oxo-2-sulfanylidene-1h-pyrimidin-5-yl)methylamino]acetic acid Chemical compound OC(=O)CNCC1=CNC(=S)NC1=O SVBOROZXXYRWJL-UHFFFAOYSA-N 0.000 description 1
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 description 1
- XMSMHKMPBNTBOD-UHFFFAOYSA-N 2-dimethylamino-6-hydroxypurine Chemical compound N1C(N(C)C)=NC(=O)C2=C1N=CN2 XMSMHKMPBNTBOD-UHFFFAOYSA-N 0.000 description 1
- CQOQDQWUFQDJMK-SSTWWWIQSA-N 2-methoxy-17beta-estradiol Chemical compound C([C@@H]12)C[C@]3(C)[C@@H](O)CC[C@H]3[C@@H]1CCC1=C2C=C(OC)C(O)=C1 CQOQDQWUFQDJMK-SSTWWWIQSA-N 0.000 description 1
- SMADWRYCYBUIKH-UHFFFAOYSA-N 2-methyl-7h-purin-6-amine Chemical compound CC1=NC(N)=C2NC=NC2=N1 SMADWRYCYBUIKH-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
- KOLPWZCZXAMXKS-UHFFFAOYSA-N 3-methylcytosine Chemical compound CN1C(N)=CC=NC1=O KOLPWZCZXAMXKS-UHFFFAOYSA-N 0.000 description 1
- GJAKJCICANKRFD-UHFFFAOYSA-N 4-acetyl-4-amino-1,3-dihydropyrimidin-2-one Chemical compound CC(=O)C1(N)NC(=O)NC=C1 GJAKJCICANKRFD-UHFFFAOYSA-N 0.000 description 1
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 description 1
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 1
- UACOJOVKHNAJPX-UHFFFAOYSA-N 5-(methoxyamino)-6-methyl-2-sulfanylidene-1H-pyrimidin-4-one Chemical compound CONC=1C(NC(NC=1C)=S)=O UACOJOVKHNAJPX-UHFFFAOYSA-N 0.000 description 1
- MQJSSLBGAQJNER-UHFFFAOYSA-N 5-(methylaminomethyl)-1h-pyrimidine-2,4-dione Chemical compound CNCC1=CNC(=O)NC1=O MQJSSLBGAQJNER-UHFFFAOYSA-N 0.000 description 1
- LQLQRFGHAALLLE-UHFFFAOYSA-N 5-bromouracil Chemical compound BrC1=CNC(=O)NC1=O LQLQRFGHAALLLE-UHFFFAOYSA-N 0.000 description 1
- KELXHQACBIUYSE-UHFFFAOYSA-N 5-methoxy-1h-pyrimidine-2,4-dione Chemical compound COC1=CNC(=O)NC1=O KELXHQACBIUYSE-UHFFFAOYSA-N 0.000 description 1
- ZLAQATDNGLKIEV-UHFFFAOYSA-N 5-methyl-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound CC1=CNC(=S)NC1=O ZLAQATDNGLKIEV-UHFFFAOYSA-N 0.000 description 1
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 1
- HSPHKCOAUOJLIO-UHFFFAOYSA-N 6-(aziridin-1-ylamino)-1h-pyrimidin-2-one Chemical compound N1C(=O)N=CC=C1NN1CC1 HSPHKCOAUOJLIO-UHFFFAOYSA-N 0.000 description 1
- GTSVFOOLVUMMCX-UHFFFAOYSA-N 6-(methylaminomethyl)-2,4-dioxo-1H-pyrimidine-5-carboxylic acid Chemical compound C(=O)(O)C=1C(NC(NC=1CNC)=O)=O GTSVFOOLVUMMCX-UHFFFAOYSA-N 0.000 description 1
- CKOMXBHMKXXTNW-UHFFFAOYSA-N 6-methyladenine Chemical compound CNC1=NC=NC2=C1N=CN2 CKOMXBHMKXXTNW-UHFFFAOYSA-N 0.000 description 1
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 1
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- SWJYOKZMYFJUOY-KQYNXXCUSA-N 9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-(methylamino)-7h-purin-8-one Chemical compound OC1=NC=2C(NC)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O SWJYOKZMYFJUOY-KQYNXXCUSA-N 0.000 description 1
- MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 description 1
- YLTKNGYYPIWKHZ-ACZMJKKPSA-N Ala-Ala-Glu Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCC(O)=O YLTKNGYYPIWKHZ-ACZMJKKPSA-N 0.000 description 1
- YYSWCHMLFJLLBJ-ZLUOBGJFSA-N Ala-Ala-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YYSWCHMLFJLLBJ-ZLUOBGJFSA-N 0.000 description 1
- SVBXIUDNTRTKHE-CIUDSAMLSA-N Ala-Arg-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O SVBXIUDNTRTKHE-CIUDSAMLSA-N 0.000 description 1
- ZIBWKCRKNFYTPT-ZKWXMUAHSA-N Ala-Asn-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O ZIBWKCRKNFYTPT-ZKWXMUAHSA-N 0.000 description 1
- BTYTYHBSJKQBQA-GCJQMDKQSA-N Ala-Asp-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C)N)O BTYTYHBSJKQBQA-GCJQMDKQSA-N 0.000 description 1
- MIPWEZAIMPYQST-FXQIFTODSA-N Ala-Cys-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(O)=O MIPWEZAIMPYQST-FXQIFTODSA-N 0.000 description 1
- BGNLUHXLSAQYRQ-FXQIFTODSA-N Ala-Glu-Gln Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O BGNLUHXLSAQYRQ-FXQIFTODSA-N 0.000 description 1
- WGDNWOMKBUXFHR-BQBZGAKWSA-N Ala-Gly-Arg Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N WGDNWOMKBUXFHR-BQBZGAKWSA-N 0.000 description 1
- PCIFXPRIFWKWLK-YUMQZZPRSA-N Ala-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](C)N PCIFXPRIFWKWLK-YUMQZZPRSA-N 0.000 description 1
- CBCCCLMNOBLBSC-XVYDVKMFSA-N Ala-His-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(O)=O CBCCCLMNOBLBSC-XVYDVKMFSA-N 0.000 description 1
- HQJKCXHQNUCKMY-GHCJXIJMSA-N Ala-Ile-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](C)N HQJKCXHQNUCKMY-GHCJXIJMSA-N 0.000 description 1
- CCDFBRZVTDDJNM-GUBZILKMSA-N Ala-Leu-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O CCDFBRZVTDDJNM-GUBZILKMSA-N 0.000 description 1
- OPZJWMJPCNNZNT-DCAQKATOSA-N Ala-Leu-Met Chemical compound C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)O)N OPZJWMJPCNNZNT-DCAQKATOSA-N 0.000 description 1
- MEFILNJXAVSUTO-JXUBOQSCSA-N Ala-Leu-Thr Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MEFILNJXAVSUTO-JXUBOQSCSA-N 0.000 description 1
- LDLSENBXQNDTPB-DCAQKATOSA-N Ala-Lys-Arg Chemical compound NCCCC[C@H](NC(=O)[C@@H](N)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N LDLSENBXQNDTPB-DCAQKATOSA-N 0.000 description 1
- VCSABYLVNWQYQE-SRVKXCTJSA-N Ala-Lys-Lys Chemical compound NCCCC[C@H](NC(=O)[C@@H](N)C)C(=O)N[C@@H](CCCCN)C(O)=O VCSABYLVNWQYQE-SRVKXCTJSA-N 0.000 description 1
- VCSABYLVNWQYQE-UHFFFAOYSA-N Ala-Lys-Lys Natural products NCCCCC(NC(=O)C(N)C)C(=O)NC(CCCCN)C(O)=O VCSABYLVNWQYQE-UHFFFAOYSA-N 0.000 description 1
- OINVDEKBKBCPLX-JXUBOQSCSA-N Ala-Lys-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OINVDEKBKBCPLX-JXUBOQSCSA-N 0.000 description 1
- MDNAVFBZPROEHO-UHFFFAOYSA-N Ala-Lys-Val Natural products CC(C)C(C(O)=O)NC(=O)C(NC(=O)C(C)N)CCCCN MDNAVFBZPROEHO-UHFFFAOYSA-N 0.000 description 1
- SBYABBIDCYVZFF-BJDJZHNGSA-N Ala-Met-Gln-Gln Chemical compound CSCC[C@H](NC(=O)[C@H](C)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O SBYABBIDCYVZFF-BJDJZHNGSA-N 0.000 description 1
- DEWWPUNXRNGMQN-LPEHRKFASA-N Ala-Met-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N1CCC[C@@H]1C(=O)O)N DEWWPUNXRNGMQN-LPEHRKFASA-N 0.000 description 1
- WEZNQZHACPSMEF-QEJZJMRPSA-N Ala-Phe-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CC=CC=C1 WEZNQZHACPSMEF-QEJZJMRPSA-N 0.000 description 1
- IHMCQESUJVZTKW-UBHSHLNASA-N Ala-Phe-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](C)N)CC1=CC=CC=C1 IHMCQESUJVZTKW-UBHSHLNASA-N 0.000 description 1
- MAZZQZWCCYJQGZ-GUBZILKMSA-N Ala-Pro-Arg Chemical compound [H]N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O MAZZQZWCCYJQGZ-GUBZILKMSA-N 0.000 description 1
- IORKCNUBHNIMKY-CIUDSAMLSA-N Ala-Pro-Glu Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O IORKCNUBHNIMKY-CIUDSAMLSA-N 0.000 description 1
- WQLDNOCHHRISMS-NAKRPEOUSA-N Ala-Pro-Ile Chemical compound [H]N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WQLDNOCHHRISMS-NAKRPEOUSA-N 0.000 description 1
- ADSGHMXEAZJJNF-DCAQKATOSA-N Ala-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)N ADSGHMXEAZJJNF-DCAQKATOSA-N 0.000 description 1
- CQJHFKKGZXKZBC-BPNCWPANSA-N Ala-Pro-Tyr Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 CQJHFKKGZXKZBC-BPNCWPANSA-N 0.000 description 1
- 108010011170 Ala-Trp-Arg-His-Pro-Gln-Phe-Gly-Gly Proteins 0.000 description 1
- RIPMDCIXRYWXSH-KNXALSJPSA-N Ala-Trp-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N3CCC[C@@H]3C(=O)O)N RIPMDCIXRYWXSH-KNXALSJPSA-N 0.000 description 1
- BGGAIXWIZCIFSG-XDTLVQLUSA-N Ala-Tyr-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O BGGAIXWIZCIFSG-XDTLVQLUSA-N 0.000 description 1
- LYILPUNCKACNGF-NAKRPEOUSA-N Ala-Val-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)N LYILPUNCKACNGF-NAKRPEOUSA-N 0.000 description 1
- REWSWYIDQIELBE-FXQIFTODSA-N Ala-Val-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O REWSWYIDQIELBE-FXQIFTODSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102000004400 Aminopeptidases Human genes 0.000 description 1
- 108090000915 Aminopeptidases Proteins 0.000 description 1
- 102100034608 Angiopoietin-2 Human genes 0.000 description 1
- 108010048036 Angiopoietin-2 Proteins 0.000 description 1
- 102400000068 Angiostatin Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- 108090000644 Angiozyme Proteins 0.000 description 1
- 102100023003 Ankyrin repeat domain-containing protein 30A Human genes 0.000 description 1
- 108700031308 Antennapedia Homeodomain Proteins 0.000 description 1
- GXCSUJQOECMKPV-CIUDSAMLSA-N Arg-Ala-Gln Chemical compound C[C@H](NC(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(O)=O GXCSUJQOECMKPV-CIUDSAMLSA-N 0.000 description 1
- VBFJESQBIWCWRL-DCAQKATOSA-N Arg-Ala-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCNC(N)=N VBFJESQBIWCWRL-DCAQKATOSA-N 0.000 description 1
- GIVATXIGCXFQQA-FXQIFTODSA-N Arg-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N GIVATXIGCXFQQA-FXQIFTODSA-N 0.000 description 1
- XPSGESXVBSQZPL-SRVKXCTJSA-N Arg-Arg-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O XPSGESXVBSQZPL-SRVKXCTJSA-N 0.000 description 1
- VWVPYNGMOCSSGK-GUBZILKMSA-N Arg-Arg-Asn Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(O)=O VWVPYNGMOCSSGK-GUBZILKMSA-N 0.000 description 1
- UISQLSIBJKEJSS-GUBZILKMSA-N Arg-Arg-Ser Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CO)C(O)=O UISQLSIBJKEJSS-GUBZILKMSA-N 0.000 description 1
- RVDVDRUZWZIBJQ-CIUDSAMLSA-N Arg-Asn-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O RVDVDRUZWZIBJQ-CIUDSAMLSA-N 0.000 description 1
- IIABBYGHLYWVOS-FXQIFTODSA-N Arg-Asn-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O IIABBYGHLYWVOS-FXQIFTODSA-N 0.000 description 1
- RCAUJZASOAFTAJ-FXQIFTODSA-N Arg-Asp-Cys Chemical compound C(C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CS)C(=O)O)N)CN=C(N)N RCAUJZASOAFTAJ-FXQIFTODSA-N 0.000 description 1
- YFBGNGASPGRWEM-DCAQKATOSA-N Arg-Asp-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCN=C(N)N)N YFBGNGASPGRWEM-DCAQKATOSA-N 0.000 description 1
- OTCJMMRQBVDQRK-DCAQKATOSA-N Arg-Asp-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O OTCJMMRQBVDQRK-DCAQKATOSA-N 0.000 description 1
- YSUVMPICYVWRBX-VEVYYDQMSA-N Arg-Asp-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O YSUVMPICYVWRBX-VEVYYDQMSA-N 0.000 description 1
- YUGFLWBWAJFGKY-BQBZGAKWSA-N Arg-Cys-Gly Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CS)C(=O)NCC(O)=O YUGFLWBWAJFGKY-BQBZGAKWSA-N 0.000 description 1
- BEXGZLUHRXTZCC-CIUDSAMLSA-N Arg-Gln-Ser Chemical compound C(C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CO)C(=O)O)N)CN=C(N)N BEXGZLUHRXTZCC-CIUDSAMLSA-N 0.000 description 1
- XLWSGICNBZGYTA-CIUDSAMLSA-N Arg-Glu-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O XLWSGICNBZGYTA-CIUDSAMLSA-N 0.000 description 1
- MZRBYBIQTIKERR-GUBZILKMSA-N Arg-Glu-Gln Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O MZRBYBIQTIKERR-GUBZILKMSA-N 0.000 description 1
- UFBURHXMKFQVLM-CIUDSAMLSA-N Arg-Glu-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O UFBURHXMKFQVLM-CIUDSAMLSA-N 0.000 description 1
- GOWZVQXTHUCNSQ-NHCYSSNCSA-N Arg-Glu-Val Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O GOWZVQXTHUCNSQ-NHCYSSNCSA-N 0.000 description 1
- YNSGXDWWPCGGQS-YUMQZZPRSA-N Arg-Gly-Gln Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O YNSGXDWWPCGGQS-YUMQZZPRSA-N 0.000 description 1
- GMFAGHNRXPSSJS-SRVKXCTJSA-N Arg-Leu-Gln Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O GMFAGHNRXPSSJS-SRVKXCTJSA-N 0.000 description 1
- YLVGUOGAFAJMKP-JYJNAYRXSA-N Arg-Met-Tyr Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N YLVGUOGAFAJMKP-JYJNAYRXSA-N 0.000 description 1
- YTMKMRSYXHBGER-IHRRRGAJSA-N Arg-Phe-Asn Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N YTMKMRSYXHBGER-IHRRRGAJSA-N 0.000 description 1
- BSYKSCBTTQKOJG-GUBZILKMSA-N Arg-Pro-Ala Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O BSYKSCBTTQKOJG-GUBZILKMSA-N 0.000 description 1
- OVQJAKFLFTZDNC-GUBZILKMSA-N Arg-Pro-Asp Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(O)=O OVQJAKFLFTZDNC-GUBZILKMSA-N 0.000 description 1
- DNBMCNQKNOKOSD-DCAQKATOSA-N Arg-Pro-Gln Chemical compound NC(N)=NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(O)=O DNBMCNQKNOKOSD-DCAQKATOSA-N 0.000 description 1
- QHVRVUNEAIFTEK-SZMVWBNQSA-N Arg-Pro-Trp Chemical compound N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O QHVRVUNEAIFTEK-SZMVWBNQSA-N 0.000 description 1
- JOTRDIXZHNQYGP-DCAQKATOSA-N Arg-Ser-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCN=C(N)N)N JOTRDIXZHNQYGP-DCAQKATOSA-N 0.000 description 1
- HRCIIMCTUIAKQB-XGEHTFHBSA-N Arg-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N)O HRCIIMCTUIAKQB-XGEHTFHBSA-N 0.000 description 1
- YNSUUAOAFCVINY-OSUNSFLBSA-N Arg-Thr-Ile Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O YNSUUAOAFCVINY-OSUNSFLBSA-N 0.000 description 1
- NVPHRWNWTKYIST-BPNCWPANSA-N Arg-Tyr-Ala Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C)C(O)=O)CC1=CC=C(O)C=C1 NVPHRWNWTKYIST-BPNCWPANSA-N 0.000 description 1
- XRLOBFSLPCHYLQ-ULQDDVLXSA-N Arg-Tyr-His Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N)O XRLOBFSLPCHYLQ-ULQDDVLXSA-N 0.000 description 1
- XEOXPCNONWHHSW-AVGNSLFASA-N Arg-Val-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N XEOXPCNONWHHSW-AVGNSLFASA-N 0.000 description 1
- PDQBXRSOSCTGKY-ACZMJKKPSA-N Asn-Ala-Gln Chemical compound C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N PDQBXRSOSCTGKY-ACZMJKKPSA-N 0.000 description 1
- CMLGVVWQQHUXOZ-GHCJXIJMSA-N Asn-Ala-Ile Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O CMLGVVWQQHUXOZ-GHCJXIJMSA-N 0.000 description 1
- XYOVHPDDWCEUDY-CIUDSAMLSA-N Asn-Ala-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O XYOVHPDDWCEUDY-CIUDSAMLSA-N 0.000 description 1
- HAJWYALLJIATCX-FXQIFTODSA-N Asn-Asn-Arg Chemical compound C(C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)N)CN=C(N)N HAJWYALLJIATCX-FXQIFTODSA-N 0.000 description 1
- DAPLJWATMAXPPZ-CIUDSAMLSA-N Asn-Asn-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CC(N)=O DAPLJWATMAXPPZ-CIUDSAMLSA-N 0.000 description 1
- UPALZCBCKAMGIY-PEFMBERDSA-N Asn-Gln-Ile Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O UPALZCBCKAMGIY-PEFMBERDSA-N 0.000 description 1
- OKZOABJQOMAYEC-NUMRIWBASA-N Asn-Gln-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OKZOABJQOMAYEC-NUMRIWBASA-N 0.000 description 1
- SRUUBQBAVNQZGJ-LAEOZQHASA-N Asn-Gln-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)N SRUUBQBAVNQZGJ-LAEOZQHASA-N 0.000 description 1
- BZMWJLLUAKSIMH-FXQIFTODSA-N Asn-Glu-Glu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O BZMWJLLUAKSIMH-FXQIFTODSA-N 0.000 description 1
- UBKOVSLDWIHYSY-ACZMJKKPSA-N Asn-Glu-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O UBKOVSLDWIHYSY-ACZMJKKPSA-N 0.000 description 1
- FTCGGKNCJZOPNB-WHFBIAKZSA-N Asn-Gly-Ser Chemical compound NC(=O)C[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O FTCGGKNCJZOPNB-WHFBIAKZSA-N 0.000 description 1
- RAQMSGVCGSJKCL-FOHZUACHSA-N Asn-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC(N)=O RAQMSGVCGSJKCL-FOHZUACHSA-N 0.000 description 1
- UDSVWSUXKYXSTR-QWRGUYRKSA-N Asn-Gly-Tyr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O UDSVWSUXKYXSTR-QWRGUYRKSA-N 0.000 description 1
- OOWSBIOUKIUWLO-RCOVLWMOSA-N Asn-Gly-Val Chemical compound [H]N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O OOWSBIOUKIUWLO-RCOVLWMOSA-N 0.000 description 1
- KMCRKVOLRCOMBG-DJFWLOJKSA-N Asn-Ile-His Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CC(=O)N)N KMCRKVOLRCOMBG-DJFWLOJKSA-N 0.000 description 1
- IBLAOXSULLECQZ-IUKAMOBKSA-N Asn-Ile-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CC(N)=O IBLAOXSULLECQZ-IUKAMOBKSA-N 0.000 description 1
- UBGGJTMETLEXJD-DCAQKATOSA-N Asn-Leu-Met Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(O)=O UBGGJTMETLEXJD-DCAQKATOSA-N 0.000 description 1
- FHETWELNCBMRMG-HJGDQZAQSA-N Asn-Leu-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O FHETWELNCBMRMG-HJGDQZAQSA-N 0.000 description 1
- ZYPWIUFLYMQZBS-SRVKXCTJSA-N Asn-Lys-Lys Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)N)N ZYPWIUFLYMQZBS-SRVKXCTJSA-N 0.000 description 1
- CDGHMJJJHYKMPA-DLOVCJGASA-N Asn-Phe-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(=O)N)N CDGHMJJJHYKMPA-DLOVCJGASA-N 0.000 description 1
- YXVAESUIQFDBHN-SRVKXCTJSA-N Asn-Phe-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(O)=O YXVAESUIQFDBHN-SRVKXCTJSA-N 0.000 description 1
- YRTOMUMWSTUQAX-FXQIFTODSA-N Asn-Pro-Asp Chemical compound NC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(O)=O YRTOMUMWSTUQAX-FXQIFTODSA-N 0.000 description 1
- AWXDRZJQCVHCIT-DCAQKATOSA-N Asn-Pro-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CC(N)=O AWXDRZJQCVHCIT-DCAQKATOSA-N 0.000 description 1
- IDUUACUJKUXKKD-VEVYYDQMSA-N Asn-Pro-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O IDUUACUJKUXKKD-VEVYYDQMSA-N 0.000 description 1
- OOXUBGLNDRGOKT-FXQIFTODSA-N Asn-Ser-Arg Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O OOXUBGLNDRGOKT-FXQIFTODSA-N 0.000 description 1
- GZXOUBTUAUAVHD-ACZMJKKPSA-N Asn-Ser-Glu Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O GZXOUBTUAUAVHD-ACZMJKKPSA-N 0.000 description 1
- AMGQTNHANMRPOE-LKXGYXEUSA-N Asn-Thr-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O AMGQTNHANMRPOE-LKXGYXEUSA-N 0.000 description 1
- JNCRAQVYJZGIOW-QSFUFRPTSA-N Asn-Val-Ile Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JNCRAQVYJZGIOW-QSFUFRPTSA-N 0.000 description 1
- XOQYDFCQPWAMSA-KKHAAJSZSA-N Asn-Val-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XOQYDFCQPWAMSA-KKHAAJSZSA-N 0.000 description 1
- XBQSLMACWDXWLJ-GHCJXIJMSA-N Asp-Ala-Ile Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O XBQSLMACWDXWLJ-GHCJXIJMSA-N 0.000 description 1
- PBVLJOIPOGUQQP-CIUDSAMLSA-N Asp-Ala-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O PBVLJOIPOGUQQP-CIUDSAMLSA-N 0.000 description 1
- SDHFVYLZFBDSQT-DCAQKATOSA-N Asp-Arg-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(=O)O)N SDHFVYLZFBDSQT-DCAQKATOSA-N 0.000 description 1
- UGKZHCBLMLSANF-CIUDSAMLSA-N Asp-Asn-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O UGKZHCBLMLSANF-CIUDSAMLSA-N 0.000 description 1
- JGDBHIVECJGXJA-FXQIFTODSA-N Asp-Asp-Arg Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O JGDBHIVECJGXJA-FXQIFTODSA-N 0.000 description 1
- VZNOVQKGJQJOCS-SRVKXCTJSA-N Asp-Asp-Tyr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O VZNOVQKGJQJOCS-SRVKXCTJSA-N 0.000 description 1
- FTNVLGCFIJEMQT-CIUDSAMLSA-N Asp-Cys-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CC(=O)O)N FTNVLGCFIJEMQT-CIUDSAMLSA-N 0.000 description 1
- LJRPYAZQQWHEEV-FXQIFTODSA-N Asp-Gln-Gln Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O LJRPYAZQQWHEEV-FXQIFTODSA-N 0.000 description 1
- VFUXXFVCYZPOQG-WDSKDSINSA-N Asp-Glu-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O VFUXXFVCYZPOQG-WDSKDSINSA-N 0.000 description 1
- WBDWQKRLTVCDSY-WHFBIAKZSA-N Asp-Gly-Asp Chemical compound OC(=O)C[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O WBDWQKRLTVCDSY-WHFBIAKZSA-N 0.000 description 1
- KPNUCOPMVSGRCR-DCAQKATOSA-N Asp-His-Arg Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O KPNUCOPMVSGRCR-DCAQKATOSA-N 0.000 description 1
- GBSUGIXJAAKZOW-GMOBBJLQSA-N Asp-Ile-Arg Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O GBSUGIXJAAKZOW-GMOBBJLQSA-N 0.000 description 1
- DWOGMPWRQQWPPF-GUBZILKMSA-N Asp-Leu-Glu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O DWOGMPWRQQWPPF-GUBZILKMSA-N 0.000 description 1
- IVPNEDNYYYFAGI-GARJFASQSA-N Asp-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC(=O)O)N IVPNEDNYYYFAGI-GARJFASQSA-N 0.000 description 1
- DPNWSMBUYCLEDG-CIUDSAMLSA-N Asp-Lys-Ser Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O DPNWSMBUYCLEDG-CIUDSAMLSA-N 0.000 description 1
- MYLZFUMPZCPJCJ-NHCYSSNCSA-N Asp-Lys-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O MYLZFUMPZCPJCJ-NHCYSSNCSA-N 0.000 description 1
- IDDMGSKZQDEDGA-SRVKXCTJSA-N Asp-Phe-Asn Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(O)=O)CC1=CC=CC=C1 IDDMGSKZQDEDGA-SRVKXCTJSA-N 0.000 description 1
- PWAIZUBWHRHYKS-MELADBBJSA-N Asp-Phe-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(=O)O)N)C(=O)O PWAIZUBWHRHYKS-MELADBBJSA-N 0.000 description 1
- BWJZSLQJNBSUPM-FXQIFTODSA-N Asp-Pro-Asn Chemical compound OC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(O)=O BWJZSLQJNBSUPM-FXQIFTODSA-N 0.000 description 1
- UAXIKORUDGGIGA-DCAQKATOSA-N Asp-Pro-Lys Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CC(=O)O)N)C(=O)N[C@@H](CCCCN)C(=O)O UAXIKORUDGGIGA-DCAQKATOSA-N 0.000 description 1
- RVMXMLSYBTXCAV-VEVYYDQMSA-N Asp-Pro-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O RVMXMLSYBTXCAV-VEVYYDQMSA-N 0.000 description 1
- QSFHZPQUAAQHAQ-CIUDSAMLSA-N Asp-Ser-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O QSFHZPQUAAQHAQ-CIUDSAMLSA-N 0.000 description 1
- ITGFVUYOLWBPQW-KKHAAJSZSA-N Asp-Thr-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O ITGFVUYOLWBPQW-KKHAAJSZSA-N 0.000 description 1
- XWKBWZXGNXTDKY-ZKWXMUAHSA-N Asp-Val-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC(O)=O XWKBWZXGNXTDKY-ZKWXMUAHSA-N 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241001213911 Avian retroviruses Species 0.000 description 1
- 102000039506 BAGE family Human genes 0.000 description 1
- 108091067183 BAGE family Proteins 0.000 description 1
- 108060000903 Beta-catenin Proteins 0.000 description 1
- 102000015735 Beta-catenin Human genes 0.000 description 1
- 102100021277 Beta-secretase 2 Human genes 0.000 description 1
- 101710150190 Beta-secretase 2 Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102100027305 Box C/D snoRNA protein 1 Human genes 0.000 description 1
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 1
- 108010046080 CD27 Ligand Proteins 0.000 description 1
- 102100027207 CD27 antigen Human genes 0.000 description 1
- 101100005789 Caenorhabditis elegans cdk-4 gene Proteins 0.000 description 1
- 101100512078 Caenorhabditis elegans lys-1 gene Proteins 0.000 description 1
- 101100315624 Caenorhabditis elegans tyr-1 gene Proteins 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 206010008805 Chromosomal abnormalities Diseases 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 108091062157 Cis-regulatory element Proteins 0.000 description 1
- 241000186581 Clostridium novyi Species 0.000 description 1
- 241000737241 Cocos Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010048623 Collagen Receptors Proteins 0.000 description 1
- 108010001463 Collagen Type XVIII Proteins 0.000 description 1
- 102000047200 Collagen Type XVIII Human genes 0.000 description 1
- 102100031162 Collagen alpha-1(XVIII) chain Human genes 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- HVXBOLULGPECHP-WAYWQWQTSA-N Combretastatin A4 Chemical compound C1=C(O)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 HVXBOLULGPECHP-WAYWQWQTSA-N 0.000 description 1
- 102000000989 Complement System Proteins Human genes 0.000 description 1
- 108010069112 Complement System Proteins Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 1
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- NOCCABSVTRONIN-CIUDSAMLSA-N Cys-Ala-Leu Chemical compound C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CS)N NOCCABSVTRONIN-CIUDSAMLSA-N 0.000 description 1
- BYALSSDCQYHKMY-XGEHTFHBSA-N Cys-Arg-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CS)N)O BYALSSDCQYHKMY-XGEHTFHBSA-N 0.000 description 1
- UPJGYXRAPJWIHD-CIUDSAMLSA-N Cys-Asn-Leu Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O UPJGYXRAPJWIHD-CIUDSAMLSA-N 0.000 description 1
- FEJCUYOGOBCFOQ-ACZMJKKPSA-N Cys-Asp-Gln Chemical compound C(CC(=O)N)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CS)N FEJCUYOGOBCFOQ-ACZMJKKPSA-N 0.000 description 1
- SFRQEQGPRTVDPO-NRPADANISA-N Cys-Gln-Val Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O SFRQEQGPRTVDPO-NRPADANISA-N 0.000 description 1
- SBORMUFGKSCGEN-XHNCKOQMSA-N Cys-Glu-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CS)N)C(=O)O SBORMUFGKSCGEN-XHNCKOQMSA-N 0.000 description 1
- GUKYYUFHWYRMEU-WHFBIAKZSA-N Cys-Gly-Asp Chemical compound [H]N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O GUKYYUFHWYRMEU-WHFBIAKZSA-N 0.000 description 1
- ODDOYXKAHLKKQY-MMWGEVLESA-N Cys-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CS)N ODDOYXKAHLKKQY-MMWGEVLESA-N 0.000 description 1
- NLDWTJBJFVWBDQ-KKUMJFAQSA-N Cys-Lys-Phe Chemical compound NCCCC[C@H](NC(=O)[C@@H](N)CS)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 NLDWTJBJFVWBDQ-KKUMJFAQSA-N 0.000 description 1
- XMVZMBGFIOQONW-GARJFASQSA-N Cys-Lys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CS)N)C(=O)O XMVZMBGFIOQONW-GARJFASQSA-N 0.000 description 1
- SNHRIJBANHPWMO-XGEHTFHBSA-N Cys-Met-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)N)O SNHRIJBANHPWMO-XGEHTFHBSA-N 0.000 description 1
- UIKLEGZPIOXFHJ-DLOVCJGASA-N Cys-Phe-Ala Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C)C(O)=O UIKLEGZPIOXFHJ-DLOVCJGASA-N 0.000 description 1
- TXCCRYAZQBUCOV-CIUDSAMLSA-N Cys-Pro-Gln Chemical compound [H]N[C@@H](CS)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(O)=O TXCCRYAZQBUCOV-CIUDSAMLSA-N 0.000 description 1
- ZALVANCAZFPKIR-GUBZILKMSA-N Cys-Pro-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CS)N ZALVANCAZFPKIR-GUBZILKMSA-N 0.000 description 1
- ZLFRUAFDAIFNHN-LKXGYXEUSA-N Cys-Thr-Asp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CS)N)O ZLFRUAFDAIFNHN-LKXGYXEUSA-N 0.000 description 1
- JLZCAZJGWNRXCI-XKBZYTNZSA-N Cys-Thr-Glu Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O JLZCAZJGWNRXCI-XKBZYTNZSA-N 0.000 description 1
- ALNKNYKSZPSLBD-ZDLURKLDSA-N Cys-Thr-Gly Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O ALNKNYKSZPSLBD-ZDLURKLDSA-N 0.000 description 1
- RIONIAPMMKVUCX-IHPCNDPISA-N Cys-Trp-Tyr Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CS)N)C(O)=O)C1=CC=C(O)C=C1 RIONIAPMMKVUCX-IHPCNDPISA-N 0.000 description 1
- ALTQTAKGRFLRLR-GUBZILKMSA-N Cys-Val-Val Chemical compound CC(C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](CS)N ALTQTAKGRFLRLR-GUBZILKMSA-N 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 230000007023 DNA restriction-modification system Effects 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 208000012239 Developmental disease Diseases 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 102100028570 Drebrin-like protein Human genes 0.000 description 1
- 108010031111 EBV-encoded nuclear antigen 1 Proteins 0.000 description 1
- 101150076616 EPHA2 gene Proteins 0.000 description 1
- 238000011510 Elispot assay Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102100037241 Endoglin Human genes 0.000 description 1
- 108010036395 Endoglin Proteins 0.000 description 1
- 108010079505 Endostatins Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010020195 FLAG peptide Proteins 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 241000700662 Fowlpox virus Species 0.000 description 1
- 102000040452 GAGE family Human genes 0.000 description 1
- 108091072337 GAGE family Proteins 0.000 description 1
- 241000701047 Gallid alphaherpesvirus 2 Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 101000609762 Gallus gallus Ovalbumin Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- YJIUYQKQBBQYHZ-ACZMJKKPSA-N Gln-Ala-Ala Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O YJIUYQKQBBQYHZ-ACZMJKKPSA-N 0.000 description 1
- NNQHEEQNPQYPGL-FXQIFTODSA-N Gln-Ala-Gln Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(O)=O NNQHEEQNPQYPGL-FXQIFTODSA-N 0.000 description 1
- OYTPNWYZORARHL-XHNCKOQMSA-N Gln-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)N)N OYTPNWYZORARHL-XHNCKOQMSA-N 0.000 description 1
- OVQXQLWWJSNYFV-XEGUGMAKSA-N Gln-Ala-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CCC(N)=O)C)C(O)=O)=CNC2=C1 OVQXQLWWJSNYFV-XEGUGMAKSA-N 0.000 description 1
- JFOKLAPFYCTNHW-SRVKXCTJSA-N Gln-Arg-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(=O)N)N JFOKLAPFYCTNHW-SRVKXCTJSA-N 0.000 description 1
- INFBPLSHYFALDE-ACZMJKKPSA-N Gln-Asn-Ala Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(O)=O INFBPLSHYFALDE-ACZMJKKPSA-N 0.000 description 1
- RKAQZCDMSUQTSS-FXQIFTODSA-N Gln-Asp-Gln Chemical compound C(CC(=O)N)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N RKAQZCDMSUQTSS-FXQIFTODSA-N 0.000 description 1
- PCKOTDPDHIBGRW-CIUDSAMLSA-N Gln-Cys-Arg Chemical compound C(C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(=O)N)N)CN=C(N)N PCKOTDPDHIBGRW-CIUDSAMLSA-N 0.000 description 1
- APWLZZSLCXLDCF-CIUDSAMLSA-N Gln-Cys-Met Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(O)=O APWLZZSLCXLDCF-CIUDSAMLSA-N 0.000 description 1
- COYGBRTZEVWZBW-XKBZYTNZSA-N Gln-Cys-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCC(N)=O COYGBRTZEVWZBW-XKBZYTNZSA-N 0.000 description 1
- NVEASDQHBRZPSU-BQBZGAKWSA-N Gln-Gln-Gly Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O NVEASDQHBRZPSU-BQBZGAKWSA-N 0.000 description 1
- KVXVVDFOZNYYKZ-DCAQKATOSA-N Gln-Gln-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O KVXVVDFOZNYYKZ-DCAQKATOSA-N 0.000 description 1
- MCAVASRGVBVPMX-FXQIFTODSA-N Gln-Glu-Ala Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O MCAVASRGVBVPMX-FXQIFTODSA-N 0.000 description 1
- SNLOOPZHAQDMJG-CIUDSAMLSA-N Gln-Glu-Glu Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O SNLOOPZHAQDMJG-CIUDSAMLSA-N 0.000 description 1
- PNENQZWRFMUZOM-DCAQKATOSA-N Gln-Glu-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O PNENQZWRFMUZOM-DCAQKATOSA-N 0.000 description 1
- PXAFHUATEHLECW-GUBZILKMSA-N Gln-Glu-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)N PXAFHUATEHLECW-GUBZILKMSA-N 0.000 description 1
- NSORZJXKUQFEKL-JGVFFNPUSA-N Gln-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CCC(=O)N)N)C(=O)O NSORZJXKUQFEKL-JGVFFNPUSA-N 0.000 description 1
- XQEAVUJIRZRLQQ-SZMVWBNQSA-N Gln-His-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CC3=CN=CN3)NC(=O)[C@H](CCC(=O)N)N XQEAVUJIRZRLQQ-SZMVWBNQSA-N 0.000 description 1
- LGIKBBLQVSWUGK-DCAQKATOSA-N Gln-Leu-Gln Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O LGIKBBLQVSWUGK-DCAQKATOSA-N 0.000 description 1
- SHAUZYVSXAMYAZ-JYJNAYRXSA-N Gln-Leu-Phe Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CCC(=O)N)N SHAUZYVSXAMYAZ-JYJNAYRXSA-N 0.000 description 1
- LURQDGKYBFWWJA-MNXVOIDGSA-N Gln-Lys-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)N)N LURQDGKYBFWWJA-MNXVOIDGSA-N 0.000 description 1
- LHMWTCWZARHLPV-CIUDSAMLSA-N Gln-Met-Ser Chemical compound CSCC[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCC(=O)N)N LHMWTCWZARHLPV-CIUDSAMLSA-N 0.000 description 1
- XZUUUKNKNWVPHQ-JYJNAYRXSA-N Gln-Phe-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O XZUUUKNKNWVPHQ-JYJNAYRXSA-N 0.000 description 1
- PBYFVIQRFLNQCO-GUBZILKMSA-N Gln-Pro-Gln Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(O)=O PBYFVIQRFLNQCO-GUBZILKMSA-N 0.000 description 1
- WLRYGVYQFXRJDA-DCAQKATOSA-N Gln-Pro-Pro Chemical compound NC(=O)CC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 WLRYGVYQFXRJDA-DCAQKATOSA-N 0.000 description 1
- BYKZWDGMJLNFJY-XKBZYTNZSA-N Gln-Ser-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)N)N)O BYKZWDGMJLNFJY-XKBZYTNZSA-N 0.000 description 1
- DYVMTEWCGAVKSE-HJGDQZAQSA-N Gln-Thr-Arg Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CCC(=O)N)N)O DYVMTEWCGAVKSE-HJGDQZAQSA-N 0.000 description 1
- VEYGCDYMOXHJLS-GVXVVHGQSA-N Gln-Val-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O VEYGCDYMOXHJLS-GVXVVHGQSA-N 0.000 description 1
- ZMXZGYLINVNTKH-DZKIICNBSA-N Gln-Val-Phe Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 ZMXZGYLINVNTKH-DZKIICNBSA-N 0.000 description 1
- RUFHOVYUYSNDNY-ACZMJKKPSA-N Glu-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(O)=O RUFHOVYUYSNDNY-ACZMJKKPSA-N 0.000 description 1
- FHPXTPQBODWBIY-CIUDSAMLSA-N Glu-Ala-Arg Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O FHPXTPQBODWBIY-CIUDSAMLSA-N 0.000 description 1
- OGMQXTXGLDNBSS-FXQIFTODSA-N Glu-Ala-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(O)=O OGMQXTXGLDNBSS-FXQIFTODSA-N 0.000 description 1
- UTKUTMJSWKKHEM-WDSKDSINSA-N Glu-Ala-Gly Chemical compound OC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(O)=O UTKUTMJSWKKHEM-WDSKDSINSA-N 0.000 description 1
- BPDVTFBJZNBHEU-HGNGGELXSA-N Glu-Ala-His Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 BPDVTFBJZNBHEU-HGNGGELXSA-N 0.000 description 1
- WOMUDRVDJMHTCV-DCAQKATOSA-N Glu-Arg-Arg Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O WOMUDRVDJMHTCV-DCAQKATOSA-N 0.000 description 1
- DIXKFOPPGWKZLY-CIUDSAMLSA-N Glu-Arg-Asp Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O DIXKFOPPGWKZLY-CIUDSAMLSA-N 0.000 description 1
- OJGLIOXAKGFFDW-SRVKXCTJSA-N Glu-Arg-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(=O)O)N OJGLIOXAKGFFDW-SRVKXCTJSA-N 0.000 description 1
- CKRUHITYRFNUKW-WDSKDSINSA-N Glu-Asn-Gly Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O CKRUHITYRFNUKW-WDSKDSINSA-N 0.000 description 1
- ZJICFHQSPWFBKP-AVGNSLFASA-N Glu-Asn-Tyr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ZJICFHQSPWFBKP-AVGNSLFASA-N 0.000 description 1
- RDPOETHPAQEGDP-ACZMJKKPSA-N Glu-Asp-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(O)=O RDPOETHPAQEGDP-ACZMJKKPSA-N 0.000 description 1
- NTBDVNJIWCKURJ-ACZMJKKPSA-N Glu-Asp-Asn Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NTBDVNJIWCKURJ-ACZMJKKPSA-N 0.000 description 1
- XXCDTYBVGMPIOA-FXQIFTODSA-N Glu-Asp-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O XXCDTYBVGMPIOA-FXQIFTODSA-N 0.000 description 1
- OBIHEDRRSMRKLU-ACZMJKKPSA-N Glu-Cys-Asp Chemical compound C(CC(=O)O)[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(=O)O)C(=O)O)N OBIHEDRRSMRKLU-ACZMJKKPSA-N 0.000 description 1
- MXPBQDFWIMBACQ-ACZMJKKPSA-N Glu-Cys-Cys Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(O)=O MXPBQDFWIMBACQ-ACZMJKKPSA-N 0.000 description 1
- GFLQTABMFBXRIY-GUBZILKMSA-N Glu-Gln-Arg Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O GFLQTABMFBXRIY-GUBZILKMSA-N 0.000 description 1
- XMVLTPMCUJTJQP-FXQIFTODSA-N Glu-Gln-Cys Chemical compound C(CC(=O)O)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CS)C(=O)O)N XMVLTPMCUJTJQP-FXQIFTODSA-N 0.000 description 1
- CGOHAEBMDSEKFB-FXQIFTODSA-N Glu-Glu-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O CGOHAEBMDSEKFB-FXQIFTODSA-N 0.000 description 1
- MUSGDMDGNGXULI-DCAQKATOSA-N Glu-Glu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCC(O)=O MUSGDMDGNGXULI-DCAQKATOSA-N 0.000 description 1
- PHONAZGUEGIOEM-GLLZPBPUSA-N Glu-Glu-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PHONAZGUEGIOEM-GLLZPBPUSA-N 0.000 description 1
- PXXGVUVQWQGGIG-YUMQZZPRSA-N Glu-Gly-Arg Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N PXXGVUVQWQGGIG-YUMQZZPRSA-N 0.000 description 1
- OGNJZUXUTPQVBR-BQBZGAKWSA-N Glu-Gly-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O OGNJZUXUTPQVBR-BQBZGAKWSA-N 0.000 description 1
- OAGVHWYIBZMWLA-YFKPBYRVSA-N Glu-Gly-Gly Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)NCC(O)=O OAGVHWYIBZMWLA-YFKPBYRVSA-N 0.000 description 1
- ZWQVYZXPYSYPJD-RYUDHWBXSA-N Glu-Gly-Phe Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 ZWQVYZXPYSYPJD-RYUDHWBXSA-N 0.000 description 1
- OPAINBJQDQTGJY-JGVFFNPUSA-N Glu-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CCC(=O)O)N)C(=O)O OPAINBJQDQTGJY-JGVFFNPUSA-N 0.000 description 1
- DVLZZEPUNFEUBW-AVGNSLFASA-N Glu-His-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CCC(=O)O)N DVLZZEPUNFEUBW-AVGNSLFASA-N 0.000 description 1
- BIHMNDPWRUROFZ-JYJNAYRXSA-N Glu-His-Phe Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O BIHMNDPWRUROFZ-JYJNAYRXSA-N 0.000 description 1
- GXMXPCXXKVWOSM-KQXIARHKSA-N Glu-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)O)N GXMXPCXXKVWOSM-KQXIARHKSA-N 0.000 description 1
- PJBVXVBTTFZPHJ-GUBZILKMSA-N Glu-Leu-Asp Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CCC(=O)O)N PJBVXVBTTFZPHJ-GUBZILKMSA-N 0.000 description 1
- IRXNJYPKBVERCW-DCAQKATOSA-N Glu-Leu-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O IRXNJYPKBVERCW-DCAQKATOSA-N 0.000 description 1
- MWMJCGBSIORNCD-AVGNSLFASA-N Glu-Leu-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O MWMJCGBSIORNCD-AVGNSLFASA-N 0.000 description 1
- IVGJYOOGJLFKQE-AVGNSLFASA-N Glu-Leu-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N IVGJYOOGJLFKQE-AVGNSLFASA-N 0.000 description 1
- JJSVALISDCNFCU-SZMVWBNQSA-N Glu-Leu-Trp Chemical compound CC(C)C[C@H](NC(=O)[C@@H](N)CCC(O)=O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O JJSVALISDCNFCU-SZMVWBNQSA-N 0.000 description 1
- IOUQWHIEQYQVFD-JYJNAYRXSA-N Glu-Leu-Tyr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O IOUQWHIEQYQVFD-JYJNAYRXSA-N 0.000 description 1
- SWRVAQHFBRZVNX-GUBZILKMSA-N Glu-Lys-Asn Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O SWRVAQHFBRZVNX-GUBZILKMSA-N 0.000 description 1
- CUPSDFQZTVVTSK-GUBZILKMSA-N Glu-Lys-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCC(O)=O CUPSDFQZTVVTSK-GUBZILKMSA-N 0.000 description 1
- YKBUCXNNBYZYAY-MNXVOIDGSA-N Glu-Lys-Ile Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O YKBUCXNNBYZYAY-MNXVOIDGSA-N 0.000 description 1
- PAZQYODKOZHXGA-SRVKXCTJSA-N Glu-Pro-His Chemical compound N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O PAZQYODKOZHXGA-SRVKXCTJSA-N 0.000 description 1
- WIKMTDVSCUJIPJ-CIUDSAMLSA-N Glu-Ser-Arg Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCN=C(N)N WIKMTDVSCUJIPJ-CIUDSAMLSA-N 0.000 description 1
- IDEODOAVGCMUQV-GUBZILKMSA-N Glu-Ser-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O IDEODOAVGCMUQV-GUBZILKMSA-N 0.000 description 1
- HMJULNMJWOZNFI-XHNCKOQMSA-N Glu-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)O)N)C(=O)O HMJULNMJWOZNFI-XHNCKOQMSA-N 0.000 description 1
- UMZHHILWZBFPGL-LOKLDPHHSA-N Glu-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)O)N)O UMZHHILWZBFPGL-LOKLDPHHSA-N 0.000 description 1
- NTHIHAUEXVTXQG-KKUMJFAQSA-N Glu-Tyr-Arg Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CCC(=O)O)N)O NTHIHAUEXVTXQG-KKUMJFAQSA-N 0.000 description 1
- RMWAOBGCZZSJHE-UMNHJUIQSA-N Glu-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)O)N RMWAOBGCZZSJHE-UMNHJUIQSA-N 0.000 description 1
- GZUKEVBTYNNUQF-WDSKDSINSA-N Gly-Ala-Gln Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(O)=O GZUKEVBTYNNUQF-WDSKDSINSA-N 0.000 description 1
- MFVQGXGQRIXBPK-WDSKDSINSA-N Gly-Ala-Glu Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O MFVQGXGQRIXBPK-WDSKDSINSA-N 0.000 description 1
- QXPRJQPCFXMCIY-NKWVEPMBSA-N Gly-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)CN QXPRJQPCFXMCIY-NKWVEPMBSA-N 0.000 description 1
- XUDLUKYPXQDCRX-BQBZGAKWSA-N Gly-Arg-Asn Chemical compound [H]NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(O)=O XUDLUKYPXQDCRX-BQBZGAKWSA-N 0.000 description 1
- RJIVPOXLQFJRTG-LURJTMIESA-N Gly-Arg-Gly Chemical compound OC(=O)CNC(=O)[C@@H](NC(=O)CN)CCCN=C(N)N RJIVPOXLQFJRTG-LURJTMIESA-N 0.000 description 1
- KKBWDNZXYLGJEY-UHFFFAOYSA-N Gly-Arg-Pro Natural products NCC(=O)NC(CCNC(=N)N)C(=O)N1CCCC1C(=O)O KKBWDNZXYLGJEY-UHFFFAOYSA-N 0.000 description 1
- GWCRIHNSVMOBEQ-BQBZGAKWSA-N Gly-Arg-Ser Chemical compound [H]NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O GWCRIHNSVMOBEQ-BQBZGAKWSA-N 0.000 description 1
- DWUKOTKSTDWGAE-BQBZGAKWSA-N Gly-Asn-Arg Chemical compound NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N DWUKOTKSTDWGAE-BQBZGAKWSA-N 0.000 description 1
- AIJAPFVDBFYNKN-WHFBIAKZSA-N Gly-Asn-Asp Chemical compound C([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)CN)C(=O)N AIJAPFVDBFYNKN-WHFBIAKZSA-N 0.000 description 1
- WJZLEENECIOOSA-WDSKDSINSA-N Gly-Asn-Gln Chemical compound NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)O WJZLEENECIOOSA-WDSKDSINSA-N 0.000 description 1
- XRTDOIOIBMAXCT-NKWVEPMBSA-N Gly-Asn-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)N)NC(=O)CN)C(=O)O XRTDOIOIBMAXCT-NKWVEPMBSA-N 0.000 description 1
- GNBMOZPQUXTCRW-STQMWFEESA-N Gly-Asn-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)CN)C(O)=O)=CNC2=C1 GNBMOZPQUXTCRW-STQMWFEESA-N 0.000 description 1
- KQDMENMTYNBWMR-WHFBIAKZSA-N Gly-Asp-Ala Chemical compound [H]NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(O)=O KQDMENMTYNBWMR-WHFBIAKZSA-N 0.000 description 1
- SUDUYJOBLHQAMI-WHFBIAKZSA-N Gly-Asp-Cys Chemical compound NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CS)C(O)=O SUDUYJOBLHQAMI-WHFBIAKZSA-N 0.000 description 1
- NMROINAYXCACKF-WHFBIAKZSA-N Gly-Cys-Cys Chemical compound NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(O)=O NMROINAYXCACKF-WHFBIAKZSA-N 0.000 description 1
- DTRUBYPMMVPQPD-YUMQZZPRSA-N Gly-Gln-Arg Chemical compound [H]NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O DTRUBYPMMVPQPD-YUMQZZPRSA-N 0.000 description 1
- JUGQPPOVWXSPKJ-RYUDHWBXSA-N Gly-Gln-Phe Chemical compound [H]NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O JUGQPPOVWXSPKJ-RYUDHWBXSA-N 0.000 description 1
- MOJKRXIRAZPZLW-WDSKDSINSA-N Gly-Glu-Ala Chemical compound [H]NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O MOJKRXIRAZPZLW-WDSKDSINSA-N 0.000 description 1
- ZQIMMEYPEXIYBB-IUCAKERBSA-N Gly-Glu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CN ZQIMMEYPEXIYBB-IUCAKERBSA-N 0.000 description 1
- BEQGFMIBZFNROK-JGVFFNPUSA-N Gly-Glu-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)O)NC(=O)CN)C(=O)O BEQGFMIBZFNROK-JGVFFNPUSA-N 0.000 description 1
- QSVCIFZPGLOZGH-WDSKDSINSA-N Gly-Glu-Ser Chemical compound NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O QSVCIFZPGLOZGH-WDSKDSINSA-N 0.000 description 1
- KMSGYZQRXPUKGI-BYPYZUCNSA-N Gly-Gly-Asn Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CC(N)=O KMSGYZQRXPUKGI-BYPYZUCNSA-N 0.000 description 1
- AYBKPDHHVADEDA-YUMQZZPRSA-N Gly-His-Asn Chemical compound [H]NCC(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(N)=O)C(O)=O AYBKPDHHVADEDA-YUMQZZPRSA-N 0.000 description 1
- HMHRTKOWRUPPNU-RCOVLWMOSA-N Gly-Ile-Gly Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(O)=O HMHRTKOWRUPPNU-RCOVLWMOSA-N 0.000 description 1
- UESJMAMHDLEHGM-NHCYSSNCSA-N Gly-Ile-Leu Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O UESJMAMHDLEHGM-NHCYSSNCSA-N 0.000 description 1
- IUZGUFAJDBHQQV-YUMQZZPRSA-N Gly-Leu-Asn Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O IUZGUFAJDBHQQV-YUMQZZPRSA-N 0.000 description 1
- ULZCYBYDTUMHNF-IUCAKERBSA-N Gly-Leu-Glu Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O ULZCYBYDTUMHNF-IUCAKERBSA-N 0.000 description 1
- UHPAZODVFFYEEL-QWRGUYRKSA-N Gly-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)CN UHPAZODVFFYEEL-QWRGUYRKSA-N 0.000 description 1
- TVUWMSBGMVAHSJ-KBPBESRZSA-N Gly-Leu-Phe Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 TVUWMSBGMVAHSJ-KBPBESRZSA-N 0.000 description 1
- GAFKBWKVXNERFA-QWRGUYRKSA-N Gly-Phe-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CC=CC=C1 GAFKBWKVXNERFA-QWRGUYRKSA-N 0.000 description 1
- JPVGHHQGKPQYIL-KBPBESRZSA-N Gly-Phe-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CC=CC=C1 JPVGHHQGKPQYIL-KBPBESRZSA-N 0.000 description 1
- IEGFSKKANYKBDU-QWHCGFSZSA-N Gly-Phe-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=CC=C2)NC(=O)CN)C(=O)O IEGFSKKANYKBDU-QWHCGFSZSA-N 0.000 description 1
- GGAPHLIUUTVYMX-QWRGUYRKSA-N Gly-Phe-Ser Chemical compound OC[C@@H](C([O-])=O)NC(=O)[C@@H](NC(=O)C[NH3+])CC1=CC=CC=C1 GGAPHLIUUTVYMX-QWRGUYRKSA-N 0.000 description 1
- GLACUWHUYFBSPJ-FJXKBIBVSA-N Gly-Pro-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)CN GLACUWHUYFBSPJ-FJXKBIBVSA-N 0.000 description 1
- BMWFDYIYBAFROD-WPRPVWTQSA-N Gly-Pro-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)CN BMWFDYIYBAFROD-WPRPVWTQSA-N 0.000 description 1
- LCRDMSSAKLTKBU-ZDLURKLDSA-N Gly-Ser-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CN LCRDMSSAKLTKBU-ZDLURKLDSA-N 0.000 description 1
- ZLCLYFGMKFCDCN-XPUUQOCRSA-N Gly-Ser-Val Chemical compound CC(C)[C@H](NC(=O)[C@H](CO)NC(=O)CN)C(O)=O ZLCLYFGMKFCDCN-XPUUQOCRSA-N 0.000 description 1
- FKESCSGWBPUTPN-FOHZUACHSA-N Gly-Thr-Asn Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(O)=O FKESCSGWBPUTPN-FOHZUACHSA-N 0.000 description 1
- CQMFNTVQVLQRLT-JHEQGTHGSA-N Gly-Thr-Gln Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O CQMFNTVQVLQRLT-JHEQGTHGSA-N 0.000 description 1
- ZZWUYQXMIFTIIY-WEDXCCLWSA-N Gly-Thr-Leu Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O ZZWUYQXMIFTIIY-WEDXCCLWSA-N 0.000 description 1
- FOKISINOENBSDM-WLTAIBSBSA-N Gly-Thr-Tyr Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O FOKISINOENBSDM-WLTAIBSBSA-N 0.000 description 1
- SFOXOSKVTLDEDM-HOTGVXAUSA-N Gly-Trp-Leu Chemical compound C1=CC=C2C(C[C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CN)=CNC2=C1 SFOXOSKVTLDEDM-HOTGVXAUSA-N 0.000 description 1
- YJDALMUYJIENAG-QWRGUYRKSA-N Gly-Tyr-Asn Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)CN)O YJDALMUYJIENAG-QWRGUYRKSA-N 0.000 description 1
- BAYQNCWLXIDLHX-ONGXEEELSA-N Gly-Val-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)CN BAYQNCWLXIDLHX-ONGXEEELSA-N 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 101710113864 Heat shock protein 90 Proteins 0.000 description 1
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- SVHKVHBPTOMLTO-DCAQKATOSA-N His-Arg-Asp Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O SVHKVHBPTOMLTO-DCAQKATOSA-N 0.000 description 1
- ZIMTWPHIKZEHSE-UWVGGRQHSA-N His-Arg-Gly Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O ZIMTWPHIKZEHSE-UWVGGRQHSA-N 0.000 description 1
- JWTKVPMQCCRPQY-SRVKXCTJSA-N His-Asn-Leu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O JWTKVPMQCCRPQY-SRVKXCTJSA-N 0.000 description 1
- MDBYBTWRMOAJAY-NHCYSSNCSA-N His-Asn-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC1=CN=CN1)N MDBYBTWRMOAJAY-NHCYSSNCSA-N 0.000 description 1
- DGYNAJNQMBFYIF-SZMVWBNQSA-N His-Glu-Trp Chemical compound C([C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)C1=CN=CN1 DGYNAJNQMBFYIF-SZMVWBNQSA-N 0.000 description 1
- YADRBUZBKHHDAO-XPUUQOCRSA-N His-Gly-Ala Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)NCC(=O)N[C@@H](C)C(O)=O YADRBUZBKHHDAO-XPUUQOCRSA-N 0.000 description 1
- FDQYIRHBVVUTJF-ZETCQYMHSA-N His-Gly-Gly Chemical compound [O-]C(=O)CNC(=O)CNC(=O)[C@@H]([NH3+])CC1=CN=CN1 FDQYIRHBVVUTJF-ZETCQYMHSA-N 0.000 description 1
- VTMLJMNQHKBPON-QWRGUYRKSA-N His-Gly-His Chemical compound C([C@H](N)C(=O)NCC(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CN=CN1 VTMLJMNQHKBPON-QWRGUYRKSA-N 0.000 description 1
- UVDDTHLDZBMBAV-SRVKXCTJSA-N His-His-Cys Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CS)C(=O)O)N UVDDTHLDZBMBAV-SRVKXCTJSA-N 0.000 description 1
- SKYULSWNBYAQMG-IHRRRGAJSA-N His-Leu-Arg Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SKYULSWNBYAQMG-IHRRRGAJSA-N 0.000 description 1
- LVXFNTIIGOQBMD-SRVKXCTJSA-N His-Leu-Ser Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O LVXFNTIIGOQBMD-SRVKXCTJSA-N 0.000 description 1
- YXXKBPJEIYFGOD-MGHWNKPDSA-N His-Phe-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC2=CN=CN2)N YXXKBPJEIYFGOD-MGHWNKPDSA-N 0.000 description 1
- IAYPZSHNZQHQNO-KKUMJFAQSA-N His-Ser-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC2=CN=CN2)N IAYPZSHNZQHQNO-KKUMJFAQSA-N 0.000 description 1
- HIJIJPFILYPTFR-ACRUOGEOSA-N His-Tyr-Tyr Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O HIJIJPFILYPTFR-ACRUOGEOSA-N 0.000 description 1
- WYKXJGWSJUULSL-AVGNSLFASA-N His-Val-Arg Chemical compound CC(C)[C@H](NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O WYKXJGWSJUULSL-AVGNSLFASA-N 0.000 description 1
- 102100023920 Histone H1t Human genes 0.000 description 1
- 101000757191 Homo sapiens Ankyrin repeat domain-containing protein 30A Proteins 0.000 description 1
- 101000937756 Homo sapiens Box C/D snoRNA protein 1 Proteins 0.000 description 1
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 1
- 101000915399 Homo sapiens Drebrin-like protein Proteins 0.000 description 1
- 101000905044 Homo sapiens Histone H1t Proteins 0.000 description 1
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 1
- 101001008951 Homo sapiens Kinesin-like protein KIF15 Proteins 0.000 description 1
- 101001063392 Homo sapiens Lymphocyte function-associated antigen 3 Proteins 0.000 description 1
- 101001014223 Homo sapiens MAPK/MAK/MRK overlapping kinase Proteins 0.000 description 1
- 101000579484 Homo sapiens Period circadian protein homolog 1 Proteins 0.000 description 1
- 101000831887 Homo sapiens STE20-related kinase adapter protein alpha Proteins 0.000 description 1
- 101000632529 Homo sapiens Shugoshin 1 Proteins 0.000 description 1
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 description 1
- 108010070875 Human Immunodeficiency Virus tat Gene Products Proteins 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 102000039966 ICAM family Human genes 0.000 description 1
- 108091069108 ICAM family Proteins 0.000 description 1
- HLYBGMZJVDHJEO-CYDGBPFRSA-N Ile-Arg-Arg Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N HLYBGMZJVDHJEO-CYDGBPFRSA-N 0.000 description 1
- WECYRWOMWSCWNX-XUXIUFHCSA-N Ile-Arg-Leu Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(C)C)C(O)=O WECYRWOMWSCWNX-XUXIUFHCSA-N 0.000 description 1
- RGSOCXHDOPQREB-ZPFDUUQYSA-N Ile-Asp-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)O)N RGSOCXHDOPQREB-ZPFDUUQYSA-N 0.000 description 1
- KBHYLOIVRVBBEB-JBDRJPRFSA-N Ile-Cys-Cys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)O)N KBHYLOIVRVBBEB-JBDRJPRFSA-N 0.000 description 1
- DURWCDDDAWVPOP-JBDRJPRFSA-N Ile-Cys-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)O)N DURWCDDDAWVPOP-JBDRJPRFSA-N 0.000 description 1
- LPXHYGGZJOCAFR-MNXVOIDGSA-N Ile-Glu-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)O)N LPXHYGGZJOCAFR-MNXVOIDGSA-N 0.000 description 1
- WUKLZPHVWAMZQV-UKJIMTQDSA-N Ile-Glu-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)O)N WUKLZPHVWAMZQV-UKJIMTQDSA-N 0.000 description 1
- APDIECQNNDGFPD-PYJNHQTQSA-N Ile-His-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](C(C)C)C(=O)O)N APDIECQNNDGFPD-PYJNHQTQSA-N 0.000 description 1
- KLBVGHCGHUNHEA-BJDJZHNGSA-N Ile-Leu-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)O)N KLBVGHCGHUNHEA-BJDJZHNGSA-N 0.000 description 1
- HUORUFRRJHELPD-MNXVOIDGSA-N Ile-Leu-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N HUORUFRRJHELPD-MNXVOIDGSA-N 0.000 description 1
- FZWVCYCYWCLQDH-NHCYSSNCSA-N Ile-Leu-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)O)N FZWVCYCYWCLQDH-NHCYSSNCSA-N 0.000 description 1
- PMMMQRVUMVURGJ-XUXIUFHCSA-N Ile-Leu-Pro Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(O)=O PMMMQRVUMVURGJ-XUXIUFHCSA-N 0.000 description 1
- PHRWFSFCNJPWRO-PPCPHDFISA-N Ile-Leu-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N PHRWFSFCNJPWRO-PPCPHDFISA-N 0.000 description 1
- GVNNAHIRSDRIII-AJNGGQMLSA-N Ile-Lys-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)O)N GVNNAHIRSDRIII-AJNGGQMLSA-N 0.000 description 1
- FFJQAEYLAQMGDL-MGHWNKPDSA-N Ile-Lys-Tyr Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 FFJQAEYLAQMGDL-MGHWNKPDSA-N 0.000 description 1
- IALVDKNUFSTICJ-GMOBBJLQSA-N Ile-Met-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)O)N IALVDKNUFSTICJ-GMOBBJLQSA-N 0.000 description 1
- HQEPKOFULQTSFV-JURCDPSOSA-N Ile-Phe-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C)C(=O)O)N HQEPKOFULQTSFV-JURCDPSOSA-N 0.000 description 1
- XQLGNKLSPYCRMZ-HJWJTTGWSA-N Ile-Phe-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)O)N XQLGNKLSPYCRMZ-HJWJTTGWSA-N 0.000 description 1
- IVXJIMGDOYRLQU-XUXIUFHCSA-N Ile-Pro-Leu Chemical compound CC[C@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(O)=O IVXJIMGDOYRLQU-XUXIUFHCSA-N 0.000 description 1
- MLSUZXHSNRBDCI-CYDGBPFRSA-N Ile-Pro-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)O)N MLSUZXHSNRBDCI-CYDGBPFRSA-N 0.000 description 1
- JHNJNTMTZHEDLJ-NAKRPEOUSA-N Ile-Ser-Arg Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O JHNJNTMTZHEDLJ-NAKRPEOUSA-N 0.000 description 1
- JODPUDMBQBIWCK-GHCJXIJMSA-N Ile-Ser-Asn Chemical compound [H]N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O JODPUDMBQBIWCK-GHCJXIJMSA-N 0.000 description 1
- FBGXMKUWQFPHFB-JBDRJPRFSA-N Ile-Ser-Cys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N FBGXMKUWQFPHFB-JBDRJPRFSA-N 0.000 description 1
- YCKPUHHMCFSUMD-IUKAMOBKSA-N Ile-Thr-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)N YCKPUHHMCFSUMD-IUKAMOBKSA-N 0.000 description 1
- QHUREMVLLMNUAX-OSUNSFLBSA-N Ile-Thr-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)O)N QHUREMVLLMNUAX-OSUNSFLBSA-N 0.000 description 1
- PRTZQMBYUZFSFA-XEGUGMAKSA-N Ile-Tyr-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)NCC(=O)O)N PRTZQMBYUZFSFA-XEGUGMAKSA-N 0.000 description 1
- DZMWFIRHFFVBHS-ZEWNOJEFSA-N Ile-Tyr-Phe Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)O)N DZMWFIRHFFVBHS-ZEWNOJEFSA-N 0.000 description 1
- DLEBSGAVWRPTIX-PEDHHIEDSA-N Ile-Val-Ile Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)[C@@H](C)CC DLEBSGAVWRPTIX-PEDHHIEDSA-N 0.000 description 1
- 235000003325 Ilex Nutrition 0.000 description 1
- 241000209035 Ilex Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 108010043496 Immunoglobulin Idiotypes Proteins 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 102100025305 Integrin alpha-2 Human genes 0.000 description 1
- 108010064600 Intercellular Adhesion Molecule-3 Proteins 0.000 description 1
- 102100037872 Intercellular adhesion molecule 2 Human genes 0.000 description 1
- 101710148794 Intercellular adhesion molecule 2 Proteins 0.000 description 1
- 102100037871 Intercellular adhesion molecule 3 Human genes 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 102100027630 Kinesin-like protein KIF15 Human genes 0.000 description 1
- 102100023426 Kinesin-like protein KIF2A Human genes 0.000 description 1
- 101710134365 Kinesin-like protein KIF2A Proteins 0.000 description 1
- IBMVEYRWAWIOTN-UHFFFAOYSA-N L-Leucyl-L-Arginyl-L-Proline Natural products CC(C)CC(N)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(O)=O IBMVEYRWAWIOTN-UHFFFAOYSA-N 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- SENJXOPIZNYLHU-UHFFFAOYSA-N L-leucyl-L-arginine Natural products CC(C)CC(N)C(=O)NC(C(O)=O)CCCN=C(N)N SENJXOPIZNYLHU-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010024218 Lentigo maligna Diseases 0.000 description 1
- MJOZZTKJZQFKDK-GUBZILKMSA-N Leu-Ala-Gln Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCC(N)=O MJOZZTKJZQFKDK-GUBZILKMSA-N 0.000 description 1
- WNGVUZWBXZKQES-YUMQZZPRSA-N Leu-Ala-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O WNGVUZWBXZKQES-YUMQZZPRSA-N 0.000 description 1
- XIRYQRLFHWWWTC-QEJZJMRPSA-N Leu-Ala-Phe Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 XIRYQRLFHWWWTC-QEJZJMRPSA-N 0.000 description 1
- HBJZFCIVFIBNSV-DCAQKATOSA-N Leu-Arg-Asn Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(N)=O)C(O)=O HBJZFCIVFIBNSV-DCAQKATOSA-N 0.000 description 1
- IBMVEYRWAWIOTN-RWMBFGLXSA-N Leu-Arg-Pro Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@@H]1C(O)=O IBMVEYRWAWIOTN-RWMBFGLXSA-N 0.000 description 1
- MDVZJYGNAGLPGJ-KKUMJFAQSA-N Leu-Asn-Phe Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MDVZJYGNAGLPGJ-KKUMJFAQSA-N 0.000 description 1
- WGNOPSQMIQERPK-UHFFFAOYSA-N Leu-Asn-Pro Natural products CC(C)CC(N)C(=O)NC(CC(=O)N)C(=O)N1CCCC1C(=O)O WGNOPSQMIQERPK-UHFFFAOYSA-N 0.000 description 1
- DLFAACQHIRSQGG-CIUDSAMLSA-N Leu-Asp-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O DLFAACQHIRSQGG-CIUDSAMLSA-N 0.000 description 1
- DLCOFDAHNMMQPP-SRVKXCTJSA-N Leu-Asp-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O DLCOFDAHNMMQPP-SRVKXCTJSA-N 0.000 description 1
- DKEZVKFLETVJFY-CIUDSAMLSA-N Leu-Cys-Asn Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(=O)N)C(=O)O)N DKEZVKFLETVJFY-CIUDSAMLSA-N 0.000 description 1
- PPBKJAQJAUHZKX-SRVKXCTJSA-N Leu-Cys-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@H](C(O)=O)CC(C)C PPBKJAQJAUHZKX-SRVKXCTJSA-N 0.000 description 1
- VPKIQULSKFVCSM-SRVKXCTJSA-N Leu-Gln-Arg Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O VPKIQULSKFVCSM-SRVKXCTJSA-N 0.000 description 1
- LOLUPZNNADDTAA-AVGNSLFASA-N Leu-Gln-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O LOLUPZNNADDTAA-AVGNSLFASA-N 0.000 description 1
- CIVKXGPFXDIQBV-WDCWCFNPSA-N Leu-Gln-Thr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O CIVKXGPFXDIQBV-WDCWCFNPSA-N 0.000 description 1
- KUEVMUXNILMJTK-JYJNAYRXSA-N Leu-Gln-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 KUEVMUXNILMJTK-JYJNAYRXSA-N 0.000 description 1
- OGUUKPXUTHOIAV-SDDRHHMPSA-N Leu-Glu-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N1CCC[C@@H]1C(=O)O)N OGUUKPXUTHOIAV-SDDRHHMPSA-N 0.000 description 1
- OXRLYTYUXAQTHP-YUMQZZPRSA-N Leu-Gly-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(O)=O OXRLYTYUXAQTHP-YUMQZZPRSA-N 0.000 description 1
- QJUWBDPGGYVRHY-YUMQZZPRSA-N Leu-Gly-Cys Chemical compound CC(C)C[C@@H](C(=O)NCC(=O)N[C@@H](CS)C(=O)O)N QJUWBDPGGYVRHY-YUMQZZPRSA-N 0.000 description 1
- CCQLQKZTXZBXTN-NHCYSSNCSA-N Leu-Gly-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(O)=O CCQLQKZTXZBXTN-NHCYSSNCSA-N 0.000 description 1
- YFBBUHJJUXXZOF-UWVGGRQHSA-N Leu-Gly-Pro Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N1CCC[C@H]1C(O)=O YFBBUHJJUXXZOF-UWVGGRQHSA-N 0.000 description 1
- UCDHVOALNXENLC-KBPBESRZSA-N Leu-Gly-Tyr Chemical compound CC(C)C[C@H]([NH3+])C(=O)NCC(=O)N[C@H](C([O-])=O)CC1=CC=C(O)C=C1 UCDHVOALNXENLC-KBPBESRZSA-N 0.000 description 1
- VZBIUJURDLFFOE-IHRRRGAJSA-N Leu-His-Arg Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O VZBIUJURDLFFOE-IHRRRGAJSA-N 0.000 description 1
- DDEMUMVXNFPDKC-SRVKXCTJSA-N Leu-His-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CS)C(=O)O)N DDEMUMVXNFPDKC-SRVKXCTJSA-N 0.000 description 1
- JFSGIJSCJFQGSZ-MXAVVETBSA-N Leu-Ile-His Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CC(C)C)N JFSGIJSCJFQGSZ-MXAVVETBSA-N 0.000 description 1
- SEMUSFOBZGKBGW-YTFOTSKYSA-N Leu-Ile-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O SEMUSFOBZGKBGW-YTFOTSKYSA-N 0.000 description 1
- ZALAVHVPPOHAOL-XUXIUFHCSA-N Leu-Ile-Met Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H](CC(C)C)N ZALAVHVPPOHAOL-XUXIUFHCSA-N 0.000 description 1
- OMHLATXVNQSALM-FQUUOJAGSA-N Leu-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC(C)C)N OMHLATXVNQSALM-FQUUOJAGSA-N 0.000 description 1
- DSFYPIUSAMSERP-IHRRRGAJSA-N Leu-Leu-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N DSFYPIUSAMSERP-IHRRRGAJSA-N 0.000 description 1
- QNBVTHNJGCOVFA-AVGNSLFASA-N Leu-Leu-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCC(O)=O QNBVTHNJGCOVFA-AVGNSLFASA-N 0.000 description 1
- LXKNSJLSGPNHSK-KKUMJFAQSA-N Leu-Leu-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)O)N LXKNSJLSGPNHSK-KKUMJFAQSA-N 0.000 description 1
- DCGXHWINSHEPIR-SRVKXCTJSA-N Leu-Lys-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)O)N DCGXHWINSHEPIR-SRVKXCTJSA-N 0.000 description 1
- HVHRPWQEQHIQJF-AVGNSLFASA-N Leu-Lys-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O HVHRPWQEQHIQJF-AVGNSLFASA-N 0.000 description 1
- BIZNDKMFQHDOIE-KKUMJFAQSA-N Leu-Phe-Asn Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(O)=O)CC1=CC=CC=C1 BIZNDKMFQHDOIE-KKUMJFAQSA-N 0.000 description 1
- AIRUUHAOKGVJAD-JYJNAYRXSA-N Leu-Phe-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O AIRUUHAOKGVJAD-JYJNAYRXSA-N 0.000 description 1
- DRWMRVFCKKXHCH-BZSNNMDCSA-N Leu-Phe-Leu Chemical compound CC(C)C[C@H]([NH3+])C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C([O-])=O)CC1=CC=CC=C1 DRWMRVFCKKXHCH-BZSNNMDCSA-N 0.000 description 1
- UHNQRAFSEBGZFZ-YESZJQIVSA-N Leu-Phe-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N2CCC[C@@H]2C(=O)O)N UHNQRAFSEBGZFZ-YESZJQIVSA-N 0.000 description 1
- FYPWFNKQVVEELI-ULQDDVLXSA-N Leu-Phe-Val Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C(C)C)C(O)=O)CC1=CC=CC=C1 FYPWFNKQVVEELI-ULQDDVLXSA-N 0.000 description 1
- WMIOEVKKYIMVKI-DCAQKATOSA-N Leu-Pro-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O WMIOEVKKYIMVKI-DCAQKATOSA-N 0.000 description 1
- VULJUQZPSOASBZ-SRVKXCTJSA-N Leu-Pro-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O VULJUQZPSOASBZ-SRVKXCTJSA-N 0.000 description 1
- UCBPDSYUVAAHCD-UWVGGRQHSA-N Leu-Pro-Gly Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O UCBPDSYUVAAHCD-UWVGGRQHSA-N 0.000 description 1
- YUTNOGOMBNYPFH-XUXIUFHCSA-N Leu-Pro-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(O)=O YUTNOGOMBNYPFH-XUXIUFHCSA-N 0.000 description 1
- PWPBLZXWFXJFHE-RHYQMDGZSA-N Leu-Pro-Thr Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O PWPBLZXWFXJFHE-RHYQMDGZSA-N 0.000 description 1
- IDGZVZJLYFTXSL-DCAQKATOSA-N Leu-Ser-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCN=C(N)N IDGZVZJLYFTXSL-DCAQKATOSA-N 0.000 description 1
- KIZIOFNVSOSKJI-CIUDSAMLSA-N Leu-Ser-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N KIZIOFNVSOSKJI-CIUDSAMLSA-N 0.000 description 1
- ADJWHHZETYAAAX-SRVKXCTJSA-N Leu-Ser-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N ADJWHHZETYAAAX-SRVKXCTJSA-N 0.000 description 1
- HWMQRQIFVGEAPH-XIRDDKMYSA-N Leu-Ser-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(C)C)C(O)=O)=CNC2=C1 HWMQRQIFVGEAPH-XIRDDKMYSA-N 0.000 description 1
- SVBJIZVVYJYGLA-DCAQKATOSA-N Leu-Ser-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O SVBJIZVVYJYGLA-DCAQKATOSA-N 0.000 description 1
- LINKCQUOMUDLKN-KATARQTJSA-N Leu-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(C)C)N)O LINKCQUOMUDLKN-KATARQTJSA-N 0.000 description 1
- LJBVRCDPWOJOEK-PPCPHDFISA-N Leu-Thr-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O LJBVRCDPWOJOEK-PPCPHDFISA-N 0.000 description 1
- DAYQSYGBCUKVKT-VOAKCMCISA-N Leu-Thr-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(O)=O DAYQSYGBCUKVKT-VOAKCMCISA-N 0.000 description 1
- URHJPNHRQMQGOZ-RHYQMDGZSA-N Leu-Thr-Met Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCSC)C(O)=O URHJPNHRQMQGOZ-RHYQMDGZSA-N 0.000 description 1
- GZRABTMNWJXFMH-UVOCVTCTSA-N Leu-Thr-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GZRABTMNWJXFMH-UVOCVTCTSA-N 0.000 description 1
- HGLKOTPFWOMPOB-MEYUZBJRSA-N Leu-Thr-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 HGLKOTPFWOMPOB-MEYUZBJRSA-N 0.000 description 1
- AIQWYVFNBNNOLU-RHYQMDGZSA-N Leu-Thr-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O AIQWYVFNBNNOLU-RHYQMDGZSA-N 0.000 description 1
- ZGGVHTQAPHVMKM-IHPCNDPISA-N Leu-Trp-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCCCN)C(=O)O)N ZGGVHTQAPHVMKM-IHPCNDPISA-N 0.000 description 1
- WPIKRJDRQVFRHP-TUSQITKMSA-N Leu-Trp-Trp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O WPIKRJDRQVFRHP-TUSQITKMSA-N 0.000 description 1
- WFCKERTZVCQXKH-KBPBESRZSA-N Leu-Tyr-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(O)=O WFCKERTZVCQXKH-KBPBESRZSA-N 0.000 description 1
- FBNPMTNBFFAMMH-UHFFFAOYSA-N Leu-Val-Arg Natural products CC(C)CC(N)C(=O)NC(C(C)C)C(=O)NC(C(O)=O)CCCN=C(N)N FBNPMTNBFFAMMH-UHFFFAOYSA-N 0.000 description 1
- AAKRWBIIGKPOKQ-ONGXEEELSA-N Leu-Val-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O AAKRWBIIGKPOKQ-ONGXEEELSA-N 0.000 description 1
- LMDVGHQPPPLYAR-IHRRRGAJSA-N Leu-Val-His Chemical compound N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)O LMDVGHQPPPLYAR-IHRRRGAJSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 1
- 102100030984 Lymphocyte function-associated antigen 3 Human genes 0.000 description 1
- MPGHETGWWWUHPY-CIUDSAMLSA-N Lys-Ala-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN MPGHETGWWWUHPY-CIUDSAMLSA-N 0.000 description 1
- PNPYKQFJGRFYJE-GUBZILKMSA-N Lys-Ala-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O PNPYKQFJGRFYJE-GUBZILKMSA-N 0.000 description 1
- UWKNTTJNVSYXPC-CIUDSAMLSA-N Lys-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN UWKNTTJNVSYXPC-CIUDSAMLSA-N 0.000 description 1
- ALSRJRIWBNENFY-DCAQKATOSA-N Lys-Arg-Asn Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(O)=O ALSRJRIWBNENFY-DCAQKATOSA-N 0.000 description 1
- CKSXSQUVEYCDIW-AVGNSLFASA-N Lys-Arg-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)N CKSXSQUVEYCDIW-AVGNSLFASA-N 0.000 description 1
- FACUGMGEFUEBTI-SRVKXCTJSA-N Lys-Asn-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CCCCN FACUGMGEFUEBTI-SRVKXCTJSA-N 0.000 description 1
- AAORVPFVUIHEAB-YUMQZZPRSA-N Lys-Asp-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O AAORVPFVUIHEAB-YUMQZZPRSA-N 0.000 description 1
- SVJRVFPSHPGWFF-DCAQKATOSA-N Lys-Cys-Arg Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SVJRVFPSHPGWFF-DCAQKATOSA-N 0.000 description 1
- KSFQPRLZAUXXPT-GARJFASQSA-N Lys-Cys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CS)NC(=O)[C@H](CCCCN)N)C(=O)O KSFQPRLZAUXXPT-GARJFASQSA-N 0.000 description 1
- QQUJSUFWEDZQQY-AVGNSLFASA-N Lys-Gln-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(O)=O)CCCCN QQUJSUFWEDZQQY-AVGNSLFASA-N 0.000 description 1
- ULUQBUKAPDUKOC-GVXVVHGQSA-N Lys-Glu-Val Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O ULUQBUKAPDUKOC-GVXVVHGQSA-N 0.000 description 1
- CANPXOLVTMKURR-WEDXCCLWSA-N Lys-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN CANPXOLVTMKURR-WEDXCCLWSA-N 0.000 description 1
- NNKLKUUGESXCBS-KBPBESRZSA-N Lys-Gly-Tyr Chemical compound [H]N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O NNKLKUUGESXCBS-KBPBESRZSA-N 0.000 description 1
- AIRZWUMAHCDDHR-KKUMJFAQSA-N Lys-Leu-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O AIRZWUMAHCDDHR-KKUMJFAQSA-N 0.000 description 1
- WRODMZBHNNPRLN-SRVKXCTJSA-N Lys-Leu-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O WRODMZBHNNPRLN-SRVKXCTJSA-N 0.000 description 1
- KFSALEZVQJYHCE-AVGNSLFASA-N Lys-Met-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)N KFSALEZVQJYHCE-AVGNSLFASA-N 0.000 description 1
- TWPCWKVOZDUYAA-KKUMJFAQSA-N Lys-Phe-Asp Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(O)=O TWPCWKVOZDUYAA-KKUMJFAQSA-N 0.000 description 1
- UQJOKDAYFULYIX-AVGNSLFASA-N Lys-Pro-Pro Chemical compound NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 UQJOKDAYFULYIX-AVGNSLFASA-N 0.000 description 1
- HMZPYMSEAALNAE-ULQDDVLXSA-N Lys-Val-Tyr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O HMZPYMSEAALNAE-ULQDDVLXSA-N 0.000 description 1
- 102100031520 MAPK/MAK/MRK overlapping kinase Human genes 0.000 description 1
- 206010025652 Malignant melanoma in situ Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 206010027145 Melanocytic naevus Diseases 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- ULNXMMYXQKGNPG-LPEHRKFASA-N Met-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCSC)N ULNXMMYXQKGNPG-LPEHRKFASA-N 0.000 description 1
- ACYHZNZHIZWLQF-BQBZGAKWSA-N Met-Asn-Gly Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O ACYHZNZHIZWLQF-BQBZGAKWSA-N 0.000 description 1
- QXEVZBXTDTVPCP-GMOBBJLQSA-N Met-Asn-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCSC)N QXEVZBXTDTVPCP-GMOBBJLQSA-N 0.000 description 1
- PTYVBBNIAQWUFV-DCAQKATOSA-N Met-Cys-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CCSC)N PTYVBBNIAQWUFV-DCAQKATOSA-N 0.000 description 1
- YLLWCSDBVGZLOW-CIUDSAMLSA-N Met-Gln-Ala Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(O)=O YLLWCSDBVGZLOW-CIUDSAMLSA-N 0.000 description 1
- UYAKZHGIPRCGPF-CIUDSAMLSA-N Met-Glu-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)N UYAKZHGIPRCGPF-CIUDSAMLSA-N 0.000 description 1
- AETNZPKUUYYYEK-CIUDSAMLSA-N Met-Glu-Asn Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O AETNZPKUUYYYEK-CIUDSAMLSA-N 0.000 description 1
- JPCHYAUKOUGOIB-HJGDQZAQSA-N Met-Glu-Thr Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O JPCHYAUKOUGOIB-HJGDQZAQSA-N 0.000 description 1
- OOSPRDCGTLQLBP-NHCYSSNCSA-N Met-Glu-Val Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O OOSPRDCGTLQLBP-NHCYSSNCSA-N 0.000 description 1
- XKJUFUPCHARJKX-UWVGGRQHSA-N Met-Gly-His Chemical compound CSCC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CNC=N1 XKJUFUPCHARJKX-UWVGGRQHSA-N 0.000 description 1
- AFVOKRHYSSFPHC-STECZYCISA-N Met-Ile-Tyr Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 AFVOKRHYSSFPHC-STECZYCISA-N 0.000 description 1
- HZVXPUHLTZRQEL-UWVGGRQHSA-N Met-Leu-Gly Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O HZVXPUHLTZRQEL-UWVGGRQHSA-N 0.000 description 1
- HSJIGJRZYUADSS-IHRRRGAJSA-N Met-Lys-Leu Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O HSJIGJRZYUADSS-IHRRRGAJSA-N 0.000 description 1
- RSOMVHWMIAZNLE-HJWJTTGWSA-N Met-Phe-Ile Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O RSOMVHWMIAZNLE-HJWJTTGWSA-N 0.000 description 1
- PHKBGZKVOJCIMZ-SRVKXCTJSA-N Met-Pro-Arg Chemical compound CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O PHKBGZKVOJCIMZ-SRVKXCTJSA-N 0.000 description 1
- YLDSJJOGQNEQJK-AVGNSLFASA-N Met-Pro-Leu Chemical compound CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(O)=O YLDSJJOGQNEQJK-AVGNSLFASA-N 0.000 description 1
- WXXNVZMWHOLNRJ-AVGNSLFASA-N Met-Pro-Lys Chemical compound CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(O)=O WXXNVZMWHOLNRJ-AVGNSLFASA-N 0.000 description 1
- RDLSEGZJMYGFNS-FXQIFTODSA-N Met-Ser-Asp Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O RDLSEGZJMYGFNS-FXQIFTODSA-N 0.000 description 1
- LXCSZPUQKMTXNW-BQBZGAKWSA-N Met-Ser-Gly Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O LXCSZPUQKMTXNW-BQBZGAKWSA-N 0.000 description 1
- PHURAEXVWLDIGT-LPEHRKFASA-N Met-Ser-Pro Chemical compound CSCC[C@@H](C(=O)N[C@@H](CO)C(=O)N1CCC[C@@H]1C(=O)O)N PHURAEXVWLDIGT-LPEHRKFASA-N 0.000 description 1
- YGNUDKAPJARTEM-GUBZILKMSA-N Met-Val-Ala Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O YGNUDKAPJARTEM-GUBZILKMSA-N 0.000 description 1
- VYDLZDRMOFYOGV-TUAOUCFPSA-N Met-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCSC)N VYDLZDRMOFYOGV-TUAOUCFPSA-N 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 1
- 102100026262 Metalloproteinase inhibitor 2 Human genes 0.000 description 1
- 102100026261 Metalloproteinase inhibitor 3 Human genes 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 108010008707 Mucin-1 Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101710107068 Myelin basic protein Proteins 0.000 description 1
- SGSSKEDGVONRGC-UHFFFAOYSA-N N(2)-methylguanine Chemical compound O=C1NC(NC)=NC2=C1N=CN2 SGSSKEDGVONRGC-UHFFFAOYSA-N 0.000 description 1
- WUGMRIBZSVSJNP-UHFFFAOYSA-N N-L-alanyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)C)C(O)=O)=CNC2=C1 WUGMRIBZSVSJNP-UHFFFAOYSA-N 0.000 description 1
- PESQCPHRXOFIPX-UHFFFAOYSA-N N-L-methionyl-L-tyrosine Natural products CSCCC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 PESQCPHRXOFIPX-UHFFFAOYSA-N 0.000 description 1
- 108010047562 NGR peptide Proteins 0.000 description 1
- BQVUABVGYYSDCJ-UHFFFAOYSA-N Nalpha-L-Leucyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)CC(C)C)C(O)=O)=CNC2=C1 BQVUABVGYYSDCJ-UHFFFAOYSA-N 0.000 description 1
- 101100202924 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) tsp-2 gene Proteins 0.000 description 1
- 208000007256 Nevus Diseases 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 206010029488 Nodular melanoma Diseases 0.000 description 1
- MSHZHSPISPJWHW-UHFFFAOYSA-N O-(chloroacetylcarbamoyl)fumagillol Chemical compound O1C(CC=C(C)C)C1(C)C1C(OC)C(OC(=O)NC(=O)CCl)CCC21CO2 MSHZHSPISPJWHW-UHFFFAOYSA-N 0.000 description 1
- 230000004989 O-glycosylation Effects 0.000 description 1
- 235000010676 Ocimum basilicum Nutrition 0.000 description 1
- 240000007926 Ocimum gratissimum Species 0.000 description 1
- 108010016076 Octreotide Proteins 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 102100028293 Period circadian protein homolog 1 Human genes 0.000 description 1
- BKWJQWJPZMUWEG-LFSVMHDDSA-N Phe-Ala-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=CC=C1 BKWJQWJPZMUWEG-LFSVMHDDSA-N 0.000 description 1
- DPUOLKQSMYLRDR-UBHSHLNASA-N Phe-Arg-Ala Chemical compound NC(N)=NCCC[C@@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 DPUOLKQSMYLRDR-UBHSHLNASA-N 0.000 description 1
- DDYIRGBOZVKRFR-AVGNSLFASA-N Phe-Asp-Glu Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N DDYIRGBOZVKRFR-AVGNSLFASA-N 0.000 description 1
- IUVYJBMTHARMIP-PCBIJLKTSA-N Phe-Asp-Ile Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O IUVYJBMTHARMIP-PCBIJLKTSA-N 0.000 description 1
- UMKYAYXCMYYNHI-AVGNSLFASA-N Phe-Gln-Asn Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)O)N UMKYAYXCMYYNHI-AVGNSLFASA-N 0.000 description 1
- KAGCQPSEVAETCA-JYJNAYRXSA-N Phe-Gln-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC1=CC=CC=C1)N KAGCQPSEVAETCA-JYJNAYRXSA-N 0.000 description 1
- FIRWJEJVFFGXSH-RYUDHWBXSA-N Phe-Glu-Gly Chemical compound OC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 FIRWJEJVFFGXSH-RYUDHWBXSA-N 0.000 description 1
- NHCKESBLOMHIIE-IRXDYDNUSA-N Phe-Gly-Phe Chemical compound C([C@H](N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 NHCKESBLOMHIIE-IRXDYDNUSA-N 0.000 description 1
- SPXWRYVHOZVYBU-ULQDDVLXSA-N Phe-His-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CC2=CC=CC=C2)N SPXWRYVHOZVYBU-ULQDDVLXSA-N 0.000 description 1
- KXUZHWXENMYOHC-QEJZJMRPSA-N Phe-Leu-Ala Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O KXUZHWXENMYOHC-QEJZJMRPSA-N 0.000 description 1
- KBVJZCVLQWCJQN-KKUMJFAQSA-N Phe-Leu-Asn Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O KBVJZCVLQWCJQN-KKUMJFAQSA-N 0.000 description 1
- SMFGCTXUBWEPKM-KBPBESRZSA-N Phe-Leu-Gly Chemical compound OC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 SMFGCTXUBWEPKM-KBPBESRZSA-N 0.000 description 1
- YTILBRIUASDGBL-BZSNNMDCSA-N Phe-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 YTILBRIUASDGBL-BZSNNMDCSA-N 0.000 description 1
- CMHTUJQZQXFNTQ-OEAJRASXSA-N Phe-Leu-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)N)O CMHTUJQZQXFNTQ-OEAJRASXSA-N 0.000 description 1
- RMKGXGPQIPLTFC-KKUMJFAQSA-N Phe-Lys-Asn Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O RMKGXGPQIPLTFC-KKUMJFAQSA-N 0.000 description 1
- JDMKQHSHKJHAHR-UHFFFAOYSA-N Phe-Phe-Leu-Tyr Natural products C=1C=C(O)C=CC=1CC(C(O)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)CC1=CC=CC=C1 JDMKQHSHKJHAHR-UHFFFAOYSA-N 0.000 description 1
- WKLMCMXFMQEKCX-SLFFLAALSA-N Phe-Phe-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC3=CC=CC=C3)N)C(=O)O WKLMCMXFMQEKCX-SLFFLAALSA-N 0.000 description 1
- IIEOLPMQYRBZCN-SRVKXCTJSA-N Phe-Ser-Cys Chemical compound N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O IIEOLPMQYRBZCN-SRVKXCTJSA-N 0.000 description 1
- HBXAOEBRGLCLIW-AVGNSLFASA-N Phe-Ser-Gln Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N HBXAOEBRGLCLIW-AVGNSLFASA-N 0.000 description 1
- ILGCZYGFYQLSDZ-KKUMJFAQSA-N Phe-Ser-His Chemical compound N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O ILGCZYGFYQLSDZ-KKUMJFAQSA-N 0.000 description 1
- IPFXYNKCXYGSSV-KKUMJFAQSA-N Phe-Ser-Lys Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)O)N IPFXYNKCXYGSSV-KKUMJFAQSA-N 0.000 description 1
- MSSXKZBDKZAHCX-UNQGMJICSA-N Phe-Thr-Val Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O MSSXKZBDKZAHCX-UNQGMJICSA-N 0.000 description 1
- ZYNBEWGJFXTBDU-ACRUOGEOSA-N Phe-Tyr-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CC2=CC=CC=C2)N ZYNBEWGJFXTBDU-ACRUOGEOSA-N 0.000 description 1
- KUSYCSMTTHSZOA-DZKIICNBSA-N Phe-Val-Gln Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N KUSYCSMTTHSZOA-DZKIICNBSA-N 0.000 description 1
- JTKGCYOOJLUETJ-ULQDDVLXSA-N Phe-Val-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 JTKGCYOOJLUETJ-ULQDDVLXSA-N 0.000 description 1
- APZNYJFGVAGFCF-JYJNAYRXSA-N Phe-Val-Val Chemical compound CC(C)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)Cc1ccccc1)C(C)C)C(O)=O APZNYJFGVAGFCF-JYJNAYRXSA-N 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 1
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 description 1
- AJLVKXCNXIJHDV-CIUDSAMLSA-N Pro-Ala-Gln Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(O)=O AJLVKXCNXIJHDV-CIUDSAMLSA-N 0.000 description 1
- CGBYDGAJHSOGFQ-LPEHRKFASA-N Pro-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@@H]2CCCN2 CGBYDGAJHSOGFQ-LPEHRKFASA-N 0.000 description 1
- HFZNNDWPHBRNPV-KZVJFYERSA-N Pro-Ala-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O HFZNNDWPHBRNPV-KZVJFYERSA-N 0.000 description 1
- OOLOTUZJUBOMAX-GUBZILKMSA-N Pro-Ala-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O OOLOTUZJUBOMAX-GUBZILKMSA-N 0.000 description 1
- OLHDPZMYUSBGDE-GUBZILKMSA-N Pro-Arg-Cys Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CS)C(=O)O OLHDPZMYUSBGDE-GUBZILKMSA-N 0.000 description 1
- QSKCKTUQPICLSO-AVGNSLFASA-N Pro-Arg-Lys Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)O QSKCKTUQPICLSO-AVGNSLFASA-N 0.000 description 1
- OYEUSRAZOGIDBY-JYJNAYRXSA-N Pro-Arg-Tyr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O OYEUSRAZOGIDBY-JYJNAYRXSA-N 0.000 description 1
- ORPZXBQTEHINPB-SRVKXCTJSA-N Pro-Arg-Val Chemical compound CC(C)[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1)C(O)=O ORPZXBQTEHINPB-SRVKXCTJSA-N 0.000 description 1
- WECYCNFPGZLOOU-FXQIFTODSA-N Pro-Asn-Cys Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CS)C(=O)O WECYCNFPGZLOOU-FXQIFTODSA-N 0.000 description 1
- SWXSLPHTJVAWDF-VEVYYDQMSA-N Pro-Asn-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SWXSLPHTJVAWDF-VEVYYDQMSA-N 0.000 description 1
- JARJPEMLQAWNBR-GUBZILKMSA-N Pro-Asp-Arg Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O JARJPEMLQAWNBR-GUBZILKMSA-N 0.000 description 1
- KPDRZQUWJKTMBP-DCAQKATOSA-N Pro-Asp-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H]1CCCN1 KPDRZQUWJKTMBP-DCAQKATOSA-N 0.000 description 1
- DEDANIDYQAPTFI-IHRRRGAJSA-N Pro-Asp-Tyr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O DEDANIDYQAPTFI-IHRRRGAJSA-N 0.000 description 1
- UPJGUQPLYWTISV-GUBZILKMSA-N Pro-Gln-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O UPJGUQPLYWTISV-GUBZILKMSA-N 0.000 description 1
- ZPPVJIJMIKTERM-YUMQZZPRSA-N Pro-Gln-Gly Chemical compound OC(=O)CNC(=O)[C@H](CCC(=O)N)NC(=O)[C@@H]1CCCN1 ZPPVJIJMIKTERM-YUMQZZPRSA-N 0.000 description 1
- PULPZRAHVFBVTO-DCAQKATOSA-N Pro-Glu-Arg Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O PULPZRAHVFBVTO-DCAQKATOSA-N 0.000 description 1
- KIPIKSXPPLABPN-CIUDSAMLSA-N Pro-Glu-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CCCN1 KIPIKSXPPLABPN-CIUDSAMLSA-N 0.000 description 1
- VPFGPKIWSDVTOY-SRVKXCTJSA-N Pro-Glu-His Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O VPFGPKIWSDVTOY-SRVKXCTJSA-N 0.000 description 1
- UEHYFUCOGHWASA-HJGDQZAQSA-N Pro-Glu-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CCCN1 UEHYFUCOGHWASA-HJGDQZAQSA-N 0.000 description 1
- DMKWYMWNEKIPFC-IUCAKERBSA-N Pro-Gly-Arg Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O DMKWYMWNEKIPFC-IUCAKERBSA-N 0.000 description 1
- UUHXBJHVTVGSKM-BQBZGAKWSA-N Pro-Gly-Asn Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O UUHXBJHVTVGSKM-BQBZGAKWSA-N 0.000 description 1
- WSRWHZRUOCACLJ-UWVGGRQHSA-N Pro-Gly-His Chemical compound C([C@@H](C(=O)O)NC(=O)CNC(=O)[C@H]1NCCC1)C1=CN=CN1 WSRWHZRUOCACLJ-UWVGGRQHSA-N 0.000 description 1
- FEPSEIDIPBMIOS-QXEWZRGKSA-N Pro-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H]1CCCN1 FEPSEIDIPBMIOS-QXEWZRGKSA-N 0.000 description 1
- FFSLAIOXRMOFIZ-GJZGRUSLSA-N Pro-Gly-Trp Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)CNC(=O)[C@@H]1CCCN1 FFSLAIOXRMOFIZ-GJZGRUSLSA-N 0.000 description 1
- BFXZQMWKTYWGCF-PYJNHQTQSA-N Pro-His-Ile Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O BFXZQMWKTYWGCF-PYJNHQTQSA-N 0.000 description 1
- FXGIMYRVJJEIIM-UWVGGRQHSA-N Pro-Leu-Gly Chemical compound OC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1 FXGIMYRVJJEIIM-UWVGGRQHSA-N 0.000 description 1
- RMODQFBNDDENCP-IHRRRGAJSA-N Pro-Lys-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O RMODQFBNDDENCP-IHRRRGAJSA-N 0.000 description 1
- QCMYJBKTMIWZAP-AVGNSLFASA-N Pro-Met-Lys Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@@H]1CCCN1 QCMYJBKTMIWZAP-AVGNSLFASA-N 0.000 description 1
- NAIPAPCKKRCMBL-JYJNAYRXSA-N Pro-Pro-Phe Chemical compound C([C@@H](C(=O)O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1NCCC1)C1=CC=CC=C1 NAIPAPCKKRCMBL-JYJNAYRXSA-N 0.000 description 1
- SBVPYBFMIGDIDX-SRVKXCTJSA-N Pro-Pro-Pro Chemical compound OC(=O)[C@@H]1CCCN1C(=O)[C@H]1N(C(=O)[C@H]2NCCC2)CCC1 SBVPYBFMIGDIDX-SRVKXCTJSA-N 0.000 description 1
- OWQXAJQZLWHPBH-FXQIFTODSA-N Pro-Ser-Asn Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O OWQXAJQZLWHPBH-FXQIFTODSA-N 0.000 description 1
- ITUDDXVFGFEKPD-NAKRPEOUSA-N Pro-Ser-Ile Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O ITUDDXVFGFEKPD-NAKRPEOUSA-N 0.000 description 1
- SXJOPONICMGFCR-DCAQKATOSA-N Pro-Ser-Lys Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)O SXJOPONICMGFCR-DCAQKATOSA-N 0.000 description 1
- SNGZLPOXVRTNMB-LPEHRKFASA-N Pro-Ser-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CO)C(=O)N2CCC[C@@H]2C(=O)O SNGZLPOXVRTNMB-LPEHRKFASA-N 0.000 description 1
- XSXABUHLKPUVLX-JYJNAYRXSA-N Pro-Ser-Trp Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)O XSXABUHLKPUVLX-JYJNAYRXSA-N 0.000 description 1
- GZNYIXWOIUFLGO-ZJDVBMNYSA-N Pro-Thr-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GZNYIXWOIUFLGO-ZJDVBMNYSA-N 0.000 description 1
- ZYJMLBCDFPIGNL-JYJNAYRXSA-N Pro-Tyr-Arg Chemical compound NC(=N)NCCC[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H]1CCCN1)C(O)=O ZYJMLBCDFPIGNL-JYJNAYRXSA-N 0.000 description 1
- YHUBAXGAAYULJY-ULQDDVLXSA-N Pro-Tyr-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O YHUBAXGAAYULJY-ULQDDVLXSA-N 0.000 description 1
- OQSGBXGNAFQGGS-CYDGBPFRSA-N Pro-Val-Ile Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O OQSGBXGNAFQGGS-CYDGBPFRSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 108010079005 RDV peptide Proteins 0.000 description 1
- 241001428754 Rat leukemia virus Species 0.000 description 1
- 241000713810 Rat sarcoma virus Species 0.000 description 1
- 101000884281 Rattus norvegicus Signal transducer CD24 Proteins 0.000 description 1
- 102000000505 Ribonucleotide Reductases Human genes 0.000 description 1
- 108010041388 Ribonucleotide Reductases Proteins 0.000 description 1
- 101710186154 S-adenosylmethionine synthase 1 Proteins 0.000 description 1
- 102100026115 S-adenosylmethionine synthase isoform type-1 Human genes 0.000 description 1
- 101710167538 S-adenosylmethionine synthase isoform type-1 Proteins 0.000 description 1
- 108010005173 SERPIN-B5 Proteins 0.000 description 1
- 102100024171 STE20-related kinase adapter protein alpha Human genes 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- ZUGXSSFMTXKHJS-ZLUOBGJFSA-N Ser-Ala-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O ZUGXSSFMTXKHJS-ZLUOBGJFSA-N 0.000 description 1
- JPIDMRXXNMIVKY-VZFHVOOUSA-N Ser-Ala-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O JPIDMRXXNMIVKY-VZFHVOOUSA-N 0.000 description 1
- NLQUOHDCLSFABG-GUBZILKMSA-N Ser-Arg-Arg Chemical compound NC(N)=NCCC[C@H](NC(=O)[C@H](CO)N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O NLQUOHDCLSFABG-GUBZILKMSA-N 0.000 description 1
- VAIZFHMTBFYJIA-ACZMJKKPSA-N Ser-Asp-Gln Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCC(N)=O VAIZFHMTBFYJIA-ACZMJKKPSA-N 0.000 description 1
- FTVRVZNYIYWJGB-ACZMJKKPSA-N Ser-Asp-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O FTVRVZNYIYWJGB-ACZMJKKPSA-N 0.000 description 1
- OLIJLNWFEQEFDM-SRVKXCTJSA-N Ser-Asp-Phe Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 OLIJLNWFEQEFDM-SRVKXCTJSA-N 0.000 description 1
- RNFKSBPHLTZHLU-WHFBIAKZSA-N Ser-Cys-Gly Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)NCC(=O)O)N)O RNFKSBPHLTZHLU-WHFBIAKZSA-N 0.000 description 1
- DSSOYPJWSWFOLK-CIUDSAMLSA-N Ser-Cys-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(O)=O DSSOYPJWSWFOLK-CIUDSAMLSA-N 0.000 description 1
- ULVMNZOKDBHKKI-ACZMJKKPSA-N Ser-Gln-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O ULVMNZOKDBHKKI-ACZMJKKPSA-N 0.000 description 1
- IXUGADGDCQDLSA-FXQIFTODSA-N Ser-Gln-Gln Chemical compound C(CC(=O)N)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CO)N IXUGADGDCQDLSA-FXQIFTODSA-N 0.000 description 1
- ZOHGLPQGEHSLPD-FXQIFTODSA-N Ser-Gln-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O ZOHGLPQGEHSLPD-FXQIFTODSA-N 0.000 description 1
- DGHFNYXVIXNNMC-GUBZILKMSA-N Ser-Gln-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)N DGHFNYXVIXNNMC-GUBZILKMSA-N 0.000 description 1
- FMDHKPRACUXATF-ACZMJKKPSA-N Ser-Gln-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O FMDHKPRACUXATF-ACZMJKKPSA-N 0.000 description 1
- DSGYZICNAMEJOC-AVGNSLFASA-N Ser-Glu-Phe Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O DSGYZICNAMEJOC-AVGNSLFASA-N 0.000 description 1
- BPMRXBZYPGYPJN-WHFBIAKZSA-N Ser-Gly-Asn Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O BPMRXBZYPGYPJN-WHFBIAKZSA-N 0.000 description 1
- YMTLKLXDFCSCNX-BYPYZUCNSA-N Ser-Gly-Gly Chemical compound OC[C@H](N)C(=O)NCC(=O)NCC(O)=O YMTLKLXDFCSCNX-BYPYZUCNSA-N 0.000 description 1
- IXCHOHLPHNGFTJ-YUMQZZPRSA-N Ser-Gly-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CO)N IXCHOHLPHNGFTJ-YUMQZZPRSA-N 0.000 description 1
- KDGARKCAKHBEDB-NKWVEPMBSA-N Ser-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CO)N)C(=O)O KDGARKCAKHBEDB-NKWVEPMBSA-N 0.000 description 1
- UIGMAMGZOJVTDN-WHFBIAKZSA-N Ser-Gly-Ser Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O UIGMAMGZOJVTDN-WHFBIAKZSA-N 0.000 description 1
- XXXAXOWMBOKTRN-XPUUQOCRSA-N Ser-Gly-Val Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O XXXAXOWMBOKTRN-XPUUQOCRSA-N 0.000 description 1
- RIAKPZVSNBBNRE-BJDJZHNGSA-N Ser-Ile-Leu Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O RIAKPZVSNBBNRE-BJDJZHNGSA-N 0.000 description 1
- UIPXCLNLUUAMJU-JBDRJPRFSA-N Ser-Ile-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O UIPXCLNLUUAMJU-JBDRJPRFSA-N 0.000 description 1
- DOSZISJPMCYEHT-NAKRPEOUSA-N Ser-Ile-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(O)=O DOSZISJPMCYEHT-NAKRPEOUSA-N 0.000 description 1
- NLOAIFSWUUFQFR-CIUDSAMLSA-N Ser-Leu-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O NLOAIFSWUUFQFR-CIUDSAMLSA-N 0.000 description 1
- VMLONWHIORGALA-SRVKXCTJSA-N Ser-Leu-Leu Chemical compound CC(C)C[C@@H](C([O-])=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]([NH3+])CO VMLONWHIORGALA-SRVKXCTJSA-N 0.000 description 1
- YUJLIIRMIAGMCQ-CIUDSAMLSA-N Ser-Leu-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YUJLIIRMIAGMCQ-CIUDSAMLSA-N 0.000 description 1
- NNFMANHDYSVNIO-DCAQKATOSA-N Ser-Lys-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O NNFMANHDYSVNIO-DCAQKATOSA-N 0.000 description 1
- XUDRHBPSPAPDJP-SRVKXCTJSA-N Ser-Lys-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CO XUDRHBPSPAPDJP-SRVKXCTJSA-N 0.000 description 1
- PMCMLDNPAZUYGI-DCAQKATOSA-N Ser-Lys-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O PMCMLDNPAZUYGI-DCAQKATOSA-N 0.000 description 1
- JAWGSPUJAXYXJA-IHRRRGAJSA-N Ser-Phe-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CO)N)CC1=CC=CC=C1 JAWGSPUJAXYXJA-IHRRRGAJSA-N 0.000 description 1
- UPLYXVPQLJVWMM-KKUMJFAQSA-N Ser-Phe-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O UPLYXVPQLJVWMM-KKUMJFAQSA-N 0.000 description 1
- MQUZANJDFOQOBX-SRVKXCTJSA-N Ser-Phe-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(O)=O MQUZANJDFOQOBX-SRVKXCTJSA-N 0.000 description 1
- FBLNYDYPCLFTSP-IXOXFDKPSA-N Ser-Phe-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O FBLNYDYPCLFTSP-IXOXFDKPSA-N 0.000 description 1
- PJIQEIFXZPCWOJ-FXQIFTODSA-N Ser-Pro-Asp Chemical compound [H]N[C@@H](CO)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(O)=O PJIQEIFXZPCWOJ-FXQIFTODSA-N 0.000 description 1
- AZWNCEBQZXELEZ-FXQIFTODSA-N Ser-Pro-Ser Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O AZWNCEBQZXELEZ-FXQIFTODSA-N 0.000 description 1
- WLJPJRGQRNCIQS-ZLUOBGJFSA-N Ser-Ser-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O WLJPJRGQRNCIQS-ZLUOBGJFSA-N 0.000 description 1
- PPCZVWHJWJFTFN-ZLUOBGJFSA-N Ser-Ser-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O PPCZVWHJWJFTFN-ZLUOBGJFSA-N 0.000 description 1
- PYTKULIABVRXSC-BWBBJGPYSA-N Ser-Ser-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PYTKULIABVRXSC-BWBBJGPYSA-N 0.000 description 1
- SZRNDHWMVSFPSP-XKBZYTNZSA-N Ser-Thr-Gln Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CO)N)O SZRNDHWMVSFPSP-XKBZYTNZSA-N 0.000 description 1
- DYEGLQRVMBWQLD-IXOXFDKPSA-N Ser-Thr-Phe Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CO)N)O DYEGLQRVMBWQLD-IXOXFDKPSA-N 0.000 description 1
- PIQRHJQWEPWFJG-UWJYBYFXSA-N Ser-Tyr-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C)C(O)=O PIQRHJQWEPWFJG-UWJYBYFXSA-N 0.000 description 1
- KIEIJCFVGZCUAS-MELADBBJSA-N Ser-Tyr-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)N)C(=O)O KIEIJCFVGZCUAS-MELADBBJSA-N 0.000 description 1
- PCMZJFMUYWIERL-ZKWXMUAHSA-N Ser-Val-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O PCMZJFMUYWIERL-ZKWXMUAHSA-N 0.000 description 1
- UKKROEYWYIHWBD-ZKWXMUAHSA-N Ser-Val-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O UKKROEYWYIHWBD-ZKWXMUAHSA-N 0.000 description 1
- BEBVVQPDSHHWQL-NRPADANISA-N Ser-Val-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O BEBVVQPDSHHWQL-NRPADANISA-N 0.000 description 1
- HSWXBJCBYSWBPT-GUBZILKMSA-N Ser-Val-Val Chemical compound CC(C)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)C(O)=O HSWXBJCBYSWBPT-GUBZILKMSA-N 0.000 description 1
- 102100030333 Serpin B5 Human genes 0.000 description 1
- 101710173693 Short transient receptor potential channel 1 Proteins 0.000 description 1
- 102100028402 Shugoshin 1 Human genes 0.000 description 1
- 102100038081 Signal transducer CD24 Human genes 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000018246 Solanum hyporhodium Nutrition 0.000 description 1
- 244000070646 Solanum topiro Species 0.000 description 1
- 235000018256 Solanum topiro Nutrition 0.000 description 1
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010042553 Superficial spreading melanoma stage unspecified Diseases 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 102000004399 TNF receptor-associated factor 3 Human genes 0.000 description 1
- 108090000922 TNF receptor-associated factor 3 Proteins 0.000 description 1
- 101710192266 Tegument protein VP22 Proteins 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 241001067453 Therion Species 0.000 description 1
- IGROJMCBGRFRGI-YTLHQDLWSA-N Thr-Ala-Ala Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O IGROJMCBGRFRGI-YTLHQDLWSA-N 0.000 description 1
- OJRNZRROAIAHDL-LKXGYXEUSA-N Thr-Asn-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O OJRNZRROAIAHDL-LKXGYXEUSA-N 0.000 description 1
- QWMPARMKIDVBLV-VZFHVOOUSA-N Thr-Cys-Ala Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@@H](C)C(O)=O QWMPARMKIDVBLV-VZFHVOOUSA-N 0.000 description 1
- ZLNWJMRLHLGKFX-SVSWQMSJSA-N Thr-Cys-Ile Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O ZLNWJMRLHLGKFX-SVSWQMSJSA-N 0.000 description 1
- ASJDFGOPDCVXTG-KATARQTJSA-N Thr-Cys-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(O)=O ASJDFGOPDCVXTG-KATARQTJSA-N 0.000 description 1
- QILPDQCTQZDHFM-HJGDQZAQSA-N Thr-Gln-Arg Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O QILPDQCTQZDHFM-HJGDQZAQSA-N 0.000 description 1
- GUZGCDIZVGODML-NKIYYHGXSA-N Thr-Gln-His Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N)O GUZGCDIZVGODML-NKIYYHGXSA-N 0.000 description 1
- UDQBCBUXAQIZAK-GLLZPBPUSA-N Thr-Glu-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O UDQBCBUXAQIZAK-GLLZPBPUSA-N 0.000 description 1
- AMXMBCAXAZUCFA-RHYQMDGZSA-N Thr-Leu-Arg Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O AMXMBCAXAZUCFA-RHYQMDGZSA-N 0.000 description 1
- HOVLHEKTGVIKAP-WDCWCFNPSA-N Thr-Leu-Gln Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O HOVLHEKTGVIKAP-WDCWCFNPSA-N 0.000 description 1
- RFKVQLIXNVEOMB-WEDXCCLWSA-N Thr-Leu-Gly Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)O)N)O RFKVQLIXNVEOMB-WEDXCCLWSA-N 0.000 description 1
- MECLEFZMPPOEAC-VOAKCMCISA-N Thr-Leu-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)O)N)O MECLEFZMPPOEAC-VOAKCMCISA-N 0.000 description 1
- YOOAQCZYZHGUAZ-KATARQTJSA-N Thr-Leu-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YOOAQCZYZHGUAZ-KATARQTJSA-N 0.000 description 1
- CJXURNZYNHCYFD-WDCWCFNPSA-N Thr-Lys-Gln Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N)O CJXURNZYNHCYFD-WDCWCFNPSA-N 0.000 description 1
- PCMDGXKXVMBIFP-VEVYYDQMSA-N Thr-Met-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(O)=O PCMDGXKXVMBIFP-VEVYYDQMSA-N 0.000 description 1
- KDGBLMDAPJTQIW-RHYQMDGZSA-N Thr-Met-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)O)N)O KDGBLMDAPJTQIW-RHYQMDGZSA-N 0.000 description 1
- KZURUCDWKDEAFZ-XVSYOHENSA-N Thr-Phe-Asn Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(=O)N)C(=O)O)N)O KZURUCDWKDEAFZ-XVSYOHENSA-N 0.000 description 1
- DEGCBBCMYWNJNA-RHYQMDGZSA-N Thr-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)[C@@H](C)O DEGCBBCMYWNJNA-RHYQMDGZSA-N 0.000 description 1
- STUAPCLEDMKXKL-LKXGYXEUSA-N Thr-Ser-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O STUAPCLEDMKXKL-LKXGYXEUSA-N 0.000 description 1
- SGAOHNPSEPVAFP-ZDLURKLDSA-N Thr-Ser-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)NCC(O)=O SGAOHNPSEPVAFP-ZDLURKLDSA-N 0.000 description 1
- HUPLKEHTTQBXSC-YJRXYDGGSA-N Thr-Ser-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 HUPLKEHTTQBXSC-YJRXYDGGSA-N 0.000 description 1
- ZMYCLHFLHRVOEA-HEIBUPTGSA-N Thr-Thr-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O ZMYCLHFLHRVOEA-HEIBUPTGSA-N 0.000 description 1
- COYHRQWNJDJCNA-NUJDXYNKSA-N Thr-Thr-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O COYHRQWNJDJCNA-NUJDXYNKSA-N 0.000 description 1
- VEENWOSZGWWKHW-SZZJOZGLSA-N Thr-Trp-His Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC3=CN=CN3)C(=O)O)N)O VEENWOSZGWWKHW-SZZJOZGLSA-N 0.000 description 1
- REJRKTOJTCPDPO-IRIUXVKKSA-N Thr-Tyr-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O REJRKTOJTCPDPO-IRIUXVKKSA-N 0.000 description 1
- JAWUQFCGNVEDRN-MEYUZBJRSA-N Thr-Tyr-Leu Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(C)C)C(=O)O)N)O JAWUQFCGNVEDRN-MEYUZBJRSA-N 0.000 description 1
- BKIOKSLLAAZYTC-KKHAAJSZSA-N Thr-Val-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O BKIOKSLLAAZYTC-KKHAAJSZSA-N 0.000 description 1
- BKVICMPZWRNWOC-RHYQMDGZSA-N Thr-Val-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)[C@@H](C)O BKVICMPZWRNWOC-RHYQMDGZSA-N 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 102000005497 Thymidylate Synthase Human genes 0.000 description 1
- 108010031374 Tissue Inhibitor of Metalloproteinase-1 Proteins 0.000 description 1
- 108010031372 Tissue Inhibitor of Metalloproteinase-2 Proteins 0.000 description 1
- 108010031429 Tissue Inhibitor of Metalloproteinase-3 Proteins 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 102400001320 Transforming growth factor alpha Human genes 0.000 description 1
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- MJBBMTOGSOSAKJ-HJXMPXNTSA-N Trp-Ala-Ile Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O MJBBMTOGSOSAKJ-HJXMPXNTSA-N 0.000 description 1
- BXKWZPXTTSCOMX-AQZXSJQPSA-N Trp-Asn-Thr Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O BXKWZPXTTSCOMX-AQZXSJQPSA-N 0.000 description 1
- CZWIHKFGHICAJX-BPUTZDHNSA-N Trp-Glu-Glu Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O)=CNC2=C1 CZWIHKFGHICAJX-BPUTZDHNSA-N 0.000 description 1
- SNJAPSVIPKUMCK-NWLDYVSISA-N Trp-Glu-Thr Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SNJAPSVIPKUMCK-NWLDYVSISA-N 0.000 description 1
- YYXIWHBHTARPOG-HJXMPXNTSA-N Trp-Ile-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N YYXIWHBHTARPOG-HJXMPXNTSA-N 0.000 description 1
- YDTKYBHPRULROG-LTHWPDAASA-N Trp-Ile-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N YDTKYBHPRULROG-LTHWPDAASA-N 0.000 description 1
- FBGDDUKYOBNZJL-WDSOQIARSA-N Trp-Met-Lys Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N FBGDDUKYOBNZJL-WDSOQIARSA-N 0.000 description 1
- LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 description 1
- IVBJBFSWJDNQFW-XIRDDKMYSA-N Trp-Pro-Glu Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O IVBJBFSWJDNQFW-XIRDDKMYSA-N 0.000 description 1
- SEXRBCGSZRCIPE-LYSGOOTNSA-N Trp-Thr-Gly Chemical compound C[C@H]([C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N)O SEXRBCGSZRCIPE-LYSGOOTNSA-N 0.000 description 1
- SUGLEXVWEJOCGN-ONUFPDRFSA-N Trp-Thr-Trp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)N)O SUGLEXVWEJOCGN-ONUFPDRFSA-N 0.000 description 1
- 102100040418 Tumor protein D52 Human genes 0.000 description 1
- 101710190247 Tumor protein D52 Proteins 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 102400000731 Tumstatin Human genes 0.000 description 1
- DKKHULUSOSWGHS-UWJYBYFXSA-N Tyr-Asn-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC1=CC=C(C=C1)O)N DKKHULUSOSWGHS-UWJYBYFXSA-N 0.000 description 1
- CKKFTIQYURNSEI-IHRRRGAJSA-N Tyr-Asn-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 CKKFTIQYURNSEI-IHRRRGAJSA-N 0.000 description 1
- CYDVHRFXDMDMGX-KKUMJFAQSA-N Tyr-Asn-His Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)N)O CYDVHRFXDMDMGX-KKUMJFAQSA-N 0.000 description 1
- AYHSJESDFKREAR-KKUMJFAQSA-N Tyr-Asn-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 AYHSJESDFKREAR-KKUMJFAQSA-N 0.000 description 1
- SCCKSNREWHMKOJ-SRVKXCTJSA-N Tyr-Asn-Ser Chemical compound N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O SCCKSNREWHMKOJ-SRVKXCTJSA-N 0.000 description 1
- JWHOIHCOHMZSAR-QWRGUYRKSA-N Tyr-Asp-Gly Chemical compound OC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 JWHOIHCOHMZSAR-QWRGUYRKSA-N 0.000 description 1
- ARPONUQDNWLXOZ-KKUMJFAQSA-N Tyr-Gln-Arg Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O ARPONUQDNWLXOZ-KKUMJFAQSA-N 0.000 description 1
- QUILOGWWLXMSAT-IHRRRGAJSA-N Tyr-Gln-Gln Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O QUILOGWWLXMSAT-IHRRRGAJSA-N 0.000 description 1
- HKYTWJOWZTWBQB-AVGNSLFASA-N Tyr-Glu-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 HKYTWJOWZTWBQB-AVGNSLFASA-N 0.000 description 1
- FMOSEWZYZPMJAL-KKUMJFAQSA-N Tyr-Glu-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N FMOSEWZYZPMJAL-KKUMJFAQSA-N 0.000 description 1
- HDSKHCBAVVWPCQ-FHWLQOOXSA-N Tyr-Glu-Phe Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O HDSKHCBAVVWPCQ-FHWLQOOXSA-N 0.000 description 1
- NMKJPMCEKQHRPD-IRXDYDNUSA-N Tyr-Gly-Tyr Chemical compound C([C@H](N)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 NMKJPMCEKQHRPD-IRXDYDNUSA-N 0.000 description 1
- AVIQBBOOTZENLH-KKUMJFAQSA-N Tyr-Leu-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N AVIQBBOOTZENLH-KKUMJFAQSA-N 0.000 description 1
- GITNQBVCEQBDQC-KKUMJFAQSA-N Tyr-Lys-Asn Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O GITNQBVCEQBDQC-KKUMJFAQSA-N 0.000 description 1
- JXGUUJMPCRXMSO-HJOGWXRNSA-N Tyr-Phe-Phe Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 JXGUUJMPCRXMSO-HJOGWXRNSA-N 0.000 description 1
- BIWVVOHTKDLRMP-ULQDDVLXSA-N Tyr-Pro-Leu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(O)=O BIWVVOHTKDLRMP-ULQDDVLXSA-N 0.000 description 1
- SOAUMCDLIUGXJJ-SRVKXCTJSA-N Tyr-Ser-Asn Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O SOAUMCDLIUGXJJ-SRVKXCTJSA-N 0.000 description 1
- MQGGXGKQSVEQHR-KKUMJFAQSA-N Tyr-Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 MQGGXGKQSVEQHR-KKUMJFAQSA-N 0.000 description 1
- HRHYJNLMIJWGLF-BZSNNMDCSA-N Tyr-Ser-Phe Chemical compound C([C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 HRHYJNLMIJWGLF-BZSNNMDCSA-N 0.000 description 1
- SYFHQHYTNCQCCN-MELADBBJSA-N Tyr-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CC2=CC=C(C=C2)O)N)C(=O)O SYFHQHYTNCQCCN-MELADBBJSA-N 0.000 description 1
- PLVVHGFEMSDRET-IHPCNDPISA-N Tyr-Ser-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CC=C(C=C3)O)N PLVVHGFEMSDRET-IHPCNDPISA-N 0.000 description 1
- LVFZXRQQQDTBQH-IRIUXVKKSA-N Tyr-Thr-Glu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O LVFZXRQQQDTBQH-IRIUXVKKSA-N 0.000 description 1
- YMZYSCDRTXEOKD-IHPCNDPISA-N Tyr-Trp-Asn Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CC3=CC=C(C=C3)O)N YMZYSCDRTXEOKD-IHPCNDPISA-N 0.000 description 1
- HMPMGPISLMLHSI-JBACZVJFSA-N Tyr-Trp-Gln Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC3=CC=C(C=C3)O)N HMPMGPISLMLHSI-JBACZVJFSA-N 0.000 description 1
- HZWPGKAKGYJWCI-ULQDDVLXSA-N Tyr-Val-Leu Chemical compound CC(C)C[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(C)C)C(O)=O HZWPGKAKGYJWCI-ULQDDVLXSA-N 0.000 description 1
- 108010042606 Tyrosine transaminase Proteins 0.000 description 1
- 241001024096 Uleiota Species 0.000 description 1
- 102100031358 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 101100534084 Vaccinia virus (strain Copenhagen) B14R gene Proteins 0.000 description 1
- 101100004092 Vaccinia virus (strain Western Reserve) VACWR196 gene Proteins 0.000 description 1
- YFOCMOVJBQDBCE-NRPADANISA-N Val-Ala-Glu Chemical compound C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)N YFOCMOVJBQDBCE-NRPADANISA-N 0.000 description 1
- SLLKXDSRVAOREO-KZVJFYERSA-N Val-Ala-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)N)O SLLKXDSRVAOREO-KZVJFYERSA-N 0.000 description 1
- CVUDMNSZAIZFAE-TUAOUCFPSA-N Val-Arg-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@@H]1C(=O)O)N CVUDMNSZAIZFAE-TUAOUCFPSA-N 0.000 description 1
- CVUDMNSZAIZFAE-UHFFFAOYSA-N Val-Arg-Pro Natural products NC(N)=NCCCC(NC(=O)C(N)C(C)C)C(=O)N1CCCC1C(O)=O CVUDMNSZAIZFAE-UHFFFAOYSA-N 0.000 description 1
- GXAZTLJYINLMJL-LAEOZQHASA-N Val-Asn-Gln Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N GXAZTLJYINLMJL-LAEOZQHASA-N 0.000 description 1
- OGNMURQZFMHFFD-NHCYSSNCSA-N Val-Asn-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)O)N OGNMURQZFMHFFD-NHCYSSNCSA-N 0.000 description 1
- OVLIFGQSBSNGHY-KKHAAJSZSA-N Val-Asp-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C(C)C)N)O OVLIFGQSBSNGHY-KKHAAJSZSA-N 0.000 description 1
- BWVHQINTNLVWGZ-ZKWXMUAHSA-N Val-Cys-Asp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(=O)O)C(=O)O)N BWVHQINTNLVWGZ-ZKWXMUAHSA-N 0.000 description 1
- LHADRQBREKTRLR-DCAQKATOSA-N Val-Cys-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](C(C)C)N LHADRQBREKTRLR-DCAQKATOSA-N 0.000 description 1
- QHFQQRKNGCXTHL-AUTRQRHGSA-N Val-Gln-Glu Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O QHFQQRKNGCXTHL-AUTRQRHGSA-N 0.000 description 1
- PGBJAZDAEWPDAA-NHCYSSNCSA-N Val-Gln-Met Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCSC)C(=O)O)N PGBJAZDAEWPDAA-NHCYSSNCSA-N 0.000 description 1
- ROLGIBMFNMZANA-GVXVVHGQSA-N Val-Glu-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)N ROLGIBMFNMZANA-GVXVVHGQSA-N 0.000 description 1
- CELJCNRXKZPTCX-XPUUQOCRSA-N Val-Gly-Ala Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(O)=O CELJCNRXKZPTCX-XPUUQOCRSA-N 0.000 description 1
- KVRLNEILGGVBJX-IHRRRGAJSA-N Val-His-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)CC1=CN=CN1 KVRLNEILGGVBJX-IHRRRGAJSA-N 0.000 description 1
- HQYVQDRYODWONX-DCAQKATOSA-N Val-His-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CO)C(=O)O)N HQYVQDRYODWONX-DCAQKATOSA-N 0.000 description 1
- KDKLLPMFFGYQJD-CYDGBPFRSA-N Val-Ile-Arg Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](C(C)C)N KDKLLPMFFGYQJD-CYDGBPFRSA-N 0.000 description 1
- OTJMMKPMLUNTQT-AVGNSLFASA-N Val-Leu-Arg Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](C(C)C)N OTJMMKPMLUNTQT-AVGNSLFASA-N 0.000 description 1
- LYERIXUFCYVFFX-GVXVVHGQSA-N Val-Leu-Glu Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)N LYERIXUFCYVFFX-GVXVVHGQSA-N 0.000 description 1
- XTDDIVQWDXMRJL-IHRRRGAJSA-N Val-Leu-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](C(C)C)N XTDDIVQWDXMRJL-IHRRRGAJSA-N 0.000 description 1
- WDIWOIRFNMLNKO-ULQDDVLXSA-N Val-Leu-Tyr Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 WDIWOIRFNMLNKO-ULQDDVLXSA-N 0.000 description 1
- RWOGENDAOGMHLX-DCAQKATOSA-N Val-Lys-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)N RWOGENDAOGMHLX-DCAQKATOSA-N 0.000 description 1
- SJLVYVZBFDTRCG-DCAQKATOSA-N Val-Lys-Cys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)O)N SJLVYVZBFDTRCG-DCAQKATOSA-N 0.000 description 1
- IJGPOONOTBNTFS-GVXVVHGQSA-N Val-Lys-Glu Chemical compound [H]N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O IJGPOONOTBNTFS-GVXVVHGQSA-N 0.000 description 1
- QRVPEKJBBRYISE-XUXIUFHCSA-N Val-Lys-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)N QRVPEKJBBRYISE-XUXIUFHCSA-N 0.000 description 1
- VPGCVZRRBYOGCD-AVGNSLFASA-N Val-Lys-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O VPGCVZRRBYOGCD-AVGNSLFASA-N 0.000 description 1
- JVGHIFMSFBZDHH-WPRPVWTQSA-N Val-Met-Gly Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)O)N JVGHIFMSFBZDHH-WPRPVWTQSA-N 0.000 description 1
- YDVDTCJGBBJGRT-GUBZILKMSA-N Val-Met-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)O)N YDVDTCJGBBJGRT-GUBZILKMSA-N 0.000 description 1
- LJSZPMSUYKKKCP-UBHSHLNASA-N Val-Phe-Ala Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C)C(O)=O)CC1=CC=CC=C1 LJSZPMSUYKKKCP-UBHSHLNASA-N 0.000 description 1
- CKTMJBPRVQWPHU-JSGCOSHPSA-N Val-Phe-Gly Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)O)N CKTMJBPRVQWPHU-JSGCOSHPSA-N 0.000 description 1
- LGXUZJIQCGXKGZ-QXEWZRGKSA-N Val-Pro-Asn Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(=O)N)C(=O)O)N LGXUZJIQCGXKGZ-QXEWZRGKSA-N 0.000 description 1
- RYHUIHUOYRNNIE-NRPADANISA-N Val-Ser-Gln Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N RYHUIHUOYRNNIE-NRPADANISA-N 0.000 description 1
- GBIUHAYJGWVNLN-UHFFFAOYSA-N Val-Ser-Pro Natural products CC(C)C(N)C(=O)NC(CO)C(=O)N1CCCC1C(O)=O GBIUHAYJGWVNLN-UHFFFAOYSA-N 0.000 description 1
- NZYNRRGJJVSSTJ-GUBZILKMSA-N Val-Ser-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O NZYNRRGJJVSSTJ-GUBZILKMSA-N 0.000 description 1
- WUFHZIRMAZZWRS-OSUNSFLBSA-N Val-Thr-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C(C)C)N WUFHZIRMAZZWRS-OSUNSFLBSA-N 0.000 description 1
- LCHZBEUVGAVMKS-RHYQMDGZSA-N Val-Thr-Leu Chemical compound CC(C)C[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)[C@@H](C)O)C(O)=O LCHZBEUVGAVMKS-RHYQMDGZSA-N 0.000 description 1
- YLBNZCJFSVJDRJ-KJEVXHAQSA-N Val-Thr-Tyr Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O YLBNZCJFSVJDRJ-KJEVXHAQSA-N 0.000 description 1
- GUIYPEKUEMQBIK-JSGCOSHPSA-N Val-Tyr-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)NCC(O)=O GUIYPEKUEMQBIK-JSGCOSHPSA-N 0.000 description 1
- JXWGBRRVTRAZQA-ULQDDVLXSA-N Val-Tyr-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](C(C)C)N JXWGBRRVTRAZQA-ULQDDVLXSA-N 0.000 description 1
- LMVWCLDJNSBOEA-FKBYEOEOSA-N Val-Tyr-Trp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)O)N LMVWCLDJNSBOEA-FKBYEOEOSA-N 0.000 description 1
- ZHWZDZFWBXWPDW-GUBZILKMSA-N Val-Val-Cys Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(O)=O ZHWZDZFWBXWPDW-GUBZILKMSA-N 0.000 description 1
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
- 206010000583 acral lentiginous melanoma Diseases 0.000 description 1
- 229930183665 actinomycin Natural products 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 108010008685 alanyl-glutamyl-aspartic acid Proteins 0.000 description 1
- 108010024078 alanyl-glycyl-serine Proteins 0.000 description 1
- 108010045023 alanyl-prolyl-tyrosine Proteins 0.000 description 1
- 108010041407 alanylaspartic acid Proteins 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 1
- 108010030291 alpha-Galactosidase Proteins 0.000 description 1
- 102000005840 alpha-Galactosidase Human genes 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 1
- 229960002576 amiloride Drugs 0.000 description 1
- 230000006229 amino acid addition Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 108010009111 arginyl-glycyl-glutamic acid Proteins 0.000 description 1
- 239000000823 artificial membrane Substances 0.000 description 1
- 108010092854 aspartyllysine Proteins 0.000 description 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 229930183167 cerebroside Natural products 0.000 description 1
- RIZIAUKTHDLMQX-UHFFFAOYSA-N cerebroside D Natural products CCCCCCCCCCCCCCCCC(O)C(=O)NC(C(O)C=CCCC=C(C)CCCCCCCCC)COC1OC(CO)C(O)C(O)C1O RIZIAUKTHDLMQX-UHFFFAOYSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- ZXFCRFYULUUSDW-OWXODZSWSA-N chembl2104970 Chemical compound C([C@H]1C2)C3=CC=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2CC(O)=C(C(=O)N)C1=O ZXFCRFYULUUSDW-OWXODZSWSA-N 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 229950009003 cilengitide Drugs 0.000 description 1
- AMLYAMJWYAIXIA-VWNVYAMZSA-N cilengitide Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C(C)C)N(C)C(=O)[C@H]1CC1=CC=CC=C1 AMLYAMJWYAIXIA-VWNVYAMZSA-N 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229960005537 combretastatin A-4 Drugs 0.000 description 1
- HVXBOLULGPECHP-UHFFFAOYSA-N combretastatin A4 Natural products C1=C(O)C(OC)=CC=C1C=CC1=CC(OC)=C(OC)C(OC)=C1 HVXBOLULGPECHP-UHFFFAOYSA-N 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 108010045325 cyclic arginine-glycine-aspartic acid peptide Proteins 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 108010060199 cysteinylproline Proteins 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 108010054812 diprotin A Proteins 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000008175 fetal development Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 108010006664 gamma-glutamyl-glycyl-glycine Proteins 0.000 description 1
- 108010063718 gamma-glutamylaspartic acid Proteins 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940045109 genistein Drugs 0.000 description 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 102000018146 globin Human genes 0.000 description 1
- 108060003196 globin Proteins 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 108010080575 glutamyl-aspartyl-alanine Proteins 0.000 description 1
- 108010073628 glutamyl-valyl-phenylalanine Proteins 0.000 description 1
- 108010079547 glutamylmethionine Proteins 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical class OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Natural products NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 1
- 108010051307 glycyl-glycyl-proline Proteins 0.000 description 1
- 108010028188 glycyl-histidyl-serine Proteins 0.000 description 1
- 108010025801 glycyl-prolyl-arginine Proteins 0.000 description 1
- 108010043293 glycyl-prolyl-glycyl-glycine Proteins 0.000 description 1
- 108010037850 glycylvaline Proteins 0.000 description 1
- 108010072094 gp100(280-288) melanoma antigen peptide Proteins 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 208000037824 growth disorder Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 230000002998 immunogenetic effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 208000024312 invasive carcinoma Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 108010078274 isoleucylvaline Proteins 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- VDBNYAPERZTOOF-UHFFFAOYSA-N isoquinolin-1(2H)-one Chemical compound C1=CC=C2C(=O)NC=CC2=C1 VDBNYAPERZTOOF-UHFFFAOYSA-N 0.000 description 1
- UHEBDUAFKQHUBV-UHFFFAOYSA-N jspy-st000261 Chemical compound C1=CC=C2C3=C(C(=O)NC4)C4=C(C=4C(=CC=C(C=4)COC(C)C)N4CCCOC(=O)CN(C)C)C4=C3CC2=C1 UHEBDUAFKQHUBV-UHFFFAOYSA-N 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000011080 lentigo maligna melanoma Diseases 0.000 description 1
- 108010076756 leucyl-alanyl-phenylalanine Proteins 0.000 description 1
- 108010000761 leucylarginine Proteins 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 108010003700 lysyl aspartic acid Proteins 0.000 description 1
- 108010038320 lysylphenylalanine Proteins 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229950008959 marimastat Drugs 0.000 description 1
- OCSMOTCMPXTDND-OUAUKWLOSA-N marimastat Chemical compound CNC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO OCSMOTCMPXTDND-OUAUKWLOSA-N 0.000 description 1
- 238000013178 mathematical model Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 208000011645 metastatic carcinoma Diseases 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 108010022588 methionyl-lysyl-proline Proteins 0.000 description 1
- 108010056582 methionylglutamic acid Proteins 0.000 description 1
- 108010005942 methionylglycine Proteins 0.000 description 1
- 108010085203 methionylmethionine Proteins 0.000 description 1
- IZAGSTRIDUNNOY-UHFFFAOYSA-N methyl 2-[(2,4-dioxo-1h-pyrimidin-5-yl)oxy]acetate Chemical compound COC(=O)COC1=CNC(=O)NC1=O IZAGSTRIDUNNOY-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 238000012737 microarray-based gene expression Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- VYGYNVZNSSTDLJ-HKCOAVLJSA-N monorden Natural products CC1CC2OC2C=C/C=C/C(=O)CC3C(C(=CC(=C3Cl)O)O)C(=O)O1 VYGYNVZNSSTDLJ-HKCOAVLJSA-N 0.000 description 1
- 238000012243 multiplex automated genomic engineering Methods 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 108010065781 myosin light chain 2 Proteins 0.000 description 1
- NOCSBVQBBJVIQR-UHFFFAOYSA-N n-(3-methylbut-1-enyl)-7h-purin-6-amine Chemical compound CC(C)C=CNC1=NC=NC2=C1NC=N2 NOCSBVQBBJVIQR-UHFFFAOYSA-N 0.000 description 1
- XJVXMWNLQRTRGH-UHFFFAOYSA-N n-(3-methylbut-3-enyl)-2-methylsulfanyl-7h-purin-6-amine Chemical compound CSC1=NC(NCCC(C)=C)=C2NC=NC2=N1 XJVXMWNLQRTRGH-UHFFFAOYSA-N 0.000 description 1
- BSIZUMJRKYHEBR-QGZVFWFLSA-N n-hydroxy-2(r)-[[(4-methoxyphenyl)sulfonyl](3-picolyl)amino]-3-methylbutanamide hydrochloride Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N([C@H](C(C)C)C(=O)NO)CC1=CC=CN=C1 BSIZUMJRKYHEBR-QGZVFWFLSA-N 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- AEMBWNDIEFEPTH-UHFFFAOYSA-N n-tert-butyl-n-ethylnitrous amide Chemical compound CCN(N=O)C(C)(C)C AEMBWNDIEFEPTH-UHFFFAOYSA-N 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 201000000032 nodular malignant melanoma Diseases 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 229960002700 octreotide Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- UNEIHNMKASENIG-UHFFFAOYSA-N para-chlorophenylpiperazine Chemical compound C1=CC(Cl)=CC=C1N1CCNCC1 UNEIHNMKASENIG-UHFFFAOYSA-N 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 108010042234 peptide SVYDFFVWL Proteins 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 108010024654 phenylalanyl-prolyl-alanine Proteins 0.000 description 1
- 108010089198 phenylalanyl-prolyl-arginine Proteins 0.000 description 1
- 108010051242 phenylalanylserine Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000001095 phosphatidyl group Chemical group 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229960000688 pomalidomide Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 108010020755 prolyl-glycyl-glycine Proteins 0.000 description 1
- 108700042769 prolyl-leucyl-glycine Proteins 0.000 description 1
- 108010079317 prolyl-tyrosine Proteins 0.000 description 1
- 108010004914 prolylarginine Proteins 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- AECPBJMOGBFQDN-YMYQVXQQSA-N radicicol Chemical compound C1CCCC(=O)C[C@H]2[C@H](Cl)C(=O)CC(=O)[C@H]2C(=O)O[C@H](C)C[C@H]2O[C@@H]21 AECPBJMOGBFQDN-YMYQVXQQSA-N 0.000 description 1
- 229930192524 radicicol Natural products 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 210000003660 reticulum Anatomy 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 108010048818 seryl-histidine Proteins 0.000 description 1
- 108010048397 seryl-lysyl-leucine Proteins 0.000 description 1
- 108010071207 serylmethionine Proteins 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000003584 silencer Effects 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 108010005652 splenotritin Proteins 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 108010042747 stallimycin Proteins 0.000 description 1
- 229950009902 stallimycin Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical class C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000030457 superficial spreading melanoma Diseases 0.000 description 1
- 229960005314 suramin Drugs 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 108010071097 threonyl-lysyl-proline Proteins 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000031998 transcytosis Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 108010012374 type IV collagen alpha3 chain Proteins 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 108010035534 tyrosyl-leucyl-alanine Proteins 0.000 description 1
- 108010003137 tyrosyltyrosine Proteins 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 102000009816 urokinase plasminogen activator receptor activity proteins Human genes 0.000 description 1
- 108040001269 urokinase plasminogen activator receptor activity proteins Proteins 0.000 description 1
- 108010073969 valyllysine Proteins 0.000 description 1
- 229950000578 vatalanib Drugs 0.000 description 1
- YCOYDOIWSSHVCK-UHFFFAOYSA-N vatalanib Chemical compound C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001188—NY-ESO
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
- A61K39/001191—Melan-A/MART
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
- A61K39/001192—Glycoprotein 100 [Gp100]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
Abstract
본 발명은 펩티드, 폴리펩티드 및 핵산, 및 암을 예방 및/또는 치료하는데 있어서의 당해 펩티드, 폴리펩티드 및 핵산의 용도에 관한 것이다. 특히, 본 발명은 흑색종을 진단, 치료 또는 예방하는데 사용하기 위한 펩티드 및 이러한 펩티드를 암호화하는 핵산 서열에 관한 것이다.
흑색종, 발현 벡터, 바이러스 벡터, 다중-항원 벡터
Description
본 발명은 암을 예방 또는 치료하는데 사용하기 위한 다중-항원(multi-antigen) 벡터에 관한 것이다. 특히, 본 발명은 흑색종을 치료 및/또는 예방하는데 사용하기 위한 다중-항원 벡터에 관한 것이다.
고밀도 미세배열(microarray), SEREX, 면역조직화학 (IHC), RT-PCR, 윈-위치 하이브리드화 (ISH) 및 레이저 포획 현미경 (Rosenberg, Immunity, 1999; Sgroi et al, 1999, Schena et al, 1995, Offringa et al, 2000)과 같은 여러 기술의 도움으로 원발성 종양 세포 및 정상 세포의 발현 양상을 토대로 한 분자 동정이 크게 진전됨에 따라 종양-관련 항원(TAA)을 이용한 암 백신의 개발이 지난 몇 년 동안 크게 발전하였다. TAA는 종양 세포에 의해 발현되거나 과발현된 항원이며, 1 개 또는 수 개 종양에 특이적일 수 있으며, 예를 들어 CEA 항원은 결장직장, 유방 및 폐 암에서 발현된다. 스그로이 등(Sgroi et al., (1999))은, 레이저 포획 미세절개(micordissection) 및 cDNA 미세배열을 병용하여 침습 암종 및 전이 암종에서 차등적으로 발현되는 여러 유전자를 동정하였다. DNA 또는 바이러스와 같은 여러 전달 시스템이 사람 암에 대한 치료적 백신접종에 사용될 수 있으며[참조: Bonnet et al, 2000], 면역 반응을 일으킬 수 있고 또한 TAA에 대한 면역 내성을 약화시킬 수 있다. 특히, T-세포 공동-자극 분자, 예를 들면 B7.1 또는 사이토킨, 예를 들면 IFN-γ, IL2 또는 GM-CSF를 암호화하는 전이유전자(transgene)를 삽입함으로써, 종양 세포는 보다 면역원성이 될 수 있다. TAA 및 사이토킨 또는 공동-자극 분자의 공동-발현을 통해 효과적인 치료적 백신을 개발할 수 있다[참조 문헌: Hodge et al, 95, Bronte et al, 1995, Chamberlain et al, 1996].
암을 예방하거나 치료하기 위하여 면역 반응을 자극하는데 유용한 시약 및 방법론이 당업계에서 요구되고 있다. 본 발명은, 암 치료를 시도하던 중에 다른 사람들이 직면했던 수 많은 난관들을 극복하는 시약 및 방법론을 제공한다.
발명의 개요
본 발명은 암을 예방 및/또는 치료하기 위하여 환자에게 투여되는 다중-항원 벡터를 제공한다. 특히, 다중-항원 벡터는 하나 이상의 종양 항원("TA")을 암호화한다. 다중-항원 벡터는 또한 공동-자극 분자와 같은 면역 자극인자를 암호화하고/하거나 애주번트와 함께 투여될 수 있다.
도 1은 플라스미드 pALVAC.Tricom (#33) 및 pT1132의 구성도이다.
도 2는 플라스미드 pALVAC.Tricom (#33)의 DNA 서열 (서열번호 1 및 2)이다.
도 3은 플라스미드 pT1132의 DNA 서열 (서열번호 3 및 4)이다.
도 4는 플라스미드 pT3217의 구성도이다.
도 5는 플라스미드 pT3217의 DNA 서열 (서열번호 5 및 6)이다.
도 6은 예시적 NY-ESO-1 (서열번호 7), TRP-2 (서열번호 8), gp100 (서열번호 9), gplOOM (서열번호 10), MART-1 (서열번호 11), MAGE-1 (서열번호 12), MAGE-3 (서열번호 13), B7.1 (서열번호 14), LFA-3 (서열번호 15), 및 ICAM-1 (서열번호 16) 단백질의 아미노산 서열이다.
본 발명은 암을 치료 및/또는 예방하는데 유용한 시약 및 방법론을 제공한다. 본원에 인용된 모든 참조 문헌은 참조로서 포함된다.
일 태양으로, 본 발명은 암을 예방 및/또는 치료하기 위하여 하나 이상의 종양 항원("TA")에 대한 면역 반응을 유도 또는 증강시키는 것이다. 특정 태양에서, 하나 이상의 TA가 조합될 수 있다. 바람직한 태양에서, 당해 면역 반응은, 예를 들어 종양 항원을 암호화하는 핵산 벡터, 또는 펩티드 또는 폴리펩티드 형태의 종양 항원 그 자체를 투여한 후, 숙주 세포 내에서 TA가 발현된 결과이다.
본원에서 사용된 "항원"은 항원이 투여되었던 숙주에서 면역 반응을 일으키는 분자(예를 들어, 폴리펩티드) 또는 이의 부분이다. 면역 반응은, 항원의 하나 이상의 에피토프에 결합하는 항체의 생성 및/또는 항원의 에피토프를 발현하는 세포에 대한 세포 면역 반응의 생성을 포함할 수 있다. 상기 반응은, 예를 들면 항체 생성을 증가시키거나, 항원에 대한 친화성이 증가한 항체를 생성시키거나, 세포 면역 반응을 증가(즉, 면역반응성 T 세포의 수 또는 활성을 증가)시킴으로써, 현재의 면역 반응을 증강시킬 수 있다. 면역 반응을 일으키는 항원은 달리 면역원성 또는 면역원으로서 지칭될 수 있다. 본 발명을 기술하는 때에, TA는 "면역원성 표적"으로 지칭될 수 있다. 본 발명은 하나 이상의 면역원성 표적을 숙주에서 발현하기 위한 발현 벡터를 제공한다.
TA란 용어는 종양-관련 항원 (TAA) 및 종양-특이적 항원 (TSA) 둘 모두를 포함하며, 이때 암 세포는 당해 항원의 공급원이다. TAA는 종양 세포의 표면 상에서 정상 세포에서 관찰된 것 보다 더 많은 양으로 발현된 항원 또는 태아 발생 동안에 정상 세포에서 발현된 항원이다. TSA는 종양 세포에 특유하며, 정상 세포에서는 발현되지 않는 항원이다. TA는 또한 TAA 또는 TSA, 이의 항원성 단편, 및 이의 항원성을 보유하는 변형체를 포함한다.
통상적으로, TA는 이들의 발현 패턴, 기능 또는 유전적 기원에 따라 5개의 범주로 분류된다: 암-고환 (CT) 항원 (즉, MAGE, NY-ESO-1); 멜라닌세포 분화 항원 (즉, Melan A/MART-1, 티로신아제, gp100); 돌연변이성 항원 (즉, MUM-1, p53, CDK-4); 과발현된 '자가' 항원 (즉, HER-2/neu, p53); 및 바이러스 항원 (즉, HPV, EBV). 본 발명을 수행하기 위한 목적으로, 적합한 TA는, TA가 투여되었던 숙주에서 항-종양 면역 반응을 유도하거나 증강시키는 모든 TA이다. 적합한 TA로는, 야생형 (즉, 천연적으로 존재하는 게놈에 의해 정상적으로 암호화된 것), 변형체 및 돌연변이체 뿐만 아니라 이의 다른 단편 및 유도체를 포함하여, 예를 들어 gpl00 [참조 문헌: Cox et al., Science, 264: 716- 719 (1994); 미국 특허 제6,500,919 B1호 및 WO 01/30847 - 잔기 162에 Val 보유 - "gplOOM"로서 지칭되기도 함; 미국 특허 제6,537,560 B1호 - 잔기 162에 Phe 보유], MART-1/Melan A [참조 문헌: Kawakami et al., J. Exp. Med., 180: 347-352 (1994); 미국 특허 제5, 874,560호), gp75 (TRP-1) [참조 문헌: Wang et al., J. Exp. Med., 186: 1131-1140 (1996)], TRP-2 [참조 문헌: Wang et al. 1996 J. Exp. Med. 184: 2207; 미국 특허 제5,831,016호 및 6,083,783호], 티로신아제 [참조 문헌: Wolfel et al., Eur. J Immunol., 24: 759-764 (1994); WO 200175117; WO 200175016; WO 200175007], NY-ESO-1 [참조 문헌: WO 98/14464; WO 99/18206; GenBank 수탁번호 제P78358호; 미국 특허 제5,804,381호], 흑색종 프로테오글리칸 [참조 문헌: Hellstrom et al. , J. Immunol., 130: 1467-1472 (1983)], MAGE 계열 항원 [즉, MAGE-1, 2, 3, 4, 6, 12, 51; Van der Bruggen et al., Science, 254: 1643-1647 (1991); 미국 특허 제6,235,525호; CN 1319611], BAGE 계열 항원 [참조 문헌: Boel et al., Immnunity, 2: 167-175 (1995)], GAGE 계열 항원 [즉, GAGE-1,2; Van den Eynde et al., J. Exp. Med., 182: 689-698 (1995); 미국 특허 제6,013,765호], RAGE 계열 항원 [즉, RAGE-1; Gaugler et at., Immunogenetics, 44: 323-330 (1996); 미국 특허 제5,939,526호), N-아세틸글루코스아미닐트랜스퍼라제-V [참조 문헌: Guilloux et at., J. Exp. Med., 183: 1173-1183 (1996)], pl5 [참조 문헌: Robbins et al. , J. Immunol. 154: 5944-5950 (1995)], β-카테닌 [참조 문헌: Robbins et al., J. Exp. Med., 183: 1185-1192 (1996)], MUM-1 [참조 문헌: Coulie et al Proc. Natl. Acad. Sci. USA, 92: 7976-7980 (1995)], 사이클린 의존형 키나제-4 (CDK4) [참조 문헌: Wolfel et al., Science, 269: 1281-1284 (1995) ], p21-ras [참조 문헌: Fossum et at., Int. J. Cancer, 56: 40-45 (1994)], BCR-abl [참조 문헌: Bocchia et al., Blood, 85: 2680-2684 (1995)], p53 [참조 문헌: Theobald et al., Proc. Natl. Acad. Sci. USA, 92: 11993-11997 (1995)], pl85 HER2/neu [참조 문헌: erb-Bl; Fisk et al., J. Exp. Med., 181: 2109-2117 (1995) ], 표피 성장 인자 수용체 (EGFR) [참조 문헌: Harris et al., Breast Cancer Res. Treat, 29: 1-2 (1994)]), 암종배아 항원(CEA) [참조 문헌: Kwong et al., R Natl. Cancer Inst., 85: 982-990 (1995), 미국 특허 제5,756,103호; 제5,274,087호; 제5,571,710호; 제6,071,716호; 제5,698,530호; 제6,045,802호; EP 263933; EP 346710; 및 EP 784483]; 암종-관련 돌연변이된 무신 [즉, MUC-1 유전자 산물; Jerome et al., J. Immunol., 151:1654-1662 (1993)]; EBV의 EBNA 유전자 산물 [즉, EBNA-1; Rickinson et al., Cancer Surveys, 13: 53-80 (1992)]; 사람 파필로마바이러스의 E7, E6 단백질 [참조 문헌: Ressing et al., J. Immunol, 154: 5934-5943 (1995)]; 전립선 특이적 항원 [PSA ; Xue et al., The Prostate, 30: 73-78 (1997)]; 전립선 특이적 막 항원 [PSMA; Israeli, et al., Cancer Res., 54: 1807-1811 (1994)]; 개별특이적(idiotypic) 에피토프 또는 항원, 예를 들어 면역글로불린 개별특이형(idiotype) 또는 T 세포 수용체 개별특이형 [참조 문헌: Chen et al, J. Immunol., 153: 4775-4787 (1994)]; KSA [참조 문헌: 미국 특허 제5,348,887호], 키네신 2 [참조 문헌: Dietz, et al. Biochem Biophys Res Commun 2000 Sep 7; 275 (3): 731-8], HIP-55, TGFβ-l 항-아폽토시스 인자(apoptotic factor) [참조 문헌: Toomey, et al. Br J Biomed Sci 2001; 58 (3): 177-83], 종양 단백질 D52 [참조 문헌: Bryne J. A., et al., Genomics, 35: 523-532 (1996)], H1FT, NY-BR-1 [참조 문헌: WO 01/47959], NY-BR-62, NY-BR-75, NY-BR-85, NY-BR-87, NY-BR-96 [참조 문헌: Scanlan, M. Serologic and Bioinformatic Approaches to the Identification of Human Tumor Antigens, in Cancer Vaccines 2000, Cancer Research Institute, New York, NY]가 포함된다. 이들 TA 중 어느 것은 단독으로 이용되거나 또는 공동-면역화 프로토콜에서 서로 병용될 수 있다.
바람직한 TA는 흑색종 세포에 대한 면역 반응을 유도하는데 사용될 수 있다. "흑색종"이란 용어는 예를 들어 흑색종, 전이성 흑색종, 멜라닌세포 또는 멜라닌세포 관련 모반 세포로부터 유래된 흑색종, 악성흑색종, 흑색상피종(melanoepithelioma), 흑색육종(melanosarcoma), 상피내 흑색종(melanoma in situ), 표재 확장성 흑색종(superficial spreading melanoma), 결절형 흑색종, 악성 흑자 흑색종(lentigo maligna melanoma), 말단 흑자성 흑색종(acral lentiginous melanoma), 침습성 흑색종(invasive melanoma) 및 가족성 비전형 몰 흑색종 (FAM-M: familial atypical mole and melanoma) 증후군을 포함하나, 이에 제한되지 않는다. 일반적으로, 흑색종은, 예를 들어 염색체 비정상, 퇴행성 성장 및 발달 장애, 분열촉진제, 자외선(UV), 바이러스 감염, 유전자의 비적절한 조직 발현, 유전자 발현의 변화 또는 발암제로 인한 것이다.
특정 경우에는, 환자를 TA 및 다른 항원, 예를 들면 혈관형성-관련 항원("AA")으로 공동-면역화시키는 것이 유익할 수 있다. AA는 혈관의 유도 및/또는 지속적 발달과 관련된 세포와 연관된 면역원성 분자 (즉, 펩티드, 폴리펩티드)이다. 예를 들면, AA는 혈관의 일차 구조물인 내피 세포("EC") 상에 발현될 수 있다. 암이 암인 경우에, AA는 종양을 공급하는 혈관 내 또는 부근에서 발견되는 것이 바람직하다. AA에 대한 환자의 면역화는 바람직하게는 항-AA 면역 반응을 일으켜서, 이에 의해 종양 내 또는 부근에서 일어나는 혈관형성 과정이 방지되고/되거나 억제된다. AA의 예로는, "야생형" (즉, 천연적으로 존재하는 게놈에 의해 정상적으로 암호화된 것), 변형체, 돌연변이체 뿐만 아니라 기타 단편 및 유도체를 포함하여, 특히 혈관 내피 성장 인자 [즉, VEGF ; Bernardini, et al. J. Urol., 2001,166 (4): 1275-9; Starnes, et al. J. Thorac. Cardiovasc. Surg. ; 2001, 122 (3): 518-23; Dias, et al. Blood, 2002,99 : 2179-2184], VEGF 수용체 [즉, VEGF-R, flk-1/KDR; Starnes, et al. J. Thorac. Cardiovasc. Surg, 2001,122 (3): 518-23], EPH 수용체 [즉, EPHA2; Gerety, et al. 1999, Cell, 4: 403-414], 표피 성장 인자 수용체 [즉, EGFR; Ciardeillo, et al. Clin. Cancer Res., 2001, 7 (10): 2958-70], 염기성 섬유아세포 성장 인자 [즉, bFGF; Davidson, et al. Clin. Exp. Metastasis 2000,18 (6): 501-7; Poon, et al. Am J. Surg., 2001, 182 (3): 298-304], 혈소판-유래된 세포 성장 인자 [즉, PDGF-B], 혈소판-유래된 내피 세포 성장 인자 [즉, PD-ECGF; Hong, et al. J. Mol. Med., 2001,8 (2): 141-8], 형질전환성 성장 인자 [즉, TGF-α; Hong, et al. J. Mol. Med., 2001, 8 (2): 141-8], 엔도글린(endoglin) [Balza, et al. Int. J. Cancer, 2001, 94: 579-585], Id 단백질 [Benezra, R. Trends Cardiovasc. Med., 2001, 11(6): 237-41], uPA, uPAR, 및 매트릭스 메탈로프로테인아제와 같은 프로테아제 [MMP-2, MMP-9; Djonov, et al. J. Pathol., 2001, 195(2): 147-55], 산화질소 신타제 [Am. J. Ophthalmol., 2001, 132(4): 551-6], 아미노펩티다제 [Rouslhati, E. Nature Cancer, 2: 84-90, 2002], 트롬보스폰딘 [즉, TSP-1, TSP-2; Alvarez, et al. Gynecol. Oncol., 2001, 82 (2): 273-8; Seki, et al. Int. J. Oncol., 2001, 19 (2): 305-10], k-ras [Zhang, et al. Cancer Res. , 2001, 61 (16): 6050-4], Wnt [Zhang, et al. Cancer Res., 2001, 61(16): 6050-4], 사이클린-의존형 키나제 [CDK; Drug Resist. Updat. 2000, 3(2): 83-88], 미세관 [Timar, et al. 2001. Path. Oncol. Res., 7(2): 85-94], 열 쇽크 단백질 [즉, HSP90 (Timar, supra)], 헤파린-결합 인자 [즉, 헤파린아제; Gohji, et al. Int. J. Cancer, 2001, 95(5): 295-301], 신타제 [즉, ATP 신타제, 티미딜레이트 신타제), 콜라겐 수용체, 인테그린 [즉, αυ3, αυβ5, α1β1, α2β1, α5β1], 표면 프로테오글리칸 NG2, AAC2-1 또는 AAC2-2가 포함된다. 이들 표적 중의 어떤 것은 단독으로, 또는 서로 함께, 또는 다른 제제와 함께 사용하여 본 발명을 수행하는데 적합할 수 있다.
핵산 분자는 하나 이상의 면역원성 표적을 암호화하는 뉴클레오티드 서열, 또는 이의 단편 또는 유도체, 예를 들어 ATCC 기탁물 중의 DNA 삽입체 내에 함유된 것으로 이루어지거나 이를 포함할 수 있다. "핵산 서열" 또는 "핵산 분자"란 용어는 DNA 또는 RNA 서열을 말한다. 당해 용어는 DNA 및 RNA의 공지된 염기 동족체, 예를 들어 특히 4-아세틸시토신, 8-하이드록시-N6-메틸아데노신, 아지리디닐-시토신, 슈도이소시토신, 5-(카복시하이드록실메틸)우라실, 5-플루오로우라실, 5-브로모우라실, 5-카복시메틸아미노메틸-2-티오우라실, 5-카복시-메틸아미노메틸우라실, 디하이드로우라실, 이노신, N6-이소-펜테닐아데닌, 1-메틸아데닌, 1-메틸슈도우라실, 1-메틸구아닌, 1-메틸이노신, 2,2-디메틸-구아닌, 2-메틸아데닌, 2-메틸구아닌, 3-메틸시토신, 5-메틸시토신, N6-메틸아데닌, 7-메틸구아닌, 5-메틸아미노메틸우라실, 5-메톡시아미노-메틸-2-티오우라실, 베타-D-만노실큐에오신, 5'-메톡시카보닐-메틸우라실, 5-메톡시우라실, 2-메틸티오-N6-이소펜테닐아데닌, 우라실-5-옥시아세트산 메틸에스테르, 우라실-5-옥시아세트산, 옥시부톡소신, 슈도우라실, 큐에오신, 2-티오시토신, 5-메틸-2-티오우라실, 2-티오우라실, 4-티오우라실, 5-메틸우라실, N-우라실-5-옥시아세트산 메틸에스테르, 우라실-5-옥시아세트산, 슈도우라실, 큐에오신, 2-티오시토신 및 2,6-디아미노퓨린 등으로부터 형성된 분자를 포괄한다.
분리된 핵산 분자는, (1) 전체 핵산이 공급원 세포로부터 분리될 때 분리될 핵산 분자와 함께 천연적으로 발견되는 단백질, 지질, 탄수화물 또는 기타 물질의 약 50% 이상으로부터 분리된 것; (2) 천연 상태에서 핵산 분자에 연결된 폴리뉴클레오티드의 전부 또는 일부에 연결되지 않은 것; (3) 천연 상태에서 분리될 핵산 분자에 연결되지 않은 폴리뉴클레오티드에 작동적으로 연결된 것 및/또는 (4) 거대 폴리뉴클레오티드 서열의 일부로서 천연에 존재하지 않는 것이다. 바람직하게는, 본 발명의 분리된 핵산 분자는, 폴리펩티드의 제조시에 이를 사용하는 것을 방해하거나 또는 치료학적, 진단학적, 예방학적 또는 연구용으로 이를 사용하는 것을 방해하는, 이의 천연 환경에서 발견되는 모든 기타 오염성 핵산 분자(들) 또는 기타 오염물질이 실질적으로 부존재한다. 본원에서 사용되는 "천연적으로 존재하는" 또는 "천연의" 또는 "천연적으로 발견되는"이란 용어는, 핵산 분자, 폴리펩티드, 숙주 세포 등과 같은 생물학적 물질과 관련하여 사용될 때, 천연에서 발견되고, 사람에 의해 조작되지 않은 물질을 의미한다. 유사하게, 본원에서 사용된 "비-천연적으로 존재하는" 또는 "비-천연의"란 천연에서 발견되지 않거나 사람에 의해 구조적으로 변형되거나 합성된 물질을 의미한다.
2 이상의 핵산 또는 아미노산 서열의 동일성은 서열을 비교하여 결정한다. 당업계에 공지된 바와 같이, "동일성"은 당해 분자를 구성하는 단위체 (즉, 뉴클레오티드 또는 아미노산 잔기) 사이의 합치에 의해 결정되는 핵산 또는 아미노산 서열 사이의 서열 관련도를 의미한다. 동일성은, 특정 수학 모델 또는 컴퓨터 프로그램 (즉, 알고리듬)에 의해 어드레스된 갭 얼라인먼트(존재하는 경우)를 가진 2 이상의 서열 중 보다 작은 것 사이의 동일한 합치 %를 측정한다. 핵산 서열 사이의 동일성은 당해 핵산 서열이 서로 하이브리드를 형성할 수 있는 능력에 의해 판정될 수 있다. 하이브리드화 과정을 정의할 때, "고도로 엄격한 조건" 및 "적당히 엄격한 조건"은 서열이 상보적인 핵산 쇄의 하이브리드화를 허용하고 현저히 불합치된 핵산의 하이브리드화를 배제하는 조건을 의미한다. 하이브리드화 및 세척을 위한 "고도로 엄격한 조건"의 예는 65 내지 68℃에서 0.015 M 염화나트륨, 0.0015 M 시트르산나트륨 또는 42℃에서 0.015 M 염화나트륨, 0.0015 M 시트르산나트륨, 및 50% 포름아미드이다 [참조 문헌: Sambrook, Fritsch & Maniatis, Molecular Cloning: A Laboratory Manual (2nd ed. , Cold Spring Harbor Laboratory, 1989) ; Anderson et al., Nucleic Acid Hybridisation : A Practical Approach Ch. 4 (IRL Press Limited)]. "적당히 엄격한 조건"이란 용어는 "고도로 엄격한 조건" 하에서 일어날 수 있는 것보다 더 높은 수준의 염기쌍 불합치를 가진 DNA 이중체가 형성될 수 있는 조건을 의미한다. 적당히 엄격한 조건의 예는 50 내지 65℃에서 0.015 M 염화나트륨, 0.0015 M 시트르산나트륨 또는 37 내지 50℃에서 0.015 M 염화나트륨, 0.0015 M 시트르산나트륨, 및 20% 포름아미드이다. 예로써, 0.015 M 나트륨 이온 중의 50℃의 적당히 엄격한 조건은 약 21% 불합치를 허용할 것이다. 하이브리드화 동안에, 비-특이적 및/또는 기본수준 하이브리드화를 감소시킬 목적으로 하이브리드화 및 세척 완충제 중에 다른 제제를 포함할 수 있다. 예로는 0.1% 소 혈청 알부민, 0.1% 폴리비닐-피롤리돈, 0.1% 피로인산나트륨, 0.1% 나트륨 도데실설페이트, NaDodS04, (SDS), 피콜(ficoll), 덴하르트(Denhardt's) 용액, 초음파처리된 연어 정자 DNA (또는 또 다른 비-상보적 DNA), 및 덱스트란 설페이트가 있으나, 다른 적당한 제제도 또한 사용될 수 있다. 이들 첨가물의 농도 및 유형은, 하이브드화 조건의 엄격도에 실질적으로 영향을 주지 않으면서, 변화될 수 있다. 하이브리드화 실험은 통상적으로 pH 6.8 내지 7.4에서 수행되나; 전형적인 이온 농도 조건에서는, 하이브리드화의 속도는 pH와는 거의 무관하다.
본 발명의 바람직한 태양에서, 벡터가 면역원성 표적물을 암호화하는 핵산 서열을 세포로 전달하는데 사용된다. 벡터는 핵산 서열을 숙주 세포로 전달하는데 사용되는 모든 분자이다. 특정 경우에는, 발현 벡터가 사용된다. 발현 벡터는, 숙주 세포의 형질전환에 적합하고, 전달된 핵산 서열의 발현을 지시하고/하거나 제어하는 핵산 서열을 함유하는 핵산 분자이다. 발현은 전사, 해독 및 스플라이싱(인트론이 존재하는 경우)과 같은 과정을 포함하나, 이에 제한되는 것은 아니다. 통상적으로, 발현 벡터는 폴리펩티드를 암호화하는 이종성 핵산 서열에 작동가능하게 연결된 하나 이상의 플랭킹 서열을 포함한다. 플랭킹 서열은, 예를 들면, 동종성 (즉, 숙주 세포와 동일한 종 및/또는 주(strain)로부터 유래된 것), 이종성 (즉, 숙주 세포 종 또는 주 이외의 다른 종으로부터 유래된 것), 하이브리드 (즉, 하나 이상의 공급원으로부터 유래된 플랭킹 서열의 조합), 또는 합성일 수 있다.
플랭킹 서열은 바람직하게는 암호 서열의 복제, 전사 및/또는 해독에 영향을 미칠 수 있고 암호 서열에 작동가능하게 연결된다. 본원에서 사용된 "작동가능하게 연결된"이란 용어는 폴리뉴클레오티드 요소를 기능적 관계로 연결하는 것을 의미한다. 예를 들면, 프로모터 또는 인핸서는, 암호 서열의 전사에 영향을 미치는 경우, 암호 서열에 작동가능하게 연결된다. 그러나, 플랭킹 서열은, 정확하게 기능하는 한, 암호 서열과 반드시 연속적일 필요는 없다. 따라서, 예를 들면, 전사는 되지만 해독되지 않는 개재 서열이 프로모터 서열과 암호 서열 사이에 존재할 수 있고 프로모터 서열은 여전히 암호 서열에 작동가능하게 연결된 것으로 간주될 수 있다. 유사하게, 인핸서가 암호 서열의 상류 또는 하류에 위치하여, 서열의 전사에 영향을 줄 수 있다.
특정 태양에서, 플랭킹 서열은, 표적 세포 내에서 고-수준 유전자 발현을 유도하는 전사 조절 영역인 것이 바람직하다. 전사 조절 영역은 예를 들면 프로모터, 인핸서, 사이렌서(silencer), 레프레서(repressor) 요소 또는 이의 조합을 포함할 수 있다. 전사 조절 영역은 구성적, 조직-특이적, 세포-특이적 (즉, 다른 유형에 비해 특정 유형의 조직 또는 세포에서 고 수준의 전사를 유도하는 영역), 또는 조절성 (즉, 테트라사이클린과 같은 화합물과의 상호작용에 반응성) 일 수 있다. 전사 조절 영역의 공급원은 원핵 또는 진핵 생물체, 모든 척추 또는 무척추 생물체 또는 모든 식물일 수 있으나, 단 플랭킹 서열은 그 세포 내에서 핵산의 전사를 일으킴으로써 세포 내에서 기능을 발휘한다. 매우 다양한 전사 조절 영역이 본 발명을 실행하는데 이용될 수 있다.
적합한 전사 조절 영역으로는 CMV 프로모터 (즉, CMV-즉시 초기(immediate early) 프로모터); 진핵생물 유전자 기원의 프로모터 (즉, 에스트로겐-유도성 닭 난(卵) 알부민(ovalbumin) 유전자, 인터페론 유전자, 글루코코르티코이드-유도성 티로신 아미노트랜스퍼라제 유전자, 및 티미딘 키나제 유전자); 및 주요 초기 및 후기 아데노바이러스 유전자 프로모터; SV40 초기 프로모터 영역 [참조 문헌: Bernoist and Chambon, 1981, Nature 290: 304-10]; 라우스 육종 바이러스(RSV: Rous sarcoma virus)의 3' 장말단 반복체(LTR) 내에 함유된 프로모터[참조 문헌: Yamamoto, et al., 1980, Cell 22: 787-97]; 단순 포진 바이러스 티미딘 키나제 (HSV-TK) 프로모터 [참조 문헌: Wagner et al., 1981, Proc. Natl. Acad. Sci. U.S.A. 78:1444-45]; 메탈로티오닌 유전자의 조절 서열[참조 문헌: Brinster et al., 1982, Nature 296:39-42]; 베타-락타마제 프로모터와 같은 원핵 생물 발현 벡터[참조 문헌: Villa-Kamaroff et al., 1978, Proc. Natl. Acad. Sci. U.S.A., 75: 3727-31]; 또는 tac 프로모터 [참조 문헌: DeBoer et al., 1983, Proc. Natl. Acad. Sci. U.S.A., 80: 21-25]가 포함된다. 조직- 및/또는 세포-유형 특이적 전사 제어 영역은 예를 들어 특히 췌장의 샘꽈리 세포 내에서 활성인 엘라스타제 I 유전자 제어 영역[참조 영역: Swift et al., 1984, Cell 38: 639-46; Ornitz et al., 1986, Cold Spring Harbor Symp Quant. Biol. 50: 399-409 (1986); MacDonald, 1987, Hepatology 7: 425-515]; 췌장의 베타 세포 내에서 활성인 인슐린 유전자 제어 영역[참조 문헌: Hanahan, 1985, Nature. 315: 115-22); 림프계 세포 내에서 활성인 면역글로불린 유전자 제어 영역[참조 문헌: Grosschedl et al., 1984, Cell 38: 647-58; Adames et al., 1985, Nature 318: 533-38; Alexander et al., 1987, Mol. Cell. Biol., 7: 1436-44]; 고환, 유방, 림프계 및 비만 세포 내의 마우스 유방 종양 바이러스 제어 영역[참조 문헌: Leder et al., 1986, Cell 45: 485-95]; 간 내의 알부민 유전자 제어 영역[참조 문헌: Pinkert et al., 1987, Genes and Devel. 1: 268-76]; 간 내의 알파-태아 단백질(alpha-feto-protein) 유전자 제어 영역[참조 문헌: Krumlauf et al., 1985, MoL Cell. Biol., 5: 1639-48; Hammer et al., 1987, Science 235: 53-58]; 간 내의 알파 1-항트립신 유전자 제어 영역[참조 문헌: Kelsey et al., 1987, Genes and DeveL 1: 161-71]; 골수 세포 내의 베타-글로빈 유전자 제어 영역 [참조 문헌: Mogram et al., 1985, Nature 315: 338-40; Kollias et al., 1986, Cell 46: 89-94]; 뇌의 희소돌기아교세포 내의 미엘린 염기성 단백질 유전자 제어 영역[참조 문헌:Readhead et al., 1987, Cell 48 : 703-12] ; 골격근 내의 미오신 경쇄-2 유전자 제어 영역[참조 문헌: Sani, 1985, Nature 314: 283-86]; 시상하부 내의 성선자극호르몬 방출 호르몬 유전자 제어 영역[참조 문헌: Mason et al., 1986, Science 234: 1372-78], 및 흑색종 세포 내의 티로신아제 프로모터[참조 문헌: Hart, I. Semin Oncol 1996 Feb; 23 (1): 154-8; Siders, et al. Cancer Gene Ther 1998 Sep-Oct; 5 (5): 281-91]를 포함한다. 특정 화합물 또는 조건, 예를 들면 빛, 열, 방사선, 테트라사이클린 또는 열 쇽크 단백질의 존재하에서 활성화되는 유도성 프로모터가 또한 이용될 수 있다[참조 문헌: WO 00/10612]. 기타 적합한 프로모터가 당업계에 공지되어있다.
상기한 바와 같이, 인핸서는 또한 적합한 플랭킹 서열일 수 있다. 인핸서는 프로모터에 작용하여 전사를 증가시키는 통상적으로 약 10 내지 300 bp 길이의 DNA의 시스-작용 요소이다. 통상적으로 인핸서는 배향- 및 위치-독립적이므로, 제어된 암호 서열의 5' 및 3' 모두에서 확인되었다. 포유동물 유전자로부터 구할 수 있는 몇몇 인핸서 서열이 공지되어있다 (즉, 글로빈, 엘라스타제, 알부민, 알파-태아 단백질 및 인슐린). 유사하게, SV40 인핸서, 사이토메갈로바이러스 초기 프로모터 인핸서, 폴리오마 인핸서 및 아데노바이러스 인핸서가 진핵 생물 프로모터 서열과 함께 사용될 수 있다. 인핸서는 핵산 암호 서열의 5' 또는 3' 위치에서 벡터 내로 스플라이싱될 수 있으나, 이는 통상적으로 프로모터의 5' 부위에 위치한다. 다른 적합한 인핸서가 당업계에 공지되어있으며, 본 발명에 이용될 수 있을 것이다.
본 발명의 시약을 제조하는 때에, 세포를 형질감염시키거나 형질전환시킬 필요가 있다. 형질감염은 세포에 의한 외래 또는 외인성 DNA의 섭취를 의미하며, 외인성 DNA가 세포막 내로 도입되어졌을 때 세포는 형질감염되어진다. 수 많은 형질감염 기법이 당업계에 널리 공지되어있다[참조 문헌: Graham et al., 1973, Virology 52: 456; Sambrook et al., Molecular Cloning, A Laboratory Manual. (Cold Spring Harbor Laboratories, 1989); Davis et al., Basic Methods in Molecular Biology (Elsevier, 19S6) ; and Chu et al., 1981, Gene 13: 197]. 이러한 기법은 하나 이상의 외인성 DNA 잔기를 적합한 숙주 세포 내로 도입하는데 사용될 수 있다.
특정 태양에서, 세포의 형질감염이 그 세포의 형질전환을 초래하는 것이 바람직하다. 세포의 특징 중에 변화가 있을 때 세포는 형질전환되므로, 새로운 핵산을 함유하도록 변형되어졌을 때 형질전환된다. 형질감염 후, 형질감염된 핵산은, 세포의 염색체 내로 물리적으로 통합시킴으로써 세포의 핵산과 재조합될 수 있거나, 복제되지 않으면서 에피솜 요소로서 일시적으로 유지될 수 있거나, 또는 플라스미드로서 독립적으로 복제될 수 있다. 핵산이 세포의 분열과 함께 복제되는 경우, 세포가 안정하게 형질전환된 것이다.
본 발명의 발현 벡터는 또한 면역원성 표적물의 단편의 발현을 제공한다. 단편은 아미노 말단 (리더 서열을 포함하거나 포함하지 않음) 및/또는 카복시 말단에서 절두된(truncated) 서열을 포함할 수 있다. 단편은 또한 변이체 (즉, 대립형질, 스플라이스), 오르토로그(ortholog), 동족체, 및 모(母) 서열에 비해 하나 이상의 아미노산 부가 또는 치환 또는 내부 결실을 가진 기타 변이체를 포함할 수 있다. 바람직한 태양에서, 절두물 및/또는 결실물은 약 1 내지 5개 아미노산, 5 내지 10개 아미노산, 10 내지 20개 아미노산, 20 내지 30개 아미노산, 30 내지 40개 아미노산, 40 내지 50개 아미노산, 또는 그 이상을 포함할 수 있다. 이러한 폴리펩티드 단편은 임의로 아미노 말단 메티오닌 잔기를 포함할 수 있다. 이러한 단편이 예를 들어 면역원성 표적물에 대한 항체 또는 세포 면역 반응을 발생시키는데 사용될 수 있다고 본다.
변이체는 해당 서열에 비해 하나 이상의 서열 치환, 결실 및/또는 부가를 갖는 서열이다. 변이체는 천연적으로 존재하거나 인공적으로 작제될 수 있다. 이러한 변이체는 상응하는 핵산 분자로부터 제조될 수 있다. 바람직한 태양에서, 변이체는 1 내지 3개, 1 내지 5개, 1 내지 10개, 1 내지 15개, 1 내지 20개, 1 내지 25개, 1 내지 30개, 1 내지 40개, 1 내지 50개, 또는 50개 이상의 아미노산 치환, 삽입, 부가 및/또는 결실을 갖는다.
대립형질 변이체는, 생물체 또는 생물체 집단의 염색체 상의 소정의 유전자좌를 차지하는 서열의 여러 가능한 천연적으로 존재하는 대안 형 중의 하나이다. 스플라이스 변이체는 일차 전사체의 스플라이싱의 결과로 생성된 여러 RNA 전사체 중의 하나로부터 생성된 폴리펩티드이다. 오르토로그(ortholog)는 또 다른 종 기원의 유사한 핵산 또는 폴리펩티드 서열이다. 예를 들면, 면역원성 표적물의 마우스 및 사람 형은 서로 오르토로그로 간주될 수 있다. 서열의 유도체는, 모 서열로 부터 유래된 것으로서, 치환, 부가, 결실 또는 화학적으로 변형된 변이체를 갖는 서열 중의 하나이다. 변이체는 또한 융합 단백질을 포함하며, 이는 하나 이상의 제1 서열(예를 들면, 펩티드)가 하나 이상의 다른 서열(예를 들면 이종성 펩티드)의 아미노 카복시 말단에서 융합된 것을 의미한다.
"유사성"은 동일성 관련 개념이나, 단 유사성은 동일 합치 및 보존성 치환 합치 둘 모두를 포함하는 관련도의 척도를 의미한다. 두 개의 폴리펩티드 서열이 예를 들어 10/20 동일 아미노산을 갖고 나머지는 모두 비-보존적 치환인 경우에, 동일성 및 유사성 %는 모두 50% 일 것이다. 동일한 예에서, 5개 이상의 위치에 보존적 치환이 있는 경우에, 동일성 %는 50%를 유지하지만, 유사성 %는 75% (15/20)일 것이다. 따라서, 보존적 치환이 있는 경우에, 두 개의 폴리펩티드 사이의 유사성 %는 이들 두 폴리펩티드 사이의 동일성 % 보다 더 높을 것이다.
치환은 보존적 또는 비-보존적이거나, 또는 이의 임의의 조합일 수 있다. 폴리펩티드의 서열에 대한 보존적 아미노산 변형 (및 암호화 뉴클레오티드에 대한 상응하는 변형)은, 모(母) 폴리펩티드와 유사한 기능 및 화학적 특징을 갖는 폴리펩티드를 생성할 수 있다. 예를 들면, "보존적 아미노산 치환"은 천연 아미노산 잔기가 그 위치에서 당해 아미노산 잔기의 크기, 극성, 전하, 소수성 또는 친수성에 영향을 거의 주지 않거나 전혀 주지 않으며, 특히 면역원성을 감소시키지 않도록, 비-천연 잔기로 치환되는 것을 포함할 수 있다. 적합한 보존적 아미노산 치환은 표 I에 제시된다.
당업자는 익히 공지된 기법을 이용하여 면역원성 표적의 적합한 변이체를 결정할 수 있을 것이다. 생물학적 활성(예: MHC 결합성, 면역원성)을 파괴하지 않으면서 변화시킬 수 있는 적당한 분자 영역을 확인하기 위하여, 당업자는 당해 활성에 중요한 것으로 여겨지지 않는 영역을 표적화할 수 있다. 예를 들면, 동일한 종 또는 다른 종으로부터의 유사한 활성을 가진 면역원성 표적이 공지된 경우에, 당업자는 폴리펩티드의 아미노산 서열을 이러한 유사한 폴리펩티드와 비교할 수 있다. 이러한 분석을 수행함으로써, 보존되는 분자의 잔기 및 부분을 확인할 수 있다. 이러한 유사한 면역원성 표적에 비해 보존되지 않는 분자 영역 내의 변화가 폴리펩티드의 생물학적 활성 및/또는 구조에 악영향을 줄 가능성은 적을 것이라고 생각된다. 유사하게, MHC에 대한 결합에 요구되는 잔기가 공지되었으며, 이는 결합을 개선시키도록 변형될 수 있다. 그러나, MHC에 대한 결합을 감소시키는 변형은 대부분의 경우에 적당하지 않을 것이다. 당업자는 또한 비교적 보존된 영역 내일지라도, 천연적으로 존재하는 잔기를 활성을 유지하면서 화학적으로 유사한 아미노산으로 치환할 수 있다는 것을 알 것이다. 따라서, 생물학적 활성 또는 구조에 중요할 수 있는 영역에도, 생물학적 활성을 파괴하지 않거나 또는 면역원성 표적의 구조에 악영향을 주지 않으면서, 보존적 아미노산 치환이 일어날 수 있다.
다른 바람직한 폴리펩티드 변이체는, 글리코실화 부위의 수 및/또는 유형이 해당 아미노산 서열에 비해 변형되어진 글리코실화 변이체를 포함한다. 일 태양에서, 폴리펩티드 변이체는 해당 아미노산 서열보다 더 많거나 적은 수의 N-결합된 글리코실화 부위를 포함한다. N-결합된 글리코실화 부위는 서열 Asn-X-Ser 또는 Asn-X-Thr을 특징으로 하며, 이때 X로서 표기된 아미노산 잔기는 프롤린을 제외한 모든 아미노산 잔기일 수 있다. 이러한 서열을 형성하는 아미노산 잔기의 치환은 N-결합된 탄화수소 쇄의 부가를 위한 새로운 잠재적인 부위를 제공한다. 달리, 상기 서열을 제거하는 치환은 기존의 N-결합된 탄화수소 쇄를 제거할 것이다. 또한, 하나 이상의 N-결합된 글리코실화 부위 (통상적으로 천연적으로 존재하는 것들)이 제거되고 하나 이상의 새로운 N-결합 부위가 형성되는 N-결합된 탄화수소 쇄의 재배열이 제공된다. 폴리펩티드의 O-결합된 글리코실화에 영향을 주기 위하여, 세린 및/또는 트레오닌 잔기를 변형시킬 수 있다.
추가적 바람직한 변이체는, 해당 아미노산 서열 세트에 비해 하나 이상의 시스테인 잔기가 결실되거나 다른 아미노산 (예: 세린)으로 치환된 시스테인 변이체를 포함한다. 펩티드 또는 폴리펩티드가 불용성 봉입체(inclusion body)의 분리 후와 같이 생물학적 활성 입체형태로 재폴딩되어야 할 때, 시스테인 변이체가 유용하다. 시스테인 변이체는 일반적으로 천연 단백질 보다 시스테인 잔기가 더 적고, 쌍을 형성하지 않은 시스테인에 의한 상호작용을 최소화하기 위하여 짝수의 시스테인을 갖는 것이 통상적이다.
다른 태양에서, 펩티드 또는 폴리펩티드는, 당해 폴리펩티드의 정제를 보조하는 하나 이상의 융합 절편에 부착될 수 있다. 융합은 이의 해당 폴리펩티드 변이체의 아미노 말단 또는 카복시 말단에서 이루어질 수 있다. 융합은 링커 또는 어댑터 분자 없이 직접 연결될 수 있거나, 또는 링커 또는 어댑터 분자를 통하여 연결될 수 있다. 링커 또는 어댑터 분자는 하나 이상의 아미노산 잔기, 통상적으로 약 20 내지 약 50개의 아미노산 잔기일 수 있다. 링커 또는 어댑터 분자는 또한, 융합된 부분을 분리시킬 수 있는 DNA 제한 엔도뉴클리아제 또는 프로테아제에 대한 절단 부위를 갖도록 설계될 수 있다. 일단 작제되면, 융합 폴리펩티드는 본원에 기재된 방법에 따라 유도체화될 수 있다고 생각될 것이다. 적합한 융합 절편은 특히 금속 결합 도메인 (예: 폴리-히스티딘 절편), 면역글로불린 결합 도메인 (즉, 단백질 A, 단백질 G, T 세포, B 세포, Fc 수용체, 또는 보체 단백질 항체-결합 도메인), 당류 결합 도메인 (예: 말토스 결합 도메인), 및/또는 "태그(tag)" 도메인 (즉, α-갈락토시다제의 적어도 일부, 스트렙(strep) 태그 펩티드, T7 태그 펩티드, FLAG 펩티드, 또는 모노클로날 항체와 같이 도메인에 결합된 화합물을 사용하여 정제할 수 있는 기타 도메인)을 포함한다. 이러한 태그는 통상적으로 펩티드 또는 폴리펩티드에 융합될 수 있으며, 발현시 숙주 세포로부터 목적하는 폴리펩티드 서열의 친화성 정제를 위한 수단으로서의 역할을 할 수 있다. 친화성 정제는, 예를 들면 태그에 대한 항체를 친화성 매트릭스로서 사용하여 칼럼 크로마토그래피에 의해 달성할 수 있다. 임의로, 태그는 다양한 수단, 예를 들면 절단용 특정 펩티다제를 사용하여 목적하는 폴리펩티드의 정제된 서열로부터 후속적으로 제거될 수 있다. 후술하는 바와 같이, 융합은 예를 들면 TA와 공동-자극 성분, 예컨대 케모킨 CXC10 (IP-10), CCL7 (MCP-3) 또는 CCL5 (RANTES) 사이에서 이루어질 수 있다.
융합 모티프는 면역원성 표적의 MHC 프로세싱 구획, 예를 들면 소포체로의 수송을 증가시킬 수 있다. 트랜스덕션(tranduction) 또는 트랜스사이토시스(transcytosis) 서열로서 지칭되는 이들 서열은 HIV tat[참조: Kim et al. 1997 J. Immunol. 159: 1666), 드로소필라 안테나페디아(Drosophiila antennapedia)[참조: Schutze-Redelmeier et al. 1996 J. Immunol. 157: 650], 또는 사람 1기 단백질 [hPER1; 특히 SRRHHCRSKAKRSRHH (서열번호 17)]로부터 유래된 서열을 포함한다.
또한, 폴리펩티드 또는 이의 변이체는 동종 펩티드 또는 폴리펩티드에 융합되어 동종이량체를 형성할 수 있거나 또는 이종 펩티드 또는 폴리펩티드에 융합되어 이종이량체를 형성할 수 있다. 이종 펩티드 및 폴리펩티드는, 융합 폴리펩티드의 검출 및/또는 분리를 허용하는 에피토프; 막관통(transmembrane) 수용체 단백질 또는 이의 부분, 예를 들면 세포외 도메인 또는 막관통 및 세포내 도메인; 막관통 수용체 단백질에 결합하는 리간드 또는 이의 부분; 촉매적으로 활성인 효소 또는 이의 부분; 올리고머화를 촉진하는 폴리펩티드 또는 펩티드, 예를 들면 루이신 지퍼(zipper) 도메인; 안정성을 증가시키는 폴리펩티드 또는 펩티드, 예를 들면 면역글로불린 불변 영역; 당해 펩티드 또는 폴리펩티드와 상이한 치료학적 활성을 갖는 펩티드 또는 폴리펩티드; 및/또는 이의 변이체를 포함하나, 이에 제한되는 것은 아니다.
특정 태양에서, 면역원성 표적을 암호화하는 핵산 서열과 하나 이상의 공동-자극 성분(들), 예를 들면 세포 표면 단백질, 사이토킨 또는 케모킨을 본 발명의 조성물 내에 배합하는 것이 유리할 수 있다. 공동-자극 성분은, 예를 들면 폴리펩티드 또는 당해 폴리펩티드를 암호화하는 핵산으로서 조성물 내에 포함될 수 있다. 적합한 공동-자극 분자는 예를 들어, CD28 계열의 일원(즉, CD28, ICOS; Hutloff, et al. Nature 1999, 397: 263-265; Peach, et al. J Exp Med 1994, 180: 2049-2058)에 결합하는 폴리펩티드, 예를 들어 CD28 결합 폴리펩티드 B7.1 [CD80; Schwarz, 1992; Chen et al, 1992; Ellis, et al. J. Immunol., 156 (8): 2700-9], B7.2 [CD86; Ellis, et al. J. Immunol., 156 (8): 2700-9], 및 이의 돌연변이체/변이체[WO 00/66162]; ICAM 계열의 일원(즉, ICAM-1, -2 또는 -3)을 포함하여, 인테그린 계열의 일원(즉, LFA-1 (CD1la/CD18); Sedwick, et al. J Immunol 1999, 162: 1367-1375; Wulfing, et al. Science 1998, 282: 2266-2269; Lub, et al. Immunol Today 1995, 16: 479-483]에 결합하는 폴리펩티드; CD2 계열의 일원 [즉, CD2, 시그널전달 림프구 활성화 분자 (CDw150 또는 "SLAM"; Aversa, et al. J Immunol 1997, 158: 4036-4044)]에 결합하는 폴리펩티드, 예를 들면 CD58 (LFA-3; CD2 리간드; Davis, et al. Immunol Today 1996, 17: 177-187) 또는 SLAM 리간드 (Sayos, et al. Nature 1998, 395 : 462-469); 열 안정성 항원 (HSA 또는 CD24; Zhou, et al. Eur J Immunol 1997, 27: 2524-2528)에 결합하는 폴리펩티드; TNF 수용체 (TNFR) 계열의 일원 [즉, 4-1BB (CD137; Vinay, et al. Semin Immunol 1999, 10: 481-489), OX40 (CD134; Weinberg, et al. Semin Immunol 1998, 10: 471-480; Higgins, et al. J Immunol 1999, 162: 486-493), 및 CD27 (Lens, et al. Semis Immunol 1998, 10: 491-499)]에 결합하는 폴리펩티드, 예를 들면 4-1BBL (4-1BB 리간드; Vinay, et al. Serein Immunol 1998, 10: 481-48; DeBenedette, et al. J Immunol 1997, 158: 55l-559), TNFR 관련 인자-1 (TRAF-1; 4-1BB 리간드; Saoulli, et al. J Exp Med 1998, 187: 1849-1862, Arch, et al. Mol Cell Biol 1998, 18: 558-565), TRAF-2 (4-1BB 및 OX40 리간드; Saoulli, et al. J Exp Med 1998, 187: 1849-1862; Oshima, et al. Int Immunol 1998, 10: 517-526, Kawamata, et al. J Biol Chem 1998, 273: 5808-5814), TRAF-3 (4-1BB 및 OX40 리간드; Arch, et al. Mol Cell Biol 1998, 18: 558-565; Jang, et al. Biochem Biophys Res Commun 1998, 242: 613-620; Kawamata S, et al. J Biol Chem 1998, 273: 5808-5814), OX40L (OX40 리간드; Gramaglia, et al. J Immunol 1998, 161: 6510-6517), TRAF-5 (OX40 리간드; Arch, et al. Mol Cell Biol 1998, 18: 558-565; Kawamata, et al. J Biol Chem 1998, 273: 5808-5814), 및 CD70 (CD27 리간드; Couderc, et al. Cancer Gene Ther., 5(3): 163-75)를 포함한다. CD 154 (CD40 리간드 또는 "CD40L"; Gurunathan, et al. J. Immunol., 1998, 161: 4563-4571; Sine, et al. Hum. Gene Ther., 2001, 12: 1091-1102)가 또한 적당할 수 있다.
하나 이상의 사이토킨이 또한 본 발명의 조성물 내에 함유된 폴리펩티드 또는 핵산에 의해 암호화된 것으로서 적합한 공동-자극 성분 또는 "애주번트" 일 수 있다[참조 문헌: Parmiani, et al. Immunol Lett 2000 Sep 15; 74 (1): 41-4; Berzofsky, et al. Nature Immunol. 1: 209-219]. 적합한 사이토킨은, 예를 들어 인터루킨-2 (IL-2) [참조 문헌: Rosenberg, et al. Nature Med. 4: 321-327 (1998)], IL-4, IL-7, IL-12 [참조 문헌: Pardoll, 1992; Harries, et al. J. Gene Med. 2000 Jul-Aug; 2(4): 243-9; Rao, et al. J. Immunol. 156: 3357-3365 (1996)], IL-15 [참조 문헌: Xin, et al. Vaccine, 17: 858-866, 1999], IL-16 [참조 문헌: Cruikshank, et al. J. Leuk Biol. 67(6): 757-66, 2000], IL-18 [참조 문헌: J. Cancer Res Clin. Oncol. 2001. 127(12): 718-726], GM-CSF [CSF (Disis, et al. Blood, 88: 202-210 (1996)], 종양 괴사 인자-알파 (TNF-α), 또는 INF-α또는 INF-γ와 같은 인터페론을 포함한다. 당업계에 공지된 다른 사이토킨이 또한 본 발명을 실행하는데 적합할 수 있다.
케모킨은 폴리펩티드 또는 핵산 형으로 이용될 수 있다. 종양 자가-항원에 융합된 CXCL10 (IP-10) 및 CCL7 (MCP-3)을 포함하는 융합 단백질이 항-종양 면역성을 유도한다는 것이 밝혀졌다[참조 문헌: Biragyn, et al. Nature Biotech. 1999, 17: 253-258]. 케모킨 CCL3 (MIP-lα) 및 CCL5 (RANTES) [참조 문헌: Boyer, et al. Vaccine, 1999, 17. (Supp. 2): S53-S64]이 또한 본 발명을 실행하는데 사용될 수 있다. 다른 적합한 케모킨이 당업계에 공지되어있다.
억제성 또는 음성 조절 면역 기전이 차단되면, 면역 반응이 증강될 수 있다는 것이 또한 당업계에 공지되었다. 예를 들면, 항-CTLA-4 (Shrikant, et al. Immunity, 1996, 14: 145-155; Sutmuller, et al. J. Exp. Med., 2001, 194: 823-832), 항-CD25 (Sutmuller, supra), 항-CD4 (Matsui, et al. J. Immunol., 1999, 163: 184-193), 융합 단백질 IL 13Ra2-Fc (Terabe, et al. Nature Immunol., 2000, 1: 515-520), 및 이의 조합 (즉, 항-CTLA-4 및 항-CD25, Sutmuller, supra)을 사용한 처리가 항-종양 면역 반응을 상향조절하는 것으로 밝혀졌으며 본 발명을 실행하는데 적합할 것이다. 특히, 상기와 같은 처리는 본 발명의 하나 이상의 면역원성 표적과 조합될 수 있다.
이들 성분들은 모두 단독으로 또는 다른 제제와 함께 사용될 수 있다. 예를 들면, CD80, ICAM-1 및 LFA-3 ("TRICOM")의 배합물이 항-암 면역 반응을 강화시킬 수 있다[참조 문헌: Hodge, et al. Cancer Res. 59: 5800-5807 (1999)]. 기타 효과적인 배합물은 예를 들어 IL-12 + GM-CSF [Ahlers, et al. J. Immunol., 158: 3947-3958 (1997); Iwasaki, et al. J. Immunol. 158: 4591-4601 (1997)], IL-12 + GM-CSF + TNF-α[Ahlers, et al. Int. Immunol. 13: 897-908 (2001)], CD80 + IL-12 (Fruend, et al. Int. J. Cancer, 85: 508-517 (2000); Rao, et al. supra], 및 CD86 + GM-CSF + IL-12 [Iwasaki, supra]을 포함한다. 당업자는 본 발명을 수행하는데 유용한 또 다른 배합물을 알 것이다. 또한, 당업자는 상기와 같은 기전을 조절하는데 사용될 수 있는 추가적 시약 또는 방법을 알 것이다. 이들 시약 및 방법뿐만 아니라, 당업자에 의해 공지된 그밖의 것이 본 발명을 실행하는데 이용될 수 있다.
핵산-이용 면역화의 효율을 향상시키기 위한 추가적 전략, 예를 들어 자가-복제성 바이러스 레플리콘의 사용 [참조 문헌; Caley, et al. 1999. Vaccine, 17: 3124-2135; Dubensky, et al. 2000. Mol. Med. 6: 723-732; Leitner, et al. 2000. Cancer Res. 60: 51-55], 코돈 최적화 [참조 문헌: Liu, et al. 2000. Mol. laser., 1: 497-500; Dubensky, supra ; Huang, et al. 2001. J. Virol. 75: 4947-4951], 생체내 전기천공 [참조 문헌: Widera, et al. 2000. J. Immunol. 164: 4635-3640], CpG 자극 모티프의 도입 [참조 문헌: Gurunathan, et al. Ann. Rev. Immunol., 2000, 18: 927-974; Leitner, supra ; Cho, et al. J. Immunol. 168 (10): 4907-13], 세포내이입 또는 우비퀴틴-프로세싱 경로의 표적화를 위한 서열[참조 문헌: Thomson, et al. 1998. J. Virol. 72: 2246-2252; Velders, et al. 2001. J. Immunol. 166 : 5366-5373], 마렉(Marek's) 질환 바이러스 1형 VP22 서열 [참조 문헌: J. Virol. 76(6): 2676-82, 2002], 초회감작-추가감작(prime-boost) 방법 [참조 문헌: Gurunathan, supra; Sullivan, et al. 2000. Nature, 408: 605-609; Hanke, et al. 1998. Vaccine, 16: 439-445; Amara, et al. 2001. Science, 292: 69-74], 및 살모넬라(Salmonella)와 같은 점막 전달 벡터의 사용 [참조 문헌: Darji, et al. 1997. Cell, 91: 765-775; Woo, et al. 2001] 등이 이용될 수 있다. 다른 방법들이 당업계에 공지되어있고, 그 중 일부는 후술된다.
화학요법제, 방사선조사, 항-혈관형성 화합물 또는 다른 제제가, 면역원성 표적을 사용하여 암을 치료 및/또는 예방하는데 이용될 수 있다[참조 문헌: Sebti, et al. Oncogene 2000 Dec 27; 19(56): 6566-73]. 예를 들면, 전이성 흑색종을 치료하는데 있어서, 적합한 화학요법제로는 특히 BELD (블레오마이신, 빈데신, 로무스틴 및 데카르바진; Young, et al. 1985. Cancer, 55: 1879-8i), BOLD (블레오마이신, 빈크리스틴, 로무스틴, 데카르바진; Seigler, et al. 1980. Cancer, 46: 2346-8); DD (데카르바진, 액티노마이신; Hochster, et al. Cancer Treatment Reports, 69: 39-42), 또는 POC (프로카르바진, 빈크리스틴, 로무스틴; Carmo-Pereira, et al. 1984. Cancer Treatment Reports, 68: 1211-4)가 포함될 수 있다. 다른 적합한 화학요법적 방법이 또한 이용될 수 있다.
다수의 항-혈관형성제가 당업계에 공지되어있으며, 면역원성 표적 백신 및/또는 화학요법제와 함께 공동-투여하기에 적합할 것이다[참조 문헌: Timar, et al. 2001. Pathology Oncol. Res., 7(2): 85-94]. 이러한 제제로는 예를 들면 생리학적 제제, 예컨대 성장 인자 (즉, ANG-2, NK1,2,4 (HGF), 형질전환성 성장 인자 베타 (TGF-β)), 사이토킨 (즉, 인터페론, 예를 들어 IFN-α, -β, -γ, 혈소판 인자 4 (PF-4), PR-39), 프로테아제 (즉, 절단된 AT-III, 콜라겐 XVIII 단편 (Endostatin)), HmwKallikrein-d5 플라스민 단편 (Angiostatin), 프로트롬빈-Fl-2, TSP-1), 프로테아제 억제제 (즉, 메탈로프로테아제의 조직 억제제, 예를 들어 TIMP-1, -2, 또는 -3; 매스핀(maspin); 플라스미노겐 활성인자-억제제, 예를 들어 PAI-1; 색소 상피 유래된 인자 (PEDF)), 툼스타틴(Tumstatin) (구입처: ILEX, Inc. ), 항체 생성물 (즉, 콜라겐-결합 항체 HUIV26, HUI77, XL313; 항-VEGF; 항-인테그린 (즉, Vitaxin, (Lxsys))), 및 글리코시다제 (즉, 헤파린아제-I, -III)가 포함된다. 공지되었거나 항-혈관형성 잠재력을 갖는 것으로 여겨지는 "화학적" 또는 변형된 생리학적 제제로는, 예를 들어 빈블라스틴, 탁솔, 케토코나졸, 탈리도미드(thalidomide), 돌레스타틴(dolestatin), 콤브레스타틴(combrestatin) A, 라파마이신 (Guba, et al. 2002, Nature Med., 8: 128- 135), CEP-7055 (구입처: Cephalon, Inc.), 플라본(flavone) 아세트산, Bay 12-9566 (Bayer Corp.), AG3340 (Agouron, Inc.), CGS 27023A (Novartis), 테트라사이클린 유도체 (즉, COL-3 (Collagenix, Inc.)), 네오바스타트(Neovastat) (Aeterna), BMS-275291 (Bristol-Myers Squibb), 저 용량 5-FU, 저 용량 메토트렉세이트 (MTX), 이르소플라딘(irsofladine), 라디시콜(radicicol), 사이클로스포린, 캡토프릴(captopril), 셀렉콕시브(celecoxib), D45152-설페이트화 다당류, 양이온성 단백질 (Protamine), 양이온성 펩티드-VEGF, 수라민(Suramin) (폴리설포네이트화 나프틸 우레아), VEGF의 기능 또는 생성을 방해하는 화합물 (즉, SU5416 또는 SU6668 (Sugen), PTK787/ZK22584 (Novartis)), 디스타마이신(Distamycin) A, 엔지오자임(Angiozyme) (리보자임), 이소플라비노이드, 스타우로스포린(staurosporine) 유도체, 게니스테인(genistein), EMD121974 (Merck KcgaA), 트립토스틴(tyrphostin), 이소퀴놀론, 레티노산, 카르복시아미도트라이졸, TNP-470, 옥트레오티드(octreotide), 2-메톡시에스트라디올(methoxyestradiol), 아미노스테로이드 (즉, 스쿠알라민(squalamine)), 글루타티온 유사체 (즉, N-아세틸-L-시스테인), 컴브레타스타틴 A-4 (Oxigen), Eph 수용체 차단제 (Nature, 414: 933-938, 2001), Rh-안지오스타틴(Angiostatin), Rh-엔도스타틴(Endostatin) (WO 01/93897), 사이클릭-RGD 펩티드, 액쿠틴(accutin)-디스인테그린(disintegrin), 벤조디아제펜, "사람화된 항-avb3 Ab, Rh-PAI-2, 아밀로라이드(amiloride), p-아미도벤자미딘, 항-uPA ab, 항-uPAR Ab, L-페닐알라닌-N-메틸아미드 (즉, 바티미스타트(Batimistat), 마리마스타트(Marimastat)), AG3340, 및 미노사이클린이 포함된다. 다수의 다른 적합한 제제가 당업계에 공지되어있으며 본 발명을 실행하는데 충분할 것이다.
본 발명은 또한 암 치료의 "비-전통적" 방법과 함께 병용될 수 있다. 예를 들면, 특정 혐기성 세균의 투여가 종양 성장을 지연시키는데 도움을 줄 수 있다는 것이 최근에 입증되었다. 한 연구에서, 클로스트리듐 노비(Clostridium novyi)를 변형시켜 파아지 에피솜 상에 보유되는 독소 유전자를 제거하여, 결장직장 암을 가진 마우스에 투여하였다[참조 문헌: Dang, et al. P.N.A.S. USA, 98 (26): 15155-15160, 2001]. 화학요법과 함께, 상기 치료는 동물에서 종양 괴사를 일으킨다는 것이 밝혀졌다. 본 출원에 기재된 시약 및 방법론이 상기와 같은 시약 및 방법론과 함께 병용될 수 있다.
면역원성 표적을 암호화하는 핵산은 다수의 이용가능한 기법 중의 하나에 의해 환자에게 투여될 수 있다. 핵산을 숙주에 도입하는데 성공적으로 이용되었던 다양한 바이러스 벡터로는 특히 레트로바이러스, 아데노바이러스, 아데노-수반 바이러스 (AAV: Adeno-Associated Virus), 헤르페스 바이러스 및 폭스바이러스가 포함된다. 다수의 이러한 바이러스 벡터가 당업계에 이용될 수 있다는 것이 당업계에서 이해된다. 본 발명의 벡터는 당업자에게 널리 이용된 표준 재조합 기법을 사용하여 작제할 수 있다. 이러한 기법은 통상의 분자 생물학 문헌[예를 들면, Molecular Cloning: A Laboratory Manual (Sambrook, et al., 1989, Cold Spring Harbor Laboratory Press), Gene Expression Technology (Methods in Enzymology, Vol. 185, edited by D. Goeddel, 1991. Academic Press, San Diego, CA), 및 PCR Protocols: 4 Guide to Methods and Applications (Innis, et al. 1990. Academic Press, San Diego, CA)]에서 찾아 볼 수 있다.
바람직한 레트로바이러스 벡터는 렌티바이러스의 유도체 뿐만 아니라 쥐 또는 조류 레트로바이러스의 유도체이다. 적합한 레트로바이러스의 예로는 예컨대 몰로네이(Moloney) 쥐 백혈병 바이러스 (MoMuLV), 하르베이(Harvey) 쥐 육종 바이러스 (HaMuSV), 쥐 유방 종양 바이러스 (MuMTV), SIV, BIV, HIV 및 라우스 육종 바이러스 (RSV)가 포함된다. 수 많은 레트로바이러스가 다중 외인성 핵산 서열에 도입될 수 있다. 재조합 레트로바이러스는 결함이 있기 때문에, 이들은 감염성 벡터 입자를 생성하기 위하여는 도움을 필요로 한다. 이러한 도움은 예를 들어 레트로바이러스 구조 유전자를 암호화하는 헬퍼 세포주에 의해 제공될 수 있다. 적합한 헬퍼 세포주로는 특히 Ψ2, PA317 및 PA12가 포함된다. 이러한 세포주를 사용하여 생성된 벡터 비리온(virion)을 사용하여 조직 세포주, 예를 들어 NIH 3T3 세포를 감염시켜, 다량의 키메라 레트로바이러스 비리온을 생성할 수 있다. 레트로바이러스 벡터는 전통적 방법 (즉, 주사)에 의해 또는 표적 세포 집단 가까이에 "생산자 세포주"를 이식하는 방법[참조 문헌: Culver, K., et al., 1994, Hum. Gene Iher., 5(3): 343-79; Culver, K., et al., Cold Spring Harb. Snap. Quant. Blol., 59: 685-90); Oldfield, E. , 1993, Hum. Gene Ther., 4 (1): 39-69]으로 투여될 수 있다. 생산자 세포주를 조작하여, 바이러스 벡터를 생성하고 표적 세포 근처에 바이러스 입자를 방출하도록 한다. 방출된 바이러스 입자의 일부는 표적 세포와 접촉하여 이들 세포를 감염시키므로, 본 발명의 핵산이 표적 세포로 전달된다. 표적 세표의 감염 후, 벡터의 핵산의 발현이 일어난다.
아데노바이러스 벡터는, 진핵생물 세포로의 유전자 전달 [참조 문헌: Rosenfeld, M., et al., 1991, Science, 252 (5004): 431-4; Crystal, R., et al., 1994, Nat. Genet., 8(1): 42-51], 진핵생물 유전자 발현 연구 [참조 문헌: Levrero, M., et al., 1991, Gene, 101(2): 195-202], 백신 개발 [참조 문헌: Graham, F. and Prevec, L., 1992, Biotechnology, 20: 363-90], 및 동물 모델 [참조 문헌: Stratford-Perricaudet, L., et al., 1992, Bone Marrow Transplant., 9 (Suppl. 1): 151-2; Rich, D., et al., 1993, Hum. Gene Ther., 4(4): 461-76]에서 특히 유용한 것으로 입증되었다. 재조합 Ad를 상이한 생체내 조직으로 투여하기 위한 실험 경로로는 특히 기관내 주입 [참조 문헌: Rosenfeld, M., et al., 1992, Cell, 68 (1): 143-55], 근육내 주사 [참조 문헌: Quantin, B., et al., 1992, Proc. Natl. Acad. Sci. U.S.A., 89(7): 2581-4], 말초 정맥내 주사 [참조 문헌: Herz, J., and Gerard, R., 1993, Proc. Natl. Acad. Sci. U.S.A., 90(7): 2812-6] 및 뇌에의 정위 접종 [참조 문헌: Le Gal La Salle, G., et al., 1993, Science, 259 (5097): 988-90]이 포함된다.
아데노-수반 바이러스 (AAV)는 고 수준 감염성, 넓은 숙주 범위, 및 숙주 세포 게놈 내로의 통합에서의 특이성을 보여준다[참조 문헌: Hermonat, P. , et al., 1984, Proc. Natl. Acad. Sci. U.S.A., 81 (20): 6466-70]. 또한, 단순 포진 바이러스 1형 (HSV-1)은, 이의 향신경 특성 때문에 특히 신경계에서 사용하기에 매력적인 또 다른 벡터 시스템이다[참조 문헌: Geller, A., et al., 1991, Trends Neurosci., 14(10) : 428-32; Glorioso, et al., 1995, Mol. Biotechrtol., 4(1): 87-99 ; Glorioso, et al., 1995, Annu. Rev. Microbiol., 49: 675-710].
폭스바이러스는 또 다른 유용한 발현 벡터이다 [참조 문헌: Smith, et al. 1983, Gene, 25(1): 21-8; Moss, et al, 1992, Biotechnology, 20: 345-62; Moss, et al, 1992, Curr. Top. Microbiol. Immunol., 158: 25-38; Moss, et al. 1991. Science, 252: 1662-1667]. 유용한 것으로 밝혀진 폭스바이러스로는 특히 백시니아(vaccinia), NYVAC, 조류폭스(avipox), 계두(fowlpox), 카나리폭스(canarypox), ALVAC 및 ALVAC(2)이 포함된다.
NYVAC (vP866)는, 공지된 또는 잠재적 독성 인자를 암호화하는 게놈의 6개의 비필수 영역을 제거함으로써 백시니아의 코펜하겐 백신 종으로부터 유래되었다[참조 문헌; 미국 특허 제5,364,773호 및 제5,494,807호]. 결실 유전자좌는 또한 외래 유전자의 삽입을 위해 수용체 유전자좌로서 조작되었다. 결실된 영역은 다음과 같다: 티미딘 키나제 유전자 (TK; J2R); 출혈 영역 (u; B13R+B14R); A 형 봉입체 영역 (ATI; A26L); 적혈구응집소 유전자 (HA; A56R); 숙주 범위 유전자 영역 (C7L-K1L); 및 거대 아단위, 리보뉴클레오티드 리덕타제 (I4L). NYVAC는, 독성 및 숙주 범위와 관련된 유전자 산물을 암호화하는 18개의 개방형 판독 프레임의 특이적 결실에 의해 생성된, 유전자 조작된 백시니아 바이러스 종이다. NYVAC는 TA를 발현시키는데 유용한 것으로 밝혀졌다[참조 문헌: 미국 특허 제6,265,189호]. NYVAC (vP866), vP994, vCP205, vCP1433, placZH6H4Lreverse, pMPC6H6K3E3 및 pC3H6FHVB는 또한 부다페스트 조약의 조건하에 ATCC에 수탁번호 VR-2559, VR-2558, VR-2557, VR-2556, ATCC-97913, ATCC-97912, 및 ATCC-97914로 각각 기탁되었다.
ALVAC-계 재조합 바이러스 (즉, ALVAC-1 및 ALVAC-2)가 또한 본 발명을 실행하는데 사용하기에 적합하다[참조 문헌: 미국 특허 제5,756,103호]. ALVAC(2)는 ALVAC(l)과 동일하나, 단 ALVAC(2) 게놈은 백시니아 프로모터의 제어하에 백시니아 E3L 및 K3L 유전자를 포함한다 [참조 문헌: 미국 특허 제6,130,066호; Beattie et al., 1995a, 1995b, 1991; Chang et al., 1992; Davies et al., 1993]. ALVAC(1) 및 ALVAC(2)는 둘다 모두 외래 DNA 서열, 예를 들어 TA를 발현하는데 유용한 것으로 입증되었다[참조 문헌: Tartaglia et al., 1993 a,b; 미국 특허 제5,833,975호]. ALVAC는 부다페스트 조약의 조건하에, 미국 버지니아주 20110-2209 마나사스 유니버스티 보울러버드 10801에 소재하는 아메리타 타입 컬쳐 컬렉션 (ATCC)에 ATCC 수탁번호 VR-2547로 기탁되었다.
또 다른 유용한 폭스바이러스 벡터는 TROVAC이다. TROVAC는, 1일령의 닭의 백신접종에 인가된 계두바이러스(fowlpoxvirus)의 FP-1 백신 종으로부터 유래된 플라크-클로닝된 분리물인 약독화된 계두(fowlpox)를 의미한다. TROVAC는 마찬가지로 부다페스트 조약의 조건하에 ATCC에 수탁번호 2553으로 기탁되었다.
"비-바이러스" 플라스미드 벡터가 또한 본 발명을 실행하는데 적합할 수 있다. 바람직한 플라스미드 벡터는 세균, 곤충 및/또는 포유동물 숙주 세포에 적합할 수 있다. 이러한 벡터로는 예를 들어 PCR-II, pCR3, 및 pcDNA3.1 (Invitrogen, San Diego, CA), pBSII (Stratagene, La Jolla, CA), pET15 (Novagen, Madison, WI), pGEX (Pharmacia Biotech, Piscataway, NJ), pEGFP-N2 (Clontech, Palo Alto, CA), pETL (BlueBacII, Invitrogen), pDSR-알파 (PCT 공보 제WO 90/14363호) 및 pFastBacDual (Gibco-BRL, Grand Island, NY) 뿐만아니라 블루스크립트(Bluescript)R 플라스미드 유도체 (고 복사체 수 COLEl-계 파아지미드, Stratagene Cloning Systems, La Jolla, CA), Taq-증폭된 PCR 생성물을 클로닝하기 위해 설계된 PCR 클로닝 플라스미드 (예: TOPOTM TA 클로닝R 키트, PCR2.1R 플라스미드 유도체, Invitrogen, Carlsbad, CA)가 포함된다. 세균 벡터가 또한 본 발명과 함께 사용될 수 있다. 이들 벡터로는 예를 들어 시겔라(Shigella), 살모넬라(Salmonella), 비브리오 콜레라에(Vibrio cholerae), 락토바실루스(Lactobacillus), 바실 칼메테 구에린(Bacille calmette guerin) (BCG), 및 스트렙토코코스가 포함된다 [참조 문헌: WO 88/6626; WO 90/0594; WO 91/13157; WO 92/1796; 및 WO 92/21376]. 다수의 다른 비-바이러스 플라스미드 발현 벡터 및 시스템이 당업계에 공지되었으며 본 발명과 함께 사용될 수 있다.
적합한 핵산 전달 기법으로는 특히 DNA-리간드 복합체, 아데노바이러스-리간드-DNA 복합체, DNA의 직접 주사, CaPO4 침전, 유전자 총 기법, 전기천공, 및 콜로이드 분산 시스템이 포함된다. 콜로이드 분산 시스템으로는 거대분자 복합체, 나노캡슐, 미소구, 비이드 및 지질계 시스템, 예를 들어 수중유 유탁액, 마이셀 및 혼합 마이셀 및 리포좀이 포함된다. 본 발명의 바람직한 콜로이드 시스템은 시험관내 및 생체내 전달 비히클로서 유용한 인공 막 소낭인 리포좀이다. RNA, DNA 및 온전한 비리온은 수성 내부 내에서 캡슐화되어, 생물학적 활성 형으로 세포에 전달될 수 있다 [참조 문헌: Fraley, R., et al., 1981, Trends Biochem. Sci., 6: 77]. 리포좀의 조성물은, 통상적으로 스테로이드, 특히 콜레스테롤과 배합된 인지질, 특히 고-상-전이-온도(high-phase-transition-temperature) 인지질의 배합물이다. 다른 인지질 또는 다른 지질이 또한 사용될 수 있다. 리포좀의 물리적 특징은 pH, 이온 농도, 및 이가 양이온의 존재에 따라 결정된다. 리포좀 생성에 유용한 지질의 예로는 포스파티딜 화합물, 예를 들어 포스파티딜글리세롤, 포스파티딜콜린, 포스파티딜세린, 포스파티딜에탄올아민, 스핀고지질(sphingolipid), 세레브로시드(cerebroside), 및 강글리오시드(ganglioside)가 포함된다. 지질 부분이 14 내지 18개의 탄소 원자, 특히 16 내지 18개의 탄소 원자를 함유하며, 포화된 디아실포스파티딜글리세롤이 특히 유용하다. 예시적 인지질로는 난(egg) 포스파티딜콜린, 디팔미토일포스파티딜콜린 및 디스테아로일포스파티딜콜린이 포함된다.
면역원성 표적은 또한 면역 반응을 증강시키기 위하여 하나 이상의 애주번트와 함께 투여될 수 있다. 예시적 애주번트는 표 II에 제시된다.
애주번트의 유형 | 일반적 예 | 구체적 예/참조문헌 |
겔-형 |
수산화알루미늄/포스페이트("명반 애주번트") | (Aggerbeck and Heron, 1995) |
인산칼슘 | (Relyveld, 1986) | |
미생물 |
무라밀 디펩티드 (MDP) | (Chedid et al., 1986) |
세균 외독소 | 콜레라 독소 (CT), 이.콜라이 불안정 독소 (LT) (Freytag and Clements, 1999) | |
내독소-계 애주번트 | 모노포스포릴 지질 A (MPL) (IJIrich andMyers, 1995) | |
기타 세균 | CpG 올리고뉴클레오티드 (Corraland Petray, 2000), BCG 서열 (Krieg, et al. Nature, 374: 576), 파상풍 톡소이드 (Rice, et al. J. Immunol., 2001,167 : 1558-1565) | |
미립자 |
생체분해성 중합체 미소구 |
(Gupta et al., 1998) |
면역자극성 복합체 (ISCOM) | (Morein and Bengtsson, 1999) | |
리포좀 | (Wassef et al., 1994) | |
오일-유탁액 및 계면활성제-계 애주번트 |
프로인트(Freund) 불완전 애주번트 | (Jensen et al., 1998) |
미세유동화 유탁액 |
MF59 (Ott et al., 1995) | |
SAF (Allison and Byars, 1992) (Allison, 1999) | ||
사포닌 | QS-21 (Kensil, 1996) | |
합성 |
무라밀 펩티드 공중합체 | 무라부티드 (Lederer, 1986) 트레노니-MDP (Allison, 1997) |
비이온성 블럭 공중합체 | L121 (Allison, 1999) | |
폴리포스파젠(PCPP) | (Payne et al., 1995) | |
합성 폴리뉴클레오티드 | 폴리 A:U, 폴리 I:C (Johnson, 1994) | |
탈리도미드 유도체 | CC-4047/ACTIMID (J. Immunol., 168 (10): 4914-9) |
당업자에게 공지된 각종 기법을 사용하여, 본 발명의 조성물을 숙주에 투여할 수 있다. 당해 조성물(들)은, 사람 및 기타 포유동물을 포함한 환자에게 투여하기 위한 약제(즉, "약제학적 조성물)를 제조하기 위하여 통상적인 조제술에 따라 처리될 수 있다. 약제학적 조성물은, 예를 들어 소정량의 DNA, 바이러스 벡터 입자, 폴리펩티드 또는 펩티드를 함유하는 투여 단위의 형태로 제조하는 것이 바람직하다. 사람 또는 기타 포유동물에 적합한 1일 투여량은 환자의 상태 및 기타 인자에 따라 크게 달라질 수 있으나, 다시 한번, 통상의 방법을 사용하여 결정할 수 있다.
약제학적 조성물은 경구로, 비경구로, 흡입 분무로, 직장으로, 결절내로 또는 국소로, 통상의 약제학적으로 허용되는 담체, 애주번트 및 비히클을 함유하는 투여 단위 제형으로 투여될 수 있다. 본원에서 사용된 "약제학적으로 허용되는 담체" 또는 "생리학적으로 허용되는 담체"란 용어는, 약제학적 조성물로서 핵산, 폴리펩티드 또는 펩티드의 전달을 달성하거나 증가시키기에 적합한 하나 이상의 제형 물질을 의미한다. "약제학적 조성물"은 치료학적 유효량의 핵산 또는 폴리펩티드를 포함하는 조성물이다. "유효량" 및 "치료학적 유효량"이란 용어는 각각 효과적인 면역 반응을 유도하거나 증강시키는데 사용된 핵산 또는 폴리펩티드의 양을 의미한다. 본 발명의 조성물은, 숙주에서 항-종양 면역 반응의 유도 또는 증강을 제공하여, 숙주를 종양의 발달로부터 보호하고/하거나 숙주가 기존 종양을 체내로부터 제거할 수 있는 것이 바람직하다.
경구 투여의 경우에, 약제학적 조성물은, 예를 들어 특히 캡슐제, 정제, 현탁제 또는 액제를 포함한 여러 형태 중 하나 일 수 있다. 액제는 염수, 덱스트로스 또는 물을 포함한 적합한 담체를 함유하는 조성물로서 주사에 의해 투여될 수 있다. 본원에 사용된 "비경구"란 용어는 피하, 정맥내, 근육내, 복장내, 주입 또는 복막내 투여를 포함한다. 약물의 직장 투여를 위한 좌제는, 코코나 버터 및 폴리에틸렌 글리콜과 같이 통상의 온도에서는 고체이나 직장 온도에서는 액체인 적당한 비-자극성 부형제와 약물을 혼합하여 제조할 수 있다.
본 발명의 조성물을 사용하여 숙주를 면역화시키거나 또는 달리 장애 또는 질환을 치료하기 위한 투여 방법은 질환의 유형, 환자의 연령, 체중, 성별, 의학적 상태, 상태의 중증도, 투여 경로, 및 사용된 특정 화합물을 포함한 각종 인자를 토대로 한다. 예를 들면, 폭스바이러스 벡터는, 용량당 1 x 106개의 감염성 입자를 포함하는 조성물로서 투여될 수 있다. 따라서, 투여 방법은 매우 다양할 수 있으나, 표준 방법을 사용하여 통상적으로 결정될 수 있다.
초회감작-추가감작(prime-boost) 방법 (WO 01/30382 Al)이 또한 이용될 수 있는데, 이에 따르면, 표적화된 면역원이 최초로 초회감작(priming) 단계에서 한가지 형태로 투여된 후, 추가감작(boosting) 단계에서 표적화된 면역원이 또 다른 형태로 투여된다. 초회감작 단계 및 추가감작 단계에서 표적화된 면역원의 형태는 상이하다. 예를 들면, 초회감작 단계에서 핵산이 이용된 경우에, 추가감작물은 펩티드로서 투여된다. 유사하게, 초회감작 단계에서 한가지 유형의 재조합 바이러스 (즉, ALVAC)가 이용된 경우에, 추가감작 단계에서는 다른 유형의 바이러스 (즉, NYVAC)가 이용될 수 있다. 이러한 초회감작-추가감작 투여 방법이 강한 면역학적방법을 유도한다는 것이 밝혀졌다. 각종 배합 형이 본 발명을 실행하는데 적합하다.
본 발명의 조성물이 단일 활성 약제학적 제제로서 투여될 수 있는 경우에, 이는 하나 이상의 또 다른 조성물 또는 제제 (즉, 다른 면역원성 표적, 공동-자극 분자, 애주번트)와 함께 사용될 수 있다. 배합물로서 투여되는 경우에, 개개의 성분은 동시에 또는 다른 시기에 투여되는 별개의 조성물로서 제형화될 수 있거나, 또는 단일 조성물로서 배합될 수 있다.
주사용 제제, 예를 들면 멸균 주사용 수성 또는 유성 현탁액은, 적합한 분산제 또는 습윤화제 및 현탁화제를 사용하여 공지된 방법에 따라 제형화될 수 있다. 주사용 제제는 또한 비경구적으로 허용되는 비독성의 희석제 또는 용매 중의 멸균 주사용 용액 또는 현탁액일 수 있다. 사용될 수 있는 적합한 비히클 및 용매로는 특히 물, 링거 용액 및 등장성 염화나트륨 용액이 있다. 예를 들면, 폭스바이러스와 같은 바이러스 벡터는 0.4% NaCl 중에 제조될 수 있다. 추가로, 멸균 고정유가 용매 또는 현탁 매질로서 통상적으로 사용된다. 이러한 목적을 위하여, 합성 모노- 또는 디글리세리드를 포함한 모든 무자극 고정유가 사용될 수 있다. 추가로, 올레산과 같은 지방산이 주사제의 제조에 사용될 수 있다.
국소 투여의 경우에, 조성물의 적당한 국소 투여량이 1일에 1 내지 4회, 바람직하게는 2 또는 3회 투여될 수 있다. 당해 투여량은 또한 투여를 하지 않는 조정 기간을 두고 투여될 수 있다. 적합한 조성물은 제형의 0.001% 내지 10% w/w, 예를 들면 1중량% 내지 2중량%를 포함할 수 있으나, 이는 제형의 10% w/w 정도, 바람직하게는 5% w/w 이하, 보다 바람직하게는 0.1% 내지 1%를 포함할 수 있다. 국소 투여에 적합한 제형은 피부를 통한 침투에 적합한 액제 또는 반-액제 (예: 도찰제, 로션제, 연고제, 크림제 또는 페이스트제) 및 눈, 귀 또는 코에 투여하기에 적합한 점적제를 포함한다.
약제학적 조성물은 또한 고체 형태(과립제, 산제 또는 좌제 포함)로 제조될 수 있다. 약제학적 조성물은 멸균과 같은 통상의 제약 작업으로 처리되고/되거나 통상의 보조제, 예를 들어 보존제, 안정화제, 습윤화제, 유화제, 완충제 등을 함유할 수 있다. 경구 투여를 위한 고체 투여형은 캡슐제, 정제, 환제, 산제 및 과립제를 포함할 수 있다. 이러한 고체 투여형에서, 활성 화합물은 하나 이상의 불활성 희석제, 예를 들면 수크로스, 락토스 또는 전분과 혼합될 수 있다. 이러한 투여형은 또한 통상적으로 불활성 희석제 이외의 추가 물질, 예를 들어 마그네슘 스테아레이트와 같은 윤활제를 포함할 수 있다. 캡슐제, 정제 및 환제의 경우에, 투여형은 또한 완충제를 포함할 수 있다. 정제 및 환제는 추가로 장용 제피제로 제조될 수 있다. 경구 투여를 위한 액체 투여형으로는, 당업계에 통상적으로 사용되는 불활성 희석제, 예를 들어 물을 함유하는, 약제학적으로 허용되는 유탁액제, 용액제, 현탁액제, 시럽제, 및 엘릭서제가 포함될 수 있다. 이러한 조성물은 또한 보조제, 예를 들어 습윤화제, 감미제, 향신제 및 방향제를 포함할 수 있다.
본 발명의 핵산 또는 폴리펩티드를 포함하는 약제학적 조성물은 여러 형태 중 하나를 취할 수 있으며 여러 경로 중 하나로 투여될 수 있다. 바람직한 태양에서, 당해 조성물은 숙주에서 면역 반응을 유도하기 위하여 비경구 경로 (피내, 근육내 또는 피하)를 통해 투여된다. 달리, 당해 조성물은 림프절 (결절내) 또는 종양 덩어리 (즉, 종양내 투여)로 직접 투여될 수 있다. 예를 들면, 용량이 0, 7 및 14일에 피하로 투여될 수 있다. 특히 p53 (Hollstein et al., 1991), p21-ras (Almoguera et al., 1988), HER-2 (Fendly et al., 1990), 흑색종-관련 항원 (MAGE-1; MAGE-2) (van der Bruggen et al., 1991), p97 (Hu et al., 1988), 흑색종-관련 항원 E (WO 99/30737) 및 암배아 항원 (CEA) (Kantor et al., 1993; Fishbein et al., 1992; Kaufman et al., 1991)에 대해 밝혀진 바와 같이, TA를 포함하는 조성물을 사용하여 면역화하는 적합한 방법이 당업계에 공지되어있다.
투여가능 조성물의 바람직한 태양은, 예를 들어 현탁액제, 시럽제 또는 엘릭서제와 같은 액제 제제 중에 핵산 또는 폴리펩티드를 포함한다. 바람직한 주사용 제제는 멸균 현탁액 또는 유탁액과 같이 비경구, 즉 피내, 근육내 또는 정맥내 투여에 적합한 핵산 또는 폴리펩티드를 포함한다. 예를 들면, 재조합 폭스바이러스는 적합한 담체, 희석제 또는 부형제, 예를 들어 멸균수, 생리학적 염수, 글루코스 등과 혼합될 수 있다. 당해 조성물은 또한 예를 들어 등장성 수성 염수 완충제 중에서 재구성하기 위한 동결건조형으로 제공될 수 있다. 추가로, 당해 조성물은 다른 항신생물제, 항종양제 또는 항암제 및/또는 항신생물제, 항종양제 또는 항암제의 해로운 효과를 감소 또는 완화시키는 제제와 함께 공동-투여되거나 또는 연속적으로 투여될 수 있다.
본 발명의 조성물을 포함하는 키트가 또한 제공된다. 당해 키트는 적당한 담체, 희석제 또는 부형제를 함유하는 별개의 용기를 포함할 수 있다. 당해 키트는 또한 추가적 항암제, 항종양제 또는 항신생물제 및/또는 공동- 또는 연속-투여를 위한 항신생물제, 항종양제 또는 항암제의 해로운 효과를 감소 또는 완화시키는 제제를 포함할 수 있다. 추가로, 당해 키트는 성분의 혼합 또는 배합 및/또는 투여를 위한 지침을 포함할 수 있다.
본 발명의 보다 나은 이해 및 본 발명의 다수의 이점은 설명을 위해 제공된 후술되는 실시예로부터 밝혀질 것이다.
실시예
1
다중-항원
작제물
vT416
의 구축
발현 벡터 vT416 (ALVAC-NY-ESO-l/Trp-2-LFA-31ICAM-l/B7.1-E3L/K3L)를 표준 기법을 사용하여 ALVAC 벡터 내에 구축하였다. NY-ESO-1, Trp-2, LFA-3, ICAM-1, B7.1, vvE3L 및 wK3L를 암호화하는 DNA 서열을 ALVAC 게놈 내의 다양한 유전자좌 속에 삽입하였다. NY-ESO-1 (Chen et al. 1997 PNAS 94: 1914) 및 TRP-2 (Wang et al. 1996 J. Exp. Med. 184: 2207)를 암호화하는 DNA 서열을 C5 유전자좌 속에 삽입하였다. LFA-3 (Wallner, et al. (1987) J. Exp. Med. 166: 923-932), ICAM-1 (Staunton, et al. (1988) Cell 52: 925-933) 및 B7.1 (Chen, et al. (1992) Cell 71: 1093-1102)를 암호화하는 DNA 서열을 C3 유전자좌 속에 삽입하였다. LFA-3, ICAM-1 및 B7.1은 TRICOM으로서 공지된 발현 카세트를 형성한다. vvE3L (Chang, et al. 1992. Proc. Natl. Acad. Sci. U.S.A 89: 4825-4829) 및 wK3L (Beattie, et al. 1991. Virology 183: 419-422)를 암호화하는 DNA 서열을 C6 유전자좌 속에 삽입하였다. 프로모터를 아래와 같이 사용하였다:
프로모터 sE/L은 문헌[Chakrabarti, et al., BioTechniques 23: 1094-1097, 1997]에 기재되어있다. 사용된 공여체 플라스미드는 아래에 제시된다:
NY-ESO-1 및 TRP-2 DNA 서열을 ALVAC 공여체 플라스미드 pT1132 속에 삽입하였다. 이어서, 상기 공여체 플라스미드를 pALVAC.Tricom(C3) #33와 함께 사용하여 표준 기법에 의해 이들 유전자를 발현하는 ALVAC-TRICOM 재조합체를 제조하였다. 플라스미드 pALVAC.Tricom(C3) #33 및 pT1132는 도 1에 도시되어있다. pALVAC.Tricom(C3) #33 및 pT1132의 DNA 서열은 각각 도 2 및 3에 도시되어있다.
실시예
2
다중-항원
작제물
vT419
의 구축
발현 벡터 vT419 (ALVAC-gplOOM/Mart-l/Mage-1,3 미니유전자-LFA-3/ICAM-1/B7.1-E3L/K3L)를 표준 기법을 사용하여 ALVAC 벡터 내에 구축하였다. gplOOM/MART-l/MAGE-1,3 미니유전자, LFA-3, ICAM-1, B7.1, wE3L 및 wK3L를 암호화하는 DNA 서열을 ALVAC 게놈 내의 다양한 유전자좌 속에 삽입하였다. gp100M/ MART-1/MAGE-1,3 미니유전자를 C5 유전자좌 속에 삽입하였다. LFA-3 (Wallner, et al. (1987) J. Exp. Med. 166: 923-932), ICAM-1 (Staunton, et al. (1988) Cell 52: 925-933) 및 B7.1 (Chen, et al. (1992) Cell 71: 1093-1102)를 암호화하는 DNA 서열을 C3 유전자좌 속에 삽입하였다. LFA-3, ICAM-1 및 B7.1은 TRICOM으로서 공지된 발현 카세트를 형성한다. vvE3L (Chang, et al. 1992. Proc. Natl. Acad. Sci. U. S. A 89: 4825-4829) 및 vvK3L (Beattie, et al. 1991. Virology 183: 419-422)를 암호화하는 DNA 서열을 C6 유전자좌 속에 삽입하였다. 프로모터를 아래와 같이 사용하였다:
프로모터 sE/L은 문헌[Chakrabarti, et al., BioTechniques 23: 1094-1097, 1997]에 기재되어있다. 사용된 공여체 플라스미드는 아래에 제시된다:
gp100(M), Mart-1 및 Mage-1,3 미니유전자를 ALVAC C5 공여체 플라스미드pT3217 속에 삽입하였다. 이어서, 상기 공여체 플라스미드를 pALVAC.Tricom(C3) #33와 함께 사용하여 표준 기법에 의해 이들 유전자를 발현하는 ALVAC-TRICOM 재조합체를 제조하였다. 상기 공여체 플라스미드를 C5 부위에 삽입한다. pALVAC.Tricom(C3) #33은 도 1 및 2에 도시되어있다. pT3217 플라스미드는 도 4에 도시되어있다. pT3217의 DNA 서열은 도 5에 도시되어있다.
실시예
3
다중-항원 벡터의 면역학적 평가
제1 동물 실험의 결과는, 백신을 2종의 별개의 주사제로서 제공했을 때, 4개의 항원 중 3개(Mart 1, NY-ESO-1 및 gp100)에 대한 보다 높은 면역학적 반응에 대한 경향을 나타내었다. 그러나, 이들 차이는 통계학적으로 유의적이지 않았다. 상세히, HLA-A2/Kb 유전자전이된(transgenic) 마우스 (5/그룹)를 한 부위에, 배합된 또는 별개의 주사제로 제공된 vT419 (ALVAC (2)-gpl00M/MART-l/MAGE-1/3 미니유전자/TRICOM) 및 vT416 (ALVAC(2)-TRP-2/NY-ESO-1/TRICOM)로 피하로 면역화시켰다. 대조군 마우스를 모(母) ALVAC(2)로 면역화시켰다. 마우스를 3회 (3주 간격으로) 백신접종하고, 최종 추가감작 후 3주가 지나고, 펩티드로 시험관내 재자극한 다음에 개개의 마우스에서 T 세포 반응을 IFN-g ELISPOT 및 CTL 검정으로 분석하였다. 대조군 동물에 비해, 다중-항원 벡터로 (2 부위에서) 백신접종된 마우스는 MART-1에 대해 통계학적으로 유의적인 ELISPOT 반응을 나타내었다. gpl00M 및 NY-ESO-1에 대한 IFN-감마 반응이 또한 검출될 수 있었으나, 이들 반응은, 반응 가변성 및 시험된 배양물의 수가 적음으로 인해, 통계학적으로 유의적이지 않았다. TRP-2 항원에 대한 ELISPOT 반응은 시험된 모든 그룹 (대조군 동물 포함)에서 상승하였는데, 이는 추측컨대 우성 A2-제한된 TRP-2 펩티드 (180-188)가 H-2Kb와 교차반응하여, 시험관내 배양 후 무감작(naive) 마우스에서 낮은 결합력(avidity) T 세포 반응을 유도할 수 있으므로, 통계학적으로 유의적이지 않았기 때문이다. 흥미롭게도, vT416 및 vT419의 혼합물을 주사한 마우스에서의 ELISPOT 반응은 일반적으로 각 바이러스를 별개로 투여한 마우스에서 보다 더 낮았으나, 이들 차이가 통계학적 유의성을 갖지는 않았다. CTL 데이터는 주로 음성적이었으나, 예외적으로 하나의 강한 항-gp100 반응 및 하나의 불충분한 항-MART-1 반응이 있었으며, 이 둘은 모두 vT416 및 vT419를 (2 부위에) 백신접종한 마우스에서 나타났다. 전체적으로, 이들 결과는, 다중-항원 벡터가 MAT-1에 대해 반응을 일으킬 수 있음을 확립하며, 또한 항-gp100 및 항-NY-ESO-1 반응이 유도될 수 있음을 암시하는 고무적인 데이터를 제공한다.
흑색종 다중-항원 ALVAC 재조합체를 사용하여, 2종의 추가적인 예비-임상 동물 연구를 완료하였다. 이들 실험에서, HLA-A2/Kb 유전자전이된 마우스 (5/그룹)를 한 부위에, 배합된 또는 별개의 주사제로 제공된 vT419 (ALVAC(2)-gplOOM/MART-l/MAGE-1/3 미니유전자/TRICOM) 및 vT416 (ALVAC (2)-TRP-2/NY-ESO-1/TRICOM)로 피하로 면역화시켰다. 대조군 마우스를 모(母) ALVAC(2)로 면역화시켰다. 백신접종 후, 개개의 마우스에서의 T 세포 반응을, 펩티드로 시험관내 재자극한 다음에, IFN-감마 ELISPOT 검정으로 분석하였다. 고무적인 면역원성 데이터를 제공하는 이전의 다중-항원 실험과는 달리, 상기 2종의 가장 최근의 연구는, 대조-면역화된 동물에서 높은 기본수준 반응으로 인해, 결정적이 않은 데이터를 제공하였다. 따라서, 전체적인 결과는 결정적이지 않은 것으로 여겨진다.
다중-항원 작제물의 면역원성을 확인하고 제1 연구로부터의 결과를 재현하기 위하여, 또 다른 예비-임상 동물 연구를 완료하였다. HLA-A2/Kb 유전자전이된 마우스 (10/그룹)을, 별개의 주사제로 제공된 vT419 (ALVAC(2)-gplO0M/MART-l/MAGE-1/3 미니유전자/TRICOM) 및 vT416 (ALVAC(2)-TRP-2/NY-ESO-1/TRICOM)로 피하로 면역시켰다. 대조군 마우스를 모(母) ALVAC(2)로 면역화시켰다. 통계학적으로 유의적인 ELISPOT 반응이 gplO0, Mart-l 및 TRP-2에 대해 검출될 수 있었으며, 몇몇 반응은 NY-ESO-1에 대해 검출되었는데, 이는 통계학적으로 유의적인 경계에 있는 것이다.
본 발명이 바람직한 태양의 관점에서 기재되었지만, 당업자가 변화 및 변형을 생각할 수 있음을 이해해야 한다. 따라서, 첨부된 청구범위는, 청구된 본 발명의 범위 내에 해당하는 이러한 모든 동등한 변형을 포괄한다고 본다.
<110> Sanofi Pasteur, Ltd.; Therion Biologics, Inc.
<120> Multi-Antigen Vector For Melanoma
<130> API-03-12-PCT
<150> US 60/500,572
<151> 2003-09-05
<150> US 60/504,007
<151> 2003-09-18
<160> 17
<170> KopatentIn 1.71
<210> 1
<211> 10470
<212> DNA
<213> Synthetic
<223> ALVAC
<400> 1
ggaaattgta aacgttaata ttttgttaaa attcgcgtta aatttttgtt aaatcagctc 60
attttttaac caataggccg aaatcggcaa aatcccttat aaatcaaaag aatagaccga 120
gatagggttg agtgttgttc cagtttggaa caagagtcca ctattaaaga acgtggactc 180
caacgtcaaa gggcgaaaaa ccgtctatca gggcgatggc ccactacgtg aaccatcacc 240
ctaatcaagt tttttggggt cgaggtgccg taaagcacta aatcggaacc ctaaagggag 300
cccccgattt agagcttgac ggggaaagcc ggcgaacgtg gcgagaaagg aagggaagaa 360
agcgaaagga gcgggcgcta gggcgctggc aagtgtagcg gtcacgctgc gcgtaaccac 420
cacacccgcc gcgcttaatg cgccgctaca gggcgcgtcg cgccattcgc cattcaggct 480
gcgcaactgt tgggaagggc gatcggtgcg ggcctcttcg ctattacgcc agctggcgaa 540
agggggatgt gctgcaaggc gattaagttg ggtaacgcca gggttttccc agtcacgacg 600
ttgtaaaacg acggccagtg aattgtaata cgactcacta tagggcgaat tgggtaccgc 660
ggccgcgtcg acatgcattg ttagttctgt agatcagtaa cgtatagcat acgagtataa 720
ttatcgtagg tagtaggtat cctaaaataa atctgataca gataataact ttgtaaatca 780
attcagcaat ttctctatta tcatgataat gattaataca cagcgtgtcg ttattttttg 840
ttacgatagt atttctaaag taaagagcag gaatccctag tataatagaa ataatccata 900
tgaaaaatat agtaatgtac atatttctaa tgttaacata tttataggta aatccaggaa 960
gggtaatttt tacatatcta tatacgctta ttacagttat taaaaatata cttgcaaaca 1020
tgttagaagt aaaaaagaaa gaactaattt tacaaagtgc tttaccaaaa tgccaatgga 1080
aattacttag tatgtatata atgtataaag gtatgaatat cacaaacagc aaatcggcta 1140
ttcccaagtt gagaaacggt ataatagata tatttctaga taccattaat aaccttataa 1200
gcttgacgtt tcctataatg cctactaaga aaactagaag atacatacat actaacgcca 1260
tacgagagta actactcatc gtataactac tgttgctaac agtgacactg atgttataac 1320
tcatctttga tgtggtataa atgtataata actatattac actggtattt tatttcagtt 1380
atatactata tagtattaaa aattatattt gtataattat attattatat tcagtgtaga 1440
aagtaaaata ctataaatat gtatctctta tttataactt attagtaaag tatgtactat 1500
tcagttatat tgttttataa aagctaaatg ctactagatt gatataaatg aatatgtaat 1560
aaattagtaa tgtagtatac taatattaac tcacatttga ctaattagct ataaaaaccc 1620
taaggtaggc ggccgcacta gaggattcga caaacaccaa taattccctt ctcttcattc 1680
cggacattaa attggctata gataataaag acattgagat gttacaggct ctgttcaaat 1740
acgacattaa tatctattct gctaatctgg aaaatgtact attggatgat gccgaaatag 1800
ctaaaatgat tatagaaaag catgttgaat acaagtctga ctcctataca aaagatctcg 1860
atatagtcaa gaataataaa ttggatgaaa taattagcaa aaacaaggaa ctcagactca 1920
tgtacgtcaa ttgtgtaaag aaaaactaat tagattctcc cacatttttg ttaacattac 1980
actaactaat tggtaaaatt gatagaataa ttatgtgtat ataagataga tttcctattg 2040
tcttactcat tgcatcgtgg gaattcagat cagcttccgc ggcatggttg ctgggagcga 2100
cgcggggcgg gccctggggg tcctcagcgt ggtctgcctg ctgcactgct ttggtttcat 2160
cagctgtttt tcccaacaaa tatatggtgt tgtgtatggg aatgtaactt tccatgtacc 2220
aagcaatgtg cctttaaaag aggtcctatg gaaaaaacaa aaggataaag ttgcagaact 2280
ggaaaattct gaattcagag ctttctcatc ttttaaaaat agggtttatt tagacactgt 2340
gtcaggtagc ctcactatct acaacttaac atcatcagat gaagatgagt atgaaatgga 2400
atcgccaaat attactgata ccatgaagtt ctttctttat gtgcttgagt ctcttccatc 2460
tcccacacta acttgtgcat tgactaatgg aagcattgaa gtccaatgca tgataccaga 2520
gcattacaac agccatcgag gacttataat gtactcatgg gattgtccta tggagcaatg 2580
taaacgtaac tcaaccagta tatattttaa gatggaaaat gatcttccac aaaaaataca 2640
gtgtactctt agcaatccat tatttaatac aacatcatca atcattttga caacctgtat 2700
cccaagcagc ggtcattcaa gacacagata tgcacttata cccataccat tagcagtaat 2760
tacaacatgt attgtgctgt atatgaatgg tattctgaaa tgtgacagaa aaccagacag 2820
aaccaactcc aattgattgg ctcgaccggg aatgtactat ctacgtacga aacccgcatc 2880
cgctcccatt caattcacat tggacaagga taaaataaaa ccactggtgg tttgcgattc 2940
cgaaatctgt acatcatgca gtggttaaac aaaaacattt ttattctcaa atgagataaa 3000
gtgaaaatat atatcattat attacaaagt acaattattt aggtttaatc aatcccgcgg 3060
gctatggctc ccagcagccc ccggcccgcg ctgcccgcac tcctggtcct gctcggggct 3120
ctgttcccag gacctggcaa tgcccagaca tctgtgtccc cctcaaaagt catcctgccc 3180
cggggaggct ccgtgctggt gacatgcagc acctcctgtg accagcccaa gttgttgggc 3240
atagagaccc cgttgcctaa aaaggagttg ctcctgcctg ggaacaaccg gaaggtgtat 3300
gaactgagca atgtgcaaga agatagccaa ccaatgtgct attcaaactg ccctgatggg 3360
cagtcaacag ctaaaacctt cctcaccgtg tactggactc cagaacgggt ggaactggca 3420
cccctcccct cttggcagcc agtgggcaag aaccttaccc tacgctgcca ggtggagggt 3480
ggggcacccc gggccaacct caccgtggtg ctgctccgtg gggagaagga gctgaaacgg 3540
gagccagctg tgggggagcc cgctgaggtc acgaccacgg tgctggtgag gagagatcac 3600
catggagcca atttctcgtg ccgcactgaa ctggacctgc ggccccaagg gctggagctg 3660
tttgagaaca cctcggcccc ctaccagctc cagacctttg tcctgccagc gactccccca 3720
caacttgtca gcccccgggt cctagaggtg gacacgcagg ggaccgtggt ctgttccctg 3780
gacgggctgt tcccagtctc ggaggcccag gtccacctgg cactggggga ccagaggttg 3840
aaccccacag tcacctatgg caacgactcc ttctcggcca aggcctcagt cagtgtgacc 3900
gcagaggacg agggcaccca gcggctgacg tgtgcagtaa tactggggaa ccagagccag 3960
gagacactgc agacagtgac catctacagc tttccggcgc ccaacgtgat tctgacgaag 4020
ccagaggtct cagaagggac cgaggtgaca gtgaagtgtg aggcccaccc tagagccaag 4080
gtgacgctga atggggttcc agcccagcca ctgggcccga gggcccagct cctgctgaag 4140
gccaccccag aggacaacgg gcgcagcttc tcctgctctg caaccctgga ggtggccggc 4200
cagcttatac acaagaacca gacccgggag cttcgtgtcc tgtatggccc ccgactggac 4260
gagagggatt gtccgggaaa ctggacgtgg ccagaaaatt cccagcagac tccaatgtgc 4320
caggcttggg ggaacccatt gcccgagctc aagtgtctaa aggatggcac tttcccactg 4380
cccatcgggg aatcagtgac tgtcactcga gatcttgagg gcacctacct ctgtcgggcc 4440
aggagcactc aaggggaggt cacccgcgag gtgaccgtga atgtgctctc cccccggtat 4500
gagattgtca tcatcactgt ggtagcagcc gcagtcataa tgggcactgc aggcctcagc 4560
acgtacctct ataaccgcca gcggaagatc aagaaataca gactacaaca ggcccaaaaa 4620
gggaccccca tgaaaccgaa cacacaagcc acgcctccct gagcatgcat gtagcttaaa 4680
aattgaaatt ttattttttt tttttggaat ataaataagc tcgaagtcga aattcctgca 4740
gcccggggcc atgggccaca cacggaggca gggaacatca ccatccaagt gtccatacct 4800
caatttcttt cagctcttgg tgctggctgg tctttctcac ttctgttcag gtgttatcca 4860
cgtgaccaag gaagtgaaag aagtggcaac gctgtcctgt ggtcacaatg tttctgttga 4920
agagctggca caaactcgca tctactggca aaaggagaag aaaatggtgc tgactatgat 4980
gtctggagac atgaatatat ggcccgagta caagaaccgg accatctttg atatcactaa 5040
taacctctcc attgtgatcc tggctctgcg cccatctgac gagggcacat acgagtgtgt 5100
tgttctgaag tatgaaaaag acgctttcaa gcgggaacac ctggctgaag tgacgttatc 5160
agtcaaagct gacttcccta cacctagtat atctgacttt gaaattccaa cttctaatat 5220
tagaaggata atttgctcaa cctctggagg ttttccagag cctcacctct cctggttgga 5280
aaatggagaa gaattaaatg ccatcaacac aacagtttcc caagatcctg aaactgagct 5340
ctatgctgtt agcagcaaac tggatttcaa tatgacaacc aaccacagct tcatgtgtct 5400
catcaagtat ggacatttaa gagtgaatca gaccttcaac tggaatacaa ccaagcaaga 5460
gcattttcct gataacctgc tcccatcctg ggccattacc ttaatctcag taaatggaat 5520
tttcgtgata tgctgcctga cctactgctt tgccccacgc tgcagagaga gaaggaggaa 5580
tgagagattg agaagggaaa gtgtacgccc tgtataaaag ctttctaggt ttttgtttag 5640
ggctgcagga attcctcgag ggatcccgat ttttatgact agttaatcaa ataaaaagca 5700
tacaagctat tgcttcgcta tcgttacaaa atggcaggaa ttttgtgtaa actaagccac 5760
atacttgcca atgaaaaaaa tagtagaaag gatactattt taatgggatt agatgttaag 5820
gttccttggg attatagtaa ctgggcatct gttaactttt acgacgttag gttagatact 5880
gatgttacag attataataa tgttacaata aaatacatga caggatgtga tatttttcct 5940
catataactc ttggaatagc aaatatggat caatgtgata gatttgaaaa tttcaaaaag 6000
caaataactg atcaagattt acagactatt tctatagtct gtaaagaaga gatgtgtttt 6060
cctcagagta acgcctctaa acagttggga gcgaaaggat gcgctgtagt tatgaaactg 6120
gaggtatctg atgaacttag agccctaaga aatgttctgc tgaatgcggt accctgttcg 6180
aaggacgtgt ttggtgatat cacagtagat aatccgtgga atcctcacat aacagtagga 6240
tatgttaagg aggacgatgt cgaaaacaag aaacgcctaa tggagtgcat gtccaagttt 6300
agggggcaag aaatacaagt tctaggatgg tattaataag tatctaagta tttggtataa 6360
tttattaaat agtataatta taacaaataa taaataacat gataacggtt tttattagaa 6420
taaaatagag ataatatcat aatgatatat aatacttcat taccagaaat gagtaatgga 6480
agacttataa atgaactgca taaagctata aggtatagag atataaattt agtaaggtat 6540
atacttaaaa aatgcaaata caataacgta aatatactat caacgtcttt gtatttagcc 6600
gtaagtattt ctgatataga aatggtaaaa ttattactag aacacggtgc cgatatttta 6660
aaatgtaaaa atcctcctct tcataaagct gctagtttag ataatacaga aattgctaaa 6720
ctactaatag attctggcgc tgacatagaa cagatacatt ctggaaatag tccgttatat 6780
atttctgtat atagaaacaa taagtcatta actagatatt tattaaaaaa aggtgttaat 6840
tgtaatagat tctttctaaa ttattacgat gtactgtatg ataagatatc tgatgatatg 6900
tataaaatat ttatagattt taatattgat cttaatatac aaactagaaa ttttgaaact 6960
ccgttacatt acgctataaa gtataagaat atagatttaa ttaggatatt gttagataat 7020
agtattaaaa tagataaaag tttatttttg cataaacagt atctcataaa ggcacttaaa 7080
aataattgta gttacgatat aatagcgtta cttataaatc acggagtgcc tataaacgaa 7140
caagatgatt taggtaaaac cccattacat cattcggtaa ttaatagaag aaaagatgta 7200
acagcacttc tgttaaatct aggagctgat ataaacgtaa tagatgactg tatgggcagt 7260
cccttacatt acgctgtttc acgtaacgat atcgaaacaa caaagacact tttagaaaga 7320
ggatctaatg ttaatgtggt taataatcat atagataccg ttctaaatat agctgttgca 7380
tctaaaaaca aaactatagt aaacttatta ctgaagtacg gtactgatac aaagttggta 7440
ggattagata aacatgttat tcacatagct atagaaatga aagatattaa tatactgaat 7500
gcgatcttat tatatggttg ctatgtaaac gtctataatc ataaaggttt cactcctcta 7560
tacatggcag ttagttctat gaaaacagaa tttgttaaac tcttacttga ccacggtgct 7620
tacgtaaatg ctaaagctaa gttatctgga aatactcctt tacataaagc tatgttatct 7680
aatagtttta ataatataaa attactttta tcttataacg ccgactataa ttctctaaat 7740
aatcacggta atacgcctct aacttgtgtt agctttttag atgacaagat agctattatg 7800
ataatatcta aaatgatgtt agaaatatct aaaaatcctg aaatagctaa ttcagaaggt 7860
tttatagtaa acatggaaca tataaacagt aataaaagac tactatctat aaaagaatca 7920
tgcgaaaaag aactagatgt tataacacat ataaagttaa attctatata ttcttttaat 7980
atctttcttg acaataacat agatcttatg gtaaagttcg taactaatcc tagagttaat 8040
aagatacctg catgtatacg tatatatagg gaattaatac ggaaaaataa atcattagct 8100
tttcatagac atcagctaat agttaaagct gtaaaagaga gtaagaatct aggaataata 8160
ggtaggttac ctatagatat caaacatata ataatggaac tattaagtaa taatgattta 8220
cattctgtta tcaccagctg ttgtaaccca gtagtataaa gagctccagc ttttgttccc 8280
tttagtgagg gttaattccg agcttggcgt aatcatggtc atagctgttt cctgtgtgaa 8340
attgttatcc gctcacaatt ccacacaaca tacgagccgg aagcataaag tgtaaagcct 8400
ggggtgccta atgagtgagc taactcacat taattgcgtt gcgctcactg cccgctttcc 8460
agtcgggaaa cctgtcgtgc cagctgcatt aatgaatcgg ccaacgcgcg gggagaggcg 8520
gtttgcgtat tgggcgctct tccgcttcct cgctcactga ctcgctgcgc tcggtcgttc 8580
ggctgcggcg agcggtatca gctcactcaa aggcggtaat acggttatcc acagaatcag 8640
gggataacgc aggaaagaac atgtgagcaa aaggccagca aaaggccagg aaccgtaaaa 8700
aggccgcgtt gctggcgttt ttccataggc tccgcccccc tgacgagcat cacaaaaatc 8760
gacgctcaag tcagaggtgg cgaaacccga caggactata aagataccag gcgtttcccc 8820
ctggaagctc cctcgtgcgc tctcctgttc cgaccctgcc gcttaccgga tacctgtccg 8880
cctttctccc ttcgggaagc gtggcgcttt ctcatagctc acgctgtagg tatctcagtt 8940
cggtgtaggt cgttcgctcc aagctgggct gtgtgcacga accccccgtt cagcccgacc 9000
gctgcgcctt atccggtaac tatcgtcttg agtccaaccc ggtaagacac gacttatcgc 9060
cactggcagc agccactggt aacaggatta gcagagcgag gtatgtaggc ggtgctacag 9120
agttcttgaa gtggtggcct aactacggct acactagaag gacagtattt ggtatctgcg 9180
ctctgctgaa gccagttacc ttcggaaaaa gagttggtag ctcttgatcc ggcaaacaaa 9240
ccaccgctgg tagcggtggt ttttttgttt gcaagcagca gattacgcgc agaaaaaaag 9300
gatctcaaga agatcctttg atcttttcta cggggtctga cgctcagtgg aacgaaaact 9360
cacgttaagg gattttggtc atgagattat caaaaaggat cttcacctag atccttttaa 9420
attaaaaatg aagttttaaa tcaatctaaa gtatatatga gtaaacttgg tctgacagtt 9480
accaatgctt aatcagtgag gcacctatct cagcgatctg tctatttcgt tcatccatag 9540
ttgcctgact ccccgtcgtg tagataacta cgatacggga gggcttacca tctggcccca 9600
gtgctgcaat gataccgcga gacccacgct caccggctcc agatttatca gcaataaacc 9660
agccagccgg aagggccgag cgcagaagtg gtcctgcaac tttatccgcc tccatccagt 9720
ctattaattg ttgccgggaa gctagagtaa gtagttcgcc agttaatagt ttgcgcaacg 9780
ttgttgccat tgctacaggc atcgtggtgt cacgctcgtc gtttggtatg gcttcattca 9840
gctccggttc ccaacgatca aggcgagtta catgatcccc catgttgtgc aaaaaagcgg 9900
ttagctcctt cggtcctccg atcgttgtca gaagtaagtt ggccgcagtg ttatcactca 9960
tggttatggc agcactgcat aattctctta ctgtcatgcc atccgtaaga tgcttttctg 10020
tgactggtga gtactcaacc aagtcattct gagaatagtg tatgcggcga ccgagttgct 10080
cttgcccggc gtcaatacgg gataataccg cgccacatag cagaacttta aaagtgctca 10140
tcattggaaa acgttcttcg gggcgaaaac tctcaaggat cttaccgctg ttgagatcca 10200
gttcgatgta acccactcgt gcacccaact gatcttcagc atcttttact ttcaccagcg 10260
tttctgggtg agcaaaaaca ggaaggcaaa atgccgcaaa aaagggaata agggcgacac 10320
ggaaatgttg aatactcata ctcttccttt ttcaatatta ttgaagcatt tatcagggtt 10380
attgtctcat gagcggatac atatttgaat gtatttagaa aaataaacaa ataggggttc 10440
cgcgcacatt tccccgaaaa gtgccacctg 10470
<210> 2
<211> 10470
<212> DNA
<213> Synthetic
<223> ALVAC
<400> 2
cctttaacat ttgcaattat aaaacaattt taagcgcaat ttaaaaacaa tttagtcgag 60
taaaaaattg gttatccggc tttagccgtt ttagggaata tttagttttc ttatctggct 120
ctatcccaac tcacaacaag gtcaaacctt gttctcaggt gataatttct tgcacctgag 180
gttgcagttt cccgcttttt ggcagatagt cccgctaccg ggtgatgcac ttggtagtgg 240
gattagttca aaaaacccca gctccacggc atttcgtgat ttagccttgg gatttccctc 300
gggggctaaa tctcgaactg cccctttcgg ccgcttgcac cgctctttcc ttcccttctt 360
tcgctttcct cgcccgcgat cccgcgaccg ttcacatcgc cagtgcgacg cgcattggtg 420
gtgtgggcgg cgcgaattac gcggcgatgt cccgcgcagc gcggtaagcg gtaagtccga 480
cgcgttgaca acccttcccg ctagccacgc ccggagaagc gataatgcgg tcgaccgctt 540
tccccctaca cgacgttccg ctaattcaac ccattgcggt cccaaaaggg tcagtgctgc 600
aacattttgc tgccggtcac ttaacattat gctgagtgat atcccgctta acccatggcg 660
ccggcgcagc tgtacgtaac aatcaagaca tctagtcatt gcatatcgta tgctcatatt 720
aatagcatcc atcatccata ggattttatt tagactatgt ctattattga aacatttagt 780
taagtcgtta aagagataat agtactatta ctaattatgt gtcgcacagc aataaaaaac 840
aatgctatca taaagatttc atttctcgtc cttagggatc atattatctt tattaggtat 900
actttttata tcattacatg tataaagatt acaattgtat aaatatccat ttaggtcctt 960
cccattaaaa atgtatagat atatgcgaat aatgtcaata atttttatat gaacgtttgt 1020
acaatcttca ttttttcttt cttgattaaa atgtttcacg aaatggtttt acggttacct 1080
ttaatgaatc atacatatat tacatatttc catacttata gtgtttgtcg tttagccgat 1140
aagggttcaa ctctttgcca tattatctat ataaagatct atggtaatta ttggaatatt 1200
cgaactgcaa aggatattac ggatgattct tttgatcttc tatgtatgta tgattgcggt 1260
atgctctcat tgatgagtag catattgatg acaacgattg tcactgtgac tacaatattg 1320
agtagaaact acaccatatt tacatattat tgatataatg tgaccataaa ataaagtcaa 1380
tatatgatat atcataattt ttaatataaa catattaata taataatata agtcacatct 1440
ttcattttat gatatttata catagagaat aaatattgaa taatcatttc atacatgata 1500
agtcaatata acaaaatatt ttcgatttac gatgatctaa ctatatttac ttatacatta 1560
tttaatcatt acatcatatg attataattg agtgtaaact gattaatcga tatttttggg 1620
attccatccg ccggcgtgat ctcctaagct gtttgtggtt attaagggaa gagaagtaag 1680
gcctgtaatt taaccgatat ctattatttc tgtaactcta caatgtccga gacaagttta 1740
tgctgtaatt atagataaga cgattagacc ttttacatga taacctacta cggctttatc 1800
gattttacta atatcttttc gtacaactta tgttcagact gaggatatgt tttctagagc 1860
tatatcagtt cttattattt aacctacttt attaatcgtt tttgttcctt gagtctgagt 1920
acatgcagtt aacacatttc tttttgatta atctaagagg gtgtaaaaac aattgtaatg 1980
tgattgatta accattttaa ctatcttatt aatacacata tattctatct aaaggataac 2040
agaatgagta acgtagcacc cttaagtcta gtcgaaggcg ccgtaccaac gaccctcgct 2100
gcgccccgcc cgggaccccc aggagtcgca ccagacggac gacgtgacga aaccaaagta 2160
gtcgacaaaa agggttgttt atataccaca acacataccc ttacattgaa aggtacatgg 2220
ttcgttacac ggaaattttc tccaggatac cttttttgtt ttcctatttc aacgtcttga 2280
ccttttaaga cttaagtctc gaaagagtag aaaattttta tcccaaataa atctgtgaca 2340
cagtccatcg gagtgataga tgttgaattg tagtagtcta cttctactca tactttacct 2400
tagcggttta taatgactat ggtacttcaa gaaagaaata cacgaactca gagaaggtag 2460
agggtgtgat tgaacacgta actgattacc ttcgtaactt caggttacgt actatggtct 2520
cgtaatgttg tcggtagctc ctgaatatta catgagtacc ctaacaggat acctcgttac 2580
atttgcattg agttggtcat atataaaatt ctacctttta ctagaaggtg ttttttatgt 2640
cacatgagaa tcgttaggta ataaattatg ttgtagtagt tagtaaaact gttggacata 2700
gggttcgtcg ccagtaagtt ctgtgtctat acgtgaatat gggtatggta atcgtcatta 2760
atgttgtaca taacacgaca tatacttacc ataagacttt acactgtctt ttggtctgtc 2820
ttggttgagg ttaactaacc gagctggccc ttacatgata gatgcatgct ttgggcgtag 2880
gcgagggtaa gttaagtgta acctgttcct attttatttt ggtgaccacc aaacgctaag 2940
gctttagaca tgtagtacgt caccaatttg tttttgtaaa aataagagtt tactctattt 3000
cacttttata tatagtaata taatgtttca tgttaataaa tccaaattag ttagggcgcc 3060
cgataccgag ggtcgtcggg ggccgggcgc gacgggcgtg aggaccagga cgagccccga 3120
gacaagggtc ctggaccgtt acgggtctgt agacacaggg ggagttttca gtaggacggg 3180
gcccctccga ggcacgacca ctgtacgtcg tggaggacac tggtcgggtt caacaacccg 3240
tatctctggg gcaacggatt tttcctcaac gaggacggac ccttgttggc cttccacata 3300
cttgactcgt tacacgttct tctatcggtt ggttacacga taagtttgac gggactaccc 3360
gtcagttgtc gattttggaa ggagtggcac atgacctgag gtcttgccca ccttgaccgt 3420
ggggagggga gaaccgtcgg tcacccgttc ttggaatggg atgcgacggt ccacctccca 3480
ccccgtgggg cccggttgga gtggcaccac gacgaggcac ccctcttcct cgactttgcc 3540
ctcggtcgac accccctcgg gcgactccag tgctggtgcc acgaccactc ctctctagtg 3600
gtacctcggt taaagagcac ggcgtgactt gacctggacg ccggggttcc cgacctcgac 3660
aaactcttgt ggagccgggg gatggtcgag gtctggaaac aggacggtcg ctgagggggt 3720
gttgaacagt cgggggccca ggatctccac ctgtgcgtcc cctggcacca gacaagggac 3780
ctgcccgaca agggtcagag cctccgggtc caggtggacc gtgaccccct ggtctccaac 3840
ttggggtgtc agtggatacc gttgctgagg aagagccggt tccggagtca gtcacactgg 3900
cgtctcctgc tcccgtgggt cgccgactgc acacgtcatt atgacccctt ggtctcggtc 3960
ctctgtgacg tctgtcactg gtagatgtcg aaaggccgcg ggttgcacta agactgcttc 4020
ggtctccaga gtcttccctg gctccactgt cacttcacac tccgggtggg atctcggttc 4080
cactgcgact taccccaagg tcgggtcggt gacccgggct cccgggtcga ggacgacttc 4140
cggtggggtc tcctgttgcc cgcgtcgaag aggacgagac gttgggacct ccaccggccg 4200
gtcgaatatg tgttcttggt ctgggccctc gaagcacagg acataccggg ggctgacctg 4260
ctctccctaa caggcccttt gacctgcacc ggtcttttaa gggtcgtctg aggttacacg 4320
gtccgaaccc ccttgggtaa cgggctcgag ttcacagatt tcctaccgtg aaagggtgac 4380
gggtagcccc ttagtcactg acagtgagct ctagaactcc cgtggatgga gacagcccgg 4440
tcctcgtgag ttcccctcca gtgggcgctc cactggcact tacacgagag gggggccata 4500
ctctaacagt agtagtgaca ccatcgtcgg cgtcagtatt acccgtgacg tccggagtcg 4560
tgcatggaga tattggcggt cgccttctag ttctttatgt ctgatgttgt ccgggttttt 4620
ccctgggggt actttggctt gtgtgttcgg tgcggaggga ctcgtacgta catcgaattt 4680
ttaactttaa aataaaaaaa aaaaacctta tatttattcg agcttcagct ttaaggacgt 4740
cgggccccgg tacccggtgt gtgcctccgt cccttgtagt ggtaggttca caggtatgga 4800
gttaaagaaa gtcgagaacc acgaccgacc agaaagagtg aagacaagtc cacaataggt 4860
gcactggttc cttcactttc ttcaccgttg cgacaggaca ccagtgttac aaagacaact 4920
tctcgaccgt gtttgagcgt agatgaccgt tttcctcttc ttttaccacg actgatacta 4980
cagacctctg tacttatata ccgggctcat gttcttggcc tggtagaaac tatagtgatt 5040
attggagagg taacactagg accgagacgc gggtagactg ctcccgtgta tgctcacaca 5100
acaagacttc atactttttc tgcgaaagtt cgcccttgtg gaccgacttc actgcaatag 5160
tcagtttcga ctgaagggat gtggatcata tagactgaaa ctttaaggtt gaagattata 5220
atcttcctat taaacgagtt ggagacctcc aaaaggtctc ggagtggaga ggaccaacct 5280
tttacctctt cttaatttac ggtagttgtg ttgtcaaagg gttctaggac tttgactcga 5340
gatacgacaa tcgtcgtttg acctaaagtt atactgttgg ttggtgtcga agtacacaga 5400
gtagttcata cctgtaaatt ctcacttagt ctggaagttg accttatgtt ggttcgttct 5460
cgtaaaagga ctattggacg agggtaggac ccggtaatgg aattagagtc atttacctta 5520
aaagcactat acgacggact ggatgacgaa acggggtgcg acgtctctct cttcctcctt 5580
actctctaac tcttcccttt cacatgcggg acatattttc gaaagatcca aaaacaaatc 5640
ccgacgtcct taaggagctc cctagggcta aaaatactga tcaattagtt tatttttcgt 5700
atgttcgata acgaagcgat agcaatgttt taccgtcctt aaaacacatt tgattcggtg 5760
tatgaacggt tacttttttt atcatctttc ctatgataaa attaccctaa tctacaattc 5820
caaggaaccc taatatcatt gacccgtaga caattgaaaa tgctgcaatc caatctatga 5880
ctacaatgtc taatattatt acaatgttat tttatgtact gtcctacact ataaaaagga 5940
gtatattgag aaccttatcg tttataccta gttacactat ctaaactttt aaagtttttc 6000
gtttattgac tagttctaaa tgtctgataa agatatcaga catttcttct ctacacaaaa 6060
ggagtctcat tgcggagatt tgtcaaccct cgctttccta cgcgacatca atactttgac 6120
ctccatagac tacttgaatc tcgggattct ttacaagacg acttacgcca tgggacaagc 6180
ttcctgcaca aaccactata gtgtcatcta ttaggcacct taggagtgta ttgtcatcct 6240
atacaattcc tcctgctaca gcttttgttc tttgcggatt acctcacgta caggttcaaa 6300
tcccccgttc tttatgttca agatcctacc ataattattc atagattcat aaaccatatt 6360
aaataattta tcatattaat attgtttatt atttattgta ctattgccaa aaataatctt 6420
attttatctc tattatagta ttactatata ttatgaagta atggtcttta ctcattacct 6480
tctgaatatt tacttgacgt atttcgatat tccatatctc tatatttaaa tcattccata 6540
tatgaatttt ttacgtttat gttattgcat ttatatgata gttgcagaaa cataaatcgg 6600
cattcataaa gactatatct ttaccatttt aataatgatc ttgtgccacg gctataaaat 6660
tttacatttt taggaggaga agtatttcga cgatcaaatc tattatgtct ttaacgattt 6720
gatgattatc taagaccgcg actgtatctt gtctatgtaa gacctttatc aggcaatata 6780
taaagacata tatctttgtt attcagtaat tgatctataa ataatttttt tccacaatta 6840
acattatcta agaaagattt aataatgcta catgacatac tattctatag actactatac 6900
atattttata aatatctaaa attataacta gaattatatg tttgatcttt aaaactttga 6960
ggcaatgtaa tgcgatattt catattctta tatctaaatt aatcctataa caatctatta 7020
tcataatttt atctattttc aaataaaaac gtatttgtca tagagtattt ccgtgaattt 7080
ttattaacat caatgctata ttatcgcaat gaatatttag tgcctcacgg atatttgctt 7140
gttctactaa atccattttg gggtaatgta gtaagccatt aattatcttc ttttctacat 7200
tgtcgtgaag acaatttaga tcctcgacta tatttgcatt atctactgac atacccgtca 7260
gggaatgtaa tgcgacaaag tgcattgcta tagctttgtt gtttctgtga aaatctttct 7320
cctagattac aattacacca attattagta tatctatggc aagatttata tcgacaacgt 7380
agatttttgt tttgatatca tttgaataat gacttcatgc catgactatg tttcaaccat 7440
cctaatctat ttgtacaata agtgtatcga tatctttact ttctataatt atatgactta 7500
cgctagaata atataccaac gatacatttg cagatattag tatttccaaa gtgaggagat 7560
atgtaccgtc aatcaagata cttttgtctt aaacaatttg agaatgaact ggtgccacga 7620
atgcatttac gatttcgatt caatagacct ttatgaggaa atgtatttcg atacaataga 7680
ttatcaaaat tattatattt taatgaaaat agaatattgc ggctgatatt aagagattta 7740
ttagtgccat tatgcggaga ttgaacacaa tcgaaaaatc tactgttcta tcgataatac 7800
tattatagat tttactacaa tctttataga tttttaggac tttatcgatt aagtcttcca 7860
aaatatcatt tgtaccttgt atatttgtca ttattttctg atgatagata ttttcttagt 7920
acgctttttc ttgatctaca atattgtgta tatttcaatt taagatatat aagaaaatta 7980
tagaaagaac tgttattgta tctagaatac catttcaagc attgattagg atctcaatta 8040
ttctatggac gtacatatgc atatatatcc cttaattatg cctttttatt tagtaatcga 8100
aaagtatctg tagtcgatta tcaatttcga cattttctct cattcttaga tccttattat 8160
ccatccaatg gatatctata gtttgtatat tattaccttg ataattcatt attactaaat 8220
gtaagacaat agtggtcgac aacattgggt catcatattt ctcgaggtcg aaaacaaggg 8280
aaatcactcc caattaaggc tcgaaccgca ttagtaccag tatcgacaaa ggacacactt 8340
taacaatagg cgagtgttaa ggtgtgttgt atgctcggcc ttcgtatttc acatttcgga 8400
ccccacggat tactcactcg attgagtgta attaacgcaa cgcgagtgac gggcgaaagg 8460
tcagcccttt ggacagcacg gtcgacgtaa ttacttagcc ggttgcgcgc ccctctccgc 8520
caaacgcata acccgcgaga aggcgaagga gcgagtgact gagcgacgcg agccagcaag 8580
ccgacgccgc tcgccatagt cgagtgagtt tccgccatta tgccaatagg tgtcttagtc 8640
ccctattgcg tcctttcttg tacactcgtt ttccggtcgt tttccggtcc ttggcatttt 8700
tccggcgcaa cgaccgcaaa aaggtatccg aggcgggggg actgctcgta gtgtttttag 8760
ctgcgagttc agtctccacc gctttgggct gtcctgatat ttctatggtc cgcaaagggg 8820
gaccttcgag ggagcacgcg agaggacaag gctgggacgg cgaatggcct atggacaggc 8880
ggaaagaggg aagcccttcg caccgcgaaa gagtatcgag tgcgacatcc atagagtcaa 8940
gccacatcca gcaagcgagg ttcgacccga cacacgtgct tggggggcaa gtcgggctgg 9000
cgacgcggaa taggccattg atagcagaac tcaggttggg ccattctgtg ctgaatagcg 9060
gtgaccgtcg tcggtgacca ttgtcctaat cgtctcgctc catacatccg ccacgatgtc 9120
tcaagaactt caccaccgga ttgatgccga tgtgatcttc ctgtcataaa ccatagacgc 9180
gagacgactt cggtcaatgg aagccttttt ctcaaccatc gagaactagg ccgtttgttt 9240
ggtggcgacc atcgccacca aaaaaacaaa cgttcgtcgt ctaatgcgcg tctttttttc 9300
ctagagttct tctaggaaac tagaaaagat gccccagact gcgagtcacc ttgcttttga 9360
gtgcaattcc ctaaaaccag tactctaata gtttttccta gaagtggatc taggaaaatt 9420
taatttttac ttcaaaattt agttagattt catatatact catttgaacc agactgtcaa 9480
tggttacgaa ttagtcactc cgtggataga gtcgctagac agataaagca agtaggtatc 9540
aacggactga ggggcagcac atctattgat gctatgccct cccgaatggt agaccggggt 9600
cacgacgtta ctatggcgct ctgggtgcga gtggccgagg tctaaatagt cgttatttgg 9660
tcggtcggcc ttcccggctc gcgtcttcac caggacgttg aaataggcgg aggtaggtca 9720
gataattaac aacggccctt cgatctcatt catcaagcgg tcaattatca aacgcgttgc 9780
aacaacggta acgatgtccg tagcaccaca gtgcgagcag caaaccatac cgaagtaagt 9840
cgaggccaag ggttgctagt tccgctcaat gtactagggg gtacaacacg ttttttcgcc 9900
aatcgaggaa gccaggaggc tagcaacagt cttcattcaa ccggcgtcac aatagtgagt 9960
accaataccg tcgtgacgta ttaagagaat gacagtacgg taggcattct acgaaaagac 10020
actgaccact catgagttgg ttcagtaaga ctcttatcac atacgccgct ggctcaacga 10080
gaacgggccg cagttatgcc ctattatggc gcggtgtatc gtcttgaaat tttcacgagt 10140
agtaaccttt tgcaagaagc cccgcttttg agagttccta gaatggcgac aactctaggt 10200
caagctacat tgggtgagca cgtgggttga ctagaagtcg tagaaaatga aagtggtcgc 10260
aaagacccac tcgtttttgt ccttccgttt tacggcgttt tttcccttat tcccgctgtg 10320
cctttacaac ttatgagtat gagaaggaaa aagttataat aacttcgtaa atagtcccaa 10380
taacagagta ctcgcctatg tataaactta cataaatctt tttatttgtt tatccccaag 10440
gcgcgtgtaa aggggctttt cacggtggac 10470
<210> 3
<211> 11154
<212> DNA
<213> Synthetic
<223> ALVAC
<400> 3
tgaatgttaa atgttatact ttggatgaag ctataaatat gcattggaaa aataatccat 60
ttaaagaaag gattcaaata ctacaaaacc taagcgataa tatgttaact aagcttattc 120
ttaacgacgc tttaaatata cacaaataaa cataattttt gtataaccta acaaataact 180
aaaacataaa aataataaaa ggaaatgtaa tatcgtaatt attttactca ggaatggggt 240
taaatattta tatcacgtgt atatctatac tgttatcgta tactctttac aattactatt 300
acgaatatgc aagagataat aagattacgt atttaagaga atcttgtcat gataattggg 360
tacgacatag tgataaatgc tatttcgcat cgttacataa agtcagttgg aaagatggat 420
ttgacagatg taacttaata ggtgcaaaaa tgttaaataa cagcattcta tcggaagata 480
ggataccagt tatattatac aaaaatcact ggttggataa aacagattct gcaatattcg 540
taaaagatga agattactgc gaatttgtaa actatgacaa taaaaagcca tttatctcaa 600
cgacatcgtg taattcttcc atgttttatg tatgtgtttc agatattatg agattactat 660
aaactttttg tatacttata ttccgtaaac tatattaatc atgaagaaaa tgaaaaagta 720
tagaagctgt tcacgagcgg ttgttgaaaa caacaaaatt atacattcaa gatggcttac 780
atatacgtct gtgaggctat catggataat gacaatgcat ctctaaatag gtttttggac 840
aatggattcg accctaacac ggaatatggt actctacaat ctcctcttga aatggctgta 900
atgttcaaga ataccgaggc tataaaaatc ttgatgaggt atggagctaa acctgtagtt 960
actgaatgca caacttcttg tctgcatgat gcggtgttga gagacgacta caaaatagtg 1020
aaagatctgt tgaagaataa ctatgtaaac aatgttcttt acagcggagg ctttactcct 1080
ttgtgtttgg cagcttacct taacaaagtt aatttggtta aacttctatt ggctcattcg 1140
gcggatgtag atatttcaaa cacggatcgg ttaactcctc tacatatagc cgtatcaaat 1200
aaaaatttaa caatggttaa acttctattg aacaaaggtg ctgatactga cttgctggat 1260
aacatgggat gtactccttt aatgatcgct gtacaatctg gaaatattga aatatgtagc 1320
acactactta aaaaaaataa aatgtccaga actgggaaaa attgatcttg ccagctgtaa 1380
ttcatggtag aaaagaagtg ctcaggctac ttttcaacaa aggagcagat gtaaactaca 1440
tctttgaaag aaatggaaaa tcatatactg ttttggaatt gattaaagaa agttactctg 1500
agacacaaaa gaggtagctg aagtggtact ctcaaaggta cgtgactaat tagctataaa 1560
aaggatcggc cgctctagaa ctagtggatc gggttcttta ttctatactt aaaaagtgaa 1620
aataaataca aaggttcttg agggttgtgt taaattgaaa gcgagaaata atcataaatt 1680
atttcattat cgcgatatcc gttaagtttg tatcgtaccc cgatcccccg agccatgcag 1740
gccgaaggcc ggggcacagg gggttcgacg ggcgatgctg atggcccagg aggccctggc 1800
attcctgatg gcccaggggg caatgctggc ggcccaggag aggcgggtgc cacgggcggc 1860
agaggtcccc ggggcgcagg ggcagcaagg gcctcggggc cgggaggagg cgccccgcgg 1920
ggtccgcatg gcggcgcggc ttcagggctg aatggatgct gcagatgcgg ggccaggggg 1980
ccggagagcc gcctgcttga gttctacctc gccatgcctt tcgcgacacc catagcttga 2040
tatcgaattc tagggggatc cactagttct agaggatcat tatttaacgt aaactaaatg 2100
gaaaagctat ttacaggtac atacggtgtt tttctggaat caaatgattc tgattttgag 2160
gattttatca atacaataat gacagtgcta actggtaaaa aagaaagcaa acaattatca 2220
tggctaacaa tttttattat atttgtagta tgcatagtgg tctttacgtt tctttattta 2280
aagttaatgt gttaagatta aatggagtaa ttggatcccc catcgatggg gaattcactg 2340
gccgtcgttt tacaacgtcg tgactgggaa aaccctggcg ttacccaact taatcgcctt 2400
gcagcacatc cccctttcgc cagctggcgt aatagcgaag aggcccgcac cgatcgccct 2460
tcccaacagt tgcgcagcct gaatggcgaa tggcgctttg cctggtttcc ggcaccagaa 2520
gcggtgccgg aaagctggct ggagtgcgat cttcctgagg ccgatactgt cgtcgtcccc 2580
tcaaactggc agatgcacgg ttacgatgcg cccatctaca ccaacgtgac ctatcccatt 2640
acggtcaatc cgccgtttgt tcccacggag aatccgacgg gttgttactc gctcacattt 2700
aatgttgatg aaagctggct acaggaaggc cagacgcgaa ttatttttga tggcgttaac 2760
tcggcgtttc atctgtggtg caacgggcgc tgggtcggtt acggccagga cagtcgtttg 2820
ccgtctgaat ttgacctgag cgcattttta cgcgccggag aaaaccgcct cgcggtgatg 2880
gtgctgcgct ggagtgacgg cagttatctg gaagatcagg atatgtggcg gatgagcggc 2940
attttccgtg acgtctcgtt gctgcataaa ccgactacac aaatcagcga tttccatgtt 3000
gccactcgct ttaatgatga tttcagccgc gctgtactgg aggctgaagt tcagatgtgc 3060
ggcgagttgc gtgactacct acgggtaaca gtttctttat ggcagggtga aacgcaggtc 3120
gccagcggca ccgcgccttt cggcggtgaa attatcgatg agcgtggtgg ttatgccgat 3180
cgcgtcacac tacgtctgaa cgtcgaaaac ccgaaactgt ggagcgccga aatcccgaat 3240
ctctatcgtg cggtggttga actgcacacc gccgacggca cgctgattga agcagaagcc 3300
tgcgatgtcg gtttccgcga ggtgcggatt gaaaatggtc tgctgctgct gaacggcaag 3360
ccgttgctga ttcgaggcgt taaccgtcac gagcatcatc ctctgcatgg tcaggtcatg 3420
gatgagcaga cgatggtgca ggatatcctg ctgatgaagc agaacaactt taacgccgtg 3480
cgctgttcgc attatccgaa ccatccgctg tggtacacgc tgtgcgaccg ctacggcctg 3540
tatgtggtgg atgaagccaa tattgaaacc cacggcatgg tgccaatgaa tcgtctgacc 3600
gatgatccgc gctggctacc ggcgatgagc gaacgcgtaa cgcgaatggt gcagcgcgat 3660
cgtaatcacc cgagtgtgat catctggtcg ctggggaatg aatcaggcca cggcgctaat 3720
cacgacgcgc tgtatcgctg gatcaaatct gtcgatcctt cccgcccggt gcagtatgaa 3780
ggcggcggag ccgacaccac ggccaccgat attatttgcc cgatgtacgc gcgcgtggat 3840
gaagaccagc ccttcccggc tgtgccgaaa tggtccatca aaaaatggct ttcgctacct 3900
ggagagacgc gcccgctgat cctttgcgaa tacgcccacg cgatgggtaa cagtcttggc 3960
ggtttcgcta aatactggca ggcgtttcgt cagtatcccc gtttacaggg cggcttcgtc 4020
tgggactggg tggatcagtc gctgattaaa tatgatgaaa acggcaaccc gtggtcggct 4080
tacggcggtg attttggcga tacgccgaac gatcgccagt tctgtatgaa cggtctggtc 4140
tttgccgacc gcacgccgca tccagcgctg acggaagcaa aacaccagca gcagtttttc 4200
cagttccgtt tatccgggca aaccatcgaa gtgaccagcg aatacctgtt ccgtcatagc 4260
gataacgagc tcctgcactg gatggtggcg ctggatggta agccgctggc aagcggtgaa 4320
gtgcctctgg atgtcgctcc acaaggtaaa cagttgattg aactgcctga actaccgcag 4380
ccggagagcg ccgggcaact ctggctcaca gtacgcgtag tgcaaccgaa cgcgaccgca 4440
tggtcagaag ccgggcacat cagcgcctgg cagcagtggc gtctggcgga aaacctcagt 4500
gtgacgctcc ccgccgcgtc ccacgccatc ccgcatctga ccaccagcga aatggatttt 4560
tgcatcgagc tgggtaataa gcgttggcaa tttaaccgcc agtcaggctt tctttcacag 4620
atgtggattg gcgataaaaa acaactgctg acgccgctgc gcgatcagtt cacccgtgca 4680
ccgctggata acgacattgg cgtaagtgaa gcgacccgca ttgaccctaa cgcctgggtc 4740
gaacgctgga aggcggcggg ccattaccag gccgaagcag cgttgttgca gtgcacggca 4800
gatacacttg ctgatgcggt gctgattacg accgctcacg cgtggcagca tcaggggaaa 4860
accttattta tcagccggaa aacctaccgg attgatggta gtggtcaaat ggcgattacc 4920
gttgatgttg aagtggcgag cgatacaccg catccggcgc ggattggcct gaactgccag 4980
ctggcgcagg tagcagagcg ggtaaactgg ctcggattag ggccgcaaga aaactatccc 5040
gaccgcctta ctgccgcctg ttttgaccgc tgggatctgc cattgtcaga catgtatacc 5100
ccgtacgtct tcccgagcga aaacggtctg cgctgcggga cgcgcgaatt gaattatggc 5160
ccacaccagt ggcgcggcga cttccagttc aacatcagcc ggtacagtca acagcaattg 5220
atggaaacca gccattcgcc atctgctgca cgcggaagag gcacatggct gaatatcgac 5280
ggtttccata tggggattgg tggcgacgac tcctggagcc cgtcagtatc ggcggaattc 5340
cagctgagcg ccggtcgcta ccattaccag ttggtctggt gtcaaaaata ataataaccg 5400
ggcagggggg atccggagct tatcgcagat caattcgata tcaagcttat cgataccgtc 5460
gacggtatcg ataagctcta gtggagggtt ctttattcta tacttaaaaa gtgaaaataa 5520
atacaaaggt tcttgagggt tgtgttaaat tgaaagcgag aaataatcat aaattatttc 5580
attatcgcga tatccgttaa gtttgtatcg tacccccccc gagccatgca ggccgaaggc 5640
cggggcacag ggggttcgac gggcgatgct gatggcccag gaggccctgg cattcctgat 5700
ggcccagggg gcaatgctgg cggcccagga gaggcgggtg ccacgggcgg cagaggtccc 5760
cggggcgcag gggcagcaag ggcctcgggg ccgggaggag gcgccccgcg gggtccgcat 5820
ggcggcgcgg cttcagggct gaatggatgc tgcagatgcg gggccagggg gccggagagc 5880
cgcctgcttg agttctacct cgccatgcct ttcgcgacac ccatggaagc agagctggcc 5940
cgcaggagcc tggcccagga tgccccaccg cttcccgtgc caggggtgct tctgaaggag 6000
ttcactgtgt ccggcaacat actgactatc cgactgactg ctgcagacca ccgccaactg 6060
cagctctcca tcagctcctg tctccagcag ctttccctgt tgatgtggat cacgcaggtg 6120
tttctgcccg tgtttttggc tcagcctccc tcagggcaga ggcgctaagt aattaatttt 6180
tttttgggct gcaggatcgc tagcaaaaat tgaaatttta tttttttttt ttggaatata 6240
aataagctcg aagctcgagc catgagcccc ctttggtggg ggtttctgct cagttgcttg 6300
ggctgcaaaa tcctgccagg agcccagggt cagttccccc gagtctgcat gacggtggac 6360
agcctagtga acaaggagtg ctgcccacgc ctgggtgcag agtcggccaa tgtctgtggc 6420
tctcagcaag gccgggggca gtgcacagag gtgcgagccg acacaaggcc ctggagtggt 6480
ccctacatcc tacgaaacca ggatgaccgt gagctgtggc caagaaaatt cttccaccgg 6540
acctgcaagt gcacaggaaa ctttgccggc tataattgtg gagactgcaa gtttggctgg 6600
accggtccca actgcgagcg gaagaaacca ccagtgattc ggcagaacat ccattccttg 6660
agtcctcagg aaagagagca gttcttgggc gccttagatc tcgcgaagaa gagagtacac 6720
cccgactacg tgatcaccac acaacactgg ctgggcctgc ttgggcccaa tggaacccag 6780
ccgcagtttg ccaactgcag tgtttatgat ttcttcgtgt ggctccatta ttattctgtt 6840
agagatacat tattaggacc aggacgcccc tacagggcca tagatttctc acatcaagga 6900
cctgcatttg ttacctggca ccggtaccat ttgttgtgtc tggaaagaga tctccagcga 6960
ctcattggca atgagtcttt tgctttgccc tactggaact ttgccactgg gaggaacgag 7020
tgtgatgtgt gtacagacca gctgtttggg gcagcgagac cagacgatcc gactctgatt 7080
agtcggaact caagattctc cagctgggaa actgtctgtg atagcttgga tgactacaac 7140
cacctggtca ccttgtgcaa tggaacctat gaaggtttgc tgagaagaaa tcaaatggga 7200
agaaacagca tgaaattgcc aaccttaaaa gacatacgag attgcctgtc tctccagaag 7260
tttgacaatc ctcccttctt ccagaactct accttcagtt tcaggaatgc tttggaaggg 7320
tttgataaag cagatgggac tctggattct caagtgatga gccttcataa tttggttcat 7380
tccttcctga acgggacaaa cgctttgcca cattcagccg ccaatgatcc catcttcgtg 7440
gtgatttcta atcgtttgct ttacaatgct acaacaaaca tccttgaaca tgtaagaaaa 7500
gagaaagcga ccaaggaact cccttccctg catgtgctgg ttcttcattc ctttactgat 7560
gccatctttg atgagtggat gaaaagattt aatcctcctg cagatgcctg gcctcaggag 7620
ctggccccta ttggtcacaa tcggatgtac aacatggttc ctttcttccc tccagtgact 7680
aatgaagaac tctttttaac ctcagaccaa cttggctaca gctatgccat cgatctgcca 7740
gtttcagttg aagaaactcc aggttggccc acaactctct tagtagtcat gggaacactg 7800
gtggctttgg ttggtctgtt cgtgctgttg gcttttcttc aatatagaag acttcgaaaa 7860
ggatatacac ccctaatgga gacacattta agcagcaaga gatacacaga agaagcctag 7920
ttttttaatt aagcatgctc tagaatcgat cccgggtttt tatgactagt taatcacggc 7980
cgcttataaa gatctaaaat gcataatttc taaataatga aaaaaaagta catcatgagc 8040
aacgcgttag tatattttac aatggagatt aacgctctat accgttctat gtttattgat 8100
tcagatgatg ttttagaaaa gaaagttatt gaatatgaaa actttaatga agatgaagat 8160
gacgacgatg attattgttg taaatctgtt ttagatgaag aagatgacgc gctaaagtat 8220
actatggtta caaagtataa gtctatacta ctaatggcga cttgtgcaag aaggtatagt 8280
atagtgaaaa tgttgttaga ttatgattat gaaaaaccaa ataaatcaga tccatatcta 8340
aaggtatctc ctttgcacat aatttcatct attcctagtt tagaatactt ttcattatat 8400
ttgtttacag ctgaagacga aaaaaatata tcgataatag aagattatgt taactctgct 8460
aataagatga aattgaatga gtctgtgact gcagccaagc ttggcactgg ccgtcgtttt 8520
acaacgtcgt gactgggaaa accctggcgt tacccaactt aatcgccttg cagcacatcc 8580
ccctttcgcc agctggcgta atagcgaaga ggcccgcacc gatcgccctt cccaacagtt 8640
gcgcagcctg aatggcgaat ggcgcctgat gcggtatttt ctccttacgc atctgtgcgg 8700
tatttcacac cgcatatggt gcactctcag tacaatctgc tctgatgccg catagttaag 8760
ccagccccga cacccgccaa cacccgctga cgcgccctga cgggcttgtc tgctcccggc 8820
atccgcttac agacaagctg tgaccgtctc cgggagctgc atgtgtcaga ggttttcacc 8880
gtcatcaccg aaacgcgcga gacgaaaggg cctcgtgata cgcctatttt tataggttaa 8940
tgtcatgata ataatggttt cttagacgtc aggtggcact tttcggggaa atgtgcgcgg 9000
aacccctatt tgtttatttt tctaaataca ttcaaatatg tatccgctca tgagacaata 9060
accctgataa atgcttcaat aatattgaaa aaggaagagt atgagtattc aacatttccg 9120
tgtcgccctt attccctttt ttgcggcatt ttgccttcct gtttttgctc acccagaaac 9180
gctggtgaaa gtaaaagatg ctgaagatca gttgggtgca cgagtgggtt acatcgaact 9240
ggatctcaac agcggtaaga tccttgagag ttttcgcccc gaagaacgtt ttccaatgat 9300
gagcactttt aaagttctgc tatgtggcgc ggtattatcc cgtattgacg ccgggcaaga 9360
gcaactcggt cgccgcatac actattctca gaatgacttg gttgagtact caccagtcac 9420
agaaaagcat cttacggatg gcatgacagt aagagaatta tgcagtgctg ccataaccat 9480
gagtgataac actgcggcca acttacttct gacaacgatc ggaggaccga aggagctaac 9540
cgcttttttg cacaacatgg gggatcatgt aactcgcctt gatcgttggg aaccggagct 9600
gaatgaagcc ataccaaacg acgagcgtga caccacgatg cctgtagcaa tggcaacaac 9660
gttgcgcaaa ctattaactg gcgaactact tactctagct tcccggcaac aattaataga 9720
ctggatggag gcggataaag ttgcaggacc acttctgcgc tcggcccttc cggctggctg 9780
gtttattgct gataaatctg gagccggtga gcgtgggtct cgcggtatca ttgcagcact 9840
ggggccagat ggtaagccct cccgtatcgt agttatctac acgacgggga gtcaggcaac 9900
tatggatgaa cgaaatagac agatcgctga gataggtgcc tcactgatta agcattggta 9960
actgtcagac caagtttact catatatact ttagattgat ttaaaacttc atttttaatt 10020
taaaaggatc taggtgaaga tcctttttga taatctcatg accaaaatcc cttaacgtga 10080
gttttcgttc cactgagcgt cagaccccgt agaaaagatc aaaggatctt cttgagatcc 10140
tttttttctg cgcgtaatct gctgcttgca aacaaaaaaa ccaccgctac cagcggtggt 10200
ttgtttgccg gatcaagagc taccaactct ttttccgaag gtaactggct tcagcagagc 10260
gcagatacca aatactgtcc ttctagtgta gccgtagtta ggccaccact tcaagaactc 10320
tgtagcaccg cctacatacc tcgctctgct aatcctgtta ccagtggctg ctgccagtgg 10380
cgataagtcg tgtcttaccg ggttggactc aagacgatag ttaccggata aggcgcagcg 10440
gtcgggctga acggggggtt cgtgcacaca gcccagcttg gagcgaacga cctacaccga 10500
actgagatac ctacagcgtg agctatgaga aagcgccacg cttcccgaag ggagaaaggc 10560
ggacaggtat ccggtaagcg gcagggtcgg aacaggagag cgcacgaggg agcttccagg 10620
gggaaacgcc tggtatcttt atagtcctgt cgggtttcgc cacctctgac ttgagcgtcg 10680
atttttgtga tgctcgtcag gggggcggag cctatggaaa aacgccagca acgcggcctt 10740
tttacggttc ctggcctttt gctggccttt tgctcacatg ttctttcctg cgttatcccc 10800
tgattctgtg gataaccgta ttaccgcctt tgagtgagct gataccgctc gccgcagccg 10860
aacgaccgag cgcagcgagt cagtgagcga ggaagcggaa gagcgcccaa tacgcaaacc 10920
gcctctcccc gcgcgttggc cgattcatta atgcagctgg cacgacaggt ttcccgactg 10980
gaaagcgggc agtgagcgca acgcaattaa tgtgagttag ctcactcatt aggcacccca 11040
ggctttacac tttatgcttc cggctcgtat gttgtgtgga attgtgagcg gataacaatt 11100
tcacacagga aacagctatg accatgatta cgaattgaat tgcggccgca attc 11154
<210> 4
<211> 11154
<212> DNA
<213> Synthetic
<223> ALVAC
<400> 4
acttacaatt tacaatatga aacctacttc gatatttata cgtaaccttt ttattaggta 60
aatttctttc ctaagtttat gatgttttgg attcgctatt atacaattga ttcgaataag 120
aattgctgcg aaatttatat gtgtttattt gtattaaaaa catattggat tgtttattga 180
ttttgtattt ttattatttt cctttacatt atagcattaa taaaatgagt ccttacccca 240
atttataaat atagtgcaca tatagatatg acaatagcat atgagaaatg ttaatgataa 300
tgcttatacg ttctctatta ttctaatgca taaattctct tagaacagta ctattaaccc 360
atgctgtatc actatttacg ataaagcgta gcaatgtatt tcagtcaacc tttctaccta 420
aactgtctac attgaattat ccacgttttt acaatttatt gtcgtaagat agccttctat 480
cctatggtca atataatatg tttttagtga ccaacctatt ttgtctaaga cgttataagc 540
attttctact tctaatgacg cttaaacatt tgatactgtt atttttcggt aaatagagtt 600
gctgtagcac attaagaagg tacaaaatac atacacaaag tctataatac tctaatgata 660
tttgaaaaac atatgaatat aaggcatttg atataattag tacttctttt actttttcat 720
atcttcgaca agtgctcgcc aacaactttt gttgttttaa tatgtaagtt ctaccgaatg 780
tatatgcaga cactccgata gtacctatta ctgttacgta gagatttatc caaaaacctg 840
ttacctaagc tgggattgtg ccttatacca tgagatgtta gaggagaact ttaccgacat 900
tacaagttct tatggctccg atatttttag aactactcca tacctcgatt tggacatcaa 960
tgacttacgt gttgaagaac agacgtacta cgccacaact ctctgctgat gttttatcac 1020
tttctagaca acttcttatt gatacatttg ttacaagaaa tgtcgcctcc gaaatgagga 1080
aacacaaacc gtcgaatgga attgtttcaa ttaaaccaat ttgaagataa ccgagtaagc 1140
cgcctacatc tataaagttt gtgcctagcc aattgaggag atgtatatcg gcatagttta 1200
tttttaaatt gttaccaatt tgaagataac ttgtttccac gactatgact gaacgaccta 1260
ttgtacccta catgaggaaa ttactagcga catgttagac ctttataact ttatacatcg 1320
tgtgatgaat tttttttatt ttacaggtct tgaccctttt taactagaac ggtcgacatt 1380
aagtaccatc ttttcttcac gagtccgatg aaaagttgtt tcctcgtcta catttgatgt 1440
agaaactttc tttacctttt agtatatgac aaaaccttaa ctaatttctt tcaatgagac 1500
tctgtgtttt ctccatcgac ttcaccatga gagtttccat gcactgatta atcgatattt 1560
ttcctagccg gcgagatctt gatcacctag cccaagaaat aagatatgaa tttttcactt 1620
ttatttatgt ttccaagaac tcccaacaca atttaacttt cgctctttat tagtatttaa 1680
taaagtaata gcgctatagg caattcaaac atagcatggg gctagggggc tcggtacgtc 1740
cggcttccgg ccccgtgtcc cccaagctgc ccgctacgac taccgggtcc tccgggaccg 1800
taaggactac cgggtccccc gttacgaccg ccgggtcctc tccgcccacg gtgcccgccg 1860
tctccagggg ccccgcgtcc ccgtcgttcc cggagccccg gccctcctcc gcggggcgcc 1920
ccaggcgtac cgccgcgccg aagtcccgac ttacctacga cgtctacgcc ccggtccccc 1980
ggcctctcgg cggacgaact caagatggag cggtacggaa agcgctgtgg gtatcgaact 2040
atagcttaag atccccctag gtgatcaaga tctcctagta ataaattgca tttgatttac 2100
cttttcgata aatgtccatg tatgccacaa aaagacctta gtttactaag actaaaactc 2160
ctaaaatagt tatgttatta ctgtcacgat tgaccatttt ttctttcgtt tgttaatagt 2220
accgattgtt aaaaataata taaacatcat acgtatcacc agaaatgcaa agaaataaat 2280
ttcaattaca caattctaat ttacctcatt aacctagggg gtagctaccc cttaagtgac 2340
cggcagcaaa atgttgcagc actgaccctt ttgggaccgc aatgggttga attagcggaa 2400
cgtcgtgtag ggggaaagcg gtcgaccgca ttatcgcttc tccgggcgtg gctagcggga 2460
agggttgtca acgcgtcgga cttaccgctt accgcgaaac ggaccaaagg ccgtggtctt 2520
cgccacggcc tttcgaccga cctcacgcta gaaggactcc ggctatgaca gcagcagggg 2580
agtttgaccg tctacgtgcc aatgctacgc gggtagatgt ggttgcactg gatagggtaa 2640
tgccagttag gcggcaaaca agggtgcctc ttaggctgcc caacaatgag cgagtgtaaa 2700
ttacaactac tttcgaccga tgtccttccg gtctgcgctt aataaaaact accgcaattg 2760
agccgcaaag tagacaccac gttgcccgcg acccagccaa tgccggtcct gtcagcaaac 2820
ggcagactta aactggactc gcgtaaaaat gcgcggcctc ttttggcgga gcgccactac 2880
cacgacgcga cctcactgcc gtcaatagac cttctagtcc tatacaccgc ctactcgccg 2940
taaaaggcac tgcagagcaa cgacgtattt ggctgatgtg tttagtcgct aaaggtacaa 3000
cggtgagcga aattactact aaagtcggcg cgacatgacc tccgacttca agtctacacg 3060
ccgctcaacg cactgatgga tgcccattgt caaagaaata ccgtcccact ttgcgtccag 3120
cggtcgccgt ggcgcggaaa gccgccactt taatagctac tcgcaccacc aatacggcta 3180
gcgcagtgtg atgcagactt gcagcttttg ggctttgaca cctcgcggct ttagggctta 3240
gagatagcac gccaccaact tgacgtgtgg cggctgccgt gcgactaact tcgtcttcgg 3300
acgctacagc caaaggcgct ccacgcctaa cttttaccag acgacgacga cttgccgttc 3360
ggcaacgact aagctccgca attggcagtg ctcgtagtag gagacgtacc agtccagtac 3420
ctactcgtct gctaccacgt cctataggac gactacttcg tcttgttgaa attgcggcac 3480
gcgacaagcg taataggctt ggtaggcgac accatgtgcg acacgctggc gatgccggac 3540
atacaccacc tacttcggtt ataactttgg gtgccgtacc acggttactt agcagactgg 3600
ctactaggcg cgaccgatgg ccgctactcg cttgcgcatt gcgcttacca cgtcgcgcta 3660
gcattagtgg gctcacacta gtagaccagc gaccccttac ttagtccggt gccgcgatta 3720
gtgctgcgcg acatagcgac ctagtttaga cagctaggaa gggcgggcca cgtcatactt 3780
ccgccgcctc ggctgtggtg ccggtggcta taataaacgg gctacatgcg cgcgcaccta 3840
cttctggtcg ggaagggccg acacggcttt accaggtagt tttttaccga aagcgatgga 3900
cctctctgcg cgggcgacta ggaaacgctt atgcgggtgc gctacccatt gtcagaaccg 3960
ccaaagcgat ttatgaccgt ccgcaaagca gtcatagggg caaatgtccc gccgaagcag 4020
accctgaccc acctagtcag cgactaattt atactacttt tgccgttggg caccagccga 4080
atgccgccac taaaaccgct atgcggcttg ctagcggtca agacatactt gccagaccag 4140
aaacggctgg cgtgcggcgt aggtcgcgac tgccttcgtt ttgtggtcgt cgtcaaaaag 4200
gtcaaggcaa ataggcccgt ttggtagctt cactggtcgc ttatggacaa ggcagtatcg 4260
ctattgctcg aggacgtgac ctaccaccgc gacctaccat tcggcgaccg ttcgccactt 4320
cacggagacc tacagcgagg tgttccattt gtcaactaac ttgacggact tgatggcgtc 4380
ggcctctcgc ggcccgttga gaccgagtgt catgcgcatc acgttggctt gcgctggcgt 4440
accagtcttc ggcccgtgta gtcgcggacc gtcgtcaccg cagaccgcct tttggagtca 4500
cactgcgagg ggcggcgcag ggtgcggtag ggcgtagact ggtggtcgct ttacctaaaa 4560
acgtagctcg acccattatt cgcaaccgtt aaattggcgg tcagtccgaa agaaagtgtc 4620
tacacctaac cgctattttt tgttgacgac tgcggcgacg cgctagtcaa gtgggcacgt 4680
ggcgacctat tgctgtaacc gcattcactt cgctgggcgt aactgggatt gcggacccag 4740
cttgcgacct tccgccgccc ggtaatggtc cggcttcgtc gcaacaacgt cacgtgccgt 4800
ctatgtgaac gactacgcca cgactaatgc tggcgagtgc gcaccgtcgt agtccccttt 4860
tggaataaat agtcggcctt ttggatggcc taactaccat caccagttta ccgctaatgg 4920
caactacaac ttcaccgctc gctatgtggc gtaggccgcg cctaaccgga cttgacggtc 4980
gaccgcgtcc atcgtctcgc ccatttgacc gagcctaatc ccggcgttct tttgataggg 5040
ctggcggaat gacggcggac aaaactggcg accctagacg gtaacagtct gtacatatgg 5100
ggcatgcaga agggctcgct tttgccagac gcgacgccct gcgcgcttaa cttaataccg 5160
ggtgtggtca ccgcgccgct gaaggtcaag ttgtagtcgg ccatgtcagt tgtcgttaac 5220
tacctttggt cggtaagcgg tagacgacgt gcgccttctc cgtgtaccga cttatagctg 5280
ccaaaggtat acccctaacc accgctgctg aggacctcgg gcagtcatag ccgccttaag 5340
gtcgactcgc ggccagcgat ggtaatggtc aaccagacca cagtttttat tattattggc 5400
ccgtcccccc taggcctcga atagcgtcta gttaagctat agttcgaata gctatggcag 5460
ctgccatagc tattcgagat cacctcccaa gaaataagat atgaattttt cacttttatt 5520
tatgtttcca agaactccca acacaattta actttcgctc tttattagta tttaataaag 5580
taatagcgct ataggcaatt caaacatagc atgggggggg ctcggtacgt ccggcttccg 5640
gccccgtgtc ccccaagctg cccgctacga ctaccgggtc ctccgggacc gtaaggacta 5700
ccgggtcccc cgttacgacc gccgggtcct ctccgcccac ggtgcccgcc gtctccaggg 5760
gccccgcgtc cccgtcgttc ccggagcccc ggccctcctc cgcggggcgc cccaggcgta 5820
ccgccgcgcc gaagtcccga cttacctacg acgtctacgc cccggtcccc cggcctctcg 5880
gcggacgaac tcaagatgga gcggtacgga aagcgctgtg ggtaccttcg tctcgaccgg 5940
gcgtcctcgg accgggtcct acggggtggc gaagggcacg gtccccacga agacttcctc 6000
aagtgacaca ggccgttgta tgactgatag gctgactgac gacgtctggt ggcggttgac 6060
gtcgagaggt agtcgaggac agaggtcgtc gaaagggaca actacaccta gtgcgtccac 6120
aaagacgggc acaaaaaccg agtcggaggg agtcccgtct ccgcgattca ttaattaaaa 6180
aaaaacccga cgtcctagcg atcgttttta actttaaaat aaaaaaaaaa aaccttatat 6240
ttattcgagc ttcgagctcg gtactcgggg gaaaccaccc ccaaagacga gtcaacgaac 6300
ccgacgtttt aggacggtcc tcgggtccca gtcaaggggg ctcagacgta ctgccacctg 6360
tcggatcact tgttcctcac gacgggtgcg gacccacgtc tcagccggtt acagacaccg 6420
agagtcgttc cggcccccgt cacgtgtctc cacgctcggc tgtgttccgg gacctcacca 6480
gggatgtagg atgctttggt cctactggca ctcgacaccg gttcttttaa gaaggtggcc 6540
tggacgttca cgtgtccttt gaaacggccg atattaacac ctctgacgtt caaaccgacc 6600
tggccagggt tgacgctcgc cttctttggt ggtcactaag ccgtcttgta ggtaaggaac 6660
tcaggagtcc tttctctcgt caagaacccg cggaatctag agcgcttctt ctctcatgtg 6720
gggctgatgc actagtggtg tgttgtgacc gacccggacg aacccgggtt accttgggtc 6780
ggcgtcaaac ggttgacgtc acaaatacta aagaagcaca ccgaggtaat aataagacaa 6840
tctctatgta ataatcctgg tcctgcgggg atgtcccggt atctaaagag tgtagttcct 6900
ggacgtaaac aatggaccgt ggccatggta aacaacacag acctttctct agaggtcgct 6960
gagtaaccgt tactcagaaa acgaaacggg atgaccttga aacggtgacc ctccttgctc 7020
acactacaca catgtctggt cgacaaaccc cgtcgctctg gtctgctagg ctgagactaa 7080
tcagccttga gttctaagag gtcgaccctt tgacagacac tatcgaacct actgatgttg 7140
gtggaccagt ggaacacgtt accttggata cttccaaacg actcttcttt agtttaccct 7200
tctttgtcgt actttaacgg ttggaatttt ctgtatgctc taacggacag agaggtcttc 7260
aaactgttag gagggaagaa ggtcttgaga tggaagtcaa agtccttacg aaaccttccc 7320
aaactatttc gtctaccctg agacctaaga gttcactact cggaagtatt aaaccaagta 7380
aggaaggact tgccctgttt gcgaaacggt gtaagtcggc ggttactagg gtagaagcac 7440
cactaaagat tagcaaacga aatgttacga tgttgtttgt aggaacttgt acattctttt 7500
ctctttcgct ggttccttga gggaagggac gtacacgacc aagaagtaag gaaatgacta 7560
cggtagaaac tactcaccta cttttctaaa ttaggaggac gtctacggac cggagtcctc 7620
gaccggggat aaccagtgtt agcctacatg ttgtaccaag gaaagaaggg aggtcactga 7680
ttacttcttg agaaaaattg gagtctggtt gaaccgatgt cgatacggta gctagacggt 7740
caaagtcaac ttctttgagg tccaaccggg tgttgagaga atcatcagta cccttgtgac 7800
caccgaaacc aaccagacaa gcacgacaac cgaaaagaag ttatatcttc tgaagctttt 7860
cctatatgtg gggattacct ctgtgtaaat tcgtcgttct ctatgtgtct tcttcggatc 7920
aaaaaattaa ttcgtacgag atcttagcta gggcccaaaa atactgatca attagtgccg 7980
gcgaatattt ctagatttta cgtattaaag atttattact tttttttcat gtagtactcg 8040
ttgcgcaatc atataaaatg ttacctctaa ttgcgagata tggcaagata caaataacta 8100
agtctactac aaaatctttt ctttcaataa cttatacttt tgaaattact tctacttcta 8160
ctgctgctac taataacaac atttagacaa aatctacttc ttctactgcg cgatttcata 8220
tgataccaat gtttcatatt cagatatgat gattaccgct gaacacgttc ttccatatca 8280
tatcactttt acaacaatct aatactaata ctttttggtt tatttagtct aggtatagat 8340
ttccatagag gaaacgtgta ttaaagtaga taaggatcaa atcttatgaa aagtaatata 8400
aacaaatgtc gacttctgct ttttttatat agctattatc ttctaataca attgagacga 8460
ttattctact ttaacttact cagacactga cgtcggttcg aaccgtgacc ggcagcaaaa 8520
tgttgcagca ctgacccttt tgggaccgca atgggttgaa ttagcggaac gtcgtgtagg 8580
gggaaagcgg tcgaccgcat tatcgcttct ccgggcgtgg ctagcgggaa gggttgtcaa 8640
cgcgtcggac ttaccgctta ccgcggacta cgccataaaa gaggaatgcg tagacacgcc 8700
ataaagtgtg gcgtatacca cgtgagagtc atgttagacg agactacggc gtatcaattc 8760
ggtcggggct gtgggcggtt gtgggcgact gcgcgggact gcccgaacag acgagggccg 8820
taggcgaatg tctgttcgac actggcagag gccctcgacg tacacagtct ccaaaagtgg 8880
cagtagtggc tttgcgcgct ctgctttccc ggagcactat gcggataaaa atatccaatt 8940
acagtactat tattaccaaa gaatctgcag tccaccgtga aaagcccctt tacacgcgcc 9000
ttggggataa acaaataaaa agatttatgt aagtttatac ataggcgagt actctgttat 9060
tgggactatt tacgaagtta ttataacttt ttccttctca tactcataag ttgtaaaggc 9120
acagcgggaa taagggaaaa aacgccgtaa aacggaagga caaaaacgag tgggtctttg 9180
cgaccacttt cattttctac gacttctagt caacccacgt gctcacccaa tgtagcttga 9240
cctagagttg tcgccattct aggaactctc aaaagcgggg cttcttgcaa aaggttacta 9300
ctcgtgaaaa tttcaagacg atacaccgcg ccataatagg gcataactgc ggcccgttct 9360
cgttgagcca gcggcgtatg tgataagagt cttactgaac caactcatga gtggtcagtg 9420
tcttttcgta gaatgcctac cgtactgtca ttctcttaat acgtcacgac ggtattggta 9480
ctcactattg tgacgccggt tgaatgaaga ctgttgctag cctcctggct tcctcgattg 9540
gcgaaaaaac gtgttgtacc ccctagtaca ttgagcggaa ctagcaaccc ttggcctcga 9600
cttacttcgg tatggtttgc tgctcgcact gtggtgctac ggacatcgtt accgttgttg 9660
caacgcgttt gataattgac cgcttgatga atgagatcga agggccgttg ttaattatct 9720
gacctacctc cgcctatttc aacgtcctgg tgaagacgcg agccgggaag gccgaccgac 9780
caaataacga ctatttagac ctcggccact cgcacccaga gcgccatagt aacgtcgtga 9840
ccccggtcta ccattcggga gggcatagca tcaatagatg tgctgcccct cagtccgttg 9900
atacctactt gctttatctg tctagcgact ctatccacgg agtgactaat tcgtaaccat 9960
tgacagtctg gttcaaatga gtatatatga aatctaacta aattttgaag taaaaattaa 10020
attttcctag atccacttct aggaaaaact attagagtac tggttttagg gaattgcact 10080
caaaagcaag gtgactcgca gtctggggca tcttttctag tttcctagaa gaactctagg 10140
aaaaaaagac gcgcattaga cgacgaacgt ttgttttttt ggtggcgatg gtcgccacca 10200
aacaaacggc ctagttctcg atggttgaga aaaaggcttc cattgaccga agtcgtctcg 10260
cgtctatggt ttatgacagg aagatcacat cggcatcaat ccggtggtga agttcttgag 10320
acatcgtggc ggatgtatgg agcgagacga ttaggacaat ggtcaccgac gacggtcacc 10380
gctattcagc acagaatggc ccaacctgag ttctgctatc aatggcctat tccgcgtcgc 10440
cagcccgact tgccccccaa gcacgtgtgt cgggtcgaac ctcgcttgct ggatgtggct 10500
tgactctatg gatgtcgcac tcgatactct ttcgcggtgc gaagggcttc cctctttccg 10560
cctgtccata ggccattcgc cgtcccagcc ttgtcctctc gcgtgctccc tcgaaggtcc 10620
ccctttgcgg accatagaaa tatcaggaca gcccaaagcg gtggagactg aactcgcagc 10680
taaaaacact acgagcagtc cccccgcctc ggataccttt ttgcggtcgt tgcgccggaa 10740
aaatgccaag gaccggaaaa cgaccggaaa acgagtgtac aagaaaggac gcaatagggg 10800
actaagacac ctattggcat aatggcggaa actcactcga ctatggcgag cggcgtcggc 10860
ttgctggctc gcgtcgctca gtcactcgct ccttcgcctt ctcgcgggtt atgcgtttgg 10920
cggagagggg cgcgcaaccg gctaagtaat tacgtcgacc gtgctgtcca aagggctgac 10980
ctttcgcccg tcactcgcgt tgcgttaatt acactcaatc gagtgagtaa tccgtggggt 11040
ccgaaatgtg aaatacgaag gccgagcata caacacacct taacactcgc ctattgttaa 11100
agtgtgtcct ttgtcgatac tggtactaat gcttaactta acgccggcgt taag 11154
<210> 5
<211> 11480
<212> DNA
<213> Synthetic
<223> ALVAC
<400> 5
tgaatgttaa atgttatact ttggatgaag ctataaatat gcattggaaa aataatccat 60
ttaaagaaag gattcaaata ctacaaaacc taagcgataa tatgttaact aagcttattc 120
ttaacgacgc tttaaatata cacaaataaa cataattttt gtataaccta acaaataact 180
aaaacataaa aataataaaa ggaaatgtaa tatcgtaatt attttactca ggaatggggt 240
taaatattta tatcacgtgt atatctatac tgttatcgta tactctttac aattactatt 300
acgaatatgc aagagataat aagattacgt atttaagaga atcttgtcat gataattggg 360
tacgacatag tgataaatgc tatttcgcat cgttacataa agtcagttgg aaagatggat 420
ttgacagatg taacttaata ggtgcaaaaa tgttaaataa cagcattcta tcggaagata 480
ggataccagt tatattatac aaaaatcact ggttggataa aacagattct gcaatattcg 540
taaaagatga agattactgc gaatttgtaa actatgacaa taaaaagcca tttatctcaa 600
cgacatcgtg taattcttcc atgttttatg tatgtgtttc agatattatg agattactat 660
aaactttttg tatacttata ttccgtaaac tatattaatc atgaagaaaa tgaaaaagta 720
tagaagctgt tcacgagcgg ttgttgaaaa caacaaaatt atacattcaa gatggcttac 780
atatacgtct gtgaggctat catggataat gacaatgcat ctctaaatag gtttttggac 840
aatggattcg accctaacac ggaatatggt actctacaat ctcctcttga aatggctgta 900
atgttcaaga ataccgaggc tataaaaatc ttgatgaggt atggagctaa acctgtagtt 960
actgaatgca caacttcttg tctgcatgat gcggtgttga gagacgacta caaaatagtg 1020
aaagatctgt tgaagaataa ctatgtaaac aatgttcttt acagcggagg ctttactcct 1080
ttgtgtttgg cagcttacct taacaaagtt aatttggtta aacttctatt ggctcattcg 1140
gcggatgtag atatttcaaa cacggatcgg ttaactcctc tacatatagc cgtatcaaat 1200
aaaaatttaa caatggttaa acttctattg aacaaaggtg ctgatactga cttgctggat 1260
aacatgggat gtactccttt aatgatcgct gtacaatctg gaaatattga aatatgtagc 1320
acactactta aaaaaaataa aatgtccaga actgggaaaa attgatcttg ccagctgtaa 1380
ttcatggtag aaaagaagtg ctcaggctac ttttcaacaa aggagcagat gtaaactaca 1440
tctttgaaag aaatggaaaa tcatatactg ttttggaatt gattaaagaa agttactctg 1500
agacacaaaa gaggtagctg aagtggtact ctcaaaggta cgtgactaat tagctataaa 1560
aaggatcggg ttctttattc tatacttaaa aagtgaaaat aaatacaaag gttcttgagg 1620
gttgtgttaa attgaaagcg agaaataatc ataaattatt tcattatcgc gatatccgtt 1680
aagtttgtat cgtaatctgc agcccccacc atggatctgg tgctaaaaag atgccttctt 1740
catttggctg tgataggtgc tttgctggct gtgggggcta caaaagtacc cagaaaccag 1800
gactggcttg gtgtctcaag gcaactcaga accaaagcct ggaacaggca gctgtatcca 1860
gagtggacag aagcccagag acttgactgc tggagaggtg gtcaagtgtc cctcaaggtc 1920
agtaatgatg ggcctacact gattggtgca aatgcctcct tctctattgc cttgaacttc 1980
cctggaagcc aaaaggtatt gccagatact agttctagag gatcattatt taacgtaaac 2040
taaatggaaa agctatttac aggtacatac ggtgtttttc tggaatcaaa tgattctgat 2100
tttgaggatt ttatcaatac aataatgaca gtgctaactg gtaaaaaaga aagcaaacaa 2160
ttatcatggc taacaatttt tattatattt gtagtatgca tagtggtctt tacgtttctt 2220
tatttaaagt taatgtgtta agattaaatg gagtaattgg atcccccatc gatggggaat 2280
tcactggccg tcgttttaca acgtcgtgac tgggaaaacc ctggcgttac ccaacttaat 2340
cgccttgcag cacatccccc tttcgccagc tggcgtaata gcgaagaggc ccgcaccgat 2400
cgcccttccc aacagttgcg cagcctgaat ggcgaatggc gctttgcctg gtttccggca 2460
ccagaagcgg tgccggaaag ctggctggag tgcgatcttc ctgaggccga tactgtcgtc 2520
gtcccctcaa actggcagat gcacggttac gatgcgccca tctacaccaa cgtgacctat 2580
cccattacgg tcaatccgcc gtttgttccc acggagaatc cgacgggttg ttactcgctc 2640
acatttaatg ttgatgaaag ctggctacag gaaggccaga cgcgaattat ttttgatggc 2700
gttaactcgg cgtttcatct gtggtgcaac gggcgctggg tcggttacgg ccaggacagt 2760
cgtttgccgt ctgaatttga cctgagcgca tttttacgcg ccggagaaaa ccgcctcgcg 2820
gtgatggtgc tgcgctggag tgacggcagt tatctggaag atcaggatat gtggcggatg 2880
agcggcattt tccgtgacgt ctcgttgctg cataaaccga ctacacaaat cagcgatttc 2940
catgttgcca ctcgctttaa tgatgatttc agccgcgctg tactggaggc tgaagttcag 3000
atgtgcggcg agttgcgtga ctacctacgg gtaacagttt ctttatggca gggtgaaacg 3060
caggtcgcca gcggcaccgc gcctttcggc ggtgaaatta tcgatgagcg tggtggttat 3120
gccgatcgcg tcacactacg tctgaacgtc gaaaacccga aactgtggag cgccgaaatc 3180
ccgaatctct atcgtgcggt ggttgaactg cacaccgccg acggcacgct gattgaagca 3240
gaagcctgcg atgtcggttt ccgcgaggtg cggattgaaa atggtctgct gctgctgaac 3300
ggcaagccgt tgctgattcg aggcgttaac cgtcacgagc atcatcctct gcatggtcag 3360
gtcatggatg agcagacgat ggtgcaggat atcctgctga tgaagcagaa caactttaac 3420
gccgtgcgct gttcgcatta tccgaaccat ccgctgtggt acacgctgtg cgaccgctac 3480
ggcctgtatg tggtggatga agccaatatt gaaacccacg gcatggtgcc aatgaatcgt 3540
ctgaccgatg atccgcgctg gctaccggcg atgagcgaac gcgtaacgcg aatggtgcag 3600
cgcgatcgta atcacccgag tgtgatcatc tggtcgctgg ggaatgaatc aggccacggc 3660
gctaatcacg acgcgctgta tcgctggatc aaatctgtcg atccttcccg cccggtgcag 3720
tatgaaggcg gcggagccga caccacggcc accgatatta tttgcccgat gtacgcgcgc 3780
gtggatgaag accagccctt cccggctgtg ccgaaatggt ccatcaaaaa atggctttcg 3840
ctacctggag agacgcgccc gctgatcctt tgcgaatacg cccacgcgat gggtaacagt 3900
cttggcggtt tcgctaaata ctggcaggcg tttcgtcagt atccccgttt acagggcggc 3960
ttcgtctggg actgggtgga tcagtcgctg attaaatatg atgaaaacgg caacccgtgg 4020
tcggcttacg gcggtgattt tggcgatacg ccgaacgatc gccagttctg tatgaacggt 4080
ctggtctttg ccgaccgcac gccgcatcca gcgctgacgg aagcaaaaca ccagcagcag 4140
tttttccagt tccgtttatc cgggcaaacc atcgaagtga ccagcgaata cctgttccgt 4200
catagcgata acgagctcct gcactggatg gtggcgctgg atggtaagcc gctggcaagc 4260
ggtgaagtgc ctctggatgt cgctccacaa ggtaaacagt tgattgaact gcctgaacta 4320
ccgcagccgg agagcgccgg gcaactctgg ctcacagtac gcgtagtgca accgaacgcg 4380
accgcatggt cagaagccgg gcacatcagc gcctggcagc agtggcgtct ggcggaaaac 4440
ctcagtgtga cgctccccgc cgcgtcccac gccatcccgc atctgaccac cagcgaaatg 4500
gatttttgca tcgagctggg taataagcgt tggcaattta accgccagtc aggctttctt 4560
tcacagatgt ggattggcga taaaaaacaa ctgctgacgc cgctgcgcga tcagttcacc 4620
cgtgcaccgc tggataacga cattggcgta agtgaagcga cccgcattga ccctaacgcc 4680
tgggtcgaac gctggaaggc ggcgggccat taccaggccg aagcagcgtt gttgcagtgc 4740
acggcagata cacttgctga tgcggtgctg attacgaccg ctcacgcgtg gcagcatcag 4800
gggaaaacct tatttatcag ccggaaaacc taccggattg atggtagtgg tcaaatggcg 4860
attaccgttg atgttgaagt ggcgagcgat acaccgcatc cggcgcggat tggcctgaac 4920
tgccagctgg cgcaggtagc agagcgggta aactggctcg gattagggcc gcaagaaaac 4980
tatcccgacc gccttactgc cgcctgtttt gaccgctggg atctgccatt gtcagacatg 5040
tataccccgt acgtcttccc gagcgaaaac ggtctgcgct gcgggacgcg cgaattgaat 5100
tatggcccac accagtggcg cggcgacttc cagttcaaca tcagccggta cagtcaacag 5160
caattgatgg aaaccagcca ttcgccatct gctgcacgcg gaagaggcac atggctgaat 5220
atcgacggtt tccatatggg gattggtggc gacgactcct ggagcccgtc agtatcggcg 5280
gaattccagc tgagcgccgg tcgctaccat taccagttgg tctggtgtca aaaataataa 5340
taaccgggca ggggggatcc ggagcttatc gcagatcaat tcgatatcaa gcttatcgat 5400
accgtcgacc tcgagtctag aatcgatccc gggttcttta ttctatactt aaaaagtgaa 5460
aataaataca aaggttcttg agggttgtgt taaattgaaa gcgagaaata atcataaatt 5520
atttcattat cgcgatatcc gttaagtttg tatcgtaatc tgcagccccc accatggatc 5580
tggtgctaaa aagatgcctt cttcatttgg ctgtgatagg tgctttgctg gctgtggggg 5640
ctacaaaagt acccagaaac caggactggc ttggtgtctc aaggcaactc agaaccaaag 5700
cctggaacag gcagctgtat ccagagtgga cagaagccca gagacttgac tgctggagag 5760
gtggtcaagt gtccctcaag gtcagtaatg atgggcctac actgattggt gcaaatgcct 5820
ccttctctat tgccttgaac ttccctggaa gccaaaaggt attgccagat gggcaggtta 5880
tctgggtcaa caataccatc atcaatggga gccaggtgtg gggaggacag ccagtgtatc 5940
cccaggaaac tgacgatgcc tgcatcttcc ctgatggtgg accttgccca tctggctctt 6000
ggtctcagaa gagaagcttt gtttatgtct ggaagacctg gggccaatac tggcaagttc 6060
tagggggccc agtgtctggg ctgagcattg ggacaggcag ggcaatgctg ggcacacaca 6120
cgatggaagt gactgtctac catcgccggg gatcccggag ctatgtgcct cttgctcatt 6180
ccagctcagc cttcaccatt atggaccagg tgcctttctc cgtgagcgtg tcccagttgc 6240
gggccttgga tggagggaac aagcacttcc tgagaaatca gcctctgacc tttgccctcc 6300
agctccatga ccccagtggc tatctggctg aagctgacct ctcctacacc tgggactttg 6360
gagacagtag tggaaccctg atctctcggg cacttgtggt cactcatact tacctggagc 6420
ctggcccagt cactgttcag gtggtcctgc aggctgccat tcctctcacc tcctgtggct 6480
cctccccagt tccaggcacc acagatgggc acaggccaac tgcagaggcc cctaacacca 6540
cagctggcca agtgcctact acagaagttg tgggtactac acctggtcag gcgccaactg 6600
cagagccctc tggaaccaca tctgtgcagg tgccaaccac tgaagtcata agcactgcac 6660
ctgtgcagat gccaactgca gagagcacag gtatgacacc tgagaaggtg ccagtttcag 6720
aggtcatggg taccacactg gcagagatgt caactccaga ggctacaggt atgacacctg 6780
cagaggtatc aattgtggtg ctttctggaa ccacagctgc acaggtaaca actacagagt 6840
gggtggagac cacagctaga gagctaccta tccctgagcc tgaaggtcca gatgccagct 6900
caatcatgtc tacggaaagt attacaggtt ccctgggccc cctgctggat ggtacagcca 6960
ccttaaggct ggtgaagaga caagtccccc tggattgtgt tctgtatcga tatggttcct 7020
tttccgtcac cctggacatt gtccagggta ttgaaagtgc cgagatcctg caggctgtgc 7080
cgtccggtga gggggatgca tttgagctga ctgtgtcctg ccaaggcggg ctgcccaagg 7140
aagcctgcat ggagatctca tcgccagggt gccagccccc tgcccagcgg ctgtgccagc 7200
ctgtgctacc cagcccagcc tgccagctgg ttctgcacca gatactgaag ggtggctcgg 7260
ggacatactg cctcaatgtg tctctggctg ataccaacag cctggcagtg gtcagcaccc 7320
agcttatcat gcctggtcaa gaagcaggcc ttgggcaggt tccgctgatc gtgggcatct 7380
tgctggtgtt gatggctgtg gtccttgcat ctctgatata taggcgcaga cttatgaagc 7440
aagacttctc cgtaccccag ttgccacata gcagcagtca ctggctgcgt ctaccccgca 7500
tcttctgctc ttgtcccatt ggtgagaaca gccccctcct cagtgggcag caggtctgat 7560
ttttattcta gttcaaaaaa atataaatga ttcaccatct gatagaaaaa aaatttattg 7620
ggagaatatg ataatatttt gggatttcaa aattgaaaat atataattac aatataaatc 7680
tagaccacca tgccaagaga agatgctcac ttcatctatg gttaccccaa gaaggggcac 7740
ggccactctt acaccacggc tgaagaggcc gctgggatcg gcatcctgac agtgatcctg 7800
ggagtcttac tgctcatcgg ctgttggtat tgtagaagac gaaatggata cagagccttg 7860
atggataaaa gtcttcatgt tggcactcaa tgtgccttaa caagaagatg cccacaagaa 7920
gggtttgatc atcgggacag caaagtgtct cttcaagaga aaaactgtga acctgtggtt 7980
cccaatgctc cacctgctta tgagaaactc tctgcagaac agtcaccacc accttattca 8040
ccttaatcta gagtcgacct gcaggcatgc aaaaattgaa attttatttt ttttttttgg 8100
aatataaata atggagtcct tgcagctggt ctttggcatt gacgtgaagg aagcagaccc 8160
caccggccac tcctatgtcc ttgtcacctg cctaggtctc tcctatgatg gcaataagcg 8220
taaagaagtg gaccccatcg gccacttgta ctagttttta tcccgggttt ttatgactag 8280
ttaatcacgg ccgcttataa agatctaaaa tgcataattt ctaaataatg aaaaaaaagt 8340
acatcatgag caacgcgtta gtatatttta caatggagat taacgctcta taccgttcta 8400
tgtttattga ttcagatgat gttttagaaa agaaagttat tgaatatgaa aactttaatg 8460
aagatgaaga tgacgacgat gattattgtt gtaaatctgt tttagatgaa gaagatgacg 8520
cgctaaagta tactatggtt acaaagtata agtctatact actaatggcg acttgtgcaa 8580
gaaggtatag tatagtgaaa atgttgttag attatgatta tgaaaaacca aataaatcag 8640
atccatatct aaaggtatct cctttgcaca taatttcatc tattcctagt ttagaatact 8700
tttcattata tttgtttaca gctgaagacg aaaaaaatat atcgataata gaagattatg 8760
ttaactctgc taataagatg aaattgaatg agtctgtgac tgcagccaag cttggcactg 8820
gccgtcgttt tacaacgtcg tgactgggaa aaccctggcg ttacccaact taatcgcctt 8880
gcagcacatc cccctttcgc cagctggcgt aatagcgaag aggcccgcac cgatcgccct 8940
tcccaacagt tgcgcagcct gaatggcgaa tggcgcctga tgcggtattt tctccttacg 9000
catctgtgcg gtatttcaca ccgcatatgg tgcactctca gtacaatctg ctctgatgcc 9060
gcatagttaa gccagccccg acacccgcca acacccgctg acgcgccctg acgggcttgt 9120
ctgctcccgg catccgctta cagacaagct gtgaccgtct ccgggagctg catgtgtcag 9180
aggttttcac cgtcatcacc gaaacgcgcg agacgaaagg gcctcgtgat acgcctattt 9240
ttataggtta atgtcatgat aataatggtt tcttagacgt caggtggcac ttttcgggga 9300
aatgtgcgcg gaacccctat ttgtttattt ttctaaatac attcaaatat gtatccgctc 9360
atgagacaat aaccctgata aatgcttcaa taatattgaa aaaggaagag tatgagtatt 9420
caacatttcc gtgtcgccct tattcccttt tttgcggcat tttgccttcc tgtttttgct 9480
cacccagaaa cgctggtgaa agtaaaagat gctgaagatc agttgggtgc acgagtgggt 9540
tacatcgaac tggatctcaa cagcggtaag atccttgaga gttttcgccc cgaagaacgt 9600
tttccaatga tgagcacttt taaagttctg ctatgtggcg cggtattatc ccgtattgac 9660
gccgggcaag agcaactcgg tcgccgcata cactattctc agaatgactt ggttgagtac 9720
tcaccagtca cagaaaagca tcttacggat ggcatgacag taagagaatt atgcagtgct 9780
gccataacca tgagtgataa cactgcggcc aacttacttc tgacaacgat cggaggaccg 9840
aaggagctaa ccgctttttt gcacaacatg ggggatcatg taactcgcct tgatcgttgg 9900
gaaccggagc tgaatgaagc cataccaaac gacgagcgtg acaccacgat gcctgtagca 9960
atggcaacaa cgttgcgcaa actattaact ggcgaactac ttactctagc ttcccggcaa 10020
caattaatag actggatgga ggcggataaa gttgcaggac cacttctgcg ctcggccctt 10080
ccggctggct ggtttattgc tgataaatct ggagccggtg agcgtgggtc tcgcggtatc 10140
attgcagcac tggggccaga tggtaagccc tcccgtatcg tagttatcta cacgacgggg 10200
agtcaggcaa ctatggatga acgaaataga cagatcgctg agataggtgc ctcactgatt 10260
aagcattggt aactgtcaga ccaagtttac tcatatatac tttagattga tttaaaactt 10320
catttttaat ttaaaaggat ctaggtgaag atcctttttg ataatctcat gaccaaaatc 10380
ccttaacgtg agttttcgtt ccactgagcg tcagaccccg tagaaaagat caaaggatct 10440
tcttgagatc ctttttttct gcgcgtaatc tgctgcttgc aaacaaaaaa accaccgcta 10500
ccagcggtgg tttgtttgcc ggatcaagag ctaccaactc tttttccgaa ggtaactggc 10560
ttcagcagag cgcagatacc aaatactgtc cttctagtgt agccgtagtt aggccaccac 10620
ttcaagaact ctgtagcacc gcctacatac ctcgctctgc taatcctgtt accagtggct 10680
gctgccagtg gcgataagtc gtgtcttacc gggttggact caagacgata gttaccggat 10740
aaggcgcagc ggtcgggctg aacggggggt tcgtgcacac agcccagctt ggagcgaacg 10800
acctacaccg aactgagata cctacagcgt gagctatgag aaagcgccac gcttcccgaa 10860
gggagaaagg cggacaggta tccggtaagc ggcagggtcg gaacaggaga gcgcacgagg 10920
gagcttccag ggggaaacgc ctggtatctt tatagtcctg tcgggtttcg ccacctctga 10980
cttgagcgtc gatttttgtg atgctcgtca ggggggcgga gcctatggaa aaacgccagc 11040
aacgcggcct ttttacggtt cctggccttt tgctggcctt ttgctcacat gttctttcct 11100
gcgttatccc ctgattctgt ggataaccgt attaccgcct ttgagtgagc tgataccgct 11160
cgccgcagcc gaacgaccga gcgcagcgag tcagtgagcg aggaagcgga agagcgccca 11220
atacgcaaac cgcctctccc cgcgcgttgg ccgattcatt aatgcagctg gcacgacagg 11280
tttcccgact ggaaagcggg cagtgagcgc aacgcaatta atgtgagtta gctcactcat 11340
taggcacccc aggctttaca ctttatgctt ccggctcgta tgttgtgtgg aattgtgagc 11400
ggataacaat ttcacacagg aaacagctat gaccatgatt acgaattgaa ttgcggccgc 11460
aattcaacgc cggcgttaag 11480
<210> 6
<211> 11450
<212> DNA
<213> Synthetic
<223> ALVAC
<400> 6
acttacaatt tacaatatga aacctacttc gatatttata cgtaaccttt ttattaggta 60
aatttctttc ctaagtttat gatgttttgg attcgctatt atacaattga ttcgaataag 120
aattgctgcg aaatttatat gtgtttattt gtattaaaaa catattggat tgtttattga 180
ttttgtattt ttattatttt cctttacatt atagcattaa taaaatgagt ccttacccca 240
atttataaat atagtgcaca tatagatatg acaatagcat atgagaaatg ttaatgataa 300
tgcttatacg ttctctatta ttctaatgca taaattctct tagaacagta ctattaaccc 360
atgctgtatc actatttacg ataaagcgta gcaatgtatt tcagtcaacc tttctaccta 420
aactgtctac attgaattat ccacgttttt acaatttatt gtcgtaagat agccttctat 480
cctatggtca atataatatg tttttagtga ccaacctatt ttgtctaaga cgttataagc 540
attttctact tctaatgacg cttaaacatt tgatactgtt atttttcggt aaatagagtt 600
gctgtagcac attaagaagg tacaaaatac atacacaaag tctataatac tctaatgata 660
tttgaaaaac atatgaatat aaggcatttg atataattag tacttctttt actttttcat 720
atcttcgaca agtgctcgcc aacaactttt gttgttttaa tatgtaagtt ctaccgaatg 780
tatatgcaga cactccgata gtacctatta ctgttacgta gagatttatc caaaaacctg 840
ttacctaagc tgggattgtg ccttatacca tgagatgtta gaggagaact ttaccgacat 900
tacaagttct tatggctccg atatttttag aactactcca tacctcgatt tggacatcaa 960
tgacttacgt gttgaagaac agacgtacta cgccacaact ctctgctgat gttttatcac 1020
tttctagaca acttcttatt gatacatttg ttacaagaaa tgtcgcctcc gaaatgagga 1080
aacacaaacc gtcgaatgga attgtttcaa ttaaaccaat ttgaagataa ccgagtaagc 1140
cgcctacatc tataaagttt gtgcctagcc aattgaggag atgtatatcg gcatagttta 1200
tttttaaatt gttaccaatt tgaagataac ttgtttccac gactatgact gaacgaccta 1260
ttgtacccta catgaggaaa ttactagcga catgttagac ctttataact ttatacatcg 1320
tgtgatgaat tttttttatt ttacaggtct tgaccctttt taactagaac ggtcgacatt 1380
aagtaccatc ttttcttcac gagtccgatg aaaagttgtt tcctcgtcta catttgatgt 1440
agaaactttc tttacctttt agtatatgac aaaaccttaa ctaatttctt tcaatgagac 1500
tctgtgtttt ctccatcgac ttcaccatga gagtttccat gcactgatta atcgatattt 1560
ttcctagccc aagaaataag atatgaattt ttcactttta tttatgtttc caagaactcc 1620
caacacaatt taactttcgc tctttattag tatttaataa agtaatagcg ctataggcaa 1680
ttcaaacata gcattagacg tcgggggtgg tacctagacc acgatttttc tacggaagaa 1740
gtaaaccgac actatccacg aaacgaccga cacccccgat gttttcatgg gtctttggtc 1800
ctgaccgaac cacagagttc cgttgagtct tggtttcgga ccttgtccgt cgacataggt 1860
ctcacctgtc ttcgggtctc tgaactgacg acctctccac cagttcacag ggagttccag 1920
tcattactac ccggatgtga ctaaccacgt ttacggagga agagataacg gaacttgaag 1980
ggaccttcgg ttttccataa cggtctatga tcaagatctc ctagtaataa attgcatttg 2040
atttaccttt tcgataaatg tccatgtatg ccacaaaaag accttagttt actaagacta 2100
aaactcctaa aatagttatg ttattactgt cacgattgac cattttttct ttcgtttgtt 2160
aatagtaccg attgttaaaa ataatataaa catcatacgt atcaccagaa atgcaaagaa 2220
ataaatttca attacacaat tctaatttac ctcattaacc tagggggtag ctacccctta 2280
agtgaccggc agcaaaatgt tgcagcactg acccttttgg gaccgcaatg ggttgaatta 2340
gcggaacgtc gtgtaggggg aaagcggtcg accgcattat cgcttctccg ggcgtggcta 2400
gcgggaaggg ttgtcaacgc gtcggactta ccgcttaccg cgaaacggac caaaggccgt 2460
ggtcttcgcc acggcctttc gaccgacctc acgctagaag gactccggct atgacagcag 2520
caggggagtt tgaccgtcta cgtgccaatg ctacgcgggt agatgtggtt gcactggata 2580
gggtaatgcc agttaggcgg caaacaaggg tgcctcttag gctgcccaac aatgagcgag 2640
tgtaaattac aactactttc gaccgatgtc cttccggtct gcgcttaata aaaactaccg 2700
caattgagcc gcaaagtaga caccacgttg cccgcgaccc agccaatgcc ggtcctgtca 2760
gcaaacggca gacttaaact ggactcgcgt aaaaatgcgc ggcctctttt ggcggagcgc 2820
cactaccacg acgcgacctc actgccgtca atagaccttc tagtcctata caccgcctac 2880
tcgccgtaaa aggcactgca gagcaacgac gtatttggct gatgtgttta gtcgctaaag 2940
gtacaacggt gagcgaaatt actactaaag tcggcgcgac atgacctccg acttcaagtc 3000
tacacgccgc tcaacgcact gatggatgcc cattgtcaaa gaaataccgt cccactttgc 3060
gtccagcggt cgccgtggcg cggaaagccg ccactttaat agctactcgc accaccaata 3120
cggctagcgc agtgtgatgc agacttgcag cttttgggct ttgacacctc gcggctttag 3180
ggcttagaga tagcacgcca ccaacttgac gtgtggcggc tgccgtgcga ctaacttcgt 3240
cttcggacgc tacagccaaa ggcgctccac gcctaacttt taccagacga cgacgacttg 3300
ccgttcggca acgactaagc tccgcaattg gcagtgctcg tagtaggaga cgtaccagtc 3360
cagtacctac tcgtctgcta ccacgtccta taggacgact acttcgtctt gttgaaattg 3420
cggcacgcga caagcgtaat aggcttggta ggcgacacca tgtgcgacac gctggcgatg 3480
ccggacatac accacctact tcggttataa ctttgggtgc cgtaccacgg ttacttagca 3540
gactggctac taggcgcgac cgatggccgc tactcgcttg cgcattgcgc ttaccacgtc 3600
gcgctagcat tagtgggctc acactagtag accagcgacc ccttacttag tccggtgccg 3660
cgattagtgc tgcgcgacat agcgacctag tttagacagc taggaagggc gggccacgtc 3720
atacttccgc cgcctcggct gtggtgccgg tggctataat aaacgggcta catgcgcgcg 3780
cacctacttc tggtcgggaa gggccgacac ggctttacca ggtagttttt taccgaaagc 3840
gatggacctc tctgcgcggg cgactaggaa acgcttatgc gggtgcgcta cccattgtca 3900
gaaccgccaa agcgatttat gaccgtccgc aaagcagtca taggggcaaa tgtcccgccg 3960
aagcagaccc tgacccacct agtcagcgac taatttatac tacttttgcc gttgggcacc 4020
agccgaatgc cgccactaaa accgctatgc ggcttgctag cggtcaagac atacttgcca 4080
gaccagaaac ggctggcgtg cggcgtaggt cgcgactgcc ttcgttttgt ggtcgtcgtc 4140
aaaaaggtca aggcaaatag gcccgtttgg tagcttcact ggtcgcttat ggacaaggca 4200
gtatcgctat tgctcgagga cgtgacctac caccgcgacc taccattcgg cgaccgttcg 4260
ccacttcacg gagacctaca gcgaggtgtt ccatttgtca actaacttga cggacttgat 4320
ggcgtcggcc tctcgcggcc cgttgagacc gagtgtcatg cgcatcacgt tggcttgcgc 4380
tggcgtacca gtcttcggcc cgtgtagtcg cggaccgtcg tcaccgcaga ccgccttttg 4440
gagtcacact gcgaggggcg gcgcagggtg cggtagggcg tagactggtg gtcgctttac 4500
ctaaaaacgt agctcgaccc attattcgca accgttaaat tggcggtcag tccgaaagaa 4560
agtgtctaca cctaaccgct attttttgtt gacgactgcg gcgacgcgct agtcaagtgg 4620
gcacgtggcg acctattgct gtaaccgcat tcacttcgct gggcgtaact gggattgcgg 4680
acccagcttg cgaccttccg ccgcccggta atggtccggc ttcgtcgcaa caacgtcacg 4740
tgccgtctat gtgaacgact acgccacgac taatgctggc gagtgcgcac cgtcgtagtc 4800
cccttttgga ataaatagtc ggccttttgg atggcctaac taccatcacc agtttaccgc 4860
taatggcaac tacaacttca ccgctcgcta tgtggcgtag gccgcgccta accggacttg 4920
acggtcgacc gcgtccatcg tctcgcccat ttgaccgagc ctaatcccgg cgttcttttg 4980
atagggctgg cggaatgacg gcggacaaaa ctggcgaccc tagacggtaa cagtctgtac 5040
atatggggca tgcagaaggg ctcgcttttg ccagacgcga cgccctgcgc gcttaactta 5100
ataccgggtg tggtcaccgc gccgctgaag gtcaagttgt agtcggccat gtcagttgtc 5160
gttaactacc tttggtcggt aagcggtaga cgacgtgcgc cttctccgtg taccgactta 5220
tagctgccaa aggtataccc ctaaccaccg ctgctgagga cctcgggcag tcatagccgc 5280
cttaaggtcg actcgcggcc agcgatggta atggtcaacc agaccacagt ttttattatt 5340
attggcccgt cccccctagg cctcgaatag cgtctagtta agctatagtt cgaatagcta 5400
tggcagctgg agctcagatc ttagctaggg cccaagaaat aagatatgaa tttttcactt 5460
ttatttatgt ttccaagaac tcccaacaca atttaacttt cgctctttat tagtatttaa 5520
taaagtaata gcgctatagg caattcaaac atagcattag acgtcggggg tggtacctag 5580
accacgattt ttctacggaa gaagtaaacc gacactatcc acgaaacgac cgacaccccc 5640
gatgttttca tgggtctttg gtcctgaccg aaccacagag ttccgttgag tcttggtttc 5700
ggaccttgtc cgtcgacata ggtctcacct gtcttcgggt ctctgaactg acgacctctc 5760
caccagttca cagggagttc cagtcattac tacccggatg tgactaacca cgtttacgga 5820
ggaagagata acggaacttg aagggacctt cggttttcca taacggtcta cccgtccaat 5880
agacccagtt gttatggtag tagttaccct cggtccacac ccctcctgtc ggtcacatag 5940
gggtcctttg actgctacgg acgtagaagg gactaccacc tggaacgggt agaccgagaa 6000
ccagagtctt ctcttcgaaa caaatacaga ccttctggac cccggttatg accgttcaag 6060
atcccccggg tcacagaccc gactcgtaac cctgtccgtc ccgttacgac ccgtgtgtgt 6120
gctaccttca ctgacagatg gtagcggccc ctagggcctc gatacacgga gaacgagtaa 6180
ggtcgagtcg gaagtggtaa tacctggtcc acggaaagag gcactcgcac agggtcaacg 6240
cccggaacct acctcccttg ttcgtgaagg actctttagt cggagactgg aaacgggagg 6300
tcgaggtact ggggtcaccg atagaccgac ttcgactgga gaggatgtgg accctgaaac 6360
ctctgtcatc accttgggac tagagagccc gtgaacacca gtgagtatga atggacctcg 6420
gaccgggtca gtgacaagtc caccaggacg tccgacggta aggagagtgg aggacaccga 6480
ggaggggtca aggtccgtgg tgtctacccg tgtccggttg acgtctccgg ggattgtggt 6540
gtcgaccggt tcacggatga tgtcttcaac acccatgatg tggaccagtc cgcggttgac 6600
gtctcgggag accttggtgt agacacgtcc acggttggtg acttcagtat tcgtgacgtg 6660
gacacgtcta cggttgacgt ctctcgtgtc catactgtgg actcttccac ggtcaaagtc 6720
tccagtaccc atggtgtgac cgtctctaca gttgaggtct ccgatgtcca tactgtggac 6780
gtctccatag ttaacaccac gaaagacctt ggtgtcgacg tgtccattgt tgatgtctca 6840
cccacctctg gtgtcgatct ctcgatggat agggactcgg acttccaggt ctacggtcga 6900
gttagtacag atgcctttca taatgtccaa gggacccggg ggacgaccta ccatgtcggt 6960
ggaattccga ccacttctct gttcaggggg acctaacaca agacatagct ataccaagga 7020
aaaggcagtg ggacctgtaa caggtcccat aactttcacg gctctaggac gtccgacacg 7080
gcaggccact ccccctacgt aaactcgact gacacaggac ggttccgccc gacgggttcc 7140
ttcggacgta cctctagagt agcggtccca cggtcggggg acgggtcgcc gacacggtcg 7200
gacacgatgg gtcgggtcgg acggtcgacc aagacgtggt ctatgacttc ccaccgagcc 7260
cctgtatgac ggagttacac agagaccgac tatggttgtc ggaccgtcac cagtcgtggg 7320
tcgaatagta cggaccagtt cttcgtccgg aacccgtcca aggcgactag cacccgtaga 7380
acgaccacaa ctaccgacac caggaacgta gagactatat atccgcgtct gaatacttcg 7440
ttctgaagag gcatggggtc aacggtgtat cgtcgtcagt gaccgacgca gatggggcgt 7500
agaagacgag aacagggtaa ccactcttgt cgggggagga gtcacccgtc gtccagacta 7560
aaaataagat caagtttttt tatatttact aagtggtaga ctatcttttt tttaaataac 7620
cctcttatac tattataaaa ccctaaagtt ttaactttta tatattaatg ttatatttag 7680
atctggtggt acggttctct tctacgagtg aagtagatac caatggggtt cttccccgtg 7740
ccggtgagaa tgtggtgccg acttctccgg cgaccctagc cgtaggactg tcactaggac 7800
cctcagaatg acgagtagcc gacaaccata acatcttctg ctttacctat gtctcggaac 7860
tacctatttt cagaagtaca accgtgagtt acacggaatt gttcttctac gggtgttctt 7920
cccaaactag tagccctgtc gtttcacaga gaagttctct ttttgacact tggacaccaa 7980
gggttacgag gtggacgaat actctttgag agacgtcttg tcagtggtgg tggaataagt 8040
ggaattagat ctcagctgga cgtccgtacg tttttaactt taaaataaaa aaaaaaaacc 8100
ttatatttat tacctcagga acgtcgacca gaaaccgtaa ctgcacttcc ttcgtctggg 8160
gtggccggtg aggatacagg aacagtggac ggatccagag aggatactac cgttattcgc 8220
atttcttcac ctggggtagc cggtgaacat gatcaaaaat agggcccaaa aatactgatc 8280
aattagtgcc ggcgaatatt tctagatttt acgtattaaa gatttattac ttttttttca 8340
tgtagtactc gttgcgcaat catataaaat gttacctcta attgcgagat atggcaagat 8400
acaaataact aagtctacta caaaatcttt tctttcaata acttatactt ttgaaattac 8460
ttctacttct actgctgcta ctaataacaa catttagaca aaatctactt cttctactgc 8520
gcgatttcat atgataccaa tgtttcatat tcagatatga tgattaccgc tgaacacgtt 8580
cttccatatc atatcacttt tacaacaatc taatactaat actttttggt ttatttagtc 8640
taggtataga tttccataga ggaaacgtgt attaaagtag ataaggatca aatcttatga 8700
aaagtaatat aaacaaatgt cgacttctgc tttttttata tagctattat cttctaatac 8760
aattgagacg attattctac tttaacttac tcagacactg acgtcggttc gaaccgtgac 8820
cggcagcaaa atgttgcagc actgaccctt ttgggaccgc aatgggttga attagcggaa 8880
cgtcgtgtag ggggaaagcg gtcgaccgca ttatcgcttc tccgggcgtg gctagcggga 8940
agggttgtca acgcgtcgga cttaccgctt accgcggact acgccataaa agaggaatgc 9000
gtagacacgc cataaagtgt ggcgtatacc acgtgagagt catgttagac gagactacgg 9060
cgtatcaatt cggtcggggc tgtgggcggt tgtgggcgac tgcgcgggac tgcccgaaca 9120
gacgagggcc gtaggcgaat gtctgttcga cactggcaga ggccctcgac gtacacagtc 9180
tccaaaagtg gcagtagtgg ctttgcgcgc tctgctttcc cggagcacta tgcggataaa 9240
aatatccaat tacagtacta ttattaccaa agaatctgca gtccaccgtg aaaagcccct 9300
ttacacgcgc cttggggata aacaaataaa aagatttatg taagtttata cataggcgag 9360
tactctgtta ttgggactat ttacgaagtt attataactt tttccttctc atactcataa 9420
gttgtaaagg cacagcggga ataagggaaa aaacgccgta aaacggaagg acaaaaacga 9480
gtgggtcttt gcgaccactt tcattttcta cgacttctag tcaacccacg tgctcaccca 9540
atgtagcttg acctagagtt gtcgccattc taggaactct caaaagcggg gcttcttgca 9600
aaaggttact actcgtgaaa atttcaagac gatacaccgc gccataatag ggcataactg 9660
cggcccgttc tcgttgagcc agcggcgtat gtgataagag tcttactgaa ccaactcatg 9720
agtggtcagt gtcttttcgt agaatgccta ccgtactgtc attctcttaa tacgtcacga 9780
cggtattggt actcactatt gtgacgccgg ttgaatgaag actgttgcta gcctcctggc 9840
ttcctcgatt ggcgaaaaaa cgtgttgtac cccctagtac attgagcgga actagcaacc 9900
cttggcctcg acttacttcg gtatggtttg ctgctcgcac tgtggtgcta cggacatcgt 9960
taccgttgtt gcaacgcgtt tgataattga ccgcttgatg aatgagatcg aagggccgtt 10020
gttaattatc tgacctacct ccgcctattt caacgtcctg gtgaagacgc gagccgggaa 10080
ggccgaccga ccaaataacg actatttaga cctcggccac tcgcacccag agcgccatag 10140
taacgtcgtg accccggtct accattcggg agggcatagc atcaatagat gtgctgcccc 10200
tcagtccgtt gatacctact tgctttatct gtctagcgac tctatccacg gagtgactaa 10260
ttcgtaacca ttgacagtct ggttcaaatg agtatatatg aaatctaact aaattttgaa 10320
gtaaaaatta aattttccta gatccacttc taggaaaaac tattagagta ctggttttag 10380
ggaattgcac tcaaaagcaa ggtgactcgc agtctggggc atcttttcta gtttcctaga 10440
agaactctag gaaaaaaaga cgcgcattag acgacgaacg tttgtttttt tggtggcgat 10500
ggtcgccacc aaacaaacgg cctagttctc gatggttgag aaaaaggctt ccattgaccg 10560
aagtcgtctc gcgtctatgg tttatgacag gaagatcaca tcggcatcaa tccggtggtg 10620
aagttcttga gacatcgtgg cggatgtatg gagcgagacg attaggacaa tggtcaccga 10680
cgacggtcac cgctattcag cacagaatgg cccaacctga gttctgctat caatggccta 10740
ttccgcgtcg ccagcccgac ttgcccccca agcacgtgtg tcgggtcgaa cctcgcttgc 10800
tggatgtggc ttgactctat ggatgtcgca ctcgatactc tttcgcggtg cgaagggctt 10860
ccctctttcc gcctgtccat aggccattcg ccgtcccagc cttgtcctct cgcgtgctcc 10920
ctcgaaggtc cccctttgcg gaccatagaa atatcaggac agcccaaagc ggtggagact 10980
gaactcgcag ctaaaaacac tacgagcagt ccccccgcct cggatacctt tttgcggtcg 11040
ttgcgccgga aaaatgccaa ggaccggaaa acgaccggaa aacgagtgta caagaaagga 11100
cgcaataggg gactaagaca cctattggca taatggcgga aactcactcg actatggcga 11160
gcggcgtcgg cttgctggct cgcgtcgctc agtcactcgc tccttcgcct tctcgcgggt 11220
tatgcgtttg gcggagaggg gcgcgcaacc ggctaagtaa ttacgtcgac cgtgctgtcc 11280
aaagggctga cctttcgccc gtcactcgcg ttgcgttaat tacactcaat cgagtgagta 11340
atccgtgggg tccgaaatgt gaaatacgaa ggccgagcat acaacacacc ttaacactcg 11400
cctattgtta aagtgtgtcc tttgtcgata ctggtactaa tgcttaactt 11450
<210> 7
<211> 180
<212> PRT
<213> Homo sapiens
<400> 7
Met Gln Ala Glu Gly Arg Gly Thr Gly Gly Ser Thr Gly Asp Ala Asp
1 5 10 15
Gly Pro Gly Gly Pro Gly Ile Pro Asp Gly Pro Gly Gly Asn Ala Gly
20 25 30
Gly Pro Gly Glu Ala Gly Ala Thr Gly Gly Arg Gly Pro Arg Gly Ala
35 40 45
Gly Ala Ala Arg Ala Ser Gly Pro Gly Gly Gly Ala Pro Arg Gly Pro
50 55 60
His Gly Gly Ala Ala Ser Gly Leu Asn Gly Cys Cys Arg Cys Gly Ala
65 70 75 80
Arg Gly Pro Glu Ser Arg Leu Leu Glu Phe Tyr Leu Ala Met Pro Phe
85 90 95
Ala Thr Pro Met Glu Ala Glu Leu Ala Arg Arg Ser Leu Ala Gln Asp
100 105 110
Ala Pro Pro Leu Pro Val Pro Gly Val Leu Leu Lys Glu Phe Thr Val
115 120 125
Ser Gly Asn Ile Leu Thr Ile Arg Leu Thr Ala Ala Asp His Arg Gln
130 135 140
Leu Gln Leu Ser Ile Ser Ser Cys Leu Gln Gln Leu Ser Leu Leu Met
145 150 155 160
Trp Ile Thr Gln Val Phe Leu Pro Val Phe Leu Ala Gln Pro Pro Ser
165 170 175
Gly Gln Arg Arg
180
<210> 8
<211> 552
<212> PRT
<213> Homo sapiens
<400> 8
Met Ser Pro Leu Trp Trp Gly Phe Leu Leu Ser Cys Leu Gly Cys Lys
1 5 10 15
Ile Leu Pro Gly Ala Gln Gly Gln Phe Pro Arg Val Cys Met Thr Val
20 25 30
Asp Ser Leu Val Asn Lys Glu Cys Cys Pro Arg Leu Gly Ala Glu Ser
35 40 45
Ala Asn Val Cys Gly Ser Gln Gln Gly Arg Gly Gln Cys Thr Glu Val
50 55 60
Arg Ala Asp Thr Arg Pro Trp Ser Gly Pro Tyr Ile Leu Arg Asn Gln
65 70 75 80
Asp Asp Arg Glu Leu Trp Pro Arg Lys Phe Phe His Arg Thr Cys Lys
85 90 95
Cys Thr Gly Asn Phe Ala Gly Tyr Asn Cys Gly Asp Cys Lys Phe Gly
100 105 110
Trp Thr Gly Pro Asn Cys Glu Arg Lys Lys Pro Pro Val Ile Arg Gln
115 120 125
Asn Ile His Ser Leu Ser Pro Gln Glu Arg Glu Gln Phe Leu Gly Ala
130 135 140
Leu Asp Leu Ala Lys Lys Arg Val His Pro Asp Tyr Val Ile Thr Thr
145 150 155 160
Gln His Trp Leu Gly Leu Leu Gly Pro Asn Gly Thr Gln Pro Gln Phe
165 170 175
Ala Asn Cys Ser Val Tyr Asp Phe Phe Val Trp Leu His Tyr Tyr Ser
180 185 190
Val Arg Asp Thr Leu Leu Gly Pro Gly Arg Pro Tyr Arg Ala Ile Asp
195 200 205
Phe Ser His Gln Gly Pro Ala Phe Val Thr Trp His Arg Tyr His Leu
210 215 220
Leu Cys Leu Glu Arg Asp Leu Gln Arg Leu Ile Gly Asn Glu Ser Phe
225 230 235 240
Ala Leu Pro Tyr Trp Asn Phe Ala Thr Gly Arg Asn Glu Cys Asp Val
245 250 255
Cys Thr Asp Gln Leu Phe Gly Ala Ala Arg Pro Asp Asp Pro Thr Leu
260 265 270
Ile Ser Arg Asn Ser Arg Phe Ser Ser Trp Glu Thr Val Cys Asp Ser
275 280 285
Leu Asp Asp Tyr Asn His Leu Val Thr Leu Cys Asn Gly Thr Tyr Glu
290 295 300
Gly Leu Leu Arg Arg Asn Gln Met Gly Arg Asn Ser Met Lys Leu Pro
305 310 315 320
Thr Leu Lys Asp Ile Arg Asp Cys Leu Ser Leu Gln Lys Phe Asp Asn
325 330 335
Pro Pro Phe Phe Gln Asn Ser Thr Phe Ser Phe Arg Asn Ala Leu Glu
340 345 350
Gly Phe Asp Lys Ala Asp Gly Thr Leu Asp Ser Gln Val Met Ser Leu
355 360 365
His Asn Leu Val His Ser Phe Leu Asn Gly Thr Asn Ala Leu Pro His
370 375 380
Ser Ala Ala Asn Asp Pro Ile Phe Val Val Ile Ser Asn Arg Leu Leu
385 390 395 400
Tyr Asn Ala Thr Thr Asn Ile Leu Glu His Val Arg Lys Glu Lys Ala
405 410 415
Thr Lys Glu Leu Pro Ser Leu His Val Leu Val Leu His Ser Phe Thr
420 425 430
Asp Ala Ile Phe Asp Glu Trp Met Lys Arg Phe Asn Pro Pro Ala Asp
435 440 445
Ala Trp Pro Gln Glu Leu Ala Pro Ile Gly His Asn Arg Met Tyr Asn
450 455 460
Met Val Pro Phe Phe Pro Pro Val Thr Asn Glu Glu Leu Phe Leu Thr
465 470 475 480
Ser Asp Gln Leu Gly Tyr Ser Tyr Ala Ile Asp Leu Pro Val Ser Val
485 490 495
Glu Glu Thr Pro Gly Trp Pro Thr Thr Leu Leu Val Val Met Gly Thr
500 505 510
Leu Val Ala Leu Val Gly Leu Phe Val Leu Leu Ala Phe Leu Gln Tyr
515 520 525
Arg Arg Leu Arg Lys Gly Tyr Thr Pro Leu Met Glu Thr His Leu Ser
530 535 540
Ser Lys Arg Tyr Thr Glu Glu Ala
545 550
<210> 9
<211> 661
<212> PRT
<213> Homo sapiens
<400> 9
Met Asp Leu Val Leu Lys Arg Cys Leu Leu His Leu Ala Val Ile Gly
1 5 10 15
Ala Leu Leu Ala Val Gly Ala Thr Lys Val Pro Arg Asn Gln Asp Trp
20 25 30
Leu Gly Val Ser Arg Gln Leu Arg Thr Lys Ala Trp Asn Arg Gln Leu
35 40 45
Tyr Pro Glu Trp Thr Glu Ala Gln Arg Leu Asp Cys Trp Arg Gly Gly
50 55 60
Gln Val Ser Leu Lys Val Ser Asn Asp Gly Pro Thr Leu Ile Gly Ala
65 70 75 80
Asn Ala Ser Phe Ser Ile Ala Leu Asn Phe Pro Gly Ser Gln Lys Val
85 90 95
Leu Pro Asp Gly Gln Val Ile Trp Val Asn Asn Thr Ile Ile Asn Gly
100 105 110
Ser Gln Val Trp Gly Gly Gln Pro Val Tyr Pro Gln Glu Thr Asp Asp
115 120 125
Ala Cys Ile Phe Pro Asp Gly Gly Pro Cys Pro Ser Gly Ser Trp Ser
130 135 140
Gln Lys Arg Ser Phe Val Tyr Val Trp Lys Thr Trp Gly Gln Tyr Trp
145 150 155 160
Gln Phe Leu Gly Gly Pro Val Ser Gly Leu Ser Ile Gly Thr Gly Arg
165 170 175
Ala Met Leu Gly Thr His Thr Met Glu Val Thr Val Tyr His Arg Arg
180 185 190
Gly Ser Arg Ser Tyr Val Pro Leu Ala His Ser Ser Ser Ala Phe Thr
195 200 205
Ile Thr Asp Gln Val Pro Phe Ser Val Ser Val Ser Gln Leu Arg Ala
210 215 220
Leu Asp Gly Gly Asn Lys His Phe Leu Arg Asn Gln Pro Leu Thr Phe
225 230 235 240
Ala Leu Gln Leu His Asp Pro Ser Gly Tyr Leu Ala Glu Ala Asp Leu
245 250 255
Ser Tyr Thr Trp Asp Phe Gly Asp Ser Ser Gly Thr Leu Ile Ser Arg
260 265 270
Ala Leu Val Val Thr His Thr Tyr Leu Glu Pro Gly Pro Val Thr Ala
275 280 285
Gln Val Val Leu Gln Ala Ala Ile Pro Leu Thr Ser Cys Gly Ser Ser
290 295 300
Pro Val Pro Gly Thr Thr Asp Gly His Arg Pro Thr Ala Glu Ala Pro
305 310 315 320
Asn Thr Thr Ala Gly Gln Val Pro Thr Thr Glu Val Val Gly Thr Thr
325 330 335
Pro Gly Gln Ala Pro Thr Ala Glu Pro Ser Gly Thr Thr Ser Val Gln
340 345 350
Val Pro Thr Thr Glu Val Ile Ser Thr Ala Pro Val Gln Met Pro Thr
355 360 365
Ala Glu Ser Thr Gly Met Thr Pro Glu Lys Val Pro Val Ser Glu Val
370 375 380
Met Gly Thr Thr Leu Ala Glu Met Ser Thr Pro Glu Ala Thr Gly Met
385 390 395 400
Thr Pro Ala Glu Val Ser Ile Val Val Leu Ser Gly Thr Thr Ala Ala
405 410 415
Gln Val Thr Thr Thr Glu Trp Val Glu Thr Thr Ala Arg Glu Leu Pro
420 425 430
Ile Pro Glu Pro Glu Gly Pro Asp Ala Ser Ser Ile Met Ser Thr Glu
435 440 445
Ser Ile Thr Gly Ser Leu Gly Pro Leu Leu Asp Gly Thr Ala Thr Leu
450 455 460
Arg Leu Val Lys Arg Gln Val Pro Leu Asp Cys Val Leu Tyr Arg Tyr
465 470 475 480
Gly Ser Phe Ser Val Thr Leu Asp Ile Val Gln Gly Ile Glu Ser Ala
485 490 495
Glu Ile Leu Gln Ala Val Pro Ser Gly Glu Gly Asp Ala Phe Glu Leu
500 505 510
Thr Val Ser Cys Gln Gly Gly Leu Pro Lys Glu Ala Cys Met Glu Ile
515 520 525
Ser Ser Pro Gly Cys Gln Pro Pro Ala Gln Arg Leu Cys Gln Pro Val
530 535 540
Leu Pro Ser Pro Ala Cys Gln Leu Val Leu His Gln Ile Leu Lys Gly
545 550 555 560
Gly Ser Gly Thr Tyr Cys Leu Asn Val Ser Leu Ala Asp Thr Asn Ser
565 570 575
Leu Ala Val Val Ser Thr Gln Leu Ile Met Pro Gly Gln Glu Ala Gly
580 585 590
Leu Gly Gln Val Pro Leu Ile Val Gly Ile Leu Leu Val Leu Met Ala
595 600 605
Val Val Leu Ala Ser Leu Ile Tyr Arg Arg Arg Leu Met Lys Gln Asp
610 615 620
Phe Ser Val Pro Gln Leu Pro His Ser Ser Ser His Trp Leu Arg Leu
625 630 635 640
Pro Arg Ile Phe Cys Ser Cys Pro Ile Gly Glu Asn Ser Pro Leu Leu
645 650 655
Ser Gly Gln Gln Val
660
<210> 10
<211> 661
<212> PRT
<213> Synthetic
<223> Homo sapiens
<400> 10
Met Asp Leu Val Leu Lys Arg Cys Leu Leu His Leu Ala Val Ile Gly
1 5 10 15
Ala Leu Leu Ala Val Gly Ala Thr Lys Val Pro Arg Asn Gln Asp Trp
20 25 30
Leu Gly Val Ser Arg Gln Leu Arg Thr Lys Ala Trp Asn Arg Gln Leu
35 40 45
Tyr Pro Glu Trp Thr Glu Ala Gln Arg Leu Asp Cys Trp Arg Gly Gly
50 55 60
Gln Val Ser Leu Lys Val Ser Asn Asp Gly Pro Thr Leu Ile Gly Ala
65 70 75 80
Asn Ala Ser Phe Ser Ile Ala Leu Asn Phe Pro Gly Ser Gln Lys Val
85 90 95
Leu Pro Asp Gly Gln Val Ile Trp Val Asn Asn Thr Ile Ile Asn Gly
100 105 110
Ser Gln Val Trp Gly Gly Gln Pro Val Tyr Pro Gln Glu Thr Asp Asp
115 120 125
Ala Cys Ile Phe Pro Asp Gly Gly Pro Cys Pro Ser Gly Ser Trp Ser
130 135 140
Gln Lys Arg Ser Phe Val Tyr Val Trp Lys Thr Trp Gly Gln Tyr Trp
145 150 155 160
Gln Val Leu Gly Gly Pro Val Ser Gly Leu Ser Ile Gly Thr Gly Arg
165 170 175
Ala Met Leu Gly Thr His Thr Met Glu Val Thr Val Tyr His Arg Arg
180 185 190
Gly Ser Arg Ser Tyr Val Pro Leu Ala His Ser Ser Ser Ala Phe Thr
195 200 205
Ile Met Asp Gln Val Pro Phe Ser Val Ser Val Ser Gln Leu Arg Ala
210 215 220
Leu Asp Gly Gly Asn Lys His Phe Leu Arg Asn Gln Pro Leu Thr Phe
225 230 235 240
Ala Leu Gln Leu His Asp Pro Ser Gly Tyr Leu Ala Glu Ala Asp Leu
245 250 255
Ser Tyr Thr Trp Asp Phe Gly Asp Ser Ser Gly Thr Leu Ile Ser Arg
260 265 270
Ala Leu Val Val Thr His Thr Tyr Leu Glu Pro Gly Pro Val Thr Val
275 280 285
Gln Val Val Leu Gln Ala Ala Ile Pro Leu Thr Ser Cys Gly Ser Ser
290 295 300
Pro Val Pro Gly Thr Thr Asp Gly His Arg Pro Thr Ala Glu Ala Pro
305 310 315 320
Asn Thr Thr Ala Gly Gln Val Pro Thr Thr Glu Val Val Gly Thr Thr
325 330 335
Pro Gly Gln Ala Pro Thr Ala Glu Pro Ser Gly Thr Thr Ser Val Gln
340 345 350
Val Pro Thr Thr Glu Val Ile Ser Thr Ala Pro Val Gln Met Pro Thr
355 360 365
Ala Glu Ser Thr Gly Met Thr Pro Glu Lys Val Pro Val Ser Glu Val
370 375 380
Met Gly Thr Thr Leu Ala Glu Met Ser Thr Pro Glu Ala Thr Gly Met
385 390 395 400
Thr Pro Ala Glu Val Ser Ile Val Val Leu Ser Gly Thr Thr Ala Ala
405 410 415
Gln Val Thr Thr Thr Glu Trp Val Glu Thr Thr Ala Arg Glu Leu Pro
420 425 430
Ile Pro Glu Pro Glu Gly Pro Asp Ala Ser Ser Ile Met Ser Thr Glu
435 440 445
Ser Ile Thr Gly Ser Leu Gly Pro Leu Leu Asp Gly Thr Ala Thr Leu
450 455 460
Arg Leu Val Lys Arg Gln Val Pro Leu Asp Cys Val Leu Tyr Arg Tyr
465 470 475 480
Gly Ser Phe Ser Val Thr Leu Asp Ile Val Gln Gly Ile Glu Ser Ala
485 490 495
Glu Ile Leu Gln Ala Val Pro Ser Gly Glu Gly Asp Ala Phe Glu Leu
500 505 510
Thr Val Ser Cys Gln Gly Gly Leu Pro Lys Glu Ala Cys Met Glu Ile
515 520 525
Ser Ser Pro Gly Cys Gln Pro Pro Ala Gln Arg Leu Cys Gln Pro Val
530 535 540
Leu Pro Ser Pro Ala Cys Gln Leu Val Leu His Gln Ile Leu Lys Gly
545 550 555 560
Gly Ser Gly Thr Tyr Cys Leu Asn Val Ser Leu Ala Asp Thr Asn Ser
565 570 575
Leu Ala Val Val Ser Thr Gln Leu Ile Met Pro Gly Gln Glu Ala Gly
580 585 590
Leu Gly Gln Val Pro Leu Ile Val Gly Ile Leu Leu Val Leu Met Ala
595 600 605
Val Val Leu Ala Ser Leu Ile Tyr Arg Arg Arg Leu Met Lys Gln Asp
610 615 620
Phe Ser Val Pro Gln Leu Pro His Ser Ser Ser His Trp Leu Arg Leu
625 630 635 640
Pro Arg Ile Phe Cys Ser Cys Pro Ile Gly Glu Asn Ser Pro Leu Leu
645 650 655
Ser Gly Gln Gln Val
660
<210> 11
<211> 118
<212> PRT
<213> Homo sapiens
<400> 11
Met Pro Arg Glu Asp Ala His Phe Ile Tyr Gly Tyr Pro Lys Lys Gly
1 5 10 15
His Gly His Ser Tyr Thr Thr Ala Glu Glu Ala Ala Gly Ile Gly Ile
20 25 30
Leu Thr Val Ile Leu Gly Val Leu Leu Leu Ile Gly Cys Trp Tyr Cys
35 40 45
Arg Arg Arg Asn Gly Tyr Arg Ala Leu Met Asp Lys Ser Leu His Val
50 55 60
Gly Thr Gln Cys Ala Leu Thr Arg Arg Cys Pro Gln Glu Gly Phe Asp
65 70 75 80
His Arg Asp Ser Lys Val Ser Leu Gln Glu Lys Asn Cys Glu Pro Val
85 90 95
Val Pro Asn Ala Pro Pro Ala Tyr Glu Lys Leu Ser Ala Glu Gln Ser
100 105 110
Pro Pro Pro Tyr Ser Pro
115
<210> 12
<211> 208
<212> PRT
<213> Homo sapiens
<400> 12
Met Ser Asp Asn Lys Lys Pro Asp Leu Ala His Ser Gly Ser Gly Gly
1 5 10 15
Asp Gly Asp Gly Asn Arg Cys Asn Leu Leu His Arg Tyr Ser Leu Gln
20 25 30
Gly Ile Leu Pro Tyr Leu Gly Trp Leu Val Phe Ala Val Val Thr Thr
35 40 45
Ser Phe Leu Ala Leu Glu Met Phe Ile Asp Ala Leu Tyr Gln Gln Glu
50 55 60
Tyr Gln Arg Asp Val Ala Trp Ile Ala Arg Gln Ser Lys Arg Met Ser
65 70 75 80
Ser Val Asp Gln Asp Gln Asp Asp Gln Asp Asp Gln Asp Asp Tyr Tyr
85 90 95
Gln Gln Gln Gln Leu Gln Asn Leu Met Asp Asp Gln Ser Gln Asp Gln
100 105 110
Ala Gln Gln Gln Met Ser Val Gln Met Gly Ala Gly Ala Gln Gln Met
115 120 125
Gly Ala Gly Ala Asn Cys Ala Cys Val Pro Gly His His Leu Arg Lys
130 135 140
Asn Gln Val Lys Cys Arg Met Ile Tyr Phe Phe His Asp Pro Asn Phe
145 150 155 160
Leu Val Ser Ile Pro Val Asn Pro Lys Gln Glu Met Gln Cys Arg Cys
165 170 175
Gln Asn Ala Asp Gln Gln Val Ala Met Gln Gln Gln Gln Gln Gln Gln
180 185 190
Gln Gln Gln Gln Gln Gln Gln Met Gly Asn Pro Asp Gly Phe Ser Pro
195 200 205
<210> 13
<211> 314
<212> PRT
<213> Homo sapiens
<400> 13
Met Pro Leu Glu Gln Arg Ser Gln His Cys Lys Pro Glu Glu Ala Leu
1 5 10 15
Glu Ala Arg Gly Glu Ala Leu Gly Leu Val Gly Ala Gln Ala Pro Ala
20 25 30
Thr Glu Glu Gln Glu Ala Ala Ser Ser Ser Ser Thr Leu Val Glu Val
35 40 45
Thr Leu Gly Glu Val Pro Ala Ala Glu Ser Pro Asp Pro Pro Gln Ser
50 55 60
Pro Gln Gly Ala Ser Ser Leu Pro Thr Thr Met Asn Tyr Pro Leu Trp
65 70 75 80
Ser Gln Ser Tyr Glu Asp Ser Ser Asn Gln Glu Glu Glu Gly Pro Ser
85 90 95
Thr Phe Pro Asp Leu Glu Ser Glu Phe Gln Ala Ala Leu Ser Arg Lys
100 105 110
Val Ala Glu Leu Val His Phe Leu Leu Leu Lys Tyr Arg Ala Arg Glu
115 120 125
Pro Val Thr Lys Ala Glu Met Leu Gly Ser Val Val Gly Asn Trp Gln
130 135 140
Tyr Phe Phe Pro Val Ile Phe Ser Lys Ala Ser Ser Ser Leu Gln Leu
145 150 155 160
Val Phe Gly Ile Glu Leu Met Glu Val Asp Pro Ile Gly His Leu Tyr
165 170 175
Ile Phe Ala Thr Cys Leu Gly Leu Ser Tyr Asp Gly Leu Leu Gly Asp
180 185 190
Asn Gln Ile Met Pro Lys Ala Gly Leu Leu Ile Ile Val Leu Ala Ile
195 200 205
Ile Ala Arg Glu Gly Asp Cys Ala Pro Glu Glu Lys Ile Trp Glu Glu
210 215 220
Leu Ser Val Leu Glu Val Phe Glu Gly Arg Glu Asp Ser Ile Leu Gly
225 230 235 240
Asp Pro Lys Lys Leu Leu Thr Gln His Phe Val Gln Glu Asn Tyr Leu
245 250 255
Glu Tyr Arg Gln Val Pro Gly Ser Asp Pro Ala Cys Tyr Glu Phe Leu
260 265 270
Trp Gly Pro Arg Ala Leu Val Glu Thr Ser Tyr Val Lys Val Leu His
275 280 285
His Met Val Lys Ile Ser Gly Gly Pro His Ile Ser Tyr Pro Pro Leu
290 295 300
His Glu Trp Val Leu Arg Glu Gly Glu Glu
305 310
<210> 14
<211> 288
<212> PRT
<213> Homo sapiens
<400> 14
Met Gly His Thr Arg Arg Gln Gly Thr Ser Pro Ser Lys Cys Pro Tyr
1 5 10 15
Leu Asn Phe Phe Gln Leu Leu Val Leu Ala Gly Leu Ser His Phe Cys
20 25 30
Ser Gly Val Ile His Val Thr Lys Glu Val Lys Glu Val Ala Thr Leu
35 40 45
Ser Cys Gly His Asn Val Ser Val Glu Glu Leu Ala Gln Thr Arg Ile
50 55 60
Tyr Trp Gln Lys Glu Lys Lys Met Val Leu Thr Met Met Ser Gly Asp
65 70 75 80
Met Asn Ile Trp Pro Glu Tyr Lys Asn Arg Thr Ile Phe Asp Ile Thr
85 90 95
Asn Asn Leu Ser Ile Val Ile Leu Ala Leu Arg Pro Ser Asp Glu Gly
100 105 110
Thr Tyr Glu Cys Val Val Leu Lys Tyr Glu Lys Asp Ala Phe Lys Arg
115 120 125
Glu His Leu Ala Glu Val Thr Leu Ser Val Lys Ala Asp Phe Pro Thr
130 135 140
Pro Ser Ile Ser Asp Phe Glu Ile Pro Thr Ser Asn Ile Arg Arg Ile
145 150 155 160
Ile Cys Ser Thr Ser Gly Gly Phe Pro Glu Pro His Leu Ser Trp Leu
165 170 175
Glu Asn Gly Glu Glu Leu Asn Ala Ile Asn Thr Thr Val Ser Gln Asp
180 185 190
Pro Glu Thr Glu Leu Tyr Ala Val Ser Ser Lys Leu Asp Phe Asn Met
195 200 205
Thr Thr Asn His Ser Phe Met Cys Leu Ile Lys Tyr Gly His Leu Arg
210 215 220
Val Asn Gln Thr Phe Asn Trp Asn Thr Thr Lys Gln Glu His Phe Pro
225 230 235 240
Asp Asn Leu Leu Pro Ser Trp Ala Ile Thr Leu Ile Ser Val Asn Gly
245 250 255
Ile Phe Val Ile Cys Cys Leu Thr Tyr Cys Phe Ala Pro Arg Cys Arg
260 265 270
Glu Arg Arg Arg Asn Glu Arg Leu Arg Arg Glu Ser Val Arg Pro Val
275 280 285
<210> 15
<211> 250
<212> PRT
<213> Homo sapiens
<400> 15
Met Val Ala Gly Ser Asp Ala Gly Arg Ala Leu Gly Val Leu Ser Val
1 5 10 15
Val Cys Leu Leu His Cys Phe Gly Phe Ile Ser Cys Phe Ser Gln Gln
20 25 30
Ile Tyr Gly Val Val Tyr Gly Asn Val Thr Phe His Val Pro Ser Asn
35 40 45
Val Pro Leu Lys Glu Val Leu Trp Lys Lys Gln Lys Asp Lys Val Ala
50 55 60
Glu Leu Glu Asn Ser Glu Phe Arg Ala Phe Ser Ser Phe Lys Asn Arg
65 70 75 80
Val Tyr Leu Asp Thr Val Ser Gly Ser Leu Thr Ile Tyr Asn Leu Thr
85 90 95
Ser Ser Asp Glu Asp Glu Tyr Glu Met Glu Ser Pro Asn Ile Thr Asp
100 105 110
Thr Met Lys Phe Phe Leu Tyr Val Leu Glu Ser Leu Pro Ser Pro Thr
115 120 125
Leu Thr Cys Ala Leu Thr Asn Gly Ser Ile Glu Val Gln Cys Met Ile
130 135 140
Pro Glu His Tyr Asn Ser His Arg Gly Leu Ile Met Tyr Ser Trp Asp
145 150 155 160
Cys Pro Met Glu Gln Cys Lys Arg Asn Ser Thr Ser Ile Tyr Phe Lys
165 170 175
Met Glu Asn Asp Leu Pro Gln Lys Ile Gln Cys Thr Leu Ser Asn Pro
180 185 190
Leu Phe Asn Thr Thr Ser Ser Ile Ile Leu Thr Thr Cys Ile Pro Ser
195 200 205
Ser Gly His Ser Arg His Arg Tyr Ala Leu Ile Pro Ile Pro Leu Ala
210 215 220
Val Ile Thr Thr Cys Ile Val Leu Tyr Met Asn Gly Ile Leu Lys Cys
225 230 235 240
Asp Arg Lys Pro Asp Arg Thr Asn Ser Asn
245 250
<210> 16
<211> 532
<212> PRT
<213> Homo sapiens
<400> 16
Met Ala Pro Ser Ser Pro Arg Pro Ala Leu Pro Ala Leu Leu Val Leu
1 5 10 15
Leu Gly Ala Leu Phe Pro Gly Pro Gly Asn Ala Gln Thr Ser Val Ser
20 25 30
Pro Ser Lys Val Ile Leu Pro Arg Gly Gly Ser Val Leu Val Thr Cys
35 40 45
Ser Thr Ser Cys Asp Gln Pro Lys Leu Leu Gly Ile Glu Thr Pro Leu
50 55 60
Pro Lys Lys Glu Leu Leu Leu Pro Gly Asn Asn Arg Lys Val Tyr Glu
65 70 75 80
Leu Ser Asn Val Gln Glu Asp Ser Gln Pro Met Cys Tyr Ser Asn Cys
85 90 95
Pro Asp Gly Gln Ser Thr Ala Lys Thr Phe Leu Thr Val Tyr Trp Thr
100 105 110
Pro Glu Arg Val Glu Leu Ala Pro Leu Pro Ser Trp Gln Pro Val Gly
115 120 125
Lys Asn Leu Thr Leu Arg Cys Gln Val Glu Gly Gly Ala Pro Arg Ala
130 135 140
Asn Leu Thr Val Val Leu Leu Arg Gly Glu Lys Glu Leu Lys Arg Glu
145 150 155 160
Pro Ala Val Gly Glu Pro Ala Glu Val Thr Thr Thr Val Leu Val Arg
165 170 175
Arg Asp His His Gly Ala Asn Phe Ser Cys Arg Thr Glu Leu Asp Leu
180 185 190
Arg Pro Gln Gly Leu Glu Leu Phe Glu Asn Thr Ser Ala Pro Tyr Gln
195 200 205
Leu Gln Thr Phe Val Leu Pro Ala Thr Pro Pro Gln Leu Val Ser Pro
210 215 220
Arg Val Leu Glu Val Asp Thr Gln Gly Thr Val Val Cys Ser Leu Asp
225 230 235 240
Gly Leu Phe Pro Val Ser Glu Ala Gln Val His Leu Ala Leu Gly Asp
245 250 255
Gln Arg Leu Asn Pro Thr Val Thr Tyr Gly Asn Asp Ser Phe Ser Ala
260 265 270
Lys Ala Ser Val Ser Val Thr Ala Glu Asp Glu Gly Thr Gln Arg Leu
275 280 285
Thr Cys Ala Val Ile Leu Gly Asn Gln Ser Gln Glu Thr Leu Gln Thr
290 295 300
Val Thr Ile Tyr Ser Phe Pro Ala Pro Asn Val Ile Leu Thr Lys Pro
305 310 315 320
Glu Val Ser Glu Gly Thr Glu Val Thr Val Lys Cys Glu Ala His Pro
325 330 335
Arg Ala Lys Val Thr Leu Asn Gly Val Pro Ala Gln Pro Leu Gly Pro
340 345 350
Arg Ala Gln Leu Leu Leu Lys Ala Thr Pro Glu Asp Asn Gly Arg Ser
355 360 365
Phe Ser Cys Ser Ala Thr Leu Glu Val Ala Gly Gln Leu Ile His Lys
370 375 380
Asn Gln Thr Arg Glu Leu Arg Val Leu Tyr Gly Pro Arg Leu Asp Glu
385 390 395 400
Arg Asp Cys Pro Gly Asn Trp Thr Trp Pro Glu Asn Ser Gln Gln Thr
405 410 415
Pro Met Cys Gln Ala Trp Gly Asn Pro Leu Pro Glu Leu Lys Cys Leu
420 425 430
Lys Asp Gly Thr Phe Pro Leu Pro Ile Gly Glu Ser Val Thr Val Thr
435 440 445
Arg Asp Leu Glu Gly Thr Tyr Leu Cys Arg Ala Arg Ser Thr Gln Gly
450 455 460
Glu Val Thr Arg Glu Val Thr Val Asn Val Leu Ser Pro Arg Tyr Glu
465 470 475 480
Ile Val Ile Ile Thr Val Val Ala Ala Ala Val Ile Met Gly Thr Ala
485 490 495
Gly Leu Ser Thr Tyr Leu Tyr Asn Arg Gln Arg Lys Ile Lys Lys Tyr
500 505 510
Arg Leu Gln Gln Ala Gln Lys Gly Thr Pro Met Lys Pro Asn Thr Gln
515 520 525
Ala Thr Pro Pro
530
<210> 17
<211> 16
<212> PRT
<213> Homo sapiens
<400> 17
Ser Arg Arg His His Cys Arg Ser Lys Ala Lys Arg Ser Arg His His
1 5 10 15
Claims (22)
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- CD80, ICAM-1, LFA-3, gp100M, MART-1 및 MAGE1/3 미니유전자를 암호화하는 ALVAC(2) 발현 벡터 및 CD80, ICAM-1, LFA-3, TRP-2 및 NY-ESO-1를 암호화하는 ALVAC(2) 발현 벡터를 주요 성분으로서 포함하는, 포유동물에서 흑색종 다중 항원에 대하여 면역반응을 유도하기 위한 약제학적 조성물.
- CD80, ICAM-1, LFA-3, gp100M, MART-1 및 MAGE1/3 미니유전자를 암호화하는 ALVAC(2) 발현 벡터를 포함하는 약제학적 조성물과 CD80, ICAM-1, LFA-3, TRP-2 및 NY-ESO-1를 암호화하는 ALVAC(2) 발현 벡터를 포함하는 약제학적 조성물을 혼합함을 포함하여, 제20항의 약제학적 조성물을 제조하는 방법.
- 종양 다중 항원에 대하여 면역반응을 유도하기 위해 포유동물에게 별도로 투여되는 제1 약제학적 조성물과 제2 약제학적 조성물의 배합물로서, 상기 제1 약제학적 조성물이 CD80, ICAM-1, LFA-3, gp100M, MART-1 및 MAGE1/3 미니유전자를 암호화하는 ALVAC(2) 발현 벡터를 포함하고, 상기 제2 약제학적 조성물이 CD80, ICAM-1, LFA-3, TRP-2 및 NY-ESO-1를 암호화하는 ALVAC(2) 발현 벡터를 포함함을 특징으로 하는 배합물.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50057203P | 2003-09-05 | 2003-09-05 | |
US60/500,572 | 2003-09-05 | ||
US50400703P | 2003-09-18 | 2003-09-18 | |
US60/504,007 | 2003-09-18 | ||
PCT/US2004/028751 WO2005026370A2 (en) | 2003-09-05 | 2004-09-03 | Multi-antigen vectors for melanoma |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20060123083A KR20060123083A (ko) | 2006-12-01 |
KR101141951B1 true KR101141951B1 (ko) | 2012-05-04 |
Family
ID=34316448
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020067004548A KR101141951B1 (ko) | 2003-09-05 | 2004-09-03 | 흑색종용 다중-항원 벡터 |
Country Status (10)
Country | Link |
---|---|
US (1) | US8911991B2 (ko) |
EP (1) | EP1660119A2 (ko) |
JP (2) | JP2007503834A (ko) |
KR (1) | KR101141951B1 (ko) |
AU (2) | AU2004273034A1 (ko) |
BR (1) | BRPI0413334A (ko) |
CA (1) | CA2537931A1 (ko) |
HK (1) | HK1101352A1 (ko) |
IL (1) | IL173637A0 (ko) |
WO (1) | WO2005026370A2 (ko) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9711957D0 (en) | 1997-06-09 | 1997-08-06 | Isis Innovation | Methods and reagents for vaccination |
AU783344B2 (en) | 1999-02-17 | 2005-10-20 | Csl Limited | Immunogenic complexes and methods relating thereto |
GB0118532D0 (en) | 2001-07-30 | 2001-09-19 | Isis Innovation | Materials and methods relating to improved vaccination strategies |
WO2005033278A2 (en) * | 2003-09-30 | 2005-04-14 | Ludwig Institute For Cancer Research | In vivo efficacy of ny-eso-1 plus iscom |
US20060217893A1 (en) * | 2005-01-07 | 2006-09-28 | Yanbin Li | Method for detecting an unknown contaminant concentration in a substance |
EP1890724A2 (en) * | 2005-05-13 | 2008-02-27 | Oxxon Therapeutics Limited | Compositions for inducing an immune response |
US20100120016A1 (en) * | 2006-09-01 | 2010-05-13 | Yanbin Li | Methods and systems for detection of contaminants |
WO2009042773A1 (en) * | 2007-09-25 | 2009-04-02 | University Of Miami | Adoptively transferred tumor-specific t cells stimulated ex vivo using herpes simplex virus amplicons |
US9314516B2 (en) * | 2010-05-04 | 2016-04-19 | Cassian Yee | Conditional superagonist CTL ligands for the promotion of tumor-specific CTL responses |
KR20160140075A (ko) * | 2015-05-29 | 2016-12-07 | 코오롱생명과학 주식회사 | 폭스바이러스 유래 프로모터 및 이를 포함하는 벡터 |
TWI733719B (zh) * | 2015-12-07 | 2021-07-21 | 美商河谷控股Ip有限責任公司 | 改善的組合物及用於新表位之病毒遞送的方法及其應用 |
WO2018094309A2 (en) | 2016-11-21 | 2018-05-24 | Nant Holdings Ip, Llc | Fractal combination therapy |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003016342A2 (en) * | 2001-08-17 | 2003-02-27 | Aventis Pasteur Limited | Tumor antigens for prevention and/or treatment of cancer |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2201592A1 (en) * | 1994-10-03 | 1996-04-18 | The Government Of The United States Of America, Represented By The Secre Tary, Department Of Health And Human Services | Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule b7 gene in a recombinant virus expressing system |
US20030125536A1 (en) * | 1996-01-11 | 2003-07-03 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
US6770456B1 (en) * | 1998-07-29 | 2004-08-03 | Ludwig Institute For Cancer Research | Endogenous retrovirus tumor associated nucleic acids and antigens |
US20030235557A1 (en) * | 1998-09-30 | 2003-12-25 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
AU774076C (en) * | 1998-12-09 | 2005-04-14 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | A recombinant vector expressing multiple costimulatory molecules and uses thereof |
WO2001030847A1 (en) * | 1999-10-22 | 2001-05-03 | Aventis Pasteur Limited | Modified gp100 and uses thereof |
ES2276788T3 (es) * | 2000-05-10 | 2007-07-01 | Sanofi Pasteur Limited | Polipeptidos inmunogenos codificados por minigenes mage y sus utilizaciones. |
JP2004507231A (ja) * | 2000-06-15 | 2004-03-11 | アメリカ合衆国 | 免疫応答を向上させるための、gm−csfを発現する組換え非−複製性ウィルスおよびその使用 |
NZ526706A (en) * | 2000-11-28 | 2005-03-24 | Wyeth Corp | Use of inhibitor of differentiation markers ID-1 and ID-3 for the diagnosis and prognosis of prostate cancer |
US20040091995A1 (en) * | 2001-06-15 | 2004-05-13 | Jeffrey Schlom | Recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses |
GB0118532D0 (en) * | 2001-07-30 | 2001-09-19 | Isis Innovation | Materials and methods relating to improved vaccination strategies |
WO2003080800A2 (en) * | 2002-03-20 | 2003-10-02 | Aventis Pasteur, Inc. | Prevention and treatment of disease using angiogenesis-and/or tumor antigens |
AU2003229429A1 (en) * | 2002-05-07 | 2003-11-11 | Aventis Pasteur, Ltd. | Polyepitopes and mini-genes for cancer treatment |
-
2004
- 2004-09-03 KR KR1020067004548A patent/KR101141951B1/ko not_active IP Right Cessation
- 2004-09-03 CA CA002537931A patent/CA2537931A1/en not_active Abandoned
- 2004-09-03 WO PCT/US2004/028751 patent/WO2005026370A2/en active Application Filing
- 2004-09-03 AU AU2004273034A patent/AU2004273034A1/en not_active Abandoned
- 2004-09-03 US US10/933,874 patent/US8911991B2/en not_active Expired - Fee Related
- 2004-09-03 EP EP04783109A patent/EP1660119A2/en not_active Ceased
- 2004-09-03 BR BRPI0413334-0A patent/BRPI0413334A/pt not_active IP Right Cessation
- 2004-09-03 JP JP2006525474A patent/JP2007503834A/ja active Pending
-
2006
- 2006-02-09 IL IL173637A patent/IL173637A0/en unknown
-
2007
- 2007-06-11 HK HK07106213.1A patent/HK1101352A1/xx not_active IP Right Cessation
-
2010
- 2010-11-18 JP JP2010257738A patent/JP5373747B2/ja not_active Expired - Fee Related
-
2011
- 2011-01-13 AU AU2011200127A patent/AU2011200127B2/en not_active Ceased
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003016342A2 (en) * | 2001-08-17 | 2003-02-27 | Aventis Pasteur Limited | Tumor antigens for prevention and/or treatment of cancer |
Non-Patent Citations (3)
Title |
---|
Human Gene Therapy, 2002, Vol. 13, No. 3, pp. 569-575 * |
Vaccine, 2001, Vol. 19, pp. 2571-2575 * |
Vaccine, 2001, Vol. 19, pp. 2571-2575* |
Also Published As
Publication number | Publication date |
---|---|
KR20060123083A (ko) | 2006-12-01 |
IL173637A0 (en) | 2006-07-05 |
AU2004273034A1 (en) | 2005-03-24 |
AU2011200127A1 (en) | 2011-02-03 |
WO2005026370A2 (en) | 2005-03-24 |
AU2011200127B2 (en) | 2012-06-21 |
CA2537931A1 (en) | 2005-03-24 |
WO2005026370A3 (en) | 2005-06-16 |
JP5373747B2 (ja) | 2013-12-18 |
JP2011041578A (ja) | 2011-03-03 |
JP2007503834A (ja) | 2007-03-01 |
EP1660119A2 (en) | 2006-05-31 |
HK1101352A1 (en) | 2007-10-18 |
US8911991B2 (en) | 2014-12-16 |
US20060127360A1 (en) | 2006-06-15 |
BRPI0413334A (pt) | 2006-10-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101141951B1 (ko) | 흑색종용 다중-항원 벡터 | |
US11884947B2 (en) | Fusion proteins for base editing | |
US6218185B1 (en) | Piggybac transposon-based genetic transformation system for insects | |
JP5363446B2 (ja) | 癌の予防または治療のための腫瘍抗原 | |
JP5640237B2 (ja) | 癌関連抗原をコードする単離された核酸分子、その抗原そのものおよびその使用 | |
US8071717B2 (en) | Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof | |
GB2443186A (en) | Expression system for mediating alternative splicing | |
JP2011067207A5 (ko) | ||
CN114835821B (zh) | 一种高效特异实现碱基颠换的编辑系统、方法及用途 | |
CN111607614A (zh) | 白喉毒素调控清除免疫细胞的cd45-dtr转基因小鼠的构建方法与应用 | |
AU7507698A (en) | Human semaphorin L (H-semal) and corresponding semaphorins in other species | |
De Plaen et al. | Alternative promoters of gene MAGE4a | |
EP1496939B1 (en) | Modified cea nucleic acid and expression vectors | |
CN113789348B (zh) | 一种apex2基因敲入的小鼠动物模型、构建方法及其应用 | |
CN111991550B (zh) | Hip-55在制备用于诊断和防治心肌缺血再灌注损伤产品中的应用 | |
CN111965367A (zh) | Hip-55在作为gpcr偏向药物靶点中的应用 | |
KR20220050073A (ko) | 뇌 조직으로 유전자를 전달하기 위한 조성물 및 이의 용도 | |
EP1244796A2 (en) | Transduction of recombinases for inducible gene targeting | |
Boon et al. | Genes coding for tumor-specific rejection antigens | |
CN112480249B (zh) | Akt新底物hip-55的磷酸化抗体产品制备方法与应用 | |
CN112516287B (zh) | 心肌梗死相关蛋白hip-55及其应用 | |
CN111454962B (zh) | 基于牛安全位点的定点修饰及其应用 | |
CN112251413B (zh) | 一种跨膜表达新型冠状病毒抗原的细胞的制备方法、细胞和应用 | |
AU2004280608B2 (en) | Modified CEA/B7 vector | |
CN1878566B (zh) | 用于黑素瘤的多抗原载体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
LAPS | Lapse due to unpaid annual fee |